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IV. ABSTRACT
Background: Legislation controls the research, design, development and 
manufacture of medical devices and in vitro diagnostic devices in the United 
Kingdom (UK) and the European Union (EU). Organisations working in this field 
can demonstrate their regulatory compliance to this legislation by being accredited 
to BS EN ISO 13485 – BS EN ISO 13485:2016 ‘Medical devices - Quality 
management systems - Requirements for regulatory’(1). 
The Departments of Medical Physics and Hydatidiform Mole Follow-Up (Scotland) 
(HMFUS), collectively referred throughout this thesis as M&H, within Ninewells 
Hospital NHS Tayside are accredited to this standard to allow them to undertake 
research, design, development and manufacture of medical and in vitro diagnostic 
devices. This accreditation also enables medical and in vitro diagnostic devices to 
be European Conformity (CE) marked to the appropriate EU directive or 
regulation(180). 
Aim: The aim of this project is to ensure academics and third parties collaborating 
with M&H meet the legislative and regulatory requirements for the development of 
those medical or in vitro diagnostic devices to be placed within a healthcare 
environment. 
Method: A review of the new Medical Device Regulations (MDR)(2), In Vitro 
Diagnostic Device Regulations (IVDR)(3) and UK Medical Devices Legislation(4), 
alongside the requirements of the 2016 revision of the BS EN ISO 13485 standard, 
to ensure the continuing accreditation within M&H. A case study of the research 
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project – ‘the ‘Optical Coherence Elastography’ system, will be undertaken to gain 
an understanding of the regulatory documentation required. 
Results: The development of documentation that must be followed by academics 
and third parties carrying out research and the devolvement within M&H to ensure 
their projects meet the requirements of the legislation and BS EN ISO 13485:2016 
regulatory requirements. This documentation must also be followed by M&H to 
ensure their projects meet both the legislative and the regulatory requirements. 
Conclusion: 
1 That the documentation, required to ensure the work in relation to MDR and 
IVDR devices meets the regulatory and legislative requirements, has been 
produced. 
2 That this documentation, on being reviewed by external auditors, confirms 
compliance with BS EN ISO 13485 
3 When completed, this documentation will show that the OCE system complies 
with the legislative exemptions after review. 
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 INTRODUCTION 
1.1 Motivation and objectives 
A white paper, written and subsequently published by Arthur Cockfield, later Baron 
Cockfield in 1985,(5) outlined the measures to be taken to enable the idea of a single 
European Economic Community (EEC) market to be brought into being. This white 
paper(6) led to the adoption in the EEC of the Single European Act(7). A provision 
of this Act was that the single market had to be set up by 31st December 1993. The 
full extent of this Act has still to be fulfilled and is viewed as a work in progress.  
The EU single market has four main principles:  
• The free movement of Services  
• The free movement of People (workers and citizens)  
• The free movement of Money/Capital and  
• The free movement of Goods. 
The free movement of goods requires the removal of customs and trade barriers 
between countries. A typical trade barrier between two counties, prior to the 
adoption of the freedom of movement of goods, was to have slightly differing 
technical standards or regulatory requirements for similar, or even the same, 
products. Prior to the introduction of the medical device directive and the in vitro 
diagnostic directive, each EU member state would insist that any such device would 
have to be tested to their own country’s regulations or standards and, thereafter, 
tested by a body accredited by that country’s standards body. 
These ‘technical’ trade barriers would be removed by the implementation of 
common legislation relating to specific product grouping. The legislation, in the 
form of directives or regulations, would set out the requirements for specific 
devices. Further, harmonised standards to be introduced would detail how the 
regulations or directives were to be met. By conforming to these standards a legal 
presumption of conformance in the required areas to which the directives or 
regulations related to would allow the manufacturer a more assured/simpler route 
to compliance. For further details regarding harmonised standards please see 2.1.6 
‘ISO, EN, BS and Harmonised Standards’. 
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For medical and in vitro devices, three directives(8,9,10)  were issued in the 1990’s 
and all have undergone minor amendments and review since they were issued. All 
three directives have been criticised in a number of areas. For example the 
possibility of countries interpreting the directives in differing ways, the lack of 
oversight of the notified bodies carrying out device assessments and a device 
vigilance reporting system which was not coordinated nor were the reports fully 
analysed for trends. Two well publicised scandals(111,112) resulting from device 
failures resulted in the EU commencing a full review of the three directives. The 
first was the Poly Implant Prothèse, ‘PIP’(111), breast implant scandal. This scandal 
was closely followed by the metal-on-metal hip replacement scandal(112). This 
forced the EU member states to work in closer harmony to revise, strengthen and 
remove many of the weakness or failings of the three directives. The outcome of 
this full review was the issue/introduction of the two regulations the Medical 
Device Regulations (MDR)(2) and the In Vitro Diagnostic Device Regulations 
(IVDR)(3) in 2017. Prior to the issue of these regulations, the EU undertook 
measures to address the various problems on an interim basis, for example, the 
reclassification of breast implants(185); the recommendations detailed in the EU final 
opinion on metal on metal hip implants and the responses to the comments related 
to this opinion paper(186); and the introduction of the updated standard relating to 
the biocompatibility of medical devices ISO 10993-1:2009(187). 
It should be noted that the difference between EU regulations and EU directives is 
that EU regulations are binding legislative acts which must be applied in their 
entirety and without interpretation in each country. Whereas, EU directives set out 
the goals and aims of the required legislation but it is up to each country’s legislative 
process to determine how to enact the directives into their country’s laws.  
By changing these directives to regulations another criticism was removed i.e. that 
the directives were not equally applied across the EU.  
Directives or regulations may also require devices to be developed and 
manufactured to an appropriate quality management standard – BS EN ISO 
13485:2016(1) for medical devices and both BS EN ISO 13485:2016 and, with the 
introduction of the In Vitro Diagnostic Device Regulations, EN ISO 15189:2012 
(11), for in vitro diagnostic devices. These standards complement the two regulations 
and provide regulatory compliance for the various management systems required.  
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Of the original three directives only the in vitro diagnostic device directive  defined 
the controls under which these devices could be designed, developed and 
manufactured ‘in-house’ for ‘in-house’ use only. Subsequent to the issue of the 
Medical Device Directive, guidelines(179) were introduced to control the 
manufacture of devices by a health care institution for use ‘in-house’ only by that 
health care institution. (A health care institution is a legal entity whose primary 
purpose is the care or treatment of patients or promotion of public health.) These 
controls were not stringent, and, in most cases, no external oversight or review was 
required. With the introduction of the new regulations the control of such work has 
been considerably increased. For devices manufactured for ‘in-house’ use, that is, 
solely to be used within the manufacturing NHS Trust or Health Institution, these 
two new regulations introduced a number of new requirements.  
The need to register any device designed, developed and manufactured for ‘in-
house’ use with the local competent or designated authority. In the UK this is the 
Medicines and Healthcare products Regulatory Agency (MHRA).  
The proof that the device(s) meets the safety requirements set out in the relevant 
directive.   
That the work is carried out and conforms to an appropriate Quality Management 
System, (QMS). In the case of medical devices this would be BS EN ISO 13485. In 
the case of in vitro diagnostic devices this would be EN ISO 13485 and EN ISO 
15189. 
The Department of Medical Physics and HMFUS (M&H) design, develop and 
manufacture medical and in vitro diagnostic devices for both ‘in-house’ use as well 
as devices supplied to third parties. In order to supply these devices to third parties 
they have to meet the full requirements of the appropriate EU regulation and be CE 
marked (2, 3).  
The QMS used by M&H is accredited or certificated to a number of standards 
including BS EN ISO 13485:2016 and BS EN ISO 15189:2012. The accreditation 
to BS EN ISO 13485 was achieved in 2004 to enable the supply of light therapy 
testing and treatment units to various dermatology centres within the UK. The 
standard was also required to enable HMFUS to supply reagents, used in an in vitro 
diagnostic test, to other hospitals within the UK. Since this initial accreditation, the 
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standard has been revised and even renamed. Each time there has been a revision 
in the BS EN ISO 13485 standard, the QMS has been amended to accommodate 
these revisions. The current revision of this standard is BS EN ISO 13485:2016.  
Development work, undertaken in collaboration between M&H, educational 
institutions or other third parties, must also meet the requirements of the M&H 
QMS, especially if the output of this work is to be used in trials or by 
clinical/medical staff within NHS Tayside. As this work is regarded as ‘in-house’ 
work’ it must meet the same regulatory and statuary requirements. 
In this thesis, there is a description of  the work undertaken to review the 
requirements of the new MDR and IVDR;  the changes introduced to the new 2016 
revision of the BS NE ISO 13485 standard and a determination of  how these 
impacted on the  QMS implemented by M&H; the documentation used to control 
medical and in vitro diagnostic device design, development and manufacture; the 
control of academic and  third party collaborative work and the guidelines to be 
followed by academic and third party’s working in collaboration with M&H. 
1.2 Content of thesis  
There are 7 chapters in this thesis: 
Chapter 1 Introduction: The purpose and background of this study 
Chapter 2 Literature Review and Background: An overview of the quality 
management standards, background to the EU single market and the regulation of 
medical and in vitro diagnostic devices. This chapter also provides an overview of 
the University of Dundee’s Optical Coherence Elastography (OCE) system and a 
review of the documentation produced during the development of the device. 
Chapter 3 Update from BS EN ISO 13485:2012 to BS EN ISO 13485:2016: The 
work undertaken to ensure the M&H quality management system, accredited to BS 
EN ISO 13485:2012(12), was reviewed and the changes implemented to ensure 
compliance with BS EN ISO 13485:2016. 
Chapter 4 EU and UK Medical and In Vitro Diagnostic Device Legislation: A 
review of the new EU and UK regulations and the work undertaken to ensure that 
the M&H quality system was compliant with these new regulations.  
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Chapter 5 Case study: The work undertaken on the OCE to enable this system to 
be placed in ‘a near patient’ environment. The guidelines drawn up/developed to 
ensure Academic and Third Party collaboration with NHS Tayside, relating to the 
design and manufacture of medical and in vitro diagnostic devices, meet the 
exemption requirements of the legislation. 
Chapter 6 Conclusions: 
The implementation of the new standard to meet the legislative requirements. 
The implementation of the documentation for both M&H work and the academic 
collaboration. 
Chapter 7 Further Work:  
Continuing the review and auditing of our quality system to ensure that it is fit of 
purpose. 
The development of the OCE system to ensure that it functions correctly, meets the 
service users’ needs and that the results produced are fully validated. 
Working with the University of Dundee and other academic bodies to ensure that 
the collaborative work is correctly controlled and documented.  
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 LITERATURE REVIEW AND BACKGROUND 
2.1 History of Standards in industry  
It is important to define the meaning of standards in relation to the work being 
described in this thesis.  
The Collins Dictionary defines a ‘standard’(13)  as: 
1. ‘A standard is a level of quality or achievement, especially a level that is 
thought to be acceptable.’ 
2. ‘A standard is something that you use in order to judge the quality of 
something else.’ 
The Oxford English Dictionary however lists numerous definitions for the word 
‘standard’(14) amongst which are: 
1. Entry 10 – ‘An authoritative or recognized exemplar of correctness, 
perfection, or some definite degree of any quality.’ 
2. Entry 12 – ‘A definite level of excellence, attainment, wealth, or the like, 
or a definite degree of any quality, viewed as a prescribed object of 
endeavour or as the measure of what is adequate for some purpose; 
‘specifically’ the proper or correct quality.’ 
2.1.1 Early Standards 
The early building constructors used standard moulds to ensure that the sizing of 
the materials used in their buildings or monuments was precise. In ‘The History of 
Brick’(15) it details that Roman bricks were made to standard sizes and were 
inscribed to denote the maker, and later, additional information on the 
manufacturing dates was included. In ‘The Appearance of Bricks in Ancient 
Mesopotamia’(16) it describes the history of mud bricks being manufactured in 
ancient Mesopotamian times. The use of standard building materials and 
architectural planning in these ancient times is fully discussed by Shamil in 
‘Evidence of Architectural Planning and the Use of a Standard Unit of 
Measurement - the "Ubaid cubit" in Mesopotamia’(17). 
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2.1.2 Improving Safety and Trade via Standards. 
More recently, safety and trade have been the main drivers for the use of standards. 
The railways are a good example of this. In the early history of the railway system, 
railway companies and countries used different rail gauges(18). The proliferation of 
the gauge sizes was a direct result of the train manufacturers building to their own 
dimensions.  Different gauge sizes were also used to either stop other companies 
using their track or to stop other countries using the local rail systems to invade 
their country. The rail gauges(18, 19) of the USA and Canada in the 1800’s are an 
example of this. Once companies and countries started to realise the cost and trade 
benefits of having standard rail gauges, the move to standardise rail gauges 
increased. The Railway Regulation (Gauge) Act 1894(20, 21) brought about the 
standardisation of railway gauges in the UK. 
The use of standards and standardisation by the railways is an early example of 
industrial era governments and companies understanding the importance of 
standardisation and the use of standards. 
Standards have also been used to control trade and merchandise to ensure that goods 
are purchased to the correct weight, length or specification. The ‘balanced beam’ 
method of comparing weights has been in use since the Bronze Age times and many 
countries, during the ancient times, had standardised weights(22, 23). 
Standards, for reviewing quality of work or goods, have been in existence since 
humans have been paying for goods or work, no matter the method of payment. The 
standard used to compare goods may not have been a written document but could 
be to look at, feel, smell or even taste the goods being traded. The same is true today 
as consumers may purchase goods based on their appearance, texture, smell or taste.  
One of the first UK quality standards was the introduction for the quality mark of 
gold and silver by Edward I of England in the 1300s. This was to ensure the actual 
content of the precious metals in a given sample(24). 
Edward I also appointed William of Wrotham to report on the quality of the 
construction of warships. Wrotham was one of the first official quality control 
inspectors of ships(171). 
During the 19th century, when the industrial revolution was taking place, there was 
an increasing need to control the quality of materials being produced so as to 
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regulate their actual dimensions and physical properties. The standardisation of 
common parts used in machines and construction allowed these parts to be massed 
produced and at known standards of dimension and material quality. An example 
of an early standard in mechanical engineering is the lowly/humble screw and the 
Whitworth standard of screw threads and dimensions. 
Joseph Whitworth (1803-1897) introduced core and external diameters from a 
practical standpoint using British inch (imperial) sizes. The system proved to be so 
good that it remains in use up to this day, mainly as the standard used for pipe 
fittings(25). The Whitworth screw is detailed in British Standard BS 84:2007(26) , 
which can be traced back to the original standard of 1840(27,28). The use of such 
standard parts allowed manufacturers to produce consistent goods and ensure 
customer satisfaction. The First World War required manufacturing processes to 
become more complex with manufacturers employing larger workforces to meet 
the need to mass produce equipment and munitions for the war effort. The 
introduction of piece work and payment for the number of items made, led to poor 
quality goods being produced and passed to the next stage in the production 
line/process or the end user. To ensure that the quality of parts or the finished 
product was to the correct standard, full time inspectors were employed to check 
the items were of the correct workmanship and required quality. The practice of 
inspection grew between the First and the Second World Wars and soon 
departments of quality inspection were to be found in many industries. These 
departments were solely involved in the inspection of goods and workmanship. 
During World War II, the practice of inspection continues but in some areas, for 
example, in the manufacture of explosives, the UK government also required the 
manufacturers to document their work procedures and ensure that all the workforce 
adhered to these procedures(29). This produced a number of benefits, including a 
reduction in premature detonations of explosives(24), thus reducing the loss in 
workforce lives and a more consistent product being made resulting in the 
munitions produced being more effective in the field.  
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2.1.3 Quality Standards 
After the Second World War the UK Ministry of Defence, (MoD), continued to use 
standards to define work procedures and processes. It also used standards to set the 
required level of product quality, for example UK's Defence Standard 05-21 
‘Quality Control System Requirements for Industry’ and 05-24 ‘Inspection System 
Requirements for Industry’ and United States Department of Defence MIL-Q-9858 
‘Military Specification: Quality Program Requirements. The MoD would inspect 
the work against the documented procedures and processes to determine how well 
these were being followed. The MoD would also carry out controls on the end 
product to ensure the required product quality was being met(24). Until the end of 
the 1970’s this was also the practice in most industries, with the manufacturers 
carrying out physical visits to suppliers to determine the quality of the procedures 
and product.  
2.1.4 BS 5750 and ISO 9000 
During the late 1970’s the UK government lead a campaign to promote quality and 
reliability in all aspects of British life and industry. The slogan for this campaign 
was “Quality is everyone’s business” and in 1981the British Standards Institute 
(BSI) issued a group of UK standards the BS 9000(172) series for electronic 
component quality assurance. As a result, when electronic components 
manufactured to this standard were purchased, these components would not need to 
be inspected or tested prior to use by the purchaser. This standard started the 
transition from the buyer, inspecting the goods to ensure they were fit for purpose, 
to the producer, having the responsibility for ensuring the goods and services they 
produced being fit for purpose. This transfer of responsibility meant that the 
previous standards which had required inspection by the buyer of the supplied 
products and services to ensure they were of the correct quality and standard was 
no longer required. In 1979 BSI, after consultation with industry, published the BS 
5750 series of standards, which included BS 5750-1:1979 standard(30). This series 
of standards was proposed to the International Organisation for Standardisation, 
ISO, in 1979, and eight years later, in 1987, the ISO 9000 series of standards was 
published (31). This series of standards has undergone a number of changes and 
revisions. The current ISO 9000 series consists of ISO 9001:2015(32) / BS EN ISO 
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9001:2015(33) and two supporting standards ISO 9000:2015 and ISO 9004:2018. BS 
EN ISO 9000:2015 and BS EN ISO 9004:2018. 
Over the years, more industry specific quality management standards have evolved. 
These standards have used as their starting point the ISO 9000 standards and added 
extra requirements or demanded more stringent controls than those required by the 
ISO 9000 standards. In the USA, their US QS 9000 standard was introduced by the 
automotive industry in 1994 (34, 35). This standard has now been superseded to enable 
component manufacturers having factories in many countries, to manufacture and 
supply parts to car building plants worldwide using ISO/TS 16949 (36, 37). 
Other such standards currently used include AS9100 for the Aerospace Industry(38) 
and ISO 13485 for the Medical Device Industry(1). 
The recent history of the ISO 9000 standard, and its offshoots, have gone through 
a number of revisions. Some of these have been to remove the military style of 
language used in the earlier standards while others have been to align the standard 
with the ideas of Total Quality Management, Risk Management and Process 
Management. In other words, standards have now evolved from simply looking at 
how a product is manufactured but to overseeing the whole management structure 
of an organisation, how the organisation ensures it can meet the present and future 
needs of its customers and whether or not the organisation reviews its processes and 
procedures to ensure the customer receives the best product or service possible(39). 
The follow excerpt from the QCS International training materials for their 13485 
internal auditors training course(40) summarises  these changes as follows: 
‘Inspection - ie sorting the good from bad. It is estimated that 15% of defective 
items still pass through an inspection stage. 
Quality Control - Planning inspection operations at key stages of the production 
cycle. This helped to identify errors earlier, but did not prevent them. 
Quality Assurance - Meeting customer requirements is the main objective of any 
organisation. By meeting these requirements, problems can be anticipated and 
prevented, giving greater confidence to the customer.’ 
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2.1.5 Standard for Medical and In Vitro Diagnostic Design and Manufacture 
It should be understood that those producing devices or items under the exemptions 
given in the UK or EU legislation must still have an ‘appropriate’ quality 
management system. The internationally recognised quality management system 
standard for medical device is ISO 13485. This standard, as EN ISO 13485:2016, 
is included in the harmonised lists of standards the list of harmonised standards for 
the IMDD(176), MDD(177) and IVDD(177). At the time of writing this thesis, there are 
no harmonised list of standards for the MDR nor the IVDR. 
The work described in this thesis relates, in part, to the standard BS EN ISO 
13485:2016 – “Medical devices — Quality management systems — Requirements 
for regulatory purposes.”(1). BS EN ISO 13485:2016 is the UK implementation of 
EN ISO 13485:2016. 
The BS EN ISO 13485:2016 standard can be used to show regulatory compliance 
with EU and UK legislation relating to the design and manufacture of medical and 
in vitro diagnostic devices. The standard is also being adopted by other national 
authorities including the USA and Australia(41,42).  
A major difference between the two standards is that BS EN ISO 9001:2015 
requires ‘continual improvement of the quality management system’ while BS EN 
ISO 13485:2016 requires ‘maintaining effectiveness of the quality management 
system’ (43,44,45). Another difference between the two standards is that many of the 
requirements of BS EN ISO 13485:2016 standard are specific to the design and 
manufacture of medical devices. These requirements include the need for a file 
detailing the technical aspects of the device, how the devices are to be 
manufactured, work environment controls, how the device is to be cleaned or 
sterilised prior to shipment, stringent controls on the design, development and 
manufacturing processes and a fully documented process for gathering information 
related to product feedback once devices have been put into use. 
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2.1.6 ISO, EN, BS and Harmonised Standards 
An ISO standard is an internationally agreed standard, EN standards are those ISO 
or, other standardisation body, standards transposed for use within the EU or 
developed by a standardisation institute, nominated by the EU, to meet the needs of 
a specific EU directive or regulation(188). The original standards may have minor 
changes made to them to ensure that they meet EU requirements. These harmonised 
standards will, as required, include information detailing how the standards can be 
used to show conformance to one or more EU directive or regulation. Where 
required a list of harmonised EN standards will normally be published to support 
an EU directive or regulation. BS standards are those translated into English and 
for use within the UK. Thus, the main text, contained in either an EN or BS standard 
will be the same as the original standard. The main difference will normally be the 
inclusion of annexes detailing how the standard can be used to demonstrate 
conformance to EU regulations or directives.  
To meet the requirements of an EU directive or regulation it is necessary to 
implement only those areas of a standard relevant to the device or service being 
designed. If a harmonised standard is available, then, that is the preferred document 
to prove compliance to the requirements of the EU legislation(189). If there are no 
relevant standards, then other documentation may be referenced in showing how 
the device or service meets the requirements of the EU legislation for example 
Common Specifications and Common Technical Specifications(190).  
2.1.7 BS EN ISO 13485:2016 and ‘In-House’ Manufacture  
Devices or items for ‘in-house’ use, under the exemptions given in the UK or EU 
legislation, must still be manufactured under an ‘appropriate’ quality management 
system. This, in my opinion can only be the BS EN ISO 13485:2016 standard due 
to it being the only quality management standard listed in the harmonised standards 
list for IMDD, MDD and IVDD. BS EN ISO 13485:2016 does not fully meet the 
requirements of MDR, or, the IVDR(191,192). It should be noted that relevant parts of 
BS EN ISO 15189:2012 is explicitly stated in the exemptions given in the IVDR 
and the UK legislation. This would the appropriate standard to follow, when 
required, during the ‘in-house’ manufacture of in vitro diagnostic devices. 
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Currently, M&H carry out design and development of medical and in vitro 
diagnostic devices. The M&H QMS has been accredited to BS EN ISO 13485:2016 
standard to ensure the work undertaken to manufacture ‘in-house’ devices meets 
the requirements of current legislation. Additionally, academics or third parties 
working in collaboration with M&H must also adhere to all of the M&H QMS. 
The actions taken to ensure the M&H QMS fully complies with the 2016 revision 
of this standard are detailed in Chapter 3 ‘Update from BS EN ISO 13485:2012 to 
BS EN ISO 13485:2016’. 
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2.2 Medical and In Vitro Diagnostic Device regulation and legislation  
The current EU and UK legislation dates back to the mid-1980s when the concept 
of the single market was introduced and finally resulted in the issue of the Single 
European Act (SEA)(7). This Act sought to reduce the trade barriers between the 
member states of the European Economic Community (EEC) as detailed in the 
White Paper of 14th June 1985 entitled ‘Completing the Internal Market’(6). This 
paper detailed numerous barriers to trade and how their removal would benefit trade 
between member states of the EEC. Medical and in vitro diagnostic devices were 
included in this white paper. The following outlines the history of the medical 
device directives and why these directives became regulations.  
2.2.1 The three directives.  
In the late 1980 three directives were proposed: 
1. The Active Implantable Medical Device Directive - 90/385/EEC of 20 June 
1990(8); 
2. The Medical Device Directive - 93/42/EEC of 14 June 1993(9), and  
3. The In Vitro Diagnostic Device Directive - 98/79/EC of 27 October 
1998(10). 
In comparison to the previous legislation relating to Medical Devices, namely the 
Council Directive 84/539/EEC(48), these three directives increased the controls 
placed on manufacturers and introduced the need to have notified bodies, 
(93/465/EEC)(49), review various aspects of the manufacturers’ work and the 
designed medical device. The standards also required each country’s competent 
authority to be responsible for medical devices in their country. All this was to 
ensure that any device placed on the EU market, conformed to one of these 
directives, would be safe, fit for use, met minimum standards of safety, were 
designed to agreed standards and had been manufactured under a suitable quality 
system. 
The three medical device directives are termed new approach directives. The 
following is a review of the requirements of these new approach directives and the 
controls placed on manufacturers and EU states. 
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2.2.2 EU Legislation Basics. 
In summary, the production of legislation in the EU follows the following steps(50): 
Proposals for legislation normally come from the EU commission, which comprises 
one commissioner from each of the EU countries. These commissioners are 
delegated by each EU member state’s parliament. The proposal may come from 
interested parties within the EU, EU member states or the EU Parliament.  
All proposals are reviewed for their validity by reviewing their economic, social 
and environmental impact to determine their advantages and disadvantages. The 
assessment is carried out with interested parties including industry groups and 
scientific, technical and professional bodies. 
The legislation is drafted(51) and then passed to the EU Parliament and Council for 
scrutiny and discussion. 
If the legislation is approved by both the EU Parliament and the Council, it is given 
assent and enacted. This, in turn, may require EU member states having to draft 
corresponding domestic legislation for their own country’s use. 
If either the EU Parliament or Council require the documentation to be amended, 
or agreement cannot be reached, a secondary group arbitrate between the differing 
views to reach a consensus opinion. The legislation is passed back to the EU 
Parliament and Council for review.  
2.2.3 Layout of EU legislation  
The layout of EU legislation relating to directives and regulations follows the 
guidance given in the ‘Joint Practical Guide of the European Parliament, the 
Council and the Commission for persons involved in the drafting of European 
Union legislation’(51,52). Briefly the layout is as follows: 
1. Title of the Legislation. 
2. If required, a Preamble made up of Citations and Recitals.  
a. Citations define the legal basis of the legislation – primary and secondary 
legislation directly related to the legislation in question. Citations may 
also detail the main steps in the production of the legislation. 
b. Recitals set out reasons for the provisions of the legislation and the 
enacting terms contained in it. 
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3. Articles are the enacting terms of the legislation. Articles may call up specific 
Annexes as required. 
4. Annexes which detail technical requirements or rules to be followed to enable 
the enacting terms to be met.  
2.2.4 History of Medical Device and In Vitro Device Directives  
In 1972 the ‘Proposal for a Council Directive on the approximation of the laws of 
Member States relating to electromedical equipment’(53) was issued. The preamble 
details the need for goods across the common market to be controlled. The proposal 
concludes with the following: 
‘Electromedical devices must be designed and manufactured to a ‘high and clearly-
defined standard of safety’ 
 To maintain the safety of the device, individual states have imposed their own 
‘mandatory specifications relating to the technical safety regulations and the 
inspection procedures’. 
The requirements for the standards to be followed during the development and 
manufacture of device, and the standards themselves, varied from state to state. The 
variations are barriers to trade. If common standards for these devices were adopted 
these trade barriers could be reduced or removed. 
The common standards will be determined by the International Electrotechnical 
Commission. By following these standards, manufacturers could show conformity 
by adding a mark (symbol) to the equipment or via a declaration of conformity 
attached to the equipment. 
The proposal also stated that devices conforming to the proposed directive could 
still cause a hazard to the user or patients. Hence, it recommended that any member 
state, finding such a device, may remove it from the market and they must also 
inform the other members of the community of the reasons for doing so. 
The 11 articles contained in the proposed document establish the basis of the 
modern medical and in vitro device directives and regulations. This document 
defines medical and in vitro diagnostic devices, the use of harmonised standards to 
ensure that these are designed, manufactured or produced to international, rather 
than single country standards, and the need to report medical and in vitro devices 
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found to be unsafe or defective. The proposal also details the need for member states 
to be satisfied that the device meets the requirements.  As previously stated, to 
confirm that this has been achieved, a mark can be added to the device or a 
declaration of conformity issued with the device. 
It should be noted that that there are two unnamed Annexes attached to the proposal. 
The first annex relates only to the proposal for electro medical equipment and 
details a list of devices exempt from the requirements of the proposal. The second 
annex details a template for a certificate and a proposed mark of conformity.  
The proposal was reviewed, as detailed in ‘Opinion on the proposal for a Council 
Directive on the approximation of the laws of the Member States relating to electro-
medical equipment’(56). This document details how the report was submitted to 
various committees for review and comment, along with a report written by 
Rapporteur, Sir John Peel, UK(56), on the proposal. The outcome of the review was 
that various changes were required to be made to the proposals. These changes were 
as follows: 
The devices which were excluded and listed annex 1 above, were there due to a lack 
of technical standards. Many of these exclusion could be removed once harmonised 
standards were issued.  
There was a lack of detail relating to the training of device users and the place of 
use of the equipment required to be addressed. 
Manufacturers should not be allowed to apply to more than one member state to 
have their device approved. In addition, there was a lack of clarity on who should 
authorise the conformity of a device; was it is to be a manufacturer or an ‘approved 
laboratory’. 
The time scales for the introduction of the proposed directive was noted to be rather 
short and should be reviewed in light of the required work to produce the necessary 
harmonised standards, allow manufacturers to test equipment to these new 
standards and for the setting up of appropriate reporting structures.  
The proposed directive was eventually issued, nearly ten years later, as the ‘Council 
Directive 84/539/EEC of 17 September 1984 on the approximation of the laws of 
the Member States relating to electro-medical equipment used in human or 
veterinary medicine’(48). The Directive consisted of nine pages, a preamble, eleven 
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legislative articles and four annexes. The main thrust of the directive was to reduce 
or remove barriers to trade by adopting common standards for equipment safety and 
design. In contrast to the original negative style, the issued directive was written in 
a positive style, detailing inclusions rather than exclusions, stating matters that shall 
be done rather than maters not to be done and allowance for devices not covered by 
written standards. The articles of the directive have been expanded to give greater 
clarity but with no real change to the legal aspects of the directive when compared 
to the original proposal and requested changes. The four annexes associated with 
this directive detailed the technical requirements to be followed, a comprehensive 
list of devices included within the scope of the directive, the layout of the mark of 
conformance and a specimen of the declaration of conformance. 
During the 1990’s, the requirements relating to medical devices contained in 
directive, 84/539/EEC(48), were replaced by Directives 90/385/EEC(8) and 
93/42/EEC(9). 
The proposal(57) for Directive 90/385/EEC on active implantable medical devices 
was issued in December 1989. The directive, ‘The Active Implantable Medical 
Devices Directive, the IMDD, was then issued in June 1990. The reason for the 
introduction of this directive was to address the fact that there were no harmonised 
requirements for Active Implantable devices in the EU and that each member state 
had drawn up their own testing and safety requirements. (The route from the 
proposal to adopted legislation is available by reviewing the procedure tab of the 
proposal document(58).) 
The proposal for amending Directive 84/539/EEC was issued in August 1991(59) 
and its replacement, Council Directive 93/42/EEC(9).was issued in June 1993. This 
directive was commonly known as the Medical Device Directive or MDD. (The 
timeline from proposal to adopted legislation is given in the procedure tab of the 
proposal document(60).)  The new directive was issued to address a number of issues 
arising from the experience gained in the application of the 84/539/EEC directive. 
The final directive was Directive ‘98/79/EC of the European Parliament and of the 
Council of 27 October 1998 on in vitro diagnostic medical devices’, IVDD,(10). This 
directive was officially proposed in 1995(61) and, from proposal to adoption as a full 
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EU directive, took over five years(62). This directive was introduced as there were 
no specific requirements for such devices in the EU.  
In the veterinary field, Directive 84/539/EEC(48) was finally repealed in 2008(63) 
with the publication of a directive specifically for electro-medical equipment used 
in veterinary medicine. 
2.2.5 Overview of the Three Directives – IMDD, MDD and IVDR 
The key changes to the regulations controlling the design and manufacture of 
medical and in vitro devices following the issue of these new directives are: 
2.2.5.1 Implantable medical device directive - 90/385/EEC 
The proposal for, and subsequent issue of, the IMDD directive introduced a 
number of new concepts in EU device regulation. Some of these included: 
a) Separate definitions for medical devices, active implantable electromedical 
devices and permanently implanted devices; 
b) Defined assessment criteria for notified bodies carrying out assessments of 
implantable, medical and in vitro diagnostic devices and their 
manufacturers; 
c) Defined schemes to assess conformity of product design and manufacture 
to the appropriate directive; 
d) Specified essential requirements, for device safety, device design, device 
technical files and the information to be provided to device users; 
e) The concept that any remaining risk must be outweighed by the clinical 
benefit of using the device; 
f) Criteria of how to undertake and report device clinical evaluation; and 
g) Controls for custom made or special devices for clinical investigation. 
The IMDD was enabled into UK law on 1st January 1993 by the ‘1992 No. 3146 
CONSUMER PROTECTION The Active Implantable Medical Devices 
Regulations 1992’(64).  
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2.2.5.2 Medical Device Directive 93/42/EEC. 
The proposal for the 1993 Medical Device Directive(59) was written seven year years 
after the issue of the 1984 Directive 84/539/EEC(48). The proposal reviewed 
experience gained, and problems encountered, with the original directive. The new 
directive maintained the layout and basic requirements of the Implantable Medical 
Device Directive. The proposal for the MDD included findings from a number of 
reviews of the medical device sector and gained opinion from national bodies on 
the effectiveness and implementation of the 1984 Directive(48). These reviews and 
opinions showed that the regulation of medical devices varied between member 
states, the technical harmonisation hoped for had not occurred and the device 
vigilance also varied between countries thus compromising patient safety. To help 
improve this, the following new concepts were introduced in directive 93/42/EEC: 
a) Four risk categories for medical devices. 
b) Definition of in vitro diagnostic device as separate from a medical device. 
c) The amount of intervention by notified and country authorities will depend 
on the risk category of the device. 
d) The proposal allows for combinatorial devices; a medical device which 
incorporates a medicinal product, and gives clear requirements as to how 
medicinal products and medical devices are to be regulated. 
e) Requirements for systems and procedure packs. 
f) Definition of manufacturer and those placing products on the market and 
their role in device safety is defined. 
g) Provisions for devices emitting ionisation radiation are included in the 
93/42/EEC directive. 
h) Definition of the persons responsible for placing devices on the market 
and the need for these persons to be registered with the appropriate 
competent authority. 
Due to these extra controls and requirements the published MDD, 93/42/EEC, is 43 
pages long while the originally published 1984 directive, 84/539/EEC, was only 
nine pages long.  
Page 21 of 513 
 
 
The ‘1994 No. 3017 CONSUMER PROTECTION The Medical Devices 
Regulations 1994 ’(65) passing the MDD in to UK law came fully into force on 1st 
January 1995. 
2.2.5.3 In Vitro Diagnostic Directive 98/79/EC(10), IVDD 
The need for the IVDD directive is detailed in the proposal document of the 
European Parliament and of the Council of 27 October 1998 on in vitro diagnostic 
medical devices’(61). The proposal clearly defines an in vitro diagnostic device as a 
device used ‘outside the human body for medical examinations of samples taken 
from the patient’. The samples may be examined in a laboratory, near or at the 
patient’s bedside or by the patient, as and when required. The findings of the various 
reviews, referenced by the proposal, concluded that member states had introduced 
their own legislation and, in some cases, specific standards to control the design, 
manufacture and conformity testing of specific in vitro diagnostic devices. These 
differences in member states’ legislation and controls was hampering the free 
movement of in vitro diagnostic devices, even if these devices were performing the 
same tests, in the same manner, as others already placed on the market. The 
proposal acknowledges that some in vitro diagnostic devices would be used for self- 
testing and details special requirements to ensure their safe and correct use by those 
with little, or no knowledge, of how the device actually works. All of the 
requirements detailed in the proposal were included in the published Directive.  
The UK legislation, relating to the IVDD, was ‘2000 No. 1315 CONSUMER 
PROTECTION The In Vitro Diagnostic Medical’(66).  
The three directives were not without their problems and all three were reviewed, 
repealed and replaced by two regulations – the Medical Device Regulations, MDR,  
(EU) 2017/745 (2), which combined and replaced both the IMDD and the MDD and 
the In vitro Diagnostic Device Regulations, IVDR (EU) 2017/746(3) which had 
replaced the IVDD. Chapter 4 'EU and UK Medical and In Vitro Diagnostic Device 
Legislation’ details’ the main differences between the old directives and the new 
regulations. The main point to note is that unlike directives EU member states must 
enact the regulations with no interpretation. 
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2.2.6 ‘In-House’ manufacture and control 
Previous to the publication of the IMDD and MDD, health care institutions were 
able to carry out ‘in-house’ manufacture or modify existing medical devices, active 
implantable devices or in vitro diagnostic devices to ensure effective patient care 
and allow medical, clinical and laboratory staff to undertake their duties 
appropriately without restrictions. Examples of this include adapting medical 
devices to match patient anatomy, manufacturing an IVDD reagent to enable a 
specific test or producing a specialist surgical tool. 
Neither the IMDD nor the MDD had an exemption to allow ‘in-house’ manufacture, 
and once these directives were enacted into UK law(64,65), no ‘in-house’ 
manufacture was allowed within health care institutions. This problem was 
circumvented by the Bulletin 18A 1996 issued by the UK Medical Device Agency, 
now part of The Medicines and Healthcare products Regulatory Agency, (MHRA). 
This bulletin, which became EU guidance, detailed the view that devices made 
solely for use within a single legal entity were not placed on the market and hence 
did not come under the remit of the MDD. The Bulletin informed that the guidance 
would also apply to the IMDD. The current revision of this bulletin is given in the 
MHRA Guidance ‘In-House’ manufacture of medical devices’(179). 
Bulletin 18A suggests that healthcare institutions may not need to follow any of the 
guidance detailed in the IMDD or the MDD . This is not the case in the UK and 
other countries, as the legislation, enacting these directives, was enabled within 
legislation protecting the rights and safety of the general public. In the UK this 
legislation is within the general scope of the Consumer Protection Act. This 
legislation does not differentiate between health care institutions or general 
industry. Hence, most health institutions deemed it wise to follow the requirements 
of the directives when undertaking ‘in-house’ design and manufacture. Within NHS 
Tayside, the ‘in-house’ design and manufacture of medical and in vitro diagnostic 
devices follows the essential safety requirements and conditions/standards relating 
to device design and construction. A quality assurance system accreditation to BS 
EN 46001:1997(67) and subsequently BS EN ISO 13485:2001(68) with regular visits 
by external auditors who review our quality assurance system, samples of our 
designs and methods of manufacturing and, on occasion, visit  the users of 
manufactured equipment. The quality system also requires the retention of design 
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and manufacturing data/documentation for a minimum of five years plus the 
lifetime of the device after the manufacture of the last such device. 
It should be noted that any devices manufactured for third parties, including other 
health care institutions, must comply with the full requirements of the relevant 
directives or legislation, the device must be CE marked and accompanied by a 
certificate of conformance.  
After much lobbying by interested individuals, an exemption to enable ‘in-house’ 
manufacture of devices was added to the IVDD (‘Scope of the Regulations para 3 
(1) of the UK legislation(66)) prior to its issue. 
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2.3 Optical Coherence Tomography coupled with Vibrational 
Elastography 
The University of Dundee’s School of Science and Engineering, requested that the 
Medical Physics Department, NHS Tayside, work in conjunction with the 
University of Dundee to review the Optical Coherence Elastography Research 
scanning system for compliance to medical and in vitro diagnostic device 
legislation, to enable it to be used in a clinical area of Ninewells Hospital, Dundee, 
UK. A review of the documentation for this project will be used to fulfil one of the 
objectives of this thesis, to determine the type of guidance to be given to academics 
and third parties, to ensure medical and in vitro diagnostic devices, designed and 
manufactured, would meet UK legislation. 
2.3.1 Background  
Patients are often required to attend for minor surgery to obtain biopsy samples to 
determine if an area of clinical interest requires to be further investigated or 
removed due to an underlying condition or disease. This area of interest may have 
been highlighted through visual examination or via a medical imaging technique 
such as Magnetic Resonance Imaging, (MRI), Ultrasound scanning or Nuclear 
Medicine Imaging. These imaging techniques can highlight areas of interest but do 
not normally give a definitive outcome as to what the area of interest might be, for 
example does the image show a benign cyst, a malignant tumour or just a thickening 
of the tissue or muscle in the area of interest. 
When such an area of interest is found it is common practice for a biopsy sample to 
be taken. These biopsy samples may be taken with, or without, the use of pain 
management. They may also be taken using local or general anaesthetic. The 
samples are sent for specialist laboratory testing and reviewed by a consultant in 
the field. The NHS Tayside Pathology User Handbook(69) details the type of work 
such a laboratory undertakes and also gives testing and review turnaround times for 
biopsy samples as between two and nine days, depending on the urgency and 
sample type.  
Reducing this sample testing and review turnaround time would be of great benefit 
to both the patient and clinical/medical staff. A reduction in turnaround times may, 
potentially, allow clinical/medical staff to inform the patient as to the clinical 
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significance of the biopsy, prior to leaving the hospital. If the biopsy is negative, 
then being able to inform the patient of this fact, within hours instead of days, would 
reduce anxiety and stress to the patient. If the area of interest is clinically significant, 
it enables the clinical/medical staff to discuss the results of the biopsy with the 
patient, review possible treatment scenarios and, if prior consent from the patient 
has been given, begin treatment prior to the patient leaving the hospital i.e. excise 
the area of interest, commence chemical or drug treatment to the area of interest or 
commence any other appropriate course of action. 
2.3.2 Optical Coherence Elastography, OCE, – Clinical Need 
Devices to speed up the review of such areas of interest whether a biopsy is taken 
or the area reviewed in vivo would be of great clinical benefit. One such device 
being developed by the University of Dundee, consists of an optical coherence 
tomography ‘camera’ coupled to a vibrational elastography system to analyse 
biopsy samples. The coupling of these two modes/devices allows the microscopic 
structure of the sample to be viewed and will determine the physical properties of 
the sample. This will allow the clinical staff a ‘real time’ assessment of the biopsy 
sample. Any areas displaying a stiffer structure will normally denote a probable 
cancerous growth.   
2.3.3 Overview of Optical Coherence Elastography, OCE 
The OCE system is an Optical Coherence Tomography scanner coupled with a 
sample vibration system to enable the elasticity of the sample to be determined.  
2.3.3.1 Overview of Optical Coherence Tomography, OCT 
Optical Coherence Tomography (OCT), of a tissue sample is basically using the 
properties of a beam of light reflected from the internal structure of the sample to 
produce depth and intensity information at the point being scanned. If the beam of 
light is moved in one dimension over a tissue sample information is obtained of the 
underlying structure of a slice of the tissue. If multiple slices are then scanned, 
sequentially, over the whole tissue sample, it is possible to view this as a 3-
dimensional (3D) reconstruction of the internal structure of the tissue sample, for 
example, the retina(75). OCT can produce images to a depth of 2-3mm in tissue with 
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a resolution of 10-30µm. See Figure 2.1(76) for a comparison of various imaging 
modalities, their range of resolution and penetration depth.  
 
 
 
Figure 2.1 Comparison of various medical imaging modalities in terms of 
resolution and penetration depth(76) 
 
The basic OCT relies on the interference of light. If a beam of light is taken and 
split into two and the two beams are then recombined, the two beams can be 
recombined to constructively interfere (add together) or destructively interfere 
(subtract from each other). This is similar to waves rippling in a pool of water, 
sometimes they cancel each other out, and at other times they join to make bigger 
waves. If the effect on the recombination of the two beams of light can be measured 
to show how they interact then their interference can be measured. A simple 
interferometer system is given in Figure 2.2(77). 
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Figure 2.2 Basic Michelson laser interferometer(77). 
 
In the system shown in Figure 2.2, the laser beam is split into two. The split beams 
then travel to two different mirrors and are recombined and passed to the detector. 
The output from the detector is dependent on the optical path length taken by each 
split beam. In the gravitational wave detection system(77) the two beams of light 
recombine to cancel each other out when the system is in a state of equilibrium – 
no gravitational wave is passing through the system. If a change in length in either 
arm occurs, due to a gravitational wave, the two beams of light become misaligned 
and the signal at the detector is no longer zero. The change in the detector signal 
will depend on the change in length of the arms. If one of the arms had a tissue 
sample and the sample was scanned the change in the signal would denote the depth 
from where the light had been scattered back. 
Depending on the type of OCT system 3D images can be captured in real time and 
at a high scan rate. One method of particular interest is Phase Sensitive OCT using 
a spectrometer to simultaneously capture multiple wavelengths of light reflected 
from the sample. The outline schematic of such a system is shown in   Figure 2.3(78).  
 
Optical output 
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Figure 2.3 Outline schematic of Phase Sensitive OCT(78) 
 
The light source in this OCT system is a broad band super luminescent diode (SLD) 
so this system uses multiple wave lengths of light. The output from the SLD is split 
into two beams, one is a reference beam the other is the scanning beam. The 
scanning of a sample is carried out using a scanning galvanometer system. This 
type of system enables high speed, high precision scanning of a given sample. The 
light from the reference and scanning beams are recombined and passed to the 
optical detector. The optical detector in this case is a type of spectroradiometer. 
This type of spectroradiometer splits the light into known wavelengths and 
measures the amplitude of each wavelength simultaneously rather than stepping 
through each wavelength in turn. This speeds up the scanning of a tissue sample. A 
computer system then gathers and processes the captured optical and positional date 
(from the scanning galvanometer) and produces a 3D reconstruction of the 
sample(75, 78, 79).  
The problem with many imaging techniques, including OCT imaging techniques, 
is that they cannot give any information as to the texture of the sample. 
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2.3.4 Overview of Elastography 
When looking at an area of interest, clinical staff may touch or palpate the area to 
feel for any abnormalities in the area – is the area softer, harder, does it feel different 
from the surrounding tissue or organ mass. Normally the area of interest is gently 
squeezed to determine how it feels in comparison to the remaining tissue or organ. 
By palpating the area of interest, the specialist is essentially determining the 
physical properties of the organ. By passing pulses though a material, the movement 
of the internal structures, due to the vibration of these pulses, will be dependent on 
their stiffness and density. The pulses may be transmitted in many ways, for 
example mechanical, ultrasound, laser or even a puff of air. The movement of the 
internal structures due to these pulses or vibrations can be detected using for 
example magnetic resonance imaging, ultrasound imaging or optical coherence 
tomography. The energy imparted by the pulses or the vibrations must be such that 
the movement of the internal structure is within its normal working limits – the 
sample should not be damaged due to violent shaking. The duration and speed of 
the pulses or vibrations is such that the imaging system can see the full range of 
movement of the internal sample caused by each pulse or vibration. The imaging 
system must also be able to view the sample to a sufficient depth to be clinically 
effective. The imaging of tissue stiffness in this manner is known as Elastography. 
There are a number of wave motions/movements which can be generated within a 
solid and then analysed to determine the elastic properties of the solid’s internal 
structure(79,80,81). One of the simplest Elastography methods is the compression 
method where the sample is either compressed or, for small samples, vibrated on a 
plate. The deformation of the sample is small to ensure the mechanical properties 
of the sample are maintained. The change in internal structure gives an indication 
of the relative stiffness or density of the sample. This information can be used to 
indicate the histology of the sample. 
  
Page 30 of 513 
 
 
2.3.5 Optical Coherence Elastography - OCE 
To enable the internal structure to be viewed,  Optical Coherence Tomography can 
be used to scan the internal structures of a sample tissue as it is being vibrated to 
determine its structure, how it reacts to the vibration and hence the elasticity across 
the sample’s volume. – The structure of the sample can be viewed and an indication 
of the sample’s internal stiffness and variation in structural densities can be 
indicated. This technique is known as Optical Coherence Elastography.  
2.3.6 Optical Coherence Elastography commercial devices  
From a review of OCE systems on the market, it was found that that use of 
elastography based ultrasound imaging systems to view and analyse the scanned 
structure, dominate the market(83,84). The main areas where examination by 
Elastography is used are the breast, liver, thyroid, kidney, and lymph nodes.  
The two areas where the technique is currently best suited to detect anomalies are 
the breast and liver areas. The UK National Institute for Health Care Excellence has 
recommended using elastography as an adjunct to diagnosing breast cancer or liver 
disease.  
Other areas whereby these devices are being used for detection are in the research 
relating to   the review of testicular cancer(70) , tendon injuries (71) and 
dermatological lesions(74). Commercial devices have also been developed and 
placed on the market. For example, the Esaote ‘ElaXto: Real-time 
Elastosonography’(73)  can be used to highlight  the areas of interest but cannot be 
used to confirm exactly  what the nature of the area of interest may actually be(72).  
On reviewing the market for elastography devices, using optical coherence 
tomography as the imaging modality, it transpires that such devices are mainly used 
in imaging of the eye and, in particular, the retina(85). For imaging and diagnosis of 
biopsy samples, there are many research projects, but no actual commercial devices 
could be identified by the author during the time of this thesis.  
Hence, further development of the University of Dundee OCE system, if successful, 
could be used as a diagnostic tool which, in turn, would speed up the sample 
analysis procedure, reduce the time to commence treatment and reduce the cost to 
carry out the analysis.  
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2.3.7 Clinical trials and testing of the University of Dundee OCE system.  
A clinical trial, ethically approved (ref 2013ON47) comparing the histology of 
patient biopsy samples was conducted at Ninewells Hospital between April 2014 
and December 2015. The trial required the biopsy samples to be taken to the 
laboratory for scanning on the OCE system and then returned to the urology 
operating area. The samples were then passed to pathology for review and 
reporting. This comparison showed that the results from OCE system were on a par 
with those obtained from the pathology laboratory(79,170). 
The next phase of the development of the OCE system is to verify the results of the 
first trial by scanning a significantly larger number of samples to confirm the results 
of the initial findings. This second trial (IRAS project ID: 271421) will commence 
once the COVID-19 situation allows. 
To allow such a large number of samples to be scanned, the OCE system will need 
to be placed within close proximity to the urology theatre area. The work 
undertaken to review the OCE system to ensure that it was safe and fit for use within 
the Ninewells Hospital urology theatre, and thus, allow this trial to be undertaken, 
is detailed in Chapter 5 'Case study’. 
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 UPDATE FROM BS EN ISO 13485:2012 TO BS EN ISO 
13485:2016 
This chapter is an overview of the work carried out to align the M&H quality system 
to the requirements of BS EN ISO 13485:2016. This chapter contains the following 
sections. 
1. A brief overview of the changes between the BS EN ISO 13485:2012(12) and 
BS EN ISO 13485:2016. 
2. An overview of the M&H quality system 
3. The work done with BSI to gain accreditation to the new standard 
4. Further review of the M&H quality system against the BS EN ISO 
13485:2016 standard. 
5. The changes required to bring the M&H quality system in line with the new 
device regulations. 
3.1 A brief overview of the changes between the 2003 and 2016 revisions of 
the BS EN ISO 13485 standards 
It is accepted to be good practice to ensure that the international standards are 
reviewed to ensure they are still relevant and are kept up to date with current 
practice, by reviewing them every five years, or more often, if required(86). This five 
year review interval should be maintained even if only to determine that the 
standard does not require amendment or revision. A revision period of over five 
years is deemed unacceptable and, normally occurs, if there are major concerns with 
the standard under review(86).  
The review of the 2003 issue of the 13485 standard started in 2012(87), a gap of 
nearly nine years. The revised standard publication was delayed due to various 
problems including the provisions for the MDR and IVDR and the nonalignment to 
the standard layout used, for example in the layout used in the ISO 9001:2015 
standard(87,88). This delay resulted in the final publication of the revised standard 
taking place in 2016, a review process of nearly thirteen years. 
The review, and final amendment, of the standard had to take into account changes 
in technology, global regulatory requirements, the evolution and introduction of 
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new management systems e.g. risk management, tighter control of resource 
management and the selection and work of subcontractors is now brought fully 
under the umbrella of the contracting organisation and their management is now 
based on the risk posed to the contracting organisation and the device to be 
produced. 
Quality management systems have evolved from basic lists of actions, to looking at 
the complete management system as a set of interrelated processes and how the risk, 
associated with each process, affects the complete QMS. So, the new standard also 
had to embrace the process approach used in many other management standards, 
including ISO 9001:2015. All the management activities are treated as processes, 
and these processes, are interrelated. Each aspect of the management system will 
have defined inputs and outputs, and these have a related risk, which must be 
reviewed and reduced. This was a new concept for the BS EN ISO 13485:2016, but 
that risk is not confined only to the device but relates to all the processes in the 
management system. 
In addition, the new revision of the standard had to align with the global regulatory 
requirements of many countries including Brazil, USA and Japan to name just a 
few. 
The standard also introduced the need for the validation of the software used in all 
aspects of the organisation affecting the QMS, and not just with any software 
associated with the device or product. This need for software validation is in line 
with other standards, for example BS EN ISO 17025:2017(181) and BS EN ISO 
15189:2012(11). Other areas of note are: a new section detailing the manufacturing 
documentation to be produced; the stricter controls over external suppliers, 
especially subcontractors; and a greater emphasis on the analysis of the data 
gathered, during the development of the product and the feedback, once the product 
is in use. The 13485:2016 standard requires that the implemented quality 
management system can meet both the customers’ needs, the applicable regulatory 
requirements, and that the responsibility and the authority of the staff, is reviewed 
and documented(87,90,91,92,93,94). 
There are a large number of documents detailing the differences between the 2003 
and 2016 revisions of the 13485 standard. The documents range from an almost line 
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by line analysis to those giving a brief overview of the changes. Examples of such 
documents are given in the references 95, 96, 97, 98 of this thesis and the templates 
are available in Appendix C3.a1 and Appendix C3.a2. 
It has already been noted that there was an update to BS EN ISO 13485:2003(99) 
released in 2012. This revision is not taken as a global revision of the 13485 
standard, but as a European revision(100, 101) of the standard, as detailed in the first 
paragraph of the forward to the 2012 revision of the standard. This revision adds 
details on the links between the standard and the three EU medical device directives. 
These links are fully detailed in annex ZA to ZC of the BS EN ISO 13485:2012 
standard. The main body and content of the standard remained unchanged. 
3.2 Overview of the M&H Quality Management System(102) 
The principal document of the M&H quality system is the M&H Quality Manual. 
This document details the scope and work of M&H, how M&H controls and 
manages the work to meet the requirements of these standards. The documentation 
hierarchy of the M&H quality system is as follows: The M&H Quality manual; 
M&H quality procedures; protocols, standard operating procedures and work 
instructions.  
Documented quality procedures outline the general tasks and processes related to 
all areas within the M&H’s quality system. These include documentation control, 
product realisation, internal auditing, purchasing and the disposal of materials and 
items no longer required.  
Specific tasks are detailed in the documentation known as Work Instructions (WI), 
Standard Operating Procedures (SOP) and Protocols. Examples of these are: WIs 
detailing specific equipment repair or testing, SOPs relating to the manufacture of 
reagents and protocols for patient testing.  
The M&H quality system must be reviewed, to assess, how changes to relevant 
legislation, professional body guidance or quality standards affect the quality 
system and the work undertaken under the QMS.  
External assessment of the M&H quality system against the 13485 standards is 
undertaken by BSI auditors. After initial accreditation to the 13485 standard, BSI 
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auditors review the quality system over a three-year period, with recertification 
granted after completion of a successful audit in the third year. 
The most recent changes in legislation and the 13485 standard resulted in many 
change to the M&H QMS. The changes relating to the issue of the BS EN ISO 
13485:2016 are fully detailed in the remaining sections of this chapter. Those 
relating to changes in legislation are detailed in Chapter 4 'EU and UK Medical and 
In Vitro Diagnostic Device Legislation’ of this thesis. 
3.3 Importance of Accreditation to the new standard 
The work undertaken within M&H relies on accreditation to the appropriate quality 
standards. The HMFUS group requires accreditation to the 13485 standard to 
supply CE marked in vitro diagnostic devices to hospitals out with NHS Tayside. 
Both Clinical Engineering and Photobiology manufacture devices for ‘in-house’ 
use require accreditation to ensure these devices meet the exemption requirements 
of the new UK legislation. All certificates to the BS EN ISO 
13485:2003/13485:2012 edition of the standard expired on 28 February 
2019(182,183). This date was the end of three-year transition period allowed for 
companies to become accredited to the new 2016 revision of the 13485 standard. 
Therefore, without accreditation to BS EN ISO 13485:2016, HMFUS would not be 
able to supply their in vitro diagnostic device after this date, and all ‘in-house’ 
manufacture and associated research, design and development projects could be 
stopped. Hence, the need to obtain accreditation to BS EN ISO 13485:2016 was 
vitally important. 
3.4 Work to review and update the M&H quality system to meet the 
requirements of BS EN ISO 13485:2016 standard. 
During 2015 and early 2016, various discussions regarding how to manage the 
transition of the accreditation of the M&H quality system from the BS EN ISO 
13485:2012 revision to the BS EN ISO 13485:2016 revision were held with the  
accreditation body, British Standards  Institution, (BSI)(103) and the M&H quality 
team. The main point arising from these discussions was the transition to the new 
standard had to be completed, and the M&H quality system reaccredited, by 
February 2019. Various factors were noted including BSI being short staffed, and 
the need for them to possibly change auditors and audit dates to ensure that 
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reaccreditation was achieved by February 2019. In addition, changes to medical and 
in vitro diagnostic device legislation were being introduced, coupled with the fact 
that the UK was possibly leaving the EU, and the unknown ramifications this would 
have on the legislation. (The reality is that the UK has now left the EU but the 
ramifications to the medical and in vitro diagnostic device legislation are in some 
ways still unknown.) 
At the end of these discussions, it was agreed that, over a period of 24 months, the 
M&H quality team would carry out a review of the M&H QA manual and 
documentation against the requirements of the new standard, using the comparison 
table given in the BS EN ISO 13485:2016 standard, while at the same time, 
completing the BSI ISO 13485:2016 Readiness Review(104). The M&H quality team 
would also carry out a review of the new legislation relating to medical devices (as 
discussed in Chapter 4 'EU and UK Medical and In Vitro Diagnostic Device 
Legislation’). Once these reviews were completed, the M&H team would amend 
the documentation or produce new documentation, as required. The work was to be 
completed by the end of 2018 so as to allow BSI to carry out a recertification audit 
between late 2018 and early 2019. 
BSI, on their part, would assist in this process by working with M&H to complete 
the BSI ISO 13485:2016 Readiness Review. From the results of this review, BSI 
auditors would amend the audit plans for the next two years, to enable the changes 
to the current system to be reviewed, in a systematic manner, to determine how well 
the changes met the requirements of the new standard. After each audit, any audit 
findings relating to the changed, or new documentation, were to be discussed by the 
BSI auditor and M&H QA staff to ensure the amendments required were fully 
understood and the documents were corrected to fully meet the requirements of the 
standard.  
By working in this manner, the M&H quality system should have been able to be 
reaccredited to the new BS EN ISO 13485:2016 revision by the end of 2018 or 
early 2019. 
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3.5 Comparison against 13485 Standard 
Table A.1 given in BS EN ISO 12485:2016(1) is a comparison of content between 
the ISO 13485:2003 and ISO 13485:2016 standards. (Remembering that the 
content and body of BS EN ISO 13485:2012 is the same as the 2003 revision.) 
This comparison details the major differences between the old and new standards. 
This comparison, in conjunction with the BSI readiness review, was thought to be 
sufficient to highlight the required changes to be made to enable accreditation to 
the new 2016 revision of the standard. 
 
3.6 BSI ISO 13485:2016 Readiness Review 
The BSI ISO 13485:2016 Readiness Review, was introduced by BSI to assist 
organisations in determining how much work they would need to undertake to bring 
their current 13485:2003 compliant QA systems into line with the new 13485:2016 
standard. The Readiness Review was a summary of the changes to the new standard 
that BSI thought were the most significant. BSI determined that their clients, who 
were transitioning to the new standard, should review their quality system against 
the clauses highlighted in the reviews to ensure a smooth transition to the new issue 
of the standard. As each section of the Readiness Review was completed, 
amendments, as required to their current quality system to meet the requirements 
of the new standard, were to be carried out. Once completed, this review was to be 
submitted to BSI for review and comment. Further scrutiny of this document would 
form the basis for the various audits leading up to the full re accreditation audit at 
the end of 2018. 
It should be noted that the Readiness Review was compiled by BSI, solely to 
address the changes to BS EN ISO 13495:2016, it did not take into account the 
requirements of any EU or UK medical or in vitro diagnostic device legislation.  
3.6.1 Comparison Check and BSI Readiness Review - Result 
The completed BSI Readiness Review is given in appendix C3-a3 the A summary 
of the Readiness Review is given in Table 3.1 below. The completed review 
indicated that M&H either had many of the required elements in place, or that some 
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documentation required minor amendment to meet the requirements of the updated 
standard.  
From the completed review, it was determined that an update to M&H Quality 
Manual issue 8(108) was necessary, and a number of quality procedures would be 
need to be reviewed and amended, as detailed in Table 3.2 Quality Procedures to 
be Updated. With these documentation changes implemented, it was envisaged by 
both BSI and the M&H quality team, that the reaccreditation would be obtained 
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Table 3.1 Summary of completed BSI 13485 Readiness. 
13485 Clause Documentation which requiring to be amended.  
Quality Management System 
Clause 4.1 – General requirements 
Role: section 1 (pg 3) QM 
Regulatory / Risk: 2.2.3, 4.2.1, 5.1, 5.3, 5.5.1, 5.6.2, 6.2.2, 7.1, 7.3.2, 7.5.1 – QM 
Outsourced: 7.3, 7.5.1 - QM 
Management: 5.4, 5.6.2, 7.3.7, 7.5, 8.3 - QM 
Validation: Work Instructions, WI or Standard Operating Procedures SOP required to detail 
this work. 
Quality Management System 
Clause 4.2 – Documentation requirements 
Device File: 7.3 – QM, Updates to  QP.02 & associated R&D Work Instructions, ‘WI' 
Documentation: 4.2 – QM Updates to  QP.01, QP.24 & associated WI, SOPs, etc.  
Management Responsibility 
Review all clauses 
Device File: 7.3, & QP.02 & associated WI's 
Documentation: 4.2 – QM. And updates to QP.01, QP.24 & associated WI 
Resource Management 
Clause 6.2 – Human resources 
Human Resources including training & competence: 6.2 - QM & update to QP.27 
Resource Management  
Clause 6.3 – Infrastructure 
Infrastructure: 6.3 – QM only 
Resource Management  
Clause 6.4 – Work environment 
Work Environment: 6.4 – QM & QP.30 – both to be reviewed to determine if they need to 
be updated. 
Contamination: 6.4.1 – QM Review 
Product Realization 
Clause 7.1 – Planning of product realization 
Risk Management: 7.1, 7.3 – QM  
Storage etc: 7.5 – QM. QP.30, 03, 04, 02 review to determine if update required 
Product Realization 
Clause 7.2 – Customer related processes 
Training: 7.2 – QM  & QP.27 
Communication: 7.2 – QM & QP.02 
Product Realization 
Clause 7.3 – Design and development 
Design & Development: 7.3 – QM QP.02 & associated WI's 
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Product Realization 
Clause 7.4 – Purchasing7.4 
Purchasing: 7.4 - QM & QP.05 
Product Realization 
Clause 7.5 – Production and service provision 
Service Provision: 7.5 – QM 
Measurement, analysis and improvement 
Clause 8.2 – Monitoring and measuring 
Monitoring & Measuring: 8.2 – QM.  QP.35, QP.29 & QP.26 
Measurement, analysis and improvement 
Clause 8.3 – Control of non-conforming product 
Non-conforming products: 8.3 – QM. QP.20 
Measurement, analysis and improvement 
Clause 8.4 – Analysis of data 
Data: 8.4 – QM 
Measurement, analysis and improvement 
Clause 8.5 – Improvement 
Improvement: 8.5 – QM. QP.20 
  
Page 41 of 513 
 
 
 
Table 3.2 Quality Procedures to be Updated 
Doc No. Document name. 
QP01 Control of Documentation and Data  
QP 02 Project Control 
QP03 Requirements For Medical Physics Clinical Engineering Services 
QP05 Ordering, Receiving and Traceability of Goods and Services  
QP20 Reporting and Review of Incidents and Near Misses  
QP24 Control of Records 
QP26  Customer Feedback  
QP27 Competence, Awareness and Training  
QP29 Internal Audit 
QP30 Handling and storage  
QP35 Active Recall Procedure  
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3.7 Audits Undertaken by BSI and Findings. 
The following is a summary of the audits carried out by BSI between June 2016 
and October 2018 and the work resulting from these audits carried out. 
The reports for the BSI audit mentioned in this section of this chapter can be found 
via reference (102). 
3.7.1 Audit June 2016 
During the June 2016 BSI audit, the introduction and implementation of the revised 
standard was discussed. It was emphasised that M&H would be required to 
complete the transition to the new 13485 standard by February 2019. The plan 
proposed by BSI was to continue the cycle of biannual visits, with additional time 
to review the work undertaken to amend the M&H QMS and assess if these changes 
met the requirements of the new 13485 standard. Areas identified as ‘not compliant’ 
were not documented as an audit non-conformance, as they were outside the scope 
of the 13485:2003/2012 quality system. These areas of non-conformance were 
documented as improvement opportunities, and any work undertaken to correct 
these findings was to be reviewed at the next external audit. 
3.7.2 Audit November 2016 
The November 2016 audit started to look at the transition to 13485:2016. However, 
it was also an audit of familiarisation for our BSI auditor who had just been assigned 
to undertake our audits. The audit highlighted a serious problem with the clinical 
engineering service process and gaps in the quality system in relation to the new 
13485:2016 standard.  
These gaps identified that the quality manual did not include  reviews of process 
performance, that product conformity reviews had not be undertaken, that the 
planned audit schedule was not followed and that changes to the audit schedule 
were  not fully documented. 
3.7.3 Audit February 2017  
The focus of the February 2017 audit was a review of the M&H quality system 
against the 9001:2015 standard to determine if the transition to this revised standard 
could be granted. This accreditation was successful. During this audit, it was 
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determined that a half day from the following audit would be used to check and 
complete the readiness review check list and to discuss of the remaining work 
required to complete the transition. 
3.7.4 Audit May 2017 
During the May 2017 audit no specific area relating to the 13485:2016 standard was 
reviewed. The readiness review was completed but not reviewed.  
3.7.5 Audit November 2017 
During the November 2017 audit, the following areas of the M&H quality system 
were found to be non-compliant against the 13485:2016 standard: 
• The quality manual did not detail the areas of the 13485:2016 standard 
which were not applicable to this quality system. 
• There was no evidence of software validation nor any documentation to 
control this validation. 
• Feedback had been collected, but not annually, as detailed in the controlling 
work instruction. 
• The training received was not reviewed for its effectiveness. 
• The temperature of the HMFUS working laboratory was not effectively 
controlled as the monitoring thermometer was not calibrated. 
• The transportation temperature requirements of CE marked products was 
not defined. 
3.7.6 Audit July 2018 
The July 2018 audit highlighted the following areas that were not compliant with 
the standard: 
• The preventative and corrective action process was not fully implemented. 
• The validation and control of software used by M&H was not fully 
controlled nor validated prior to use. 
• The documentation and process relating to corrective and preventative 
action required to be fully reviewed.  
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3.7.7 Audit October 2018  
The October 2018 audit was a recertification audit to review the compliance of the 
M&H QMS to 13485:2016 standard. This audit found that the M&H QMS was 
compliant to the standard and, as detailed in the report for this audit, the 
requirements had been effectively implemented and recertification to the new 
revision of the standard was granted. 
Following on from this audit, certification was granted to M&H; certificate FM 
77843 against the BS EN ISO 13485:2016 standard. 
A number of minor problems were found, these included: a document issued with 
undeleted draft comments, a lack of knowledge in the use of a/the new equipment 
asset management system resulting in the planned preventative maintenance 
(PPM), service and repair scheduling to be adhoc and not fully controlled, an item 
of safety testing equipment lacked a calibration certificate at the time of the audit 
and poor control of storage highlighted the need to ensure that items in storage for 
repair or awaiting delivery were correctly segregated. 
3.8 Further review of the M&H quality system against the 13485:2016 
standard. 
3.8.1 Post Accreditation Audits - 2019 
BSI carried out two audits in May and November 2019. The findings of these audits 
prompted the M&H QA team to carry out another, in depth, review of the M&H 
quality system against the 13485:2016 standard. The following is a summary of 
these two audits. 
3.8.1.1 May 2019 Audit 
This audit, which was the first after the recertification audit, reviewed the M&H 
quality system against the full requirements of the 13485:2016 standard. During 
this audit, three minor non-conformities were found. One of, these relating to the 
procedure controlling design and development, found that this procedure was not 
fully effective as manufacturing requirements had been detailed. 
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3.8.1.2 November 2019 audit 
This audit reviewed the technical file for a CE marked reagent manufactured by the 
HMFUS Department, and also, an ‘in-house’ design project undertaken within the 
Medical Physics Department. 
The audit highlighted a number of areas of concern: 
• Data analysis requirements were not fully document. 
• Auditing reports lacked relevant details. 
• Procedures relating to Complaint Management, Vigilance and 
Recall/Returns did not include explicit requirements to determine 
problems with manufactured devices.  
• Reporting/analysis of ‘in-house’ design was not covered in the vigilance 
reporting procedure. 
• The effectiveness of corrective or preventative action was not detailed as 
required. 
• Planning procedures were not fully effective. 
• Evaluation of purchased parts was not compliant. 
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3.9 Second review of M&H Quality system against the BS EN ISO 
13485:2016 
3.9.1 Rational for second review  
As seen in the previous sections, there were numerous problems with the 
compliance of the M&H quality system against the BS EN ISO 13485:2016 
standard as highlighted in the audits carried out in May and November 2019. The 
problems all related to areas of the M&H system which had been thought to be 
compliant with the standard and had previously been audited successfully. If these 
and any other areas of non-compliance, were not correctly addressed, a major non-
conformity would have been raised against the M&H quality system with the real 
possibility of the accreditation to the BS EN ISO 13485:2016 standard being 
suspended, or even, removed. Thus, the decision of the M&H team to carry out a 
full review of the M&H quality system against the requirements of the BS EN ISO 
13485:2016 was seen as necessary and justified. 
3.9.2 Result of the second review 
It was determined that the second review of the system against the standard would 
be a line by line review of the standard against the M&H quality manual. This 
review is documented in appendix C3.a4 ‘Full review of the present management 
system against the 13485:2016 standard. (QM issue 10)’. 
This second review had highlighted gaps in the M&H quality system to meet the 
requirements of the 13485:2016 standard. 
The documentation to meet the requirements of the design and development clause 
was lacking, especially the documentation relating to the transfer of the final design 
to the manufacturing phase. Additionally, there was the need to have separate 
documentation to control ‘in-house’ manufacture and manufacture of devices made 
for commercial use. 
Post-production and post-market feedback controls did not comply with the 
requirements of the standard. The procedures at the time only covered ‘CE marked’ 
devices manufactured by M&H. The controls should have encompassed all devices 
even those not CE marked. 
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The standard requires data relating to specific areas of work to be analysed, the 
analysis does not have to be complex. The controls for the analysis of data were not 
present in the QA system.  
The need to meet regulatory and statutory requirements is not mentioned in the 
M&H quality manual. 
Two requirements of the standard partially covered by the M&H quality system 
were: 
1. the control and monitoring of external contractors to ensure they are fully 
controlled and evaluated and  
4. the inspection of purchased items and services, especially critical items or 
services, was not correctly documented or recorded. 
The second review also highlighted, that by having a standalone technical 
procedure for medical and in vitro diagnostic device design and manufacture would 
make the control of such work simpler to understand and control. 
In a similar manner, it was seen that a separate technical procedure detailing the 
work required related to ‘in-house’ manufactured or modified medical and in vitro 
diagnostic would ensure compliance with the exemption requirements. 
There are a number of documents within the M&H quality system used to control 
and review the design and manufacture of medical and in vitro diagnostic devices. 
These documents were reviewed to determine if they were still fit for purpose and 
if new documentation was needed to ensure the M&H quality system meets the 
required standards and legislations.  
Table 3.3 is a list of the pre-existing documentation to be reviewed. 
From the review of these documents it was determined that significant amendments 
were required. 
Table 3.4 is a list of the new documentation to be produced to address the 
requirements of the medical and in vitro device regulations. 
Appendix C3.a5 is a summary of the required changes to issue 10 of the M&H 
quality manual  
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Table 3.3 Pre-existing documentation to be reviewed 
WI Reference WI Title Changes Required 
WI-RD-01 EC Technical File Contents and Control Need to amend to include the new requirements of both the 
legislation and the 13485:2016 standard. 
WI-RD-02 Labelling and Instructions for Use Requirements Need to amend to include new requirements. 
WI-RD.03 Product Feedback Now Post Market Surveillance and greatly expanded. 
WI-RD-04 Competent Authority Notification Similar but greatly expanded plus requirement to include ‘in-
house’ only products. 
WI-RD-05 Risk Analysis Similar but new standard and also requirement to include 
information from production and post market feedback for 
lifetime of the device. 
WI-RD-10 IVDR Essential Requirements Matrix Now replaced by General Safety and Performance Requirements 
WI-RD-11 MDR Essential Requirements Matrix Now replaced by General Safety and Performance Requirements 
QP.02 Project Control To be replaced by new QP.02, QP.03F and QP.03G 
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Table 3.4 New documentation to be produced. 
WI Reference WI Title Requirement 
WI-RD-01 EC Technical File Contents and Control New requirements for both content and control. 
WI-RD-02 Labelling and Instructions for Use New labelling and instructions for use introduced. 
WI-RD.03 Post Market Surveillance The post market surveillance requirements are new and rather 
complex. 
WI-RD-04 Competent Authority Notification New requirements and includes ‘in-house’ developed devices. 
WI-RD-05 Risk Analysis Risk and hazard management requirements increase and new 
harmonised risk standard issued. 
WI-RD-06  Medical Device Classification Rules  Risk classification rules for medical devices changed. 
WI-RD-07 In Vitro Diagnostic Devices Classification Rules Risk classification rules for in vitro device changed. 
WI-RD-08 Responsible Person requirements and listing New UK and EU requirements. 
WI0RD-09 UDI Registration, Issue and Allocation New UK and EU requirements. 
WI-RD-10 IVDR General Safety and Performance Requirements 
Matrix 
New UK and EU requirements. 
WI-RD-11 MDR General Safety and Performance Requirements 
Matrix 
New UK and EU requirements. 
WI-RD-12 Software Development New UK and EU requirements regarding software development. 
WI-RD-13 Testing requirements New document - to ensure device and manufacturing testing are 
carried out as per EU and UK legislation and the 13485:2016 
standard.  
WI-RD14 Planning, Review and Change Control New document - to ensure planning, review and change control are 
carried out as required by 13485:2016. 
WI-RD-15 Routine Follow-up, Regulatory and Notified Body 
Communications and Documentation  
To include Periodic Safety Update Report, PSUR Post Market 
Clinical Follow-Up, PMCF and Post-Market Performance Follow-
Up, PMPF. 
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QP.02 Design, Development and Manufacturing not CE marked Control of work not covered by regulatory or legislative 
requirements. 
QP.03F Requirements for Product Realisation  Control of work covered by Regulatory or legislative requirements 
– Medical or In vitro Diagnostic Devices.  
QP.03G Academic and Third Party Product Realisation Control of work undertaken by academic and third parties on 
devices which may or may not enter use within NHS Tayside. 
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 EU AND UK MEDICAL AND IN VITRO DIAGNOSTIC 
DEVICE LEGISLATION 
4.1 Introduction 
In 2017, the EU issued the Medical Device Regulations(2) and the In Vitro 
Diagnostic Device Regulations(3). These new regulations were issued to rectify a 
number of failings in the previous legislation and to update the legislation to meet 
the requirements of new devices, the needs of industry, improve patient safety and 
ensure better device traceability. Both these regulations were passed into UK law 
in 2019(4). 
4.2 Comparison of the old EU directive and the new EU regulations. 
This section is a comparison of the Implantable Medical Device Directive, the 
Medical Device Directive, and the In Vitro Diagnostic Medical Directive, 
MDD/IVDD/IMDD against the Medical Device Regulations and the In Vitro 
Diagnostic Medical Device Regulations, MDR/IVDR. Prior to the UK leaving the 
EU (Brexit), the UK legislation in respect of Medical Devices and In Vitro 
Diagnostic Devices mirrored the EU legislation. The main changes in the current 
UK legislation were the removal of references, where possible, to EU legislation or 
associated bodies and to substitute these with references to UK legislation or 
relevant bodies. 
The proposals to update and amend MDD, IMDD and IVDD were issued in 
2012(105, 106). These proposals and supporting documentation(129) explain the need 
for the new legislation, and the reasoning behind the changes, additions and 
strengthening of the legislation. The new regulations were issued in 2017(2,3).  
Examples between the old directives and new regulations include: 
The MDD and IMDD are now combined into the MDR. This is to stream line the 
legislation and ensure that all implantable devices, active or otherwise, are regulated 
in a similar fashion.  
The classification of in vitro diagnostic devices has changed from being list based 
to risk based(107,108).  
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The rules for the design and manufacture of medical and in vitro diagnostic device 
for use within a health care institution have updated been updated and are now 
stricter. Dependant on use software can now be classified as a medical or in vitro 
diagnostic device in its own right. 
The most important difference is that the legislation is published as regulations and 
not directives. This means that the new regulations must be applied without change 
and in their entirety, across the EU. A directive is introduced by each country as 
they see fit, and devised by their own laws, on how to reach the goals set out in the 
directive(109).  
4.3 Impact on M&H work 
The following areas are seen to have the greatest impact on the M&H quality system 
from these new regulations and UK legislation. 
1. The exemptions which allow the manufacture or modification of medical and 
in vitro diagnostic devices for ‘in-house’ use only;  
2. The control of such projects when working in collaboration with academics 
and third parties;  
3. The replacement of the Essential Requirement, contained in the old directives 
and UK legislation, with The General Safety and Performance Requirements;  
4. The stricter requirements relating to technical file documentation, post 
market surveillance review and control, hazard and risk management, 
including the introduction of an updated standard related to risk management. 
5. The changes in classification rules. 
6. The need to have the appropriate BS EN ISO 15189 certification for in vitro 
diagnostic devices and how this will impact on the work of the HMFUS 
group. 
7. The new regulations and legislation also introduced the requirement to 
uniquely identify each manufactured ‘CE marked’ device, (Universal Device 
Identifier (UDI) system) and to appoint a responsible person or persons to 
oversee the regulatory aspects of both the MDR and IVDR against the current 
M&H quality system. 
8. A requirement to have a person or persons nominated to be responsible for 
regulatory requirements. 
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9. The need to determine if software is a device in its own right. 
Each of the above points will be discussed, and the changes made to the M&H QMS 
to meet the requirements of the new regulations and legislation, will be detailed in 
the following sections of this chapter. 
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4.4 The Exemptions Relating to ‘In-House’ Manufacturer and 
Modification 
The changes to the exemptions, which allow health care institutions to design and 
manufacture devices for ‘in-house’ use, impact on how M&H control and document 
such work. The exemptions, allowing ‘in-house’ manufacture and modification 
detailed in both the EU and the UK legislation(2,3,4) will also affect how the 
collaborative work with academics and third parties is undertaken. 
4.4.1 The Exemptions 
Article 5 of both EU Regulations(2,3), ‘Placing on the market and putting into 
service’, and the UK legislation(4), ‘Placing on the market and putting into service’ 
stated in paragraphs 71 and 140, details the exemptions allowed for the design and 
manufacture of medical or in vitro diagnostic devices or the modification of existing 
devices made by a health care institution solely for use within that institution, that 
is, ‘in-house’ use. This ‘in-house’ use relates strictly to devices designed and 
manufactured solely for the use within the legal authority of the health care facility. 
The devices may be designed and manufactured with partner organisations but for 
the sole purpose of use within that specific healthcare organisation. Partner 
organisations may include universities, technical institutes or subcontracted 
industrial partners, working in collaboration with a healthcare organisation. 
The exemptions are to allow innovation, research and development to be 
undertaken, while still maintaining patient and user safety. The exemptions detailed 
in EU and UK legislation are very similar and for clarity, are quoted in appendix 
C4 1. This similarity is shown in the side by side comparison of the three references 
given in appendix C4 2. Paragraphs 1 to 5 inclusive are the same apart from the 
reference to the UK Secretary of State, instead of competent authorities, and the 
references being made due to the differences in the documentation layout. 
The two unnumbered paragraphs after paragraph 5 and referred to as subparagraph 
‘h)’, in the EU legislation equate to UK legislation paragraphs 6, 7 and 8.  
Both EU legislation and UK law make provision for more information to be 
requested, if required, by the relevant EU competent authority or the UK Secretary 
of State. This extra information would be to allow in-depth scrutiny of a device. 
The EU Regulations and UK legislation also allow for the restriction of the 
Page 55 of 513 
 
 
manufacture and use of certain devices or device types, even if only for ‘in-house’ 
use. Hence the need, as detailed in the legislation, to allow for an inspection of the 
activities of health institutions, to ensure that the requirements of this paragraph and 
the wider legislation are being followed. 
It should also be noted that the manufacture of devices, on an industrial scale is not 
permitted. 
4.4.1.1 ‘In-House’ Exemption Requirement Summary  
The following is a summary of the exemption requirements. The paragraph 
numbers relate to the EU legislation. The differences between UK Law and the EU 
legislation are noted. 
Paragraph 6 relates to the fact that, although the legislation is supposed to be 
enacted uniformly across all member states of the EU, it may be interpreted slightly 
differently in some member states. Paragraph 6 allows for the MDR and IVDR to 
be amended to remove these differences. UK legislation does not need such a 
paragraph. 
Paragraphs 1 to 3 detail that devices that are to be placed on the marked or put into 
service, must meet the relevant requirements of EU legislation and UK law. The 
devices will operate as intended, but with the proviso, that they are used and 
maintained as detailed in the relevant user instructions.  
Paragraph 4 states that any device, manufactured and put into use within a health 
institution, has been placed into service and so the requirements of the legislation 
apply to these devices. 
Paragraph 5 details the requirements to be followed by health care institutions who 
wish to undertake the manufacture or modification of medical devices only for ‘in-
house’ use. 
The main condition, as already stated, is that, devices manufactured within a health 
care institution under these exemptions, is used only within the legal entity of that 
health care institutions’. For example, if the legal entity comprises a number of 
hospitals and locations then the device may be used in these hospitals and locations. 
If devices were transferred to another legal entity, then this would be viewed as 
placing on the device on the market, and the full requirements of the legislation 
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would have to be adhered to during the manufacture of the devices. A second 
condition is that devices are not to be manufactured on an industrial scale. The 
meaning of industrial is not fully defined in this context. The number of devices 
manufactured ‘in-house’ should be compared against the numbers a commercial 
organisation would be expected to produce of a similar product. 
In order to manufacture a new device or modify an existing device, the health 
institution must justify why currently available devices do not fulfil their needs nor 
the needs of the relevant patient group. The justification could be that there is no 
device on the market to meet the relevant clinical requirement, the level of 
performance or functionality required is not available or the device is meeting a 
new need not currently addressed on the market. In essence, the exemption is not 
to manufacture cheaper alternatives for ‘in-house’ use or to replace existing 
devices. The exemption is to enable new or innovative devices to be designed and 
manufactured or existing devices to be modified to fulfil an unmet clinical need. 
As previously stated in this thesis, devices are to be designed and manufactured in 
accordance to an appropriate quality system. For medical devices this is BS EN ISO 
13485:2016. For in vitro diagnostic devices this is BS EN ISO 13485:2016 and 
relevant parts of BS EN ISO 15189:2012. The legislation does not state that the 
quality system has to be accredited but that the manufacture of the device follows 
an appropriate quality system. This allows the health institution to implement their 
own quality system, but they must evidence how their quality system meets the 
stated requirements. By being accredited to an appropriate industrial standard, it 
can be seen that best practice is being followed and the stated requirements have 
been met. 
The exemptions, for the actual design and manufacture of a device, require that the 
device meets the General Safety and Performance Requirements set out in 
Schedules 3 and 17 (UK legislation) or Annex 1 (MDR and IVDR legislation). 
Fully documented evidence of how these requirements are met must be available 
for review. If any of these requirements cannot be fully met, the justification for the 
discrepancy is to be documented. A statement, confirming why the device is safe to 
use, must also be given.  
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To ensure that the device meets the General Safety and Performance Requirements 
criteria, the use, performance, functionality and manufacturing processes 
undertaken to produce the device, must be documented. The same documentation 
must also be produced, to explain how a modification to an existing device has been 
made, and what, if any, of the original device’s functionality has been changed, due 
to the device modification. The documentation should include a general description 
of the new medical device or the device modification, the use or purpose of the 
device or modification and a specification of the device or specification of the 
modification and how the modification affects the original device’s specification. 
This information must include, the standards which were used in the design and 
manufacture of the device or modification, the minimum performance criteria, the 
intended user and patient groups and a risk assessment of the device or 
modification. There must also be full details of how the device is to be 
manufactured along with the storage, cleaning and handling requirements. The 
manufacturing information must include instructions for monitoring, checking, 
labelling or relabelling and calibrating or testing the device, prior to issuing it to the 
user. If required, any special instructions on how the device is to be stored or 
packaged prior to moving or transporting it, should be made available.  
The device should be accompanied with relevant user instructions including repair, 
maintenance, cleaning and calibration details. 
The documentation will also detail how feedback is gathered, analysed and 
actioned, as required. The documentation should also include the actions which 
need to be taken if the competent authority (in the UK this is the Medicines and 
Healthcare Products Regulatory Agency (MHRA)) requires to be contacted 
regarding a serious incident occurring with these ‘in-house’ devices. 
The above documentation should be sufficient to enable a competent authority, or 
external auditor, to have an understanding of the manufacturing facility, the 
manufacturing process, the design and performance data of the devices, including 
the intended purpose, and be sufficiently detailed to enable the competent authority 
to ascertain whether or not the general safety and performance requirements have 
been met, and the device is fit and safe for use. 
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The final requirement is that a public record of work carried out under these 
exemptions will be maintained. The record is to include, for each device 
manufactured or device modified, the contact details of the health institution and 
where the work was undertaken, how each manufactured or modified devices is 
identified – i.e. serial number, lot number, Unique Device Identification (UDI), 
identifier, general device description or, if required, a photograph of the device. 
These publicly available records may be accessible via the health care institution 
web site, the university web site, local library or other such easily accessible 
repository.  
Further conditions are that the health institution must have the required resources, 
controls and finance available to ensure that the devices are manufactured as 
detailed in the documentation noted above. 
4.4.2 M&H documentation to meet the exemption requirements.  
Within the M&H quality system the following documentation cover the work to 
meet the above requirements.  
• Document QP.02, ‘Project and Product Realisation’, details the control and 
documentation to the design, development and manufacture of items or 
devices including non CE marked medical or in vitro diagnostic devices, 
products or services for ‘in-house’ use only. 
• Document QP.03F ‘Requirements for Product Realisation’ details the 
controls for the design, development and manufacture of CE marked 
medical or in vitro diagnostic devices, products or services. 
• Document QP.03G ‘Academics and third Party Guidelines’ are guidelines 
for those working in collaboration with M&H on non CE marked medical 
or in vitro diagnostic devices, products or services for ‘in-house’ use only 
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4.5 The General Safety and Performance Requirements 
The General Safety and Performance Requirements (GSPRs) are detailed as 
follows: 
1. For Medical Devices 
a. In Annex 1 of the MDR  
b. In Schedule 3 parts 1, 2 and 3 of UK Legislation 2019 No. 791 Exiting 
The European Union, Consumer Protection, The Medical Devices 
(Amendment etc.) (EU Exit) Regulations 2019, referenced as UK 
Legislation. 
2. For In Vitro Diagnostic devices 
a. Annex 1 of the IVDR, 
b. In Schedule 17 parts 1, 2 and 3 of UK Legislation 2019 No. 791 Exiting 
The European Union, Consumer Protection, The Medical Devices 
(Amendment etc.) (EU Exit) Regulations 2019, referenced as UK 
Legislation. 
4.5.1 Comparison of EU and UK General Safety and Performance 
Requirements 
A side by side comparison was undertaken to determine if the EU and UK GSPRs 
are, in fact the same, or similar, as had been alluded to by the UK Medicine Agency, 
when the noted that UK legislation ‘….will mirror all the key elements 
contained……’ in EU legislation(110).  
As can be seen from the two comparisons given in appendix C4 3 and C4 4, the 
current EU and UK legislation contains the same General Safety and Performance 
Requirements. The differences between the UK and EU GSPRs is detailed in tables 
4.1 and 4.2, and are due to the UK legislation referencing, were possible, UK bodies 
or UK legislation.  
This side by side comparison was also undertaken to ensure that the two M&H 
WIs(102), regarding the GSPRs for medical devices and in vitro diagnostic devices, 
contained all the required elements of both EU and UK legislation. In the future, 
the two side by side comparisons will be useful tools in reviewing new, or amended 
legislation, relating to medical and in vitro diagnostic devices. The side by side 
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comparisons are given in appendix C4 3 for Medical Devices and appendix C4 4 
for In Vitro Diagnostic Devices.  
The two comparisons show that there are no current ‘real’ differences between the 
EU and UK legislation.  
To ensure that all of these safety requirements are met during the design and 
development of a medical device, two work instructions have been produced. These 
include a matrix showing all the GSPRs, if these are applicable. If they are 
applicable, the matrix shows which standards or recognised guidelines have been 
used to meet the GSPRs and where the GSPRs have been met, it states the 
evidence/documentation showing how the particular requirement has been met. 
A sample of a blank matrix is given in Table 4.3.  
The actual matrix for each type of device is given in WI-RD11 for Medical Devices 
and WI-RD10 for In Vitro Diagnostic Devices. Both documents form part of the 
M&H quality system. 
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Table 4.1 Differences in the Medical Devices EU and UK General Safety and Performance Requirements. 
EU Legislation UK legislation Comment  
10.4.1. Design and manufacture of 
devices 
Design and manufacture of devices  
Devices, or those parts thereof or those 
materials used therein that: 
 
 
 
are invasive and come into direct contact 
with the human body, 
(re)administer medicines, body liquids 
or other substances, including gases, 
to/from the body, or 
(7) Devices, parts of those devices or 
materials used in those devices listed 
in sub- paragraph (8)  
8) The devices (or parts or materials) to 
which sub-paragraph (7) relates are 
devices which—  
(a) are invasive and come into direct 
contact with the human body; 
(b) administer or re-administer 
medicines, body liquids or other 
substances, including gases, to the 
body; or 
In UK legislation the list of devices or types is 
given in Section (8) and not Section (7) While in 
the EU  legislation  these are listed in 10.4.1. 
When taken as a whole, the two sets of 
requirements for design and manufacture of 
devices are the same. 
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transport or store such medicines, body 
fluids or substances, including gases, to 
be (re)administered to the body,  
(c) transport or store medicines, body 
fluids or substances, including gases, 
to be administered or re-
administered to the body  
10.4.Substances 
10.4.1. (a), (b) 
Substances 
10 - (7) (a), (b)  
The UK legislation gives more exact details as to 
the legislation and which parts are applicable.  
10.4.2. Justification regarding the 
presence of CMR and/or endocrine-
disrupting substances 
10.4.3 Guidelines on phthalates  
10.4.4 Guidelines on other CMR and 
endocrine-disrupting substances 
10 - (9)The justification for the presence 
of the substances listed in sub-
paragraph (7) must be based upon— 
 
The wording in these paragraphs differs but the 
meaning and the end requirements are the same.  
when either EU or UK legislation is updated or 
amended these this requirement must be reviewed 
for any differences in requirements  
Devices incorporating materials of 
biological origin 13.1 
Devices incorporating materials of 
biological origin 13 - (1) 
The EU requirement points to EU legislation while 
UK legislation point to UK legislation. These may 
differ in the future. The two sets of legislation need 
to be reviewed in the future for differences. 
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Devices incorporating materials of 
biological origin 13.2 
Devices incorporating materials of 
biological origin 13 – (2) 
The wording is different but the meaning is the 
same.  
Construction of devices and interaction 
with their environment 14.7 
Construction of devices and interaction 
with their environment 14 – (7) 
The wording is different but the meaning is the 
same. To ensure safe disposal of devices and any 
resulting waste products or sundries.  
Devices with a diagnostic or measuring 
function 15.2. 
Devices with a diagnostic or measuring 
function 15 (2) 
These two paragraph point to different legislation. 
Just now the legislation is the same but it may vary 
in the future. 
16.2.Intended radiation Point 16 (3) Words differ but their meaning and the 
requirements are the same.  
Label and instructions for use 
23.1 Points (f) and (h) 
Label and instructions for use 
23 (1) Points (f) and (h) 
The two requirements are the same but may vary 
in the future as the EU legislation alludes to future 
changes or work in other areas.  
 
  
Page 64 of 513 
 
 
Table 4.2 Differences in the In Vitro Diagnostic Devices EU and UK General Safety and Performance Requirements. 
EU Legislation UK legislation Comment  
Chemical, physical and biological 
properties 10.2. 
Chemical, physical and biological 
properties 10 – (2) 
Not the same wording but the same meaning and 
requirement. 
Information on the label 
 
Information on the label  20 – (3) Note how the UK legislation does not look outside 
of UK – for example see para (3) (p) of schedule 
17 UK legislation versus section 20.2 (p) of Annex 
1 of the IVDR. 
Information in the instructions for use 
20.4.1 
 
Information in the instructions for use 
20 – (7) 
 
 
EU legislation  paragraphs 20.4.1 (ag) and (ah) are 
noted in UK legislation point 20 – 7 (a) and 20 – 7 
(b) 
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Table 4.3 Extract from a General Safety and Performance Requirements Matrix 
Essential Requirement 11 Infection and microbial contamination A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
11.1. Devices and their manufacturing processes shall be designed 
in such a way as to eliminate or reduce as far as possible the 
risk of infection to the user or, where applicable, other 
persons. The design shall: 
(a) allow easy and safe handling; 
(b) reduce as far as possible any microbial leakage from the 
device and/or microbial exposure during use; 
 and, where necessary 
(c) prevent microbial contamination of the device during use 
and, in the case of specimen receptacles, the risk of 
contamination of the specimen. 
    
11.2. Devices labeled either as sterile or as having a specific 
microbial state shall be designed, manufactured and 
packaged to ensure that their sterile condition or microbial 
state is maintained under the transport and storage conditions 
specified by the manufacturer until that packaging is opened 
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at the point of use, unless the packaging which maintains 
their sterile condition or microbial state is damaged. 
11.3. Devices labeled as sterile shall be processed, manufactured, 
packaged and, sterilised by means of appropriate, validated 
methods. 
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4.6 Technical File documentation 
Medical or in vitro diagnostic device manufacturers (or others placing devices on 
the market) have various options for having their devices assessed against the 
relevant regulations. These options vary, from having each device, or batch of 
devices, tested by a notified body to the notified body auditing both the quality 
management system and the technical file for device in question. (See Tables 4.4 
and 4.5 and Figures 4.1 and 4.2 for the various assessment routes for both medical 
and in vitro diagnostics devices.) 
The compliance route which M&H have chosen for medical and in vitro diagnostic 
device assessment is by the conformity assessment of the M&H QMS and the 
device technical file. The conformity assessment is an audit by a notified body. The 
requirements for this type of assessment under the UK law, are detailed in Schedule 
10 for medical devices and Schedule 24 for in vitro diagnostic devices, whereas, 
for EU legislation, these are detailed in Annex IX of the MDR and the IVDR. (Note 
at the time of writing this thesis the introduction of the MDR was delayed by 12 
months. Hence the MDD is still the legislation in force and to be followed.) 
The technical file requirements for in vitro devices are detailed in Schedule 18 of 
the UK law and Annex II of the IVDR. These requirements for medical devices are 
detailed in Schedule 4 of the UK law and Annex II of the MDR. 
These documentation requirements relate to the device, device variants and 
associated accessories. 
Each device should also have a design history file or evidence as to how the design 
evolved and that the design was developed in accordance with the approved design 
plan and changes were reviewed and approved. This history file must be maintained 
until at least the end of life of the last device manufactured and preferably within 
the device’s technical file. 
The requirements contained in these Annexes and Schedules are there to ensure that 
the developed device and its associated documentation have been designed, tested 
and reviewed to verify that the use of the device outweighs any residual risk or 
hazards still associated with the device. Also required are details of how post market 
surveillance control and management is achieved and finally, that a Certificate of 
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Conformity to the relevant legislation is produced and signed by an appropriate 
senior member of staff. 
It is essential to ensure that the product meets all the legislative requirements and 
passes any audit undertaken of the device by the notified body. 
It should be noted that in the M&H QA system the technical documentation 
requirements and the post market surveillance requirements are detailed in one 
document. How post market surveillance is undertaken, controlled and as required 
reported to the relevant authorities is described in section 4.7 of this thesis ‘Post 
market surveillance and Vigilance.’  
Annex C4 5 is a comparison of the requirements for technical file documentation 
given in the EU regulations with those given in the UK Law. The comparison shows 
no substantive differences between the two.  
4.6.1 Summary of In Vitro Diagnostic Device Technical Documentation 
 
1. Certificate of Conformity as detailed in Annex IV of the IVDR(3) or Schedule 
20 Regulation 1A of UK law(4). 
2. Device Description, Variants, Accessories and Specification 
3. This section will describe the device in terms of function and use, any 
accessories included, and variants planned, plus, as a minimum, the 
following; 
3.1 UDI information as per IVDR Annex VI Part C or UK legislation Part 
C of Schedule 22. 
3.2 what the device is supposed to detect, or measure.  
3.3 is the device automated and how is this automation controlled. 
3.4 the risk classification of the device as per IVDR Annex VIII  
3.5 the intended users and the target patient population  
3.6 references to previous or similar devices. 
4. Information supplied by the Manufacturer will include a copy of the 
instructions for use and copies of all the labels placed on the device or the 
device packaging. Note that marketing materials should also be under 
document and change control. This will ensure such document is correctly 
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controlled and changes to marketing materials do not lead to errors in device 
claims or uses in marketing materials.  
5. The Design and Manufacturing Information required is as follows: 
5.1 A full understanding of how the design and development of the device 
was achieved from specification to design sign off.  
5.2 Full details of the manufacturing process and how devices are tested 
prior to release to customers/users. The information must include a list 
of where assemblies or sub-assemblies are sourced and the location of 
offsite manufacturing and subcontractors. 
6. General Safety and Performance Requirements. 
This information will be contained in the matrix given in WI-RD.10 - IVDR 
General Safety and Performance Requirements Matrix(102) once it has been 
completed. 
7. Risk/Benefit Analysis and Risk Management.  
This section will contain the rationale and results of the risk assessment 
(carried out according to WI-RD-05(102) and will include a summary 
indicating why any residual risks are outweighed by the benefits obtained 
from the device. See also EU Annex Section 1, 3 and 8, and UK Schedule 17, 
paragraph 1, 3 and 8 
8. Product Verification and Validation 
The documentation shall contain the results and critical analyses of all 
verifications and validation tests and/or studies undertaken to demonstrate 
conformity of the device with the requirements of the relevant legislation. 
9. Device Performance 
The documentation should state the type of sample to be used by the device 
and how this sample is to be obtained, including the volume or size of the 
sample. The documentation should also detail any sample preparation prior 
to being used in the device. 
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10. Device Accuracy. 
The documentation must give details of the device accuracy, how this was 
determined and proved, how the devices is initially calibrated or checked and 
how the device is maintained during its use. 
11. Clinical Performance and Clinical Evidence 
The documentation needs to detail the method and results of both laboratory 
and clinical testing to determine the device performance or evaluation of the 
device in use. Also, any trials carried out shall be summarised in this section 
along with the location of the reports resulting from these trials. Any 
documentation, which would preclude clinical trials from being carried out, 
should be detailed in this section. When required the report detailed in Annex 
XIII must be produced.  
12. Stability 
The documentation must outline the methods and the results of testing the 
device’s lifetime, in use, transport and storage stability. 
13. Software Validation and Verification 
The documentation should contain details of the rationale and the results of 
validation and verification of the software included with the device, and any 
device variants. The details should also outline the software/firmware 
included in the device, or any application software to enable the device to 
interface to external devices, user interfaces or accessories. 
14. Additional Information 
For specific types of devices, it may be necessary to provide additional 
information in the documentation to ensure that the device is correctly 
designed, developed and manufactured. These devices include:   
14.1 Sterile devices – how sterilised and how sterility is maintained during 
transport and use. Note any sterilisation process used must be 
documented and validated. 
14.2 Devices with a defined microbiological element, details of the 
sterilisation process or how they will be sterilised should be included in 
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the documentation. Also, instructions should be given for products to 
be sterilised by the user prior to application, where appropriate. 
15. Quality System 
In the documentation, this section should describe the quality system 
controlling the design, manufacture and inspection of the device and 
specifying any documentation of particular relevance.  If subcontractors are 
involved, details of their quality systems shall be included. This section may 
state a list of relevant standards to which the manufacturer, and any 
subcontractors or third parties, are accredited. 
16. Standards 
The documentation in this section should list the standards followed or 
referred to within the technical file. These shall be mentioned throughout the 
technical file where applicable, particularly in the Essential Requirements 
Matrix. Using a harmonised standard give a presumption of conformity if 
applied in the appropriate manner. A current list of the harmonised standards 
can be found at the relevant EU website. Non-harmonised standards may also 
be used. 
17. Self-testing Devices 
Class B, C and D devices for self-testing or near-patient testing the 
requirements for technical documentation assessment set out in Section 5.1 
of Annex IX will need to be met.  
18. Changes and additions 
All changes to the design or manufacture of the device shall be incorporated 
into the technical file, as required. Changes to product or devices placed on 
the market are initially documented on action forms. Copies of these forms 
will be kept in this section of the technical file. 
19. Post Market Surveillance Plan 
This documentation shall detail how the performance of the device in use is 
to be monitored; How the customer feedback is to be analysed; How 
knowledge of the device failings will be conveyed to any users of the device 
and relevant authorities; The plan needs to be reviewed against Annex III and 
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Annex XIV and Schedule 14 and 19 and or definitions given in the legislation. 
For example  
19.1 UK Law paragraph 121.Post-market surveillance system of the 
manufacturer, or 
19.2 EU Legislation, IVDR, Article 78 Chapter VII Post Market 
Surveillance, Vigilance and Market Surveillance. 
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4.6.2 Summary of Medical Device Technical Documentation 
1. A Certificate of Conformity as detailed in Annex IV of the MDR or Schedule 
6 Regulation 1A of the UK legislation. 
2. Device Description and Specification 
2.1 A technical description of the device, its operation and details of any 
novel features. 
2.2 An outline of the clinical need for the device, the indicated patient 
population and any contraindication to it’s use. 
2.3 The risk classification as per Annex VIII MDR or Schedule 9 of UK law. 
2.4 A description of the physical device - including size, weight and 
performance characteristics. 
2.5 Details of all the materials used, especially those contacting the patient. 
Where required, information relating to previous version(s) of the device 
or similar devices on the market. 
2.6 The UDI information as required by Part C of Annex VI or Schedule 8 
of UK law. 
3. Information Supplied to the User 
The documentation must state all the information supplied to the user, not just 
the user instructions but the labelling information on the packaging or the 
device, the transport packaging and multipacks etc. This information must 
also be in the languages of the countries or areas to which the device will be 
supplied. Note that marketing materials should also be under document and 
change control. This will ensure such document is correctly controlled and 
changes to marketing materials do not lead to errors in device claims or uses 
in marketing materials. 
4. Design and Manufacturing Details 
4.1 The documentation must give full details of all the design stages of the 
device. The detail of this section has to be sufficient to enable a full 
understanding of the device development, from its concept and 
specification to manufacture and completion.  
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4.2 There needs to be a comprehensive narration of the assembly and 
manufacturing instructions including the manufacturing test and 
calibration details. 
4.3  Validation and verification of the manufacturing processes must be 
fully stated. 
4.4  All information relating to manufacturing sites and third parties used 
in either the design, assembly or manufacture of the device must be 
given. 
5. General Safety and Performance Details 
The information required must be able to demonstrate compliance with 
Annex 1 of the MDR or schedule 3 of the UK law. In most cases this will be 
the completed essential requirements matrix and supporting documentation, 
See WI-RD.11, MDR General Safety and Performance Requirements(102). 
6. Risk Analysis and Management of Risk. 
The documentation should contain details of all risks foreseen or discovered 
during the development of the device; an analysis of these risks and how they 
were managed to reduce them to a low as level a possible; a statement as to 
why any residual risks are tolerated and how the benefit of the use of the 
device outweighs these risks. 
7. Product Testing 
The documentation shall contain details of the testing carried out to ensure 
that the product has: 
7.1 Achieved the specified technical requirements - verification, 
7.2 Met the requirements of the customer and that the device is fit for 
purpose – validation testing.  
The details of how the testing was carried out and the test results should also 
be included. Information should disclose how any test failures were reviewed 
and if any testing resulted in design changes.  
The testing may include pre-clinical or clinical testing and animal testing, 
laboratory testing or device hardware or software simulation. All ethics 
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approval whether NHS, academic or regulatory body, must be referenced. See 
also Annex XIV of the MDR and Schedule 14 of the UK law. 
8. Additional Details  
Specific details are required for: 
8.1 Devices which incorporate a functioning medicinal produce  
8.2 Devices incorporating a tissues or cells. 
8.3 Devices which deliver substances into the human body. 
8.4 Devices delivered sterile or predefined microbial state. 
9. Matrix of General Safety and Performance Requirements 
The documentation should contain a matrix detailing each GSPR, any 
applicable standard, a statement of how the requirement has been addressed 
and where the relevant documentation can be found. This matrix can be found 
in WI-RD.11, MDR General Safety and Performance Requirements’(102). 
10. Quality System 
This section should describe the quality system controlling the design, the 
manufacture and inspection of the device and any documentation of particular 
relevance.  If subcontractors are involved, details of their quality systems 
shall be included. This section may be a list of relevant standards to which 
the manufacturer and any subcontractors or third parties are accredited to. 
11. Standards 
This section lists the standards followed or referred to within the technical 
file. These shall be mentioned throughout the technical file where applicable, 
particularly in the Essential Requirements Matrix. Using a harmonised 
standard give a presumption of conformity if applied in the appropriate 
manner. A current list of the harmonised standards can be found at the 
relevant EU website. Non-harmonised standards may also be used. 
12. Class I Devices 
The requirements for Class I devices are controlled by WI-RD.04. The 
technical file containing copies of documentation generated under this section 
to contain the words ‘Self Declaration’ in its title. 
Page 76 of 513 
 
 
13. Changes and additions 
All changes to the design or manufacture of the device shall be incorporated 
into the technical file as required. Changes to the product or devices placed 
on the market are initially documented on action forms. Copies of these forms 
will be kept in this section of the technical file. 
14. Post Market Surveillance Plan 
At this part, the documentation shall narrate; How the performance of the 
device in use is to be monitored; How the customer feedback is to be 
analysed; How information regarding device failings will be conveyed to the 
users and relevant authorities; The post market surveillance plan must meet 
the requirements of the relevant legislation – Annex III and Annex XIV, 
MDR, or Schedule 5 and 14 of the UK law plus the supporting articles or 
definitions given in the legislation. For example: 
14.1 UK Legislation paragraph 121.Post-market surveillance system of the 
manufacturer, or 
14.2 EU MDR Legislation Article 83, Chapter VII Post Market Surveillance, 
Vigilance and Market Surveillance. 
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4.7 Post Market Surveillance and Vigilance.  
Due to the scandals surrounding defective devices(111,112), the severity of device 
faults being under estimated, faulty devices not being rectified or removed from the 
market and notified audit bodies not picking up on serious issues with devices, the 
requirements to relating to post market surveillance have been significantly 
tightened.  
Post market surveillance is used to determine how a device operates after it has 
been put into service or use. The surveillance includes reviewing the processes used 
during the manufacturing, marketing and shipping phases and not just problems 
found once the device has been put into use. 
Vigilance is used to ensure that any reports of defective devices, similar devices, 
materials or device operation are reviewed and acted upon by the appropriate 
competent authorities. This action may range from issuing a note to user to inform 
them of the possible problem and to change the method of use through to a full 
product recall. The action may also require the manufacturer to inform the relevant 
competent authority and have the problem entered in the relevant device database 
e.g. EUDAMED – See section 4.10 ‘Unique Device Identification System’ below.  
The data gathered from post market surveillance activities is used to trigger 
vigilance activities(113). 
4.7.1 Comparison of EU and UK requirements for Post market surveillance 
and Vigilance activities. 
A comparison between the EU regulations and the UK legislation was undertaken 
to compare the new legislation; MDR to IVDR and then EU against UK legislation. 
The comparison highlighted the areas where medical device requirements varied 
from in vitro diagnostic device requirements. The variations were due to the 
differences between types of devices and the information required to ensure these 
devices remained safe and fit for use.  
One of the major differences is the Post-market Performance Follow up plan 
(PMPF) for in vitro diagnostics devices, while for medical devices, there is a Post-
market Clinical Follow up plan (PMCF), is required(114). (See section 4.7.4 for 
outline of PMPF and PMCF).  
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One outcome from these comparisons has been to identify the areas which are 
similar and allow these areas to be consolidated into one quality control document. 
The areas specific to either medical devices or to in vitro diagnostic devices can 
then be placed into separate control documentation and appropriately applied to the 
intended device. 
Post market surveillance is also to be carried out on devices manufactured solely 
for ‘in-house’ use. This is a new requirement introduced in both EU and UK 
legislation and is to ensure that any device, manufactured ‘in-house’, is fully 
monitored, and problems reported are reviewed and acted upon, even to reporting 
the problem to the appropriate regulatory authority. 
4.7.2 Post Market Surveillance Summary 
As stated above, post market surveillance has a common set of requirements for 
both in vitro diagnostic devices and medical devices, and a specific set of 
requirements covering the differences in both types of devices.  
4.7.3 Activities to be undertaken and data to be collected 
A fully documented post market surveillance system, when implemented, ensures 
that the required surveillance and vigilance activities are carried out and controlled. 
Any data, gathered from these activities, should be appropriately analysed and the 
findings reported or published to those concerned, including competent authorities, 
notified bodies, and device users. 
This system of post market surveillance will ensure that the data gathered is used 
as follows:  
1. To update the risk and hazard analysis so as to ensure that the risk-benefit 
derived for the device is still valid. 
2. To identify the necessary corrective action e.g.  
a) update the user instruction or labelling requirements. 
b) review and update the manufacturing and design information for the 
device. 
c) review and update either the medical device clinical performance or 
the in vitro diagnostic device evaluation data. 
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3. Ensure that reports and corrective actions, including device safety notices or 
recalls, are intimated within the specified time scales and to the appropriate 
authorities or persons. 
4. Ensure the PMCF plan for medical devices or PMPF plan for in vitro 
diagnostics devices is produced and issued. (It is to be noted, that 
justification as to why a PMCF/PMPF is not applicable must be issued). 
5. Production of a Periodic Safety Update Report (PSUR). See section 4.7.4 
for outline of PSUR). 
The activities related to the requirements of the post market surveillance system 
will need to be defined. These activities(113, 114, 115, 116, 117) include: 
1. the processes to be used to collect and methods used to analyse the data 
required to meet the requirements detailed in  Article 83 of the MDR or 
IVDR and UK legislation para 121 and para 186),  
2. the indicators and thresholds to be used in reassessing the benefit risk, 
3. how complaints and other feedback will be investigated and assessed, 
4. the processes to be used to identify trends and determine if these are 
reportable, 
5. how to identify and initiate corrective actions, 
6. how vigilance information and other information (PSUR, PMPF and PMCF) 
are to be produced, reported and the time scales to be met in producing and 
issuing these report, and   
7. the methods used to identify devices involved in corrective actions and how 
to trace these devices if required. 
8. the output of post market surveillance activities, including PMPF, PMCF and 
PSUR will be regularly reviewed. Within the M&H QA system this review is 
undertaken during the M&H quality system management reviews. 
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4.7.4 Post Market Clinical Follow-Up, PMCF, Post Market Performance 
Follow-Up, PMPF and Production of a Periodic Safety Update Report, 
PSUR overview 
The following are short overviews of PMPF, PMCF and PSUR. 
4.7.4.1 Post Market Clinical Follow-Up, PMCF 
During the design and development of a medical device, the clinical performance 
of the device must be reviewed and tested to ensure it meets the both the customer 
requirements and design specification. The PMCF is a continuation of this process. 
The PMCF updates the clinical evaluation by assessment and analysis of clinical 
data or reports obtained from the operation of the device will in use to ensure the 
clinical safety and performance of the device when used as intended by the 
manufacturer. 
4.7.4.2 Post Market Performance Follow-Up, PMPF 
During the development of an in vitro diagnostic device the performance of the 
device must be tested to ensure it meets the required performance level. This 
performance evaluation must show the scientific validity of the device and proof 
that the device meets the required analytical and clinical performance. The 
performance evaluation must be such that it shows the device achieves the intended 
clinical benefit and safety, when used as intended by the manufacturer. PMPF is the 
ongoing evaluation of the devices scientific validity and ensuring that the devices 
continues to meet the intended analytical and clinical performance. 
4.7.4.3 Periodic Safety Update Report, PSUR 
The PSUR is a report, to be produced on a yearly basis for the lifetime of moderate 
to high risk medical or in vitro diagnostic devices. For each device, report should 
contain for example the main findings of the PMCF and PMPF, the conclusions 
from updated benefit-risk determination, the number of devices sold, analysis of the 
device users and if possible actual device usage.  
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4.7.5 Post Market Surveillance System to meet the exemptions required for 
‘in-house’ designed and manufactured devices. 
The exemptions for ‘in-house’ manufacture detail that ‘the health institution 
reviews experience gained from the clinical use of the devices and takes all 
necessary corrective actions.’(4) Hence, some form of post market surveillance is 
required, especially as the exemption required by the General Safety and 
Performance Requirements and these requirements include the need to evaluate and 
analyse the impact of information from reports from: 
1.  the manufacture or production of the devices and the information relating to 
the device and  
2. the post market surveillance related to the device once it had left the 
manufacturing or production area.  
The evaluation of this information is continuous. The evaluation needs to provide 
details on the hazards reported, their frequency of occurrence and an estimate of 
their associated risks. The result of the evaluations should indicate the overall risk 
of continued use of the device and if this risk is acceptable. 
The post market surveillance will also need to fulfil the requirements of the 
quality system implemented by the health care institution to control ‘in-house’ 
manufacture and work undertaken in collaboration with academics and third 
parties. These requirements will need to be equivalent to those detailed in both BS 
EN ISO 13485:2016 and BS EN ISO 15189:2012 related to post market 
surveillance. 
Accordingly, the health care institution will need to implement a system to meet the 
post market surveillance requirements of the exemption. 
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4.8 Risk management and Hazard reduction 
This area of the EU regulations and UK law in relation to medical devices and in 
vitro diagnostic devices is asking that during the development of the device all 
foreseeable hazards, posed by the use of the device, are reviewed to determine the 
risk they might pose to the user, the patient or others. At the end of the development, 
there needs to be a determination made that the device is safe to use and the risks, 
posed by any residual hazards, are outweighed by the benefit of using the device. 
A declaration to this effect needs to be made and formally noted in the technical 
file. 
The first area of risk management is to determine the risk classification of the device 
which determines the perceived risk in relation to the EU and UK legislation. The 
classification rules are detailed in the section 4.9 ‘Device Classification Rules'. The 
scrutiny given by the notified body and the relevant competent authority, during the 
review of the device and the results of post market surveillance analysis, will 
depend on the outcome of this determination. The scrutiny can vary from the actual 
device being tested and reviewed by an expert panel to a review of the technical 
file, or indeed, the self-declaration that the device meets the requirements. Figures 
4.1 and 4.2 outlines the assessment routes dependant on the risk classification of 
the device. 
The second area of risk management is to undertake continuous reviews to 
determine the risk or hazards posed by the transport, the manufacture and the actual 
device in use. 
All risk management and hazard identification should be undertaken according to 
the relevant issue of standard ISO 14971(169) ‘Risk management for medical devices’ 
and following the guidance given in ISO/PRF TR 24971:2020(168) ‘Medical devices 
— Guidance on the application of ISO 14971’. In the EU and UK legislation at the 
section entitled ‘General obligations of manufacturers’, point 2, requires that 
manufacturers ‘document, implement and maintain a system for risk management’. 
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The comparisons given in appendix C4 6 show that the requirements of all three 
sets of legislation are similar and the only notable differences are: 
• different authorities to report to  
• variation in legislative references and 
• no requirement for in vitro diagnostic devices relating to the reprocessing 
of single use devices.  
The EU and UK legislation require that a risk management system is established, 
adhered to and audited by notified bodies – external auditors. 
In summary the risk management system must determine the known or possible 
risks and hazards associated with a device and evaluate these risks and hazards to 
determine their severity and likelihood of occurrence. Unlike the previous 
directives – IMDD, MDD and IVDD, the MDR and IVDR require that risk are 
reduced to a low a level as possible. Hence , an action plan to reduce these risk or 
hazards to a low as level possible must be produced, and the risks and hazards re-
evaluated, once the plan has been actioned.  
This risk management process is only completed once the risks and hazards 
identified, are deemed to be acceptable. That is, the benefit gained from using the 
device, whether a medical device or an in vitro diagnostic device, outweighs the 
risk or hazard associated with using the device. 
Risk management is not about the device itself but needs to examine the device and 
possible misuse or other uses of the device, for example, the expected environment 
that the device will be used in, who the users of the device are and the intended 
patient group. 
Typical risk and hazard reduction methods include having appropriate alarm sounds 
and indicators, user instructions detailing how to use the device and the safety 
warnings and contra indications to use. User training can also be used to reduce any 
residual risks or hazards associated with the device. The sale of the device may also 
be restricted to ensure only trained or those with appropriate qualifications are 
provided with the device. All identified risk and hazards must be reduced to a low 
as level as possible. Only if the final level of risk or hazard is acceptable, should 
the device be placed on the market or into use. 
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Risk management also extends to how the device is packaged and transported to 
ensure it reaches the customer in the proper condition for use. Hence, the transport 
and storage conditions need to be evaluated to ensure that these do not cause the 
device to become hazardous. It should be noted that devices need to be evaluated 
specifically for risks and hazards associated due to their use if they are portable, 
wheeled or with use with ambulatory patients. 
The risk management system must also ensure that any feedback relating to the 
device, whether from the manufacturing phase or the in service phase (for example 
from users, patients and sales staff), is reviewed to determine if this feedback 
requires re-evaluation of the risk and hazard of the device. 
Accordingly the post market surveillance system must have a link into the risk 
management system. 
Risk management is a continuous process for the life time of the device from pre 
design phase to user phase to disposal or scrappage. All new risks or hazards 
identified during the lifetime of the device from design, development and testing 
phases are documented, analysed and reduced. 
Devices manufactured for ‘in-house’ use only will also be required, without 
exception, to meet these same risk management controls. 
A new M&H work instruction detailing the risk management system used within 
the M&H quality system is to be produced. 
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4.9 Device Classification Rules.  
These rules define the level of risk associated with the use of a particular device or 
family of devices. The risk classification of the device determines the possible 
conformity assessment routes for a device. The higher the risk classification, the 
stricter, and more onerous, the conformity assessment examination procedures will 
be. 
In order to determine the risk class of a device, it is necessary to first determine the 
nature or type of the device and then work through the appropriate classification 
rules in order.  
A comparison of the rules for the UK and EU In Vitro Diagnostic Device legislation 
given in Appendix C4 7 and Medical Devices Appendix C4 8, indicates that, in 
essence, they are the same.  
The classification rules to be followed during a development will depend on which 
market the device is intended for. 
4.9.1 Classification rules for ‘In-House’ devices 
For all cases/types of devices, items, accessories or modifications developed and 
manufactured for ‘in-house’ use (NHS Tayside) the UK classification rules will be 
reviewed. 
4.9.2 Classification rules for CE marked device 
The rules that require to be followed will depend on the eventual geographical 
market that the device is to be sold into. If in the EU only, then the EU classification 
rules apply, and if in the UK only, then the UK classification rules are applicable. 
If both EU and UK areas are the intended destinations then both sets of 
classification rules need to be invoked.  
For the time being following EU or UK classification rules should lead to the same 
device risk classification. 
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4.9.3 Classification Rules for Software 
These rules also apply to the software used in medical or in vitro diagnostic devices 
or where the software is used as the device. 
4.9.4 Background to the changes in Device Classification Rules 
The classification rules for both medical and in vitro diagnostic devices have been 
updated to bring them into line with the International Medical Device Regulators 
Forum, (which superseded the Global Harmonization Task Force(184)) guidelines. 
The changes in the device classification rules are most noticeable in the In Vitro 
Diagnostic Devices Regulations. 
The guidelines for in vitro diagnostic devices have also been driven by changes in 
the technology used in vitro diagnostic device, the need to correctly assign risk level 
to new types of in vitro diagnostic devices and to standardise device risk levels 
across the globe. 
When the original In Vitro Diagnostic Device Directive was introduced, many of 
the in vitro diagnostic devices which are in use today were not envisaged – for 
example genetic tests. At one time, these were only available via a specialist 
laboratory, but they are now readily available over the counter. Similarly, fertility 
testing and now the field of companion testing – where one test is to determine if a 
condition exists and a follow on test is to determine the response to the condition 
of a single or multiple drugs. Previously, they were not available as products(118). 
Further examples are wearable biosensors, which are coming to the market and 
which will eventually bring predictive diagnosis to the user via a smart phone or 
similar device. 
The new in vitro diagnostic device classification has been extended to 4 classes of 
device risk whereas the old IVDD had only two classes of risk – Self Certification 
and Notified Body assessment as detailed in the two lists given in Annex II of the 
IVDD directive(10). 
A point to note is that these changes in the in vitro diagnostic device classification 
rules will result in 80% of IVD being reviewed by a notified body in comparison to 
only 20% being reviewed under the old IVDD classification rules (120). This increase 
in notified body work load, coupled with a large reduction in notified bodies looking 
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to be re-designed to the IVDR, is likely to  cause problems in finding a notified 
body who can allocate time to asses a new device(120,121).  
4.9.5 In Vitro Diagnostic Devices classification rules – overview 
The IVDR classification rules are contained in Annex VIII of the IVDR and 
Schedule 23 of the UK MDR legislation. 
Both EU and UK classification rules are separated into Implementation Rules and 
Classification Rules. 
The Implementation Rules detail how the classification rules have to be applied and 
how to apply the rules for different scenarios or application. These rules also apply 
to software used in the devices or as a device. 
There are 7 Classification rules to be applied in the classification of IVDDs and 
there are currently 4 classes of devices (A, B, C and D). Class D being the 
classification of highest risk i.e. devices where an incorrect test poses a serious 
threat to life. Class A devices are the lowest risk devices; these include specimen 
holders, buffer solutions and washing solutions. 
4.9.6 In Vitro Diagnostic Device Classification and route to certification 
Table 4.4 and Figure 4.1, noted below, gives an overview of the routes to 
assessment and certification for In Vitro Diagnostic Devices(122,123,124,125). As can 
be seen these routes are heavily dependent on the device risk classification, and 
hence the importance of correctly classifying the device. External auditors will 
challenge the risk classification of a device and may request that the classification 
be reviewed by a third party,  
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Table 4.4 An overview of assessment and certification routes for In Vitro 
Diagnostic Devices(122,123,124,125) 
Class A No external review or supervision - have an 
appropriate QA system and documentation as 
required 
Low personal risk 
Low risk to public health 
Class B External body review - assessment of QA 
system. 
Moderate individual risk 
Low risk to public health 
Class C External Body review, full assessment of 
technical documentation. Production of periodic 
safety update. 
High individual risk 
Moderate risk to public 
health 
Class D External body review, full assessment of 
technical documentation and as required review 
by specialist group and testing by a reference 
laboratory. Production of periodic safety update. 
High individual risk 
High risk to public health. 
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Figure 4.1 Detailed conformity assessment for In Vitro Diagnostic Devices showing how the assessment routes vary with device risk 
classification(125) 
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4.9.7 Medical Devices Classification Rules - An Overview 
The classification rules for medical devices are contained in Annex VIII of the 
MDR and Schedule 9 of the UK Law. 
Similar to the Classification Rules for In Vitro diagnostic Devices, the EU and UK 
classification rules for Medical Devices are separated into Implementation Rules, 
Classification Rules, and a section giving definitions of terms used in these 
classification rules. 
In comparison to the seven Classification rules for In Vitro Diagnostic Devices, 
there are twenty two Classification rules to be applied in the classification of 
medical devices and four classes of devices Class I, IIA IIB and III. Class III being 
the classification of highest risk e.g. devices where there is a fault in the device or 
in its manufacture and poses a serious threat to life. Class I devices are the lowest 
risk devices where the use of the devices or poses little or no risk of harm.  
4.9.8 Medical Device Classification 
The medical device classification requirements are now a combination of the rules 
relating to implantable and active medical devices directives. The EU MDR and 
UK law retains the same number of risk classes as the old MDD – that is four. The 
changes to classification rules for medical devices have taken into account devices 
which are absorbed into the body, devices which use biological product(s) to 
provide a therapeutic effect, and that the invasiveness into the body of a device. The 
risk classification rules include the risk posed by nano-materials and also software, 
as a standalone device. Changes to the rules, including the addition of device types 
to certain of these rules, will increase the number of devices placed in the Class III 
category(126,127,128). For example, devices coming in to contact with the spinal cord 
are now class III. 
4.9.8.1 Class I devices – and a new superset - Reprocessing 
Normally class I devices are self-certificating devices, that is, the manufacturer 
declares that the device meets the requirements of the directive and places them 
onto the market without the need for an external scrutiny of the technical files. 
There is a superset of Class I devices where a particular part of the device’s 
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technical file has to be reviewed. These are Class I devices with either a measuring 
function, or are to be delivered or are to be sterilised or are to be reprocessed. An 
external review of the measuring function, sterilisation or reprocessing instructions 
will be required by an appropriately registered notified body. Reprocessing is new 
to this Class I superset. The MDR now requires device manufacturers to produce 
validated instructions for the reprocessing of reusable devices(130). Health 
Institutions also will have to abide by the Article 17 of the  MDR and Schedule 16 
of the UK legislation relating to reprocessing of medical devices(131, 194).  
4.9.8.2 Devices with a non-medical purpose 
Several devices without medical purposes are placed under the control of the MDR 
or UK legislation. Many of these devices are related to cosmetic uses, for example 
lasers for tattoo removal, contact lenses, devices for skin resurfacing and certain 
devices for modifying brain neuronal activity. Hence it is imperative to review the 
groups of products without an intended medical purpose to determine if they come 
under the remit of the MDR or the UK legislation. These non-medical products are 
detailed in MDR Annex XVI or Schedule 16 of the UK legislation. 
4.9.9 Medical Device Classification conformity assessment routes  
The routes to assessment and certification for a medical device, are like those for 
an in vitro diagnostic device, and are dependent on the risk classification of the 
device(128,132, 133). Table 4.5 and Figure 4.2 gives an overview of these routes.  
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Table 4.5 An overview of assessment and certification routes for Medical 
Devices(128,132, 133). 
Class I No external supervision but have an 
appropriate quality system and technical 
documentation 
Low individual risk 
Low risk to public health 
Class I 
with 
S, M, R 
Only the Sterility, measurement or 
reprocessing parts of the device technical file 
are reviewed by an external body 
Low to Moderate personal 
risk 
Low risk to public health 
Class IIA Produce a periodic safety up date, have 
product assessment or technical file 
assessment as required. 
Moderate individual risk 
Low risk to public health 
Class IIB Produce a periodic safety up date, assessment 
of technical files for all products to be placed 
on the market.  
High individual risk 
Moderate risk to public 
health 
Class III Produce a periodic safety up date, assessment 
of technical files for all products to be placed 
on the market. Clinical evaluation reports and 
possible reporting to notified body of batch 
manufacture results. 
High individual risk 
High risk to public health. 
S- Sterility, M – Measurement, R- Reprocessing part or all of a surgically reusable 
instrument. 
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Figure 4.2 Detailed conformity assessment procedures for Medical Devices showing how the assessment routes vary with device risk 
classification(128)  
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4.10 Unique Device Identification System 
The new medical device legislation introduces a system to enable identification of 
the device, whether a medical or an in vitro diagnostic device, to its point of origin. 
This unique identification is to ensure the control and ongoing safety of a medical 
device or an in vitro diagnostic device from the factory to the end user. 
4.10.1 The need for the Unique Device Identification System 
One of the main problems with the control and safety of medical and in vitro 
diagnostic devices within the IMDD, MDD and IVD(8,9,10) was the lack of vigilance 
and post market surveillance that related to problems with devices and reports made 
regarding devices from their production to the end user(135,144)). This lack of 
vigilance and surveillance made it difficult to analyse device faults and ensure that 
all the devices, experiencing a fault or a problem were identified, and other devices, 
affected with similar problems or faults, were located to enable them to be rectified 
or removed from use. The public did not have full access to the data relating to 
device problems or faults, as it was either not available or incomplete. A full 
analysis of device problems or faults could not be undertaken for a number of 
reasons: the data was incomplete, not recorded in a standard format or only 
accessible with the permission of the manufacturer, agent or competent authority of 
a given county(105,106).  
The new device legislation and requirements introduced a system to identify, 
individually, a medical or in vitro diagnostic device. This system is known as the 
Unique Device Identification (UDI), system. This UDI system, once fully 
implanted, will help in the traceability of devices, enable simpler and more effective 
incident reporting, improve anti-counterfeiting of devices and ensure that device 
warning notices are given to the correct end users(134,137,144). 
The databases containing the information relating to these devices, their problems 
and faults will be available for review by relevant authorities and some of the data 
will be made available to the public(138). This public data will be maintained and 
issued via the European Databank on Medical Devices, EUDAMED(193). 
By introducing the UDI system in respect of medical devices and in vitro diagnostic 
devices, the EU regulations and UK legislation were brought up to date, and in line, 
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with similar regulations throughout the world. 134,139,149). The requirements for a 
UDI number on a medical or in vitro diagnostic device is to be phased in over a 
number of years(141,142) as shown in figure 4.3 and figure 4.4 respectively(143). 
 
 
Figure 4.3 Time line for UDI implementation for Medical Devices. 
 
 
Figure 4.4 Time line for UDI implementation for In Vitro Diagnostic Devices. 
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4.10.2 What is the Unique Device Identifier?  
The UDI is not another serial number, but comprises of three identifiers, all linked 
to each other to enable the device to be uniquely identified: the manufacturer, the 
make and model number and the production identification of the device. 
These three parts of the UDI are the Basic UDI, the Universal Device Identification 
– Device Identifier (UDI-DI), and the Universal Device Identification – Production 
Identifier (UDI – PI) (145,147,148,149,151). The Basic UDI does not go on the device or 
product. The combined UDI-DI and UDI-PI will appear on the packaging and will 
give full information relating to the device, manufacturing site and if required the 
manufacturing date. (Please note that more information on the EU implementation 
of UDI can be found in the links given in ref 150.)  
4.10.2.1 The Basic UDI-DI 
This is the link between all devices of the same type, root design or base chemistry, 
risk class and manufacturing. Hence, all implantable defibrillators, using lithium 
batteries, could be assigned the same Basic UDI-DI. Similarly, pregnancy test kits, 
using the same chemistry and manufacturing processes, could be assigned the same 
Basic UDI. If a device has two functions, it will have a unique Basic UDI which 
incorporates those two functions, and not two Basic UDI’s for each function. As 
such, the Basic UDI will link all devices having the same functions and 
characteristics. By linking devices in this manner, an analysis of device faults and 
problems will be permitted, areas where a manufacturer, or third party supplier of 
devices is failing to meet the required performance levels will be highlighted and 
the public will be able to review device information prior to purchase. The 
certificate of conformity for a device will state the Basic UDI-DI for the device. 
4.10.2.2 The UDI-DI 
The UDI-DI contains sufficient details to enable the device to be traced back to the 
manufacturer of the device and the device type, model or code identifier. 
4.10.2.3 The UDI PI  
The UDI-PI contains the details of the actual device production - lot and/or serial 
number, manufacturing date, use by date and software identifier.  
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4.10.3 UDI Structure and use 
The structure of the system is, in some ways simple, and in other ways confusing. 
For devices of one type, you have a single Basic UDI Identifier.  
Under this Basic UDI identifier, you can have a number of Device Identifiers, 
different manufacturers, units of different colours, etc. 
Under the Device Identifier, you will have one or more Production Identifiers – one 
for each batch, lot or serial number. 
So, a pyramid of numbers is produced, which allows each device that has been 
manufactured to be identified back to its manufacturer and the date of being 
manufactured. The pyramid also allows data, for all similar devices, to be collected 
in a central database, by virtue of the Basic UDI identifier. 
This central database for EU and UK devices is known as the European Databank 
for Medical Devices (EUDAMED). This database was supposed to be functional in 
2020 but has now been delayed to 2022. Until then, and at the time of writing this 
thesis, those individuals or bodies placing devices on the market must apply to the 
‘local’ competent authority for a Single Registration Number. 
There are four bodies currently authorised to issue and control the use of UDI 
numbers these are(152): 
1.  GS1 (Global Standard One), 
2.  HIBCC (Health Industry Business Communications Council), 
3.  ICCBBA (International Council for Commonality in Blood Banking 
Automation), 
4.  IFA GmbH (Informationsstelle für Arzneispezialitäten).  
These four bodies will supply information to the EU central database. 
  
Page 98 of 513 
 
 
4.10.4 Identification for ‘in-house’ designed and manufactured devices. 
The above requirements for labelling are in some ways rather complex and involved 
but necessary to meet the regulatory requirements. They are also rather expensive 
for one off or low number manufacturing such as undertaken within a health care 
institution. 
The rules detailing the identification of devices manufactured ‘in-house’ and for 
‘in-house’ use only are rather vague. The exemptions given in both EU and UK 
legislation detail that devices manufactured for ‘in-house’ use by a health care 
institution should provide ‘the details necessary to identify the devices’. So, the full 
UDI identification system does not require to be used provided the devices are 
uniquely identified. 
4.10.4.1 Identification of ‘In-House’ Medical Devices 
Devices designed and manufactured within a health care institution are normally 
manufactured for a specific need or application. These devices are usually a ‘one 
off ‘or produced in very low numbers. It will be remembered that , the exemptions 
state that ‘in-house’ manufacture shall not be ‘on an industrial scale’. Medical 
devices which are manufactured for ‘in-house’ use, within NHS Tayside, are either 
manufactured within the Department of Medical Physics or in conjunction with this 
department. Each device that is manufactured prior to being issued to the user is 
given a Medical Physics asset identifier. This identifier is logged into the NHS 
Tayside Asset Management register. The register includes such details as the device 
user and user location, location of design documentation (including the technical 
files), and, if required, service and maintenance schedules. Each device is given a 
unique asset identifier, even if more than one of the specified device is 
manufactured. Other identification details of the device may also be kept on file e.g. 
software version, photograph and model number. 
4.10.4.2 Identification of ‘In-House’ In Vitro Diagnostic Devices. 
These are developed by the HMFUS department. Any IVDD developed is identified 
by its batch manufacture reference. The batch manufacture documentation also 
details the user and user location. The batch manufacture documentation contains 
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all the details necessary to manufacture the IVDD, including manufacture process, 
material lot and identifier information and the final test results. 
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4.11 Responsible Person or Persons 
The EU legislation(2,3), at Article 15, and the UK legislation(4), at paragraphs 80 and 
149, introduce a new requirement for manufacturers, distributors and those 
individuals or bodies acting as agents, to have a  ‘Person responsible for regulatory 
compliance’, a PPRC. This person or persons must be appropriately qualified and 
experienced in regulatory matters, and have the authority and responsibility to 
influence and control, the organisation’s regulatory compliance to relevant 
legislation(153). 
The persons responsible for regulatory compliance (PRRC) cannot act for both the 
manufacturer and distributors or agents; they must be separate individuals. For 
small or micro businesses(154), the role of the PRRC can be outsourced or shared 
between a numbers of such businesses, as long as there are no conflicts of interests 
between the work undertaken by these businesses. 
4.11.1 Required Qualifications and Experience 
The qualifications required for the role of responsible person or persons are a 
university degree or equivalent course of study in law, medicine, pharmacy, 
engineering or another appropriate scientific discipline, and at least one year of 
professional experience in quality or regulatory work for medical devices, or, four 
years professional experience in quality or regulatory work for medical 
devices(153,155). 
4.11.2 Person Responsible for Regulatory Compliance within Health Care 
Institutions. 
There appears to be no legal basis for a PRRC within Health Care Institutions, under 
the exemptions for health care institutions. This does not mean that such a person 
or persons is/are not required. A PRRC or several PRRCs should be nominated as 
the exemptions require the health care institution to produce documentation to 
satisfy the exemption requirements, maintain and update data that can be viewed 
by the public and ensure that ‘post market surveillance’, as detailed in the 
legislation, is undertaken and can be a point of reference for the relevant authority 
and members of the public. The PRRC must also maintain an oversight of the 
regulatory requirements, and review the quality systems, applicable within the 
Page 101 of 513 
 
 
health care institution, and used in the design, development and manufacture of 
devices, to ensure that they continue to meet the changes in the regulatory or 
associated standards. 
Within a health care institution, it may be necessary to have a small group of PRRCs 
as a health care institution may design and manufacture various types of both 
medical and in vitro diagnostic devices. These devices may not all use the same 
science, technology or chemistry and some may, in fact, be software devices. 
Accordingly, a number of individuals, with different knowledge and experience, 
will be required to ensure these various devices meet regulatory requirements.  
4.12 Software used as a medical device or in vitro diagnostic device 
The previous legislation covering in vitro devices mentioned software four times, 
but did not specify control or risk factors for the software. The legislation in the old 
medical device directive referred to software twice and stated that it was to be 
classified as being in the same risk class as the device it was to be used in or with. 
By contrast, the new UK legislation mentions software 88 times, the IVDR 44 times 
and the MDR 48 times. 
Schedules 3 and 17 of the UK requirements, (which are the same as the EU MDR 
and IVDR requirements) refer to ‘Electronic programmable systems — devices that 
incorporate electronic programmable systems and software that are devices in 
themselves’. Software could range from being a simple spread sheet, which is used 
to calculate drug dose from a person’s mass, height, age, etc to a full radiotherapy 
beam planning system.  
The risk classification of such software will either be the same as the device it is 
associated with or, if independent software, be classified as a standalone device and 
the derived risk classification will be the highest risk class associated with the use 
of the software. Risk Classification Rule 11 for medical device risk classification 
in both UK and EU medical device legislation, details the risk levels for software. 
The implementation rules for in vitro diagnostic devices informs that independent 
software is classified in its own right. 
The risk classification is dependent on the device type is it an medical device or is 
it an in vitro diagnostic device(158). 
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The standard BS EN 62304:2006+A1: Medical device software. Software life-cycle 
processes(156), details the procedure for medical device software development and 
maintenance. This standard defines three software safety classes: 
‘Class A: the software cannot cause any harm 
Class B: the software can cause minor harm such as injuries 
Class C: the software can cause major harm such as severe injuries or even 
death’ 
These definition of safety classes may assist in the risk classification of the 
software(157)  
The risk classification will influence how the software is implemented and tested. 
The level of detail concerning the software contained in the technical file and the 
user information will, also, be dependent on the risk classification of the device.  
Software will require a UDI if it is classed in its own right as a device(160). 
The documentation issued to users of software must contain details of the minimum 
requirements of both operating hardware and associated software, that is – 
operating system, processor and memory requirements, display and input device, 
etc. 
Any software developed as an ‘in-house’ device or for use within an ‘in-house’ 
device must follow industry standards for its design and development. Software 
should undergo the same rigorous design, development and testing processes as the 
other parts of the device being developed. Standalone software must be treated as 
if it were a device – and so technical documentation must be produced, testing must 
be carried out and external assessment as per the risk classification of the software 
must be undertaken. 
These new requirements will have an impact on the development of software 
applications as they will have to meet the full requirements of the relevant device 
legislation. For example, simple spreadsheets have now been classified as medical 
devices or in vitro diagnostic devices. A simple programme which takes some basic 
patient parameters, for example, height, weight and sex then uses this information 
to calculate a drug dose, could be classified as a medical device, and depending on 
the drug being dispensed, will influence the final risk classification of the software. 
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 CASE STUDY 
Academics at Dundee University have been working on a prototype OCE system 
since 2012(160,161,162). This prototype system has been developed to determine if the 
combined use of optical coherence tomography and elastography could be used to 
the review prostrate samples for possible signs of cancerous nodules in real time. 
As previously described, one of the aims of this thesis was to review the OCE 
system to determine if it was fit and safe for clinical use within NHS Tayside . This 
review determined that guidelines were needed to ensure medical and in vitro 
diagnostic devices, resulting from academic research and development, would meet 
the requirements of UK legislation. These guidelines would specifically relate only 
to devices manufactured for ‘in-house’ use within NHS Tayside.  
5.1 Background to the OCE project. 
The initial trial of the OCE system(170), was carried out by analysing prostrate biopsy 
samples prior to clinical review and reporting by a pathologist. The samples were 
transported from the urology theatre to a university laboratory within Ninewells 
hospital. Once the samples had been scanned, they were returned to the theatre, and 
finally sent to pathology for analysis and reporting of results. This multi-step 
process was required as the OCE system was classified as a research device, and 
had not been fully tested, or checked, for use within clinical areas.   
Analysis of the data collected showed that there was a good correlation between the 
results from the OCE system and the pathology results (79,170). Although this first 
study only comprised of 10 subjects, the promising results shown, were sufficient 
to justify a follow-up study.  This study would involve a larger cohort of patients, 
and the findings from this research, would, hopefully, validate the previous results.  
It was noted that to enable larger number of samples to be evaluated, it was 
important that the OCE system was located within the areas adjacent to the urology 
operating theatre.  
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5.2 Initial review of OCE system 
5.2.1 OCE Review Process 
A risk assessment of the OCE system was needed, prior to it being located within 
the urology theatre area. This assessment was carried out by staff of the Medical 
Physics Department (MPD) of NHS Tayside, to ensure it was safe, and fit for use 
within a clinical area.  
The review looked at the documentation relating to the OCE system and, in 
particular, the user information, the information relating to the system calibration, 
repair and maintenance. An additional review would also be needed, to assess the 
possible risk due to the construction of the system, or emissions being produced by 
the system, for example optical, acoustic or radiation emissions. Prior to the system 
being used within a clinical area, it would also need to be assessed by the infection 
control department of NHS Tayside. This assessment would ensure that the device 
would be cleaned, using appropriate methods, and that the use of the device would 
not pose any infection control hazards. 
The results of this review should indicate any modifications required and the 
documentation to be produced, to enable the OCE system, to be signed off as fit for 
use within NHS Tayside. 
5.2.2 Review findings 
The OCE system consisted of a control computer, (including keyboard, mouse and 
display monitor), an anti-vibration table supporting the optical coherence system 
and required laser source. The Elastography sample vibration system was mounted 
on a three axis movement, which was also located on the anti-vibration table. The 
sample vibration system was driven by an external signal source and coupled to an 
external power amplifier. 
5.2.2.1 Electrical and electronic construction and safety. 
A review of the electronics identified the following concerns regarding the safety 
of the OCE system: 
• The electrical connections within the OCE system were haphazard, 
unsecured, and not terminated correctly.  
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• The electronic layout needed to be rationalised, in particular the location of 
the PC, keyboard and monitor.  
• The power amplifier and signal generator used to power the sample 
vibration system was not secured.  
• The laser, associated with the device, was not secured, and no local rules or 
risk assessment was available 
• The power adaptors used, had not been secured and the complete system 
had never been electrically safety tested. 
The staff, responsible for electronics at the Medical Physic department and who had 
been assigned to oversee this project, rewired: the control system, the driver for the 
sample vibration system and the PC control interface. The mains power distribution 
was reconfigured and the superfluous/unnecessary mains extensions, were 
removed. 
Further work, which was undertaken included, adjusting the wiring from the control 
PC so that it was simplified, rerouted, shortened and correctly terminated. Trunking 
was used, where possible, for external cabling and wiring. It was also noted, that 
the power amplifier, driving the sample vibration system, was overrated for its 
application.  
On completion of this corrective work, the system was safety tested to ensure it met 
the requirements of ‘BS EN 61010-2-101:2002 Safety requirements for electrical 
equipment for measurement, control, and laboratory use - Part 2-101: Particular 
requirements for in vitro diagnostic (IVD) medical equipment’(163). 
 
5.2.2.2 Mechanical construction and device stability. 
A review of the systems mechanics would ensure that the manufacture and 
construction of the device was safe, i.e. that there were no exposed live electrical 
parts, no exposed sharp edges and no hazardous detachable components. The 
review would also identify any risk to the operator due to the size and weight of the 
system. 
The OCE system’s stability was not of concern as the OCE system’s weight 
distribution brought its centre of gravity closer to the ground. However, the table, 
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supporting the amplifier and signal generator was tall, with a small footprint, which 
would cause stability concerns. The wheels on this table were small in diameter, 
making the table difficult to steer and hard to get over expansion joints and 
manoeuvre into lifts. To overcome this, a lower and larger table was found and 
modified to hold the amplifier and frequency generator. This table had larger 
diameter wheels fitted to ensure ease of movement. 
It was noted that a number of the enclosure covers were missing. These were 
remade and fitted to the system protect the OCE assembly and components from 
being tampered with, to reduce the ingress of dirt and to improve the ease of 
cleaning the system. Additional support brackets were produced to ensure the 
sample vibration system, and the laser light source, were securely attached to the 
optical platform. Finally, the computer display and keyboard were replaced with 
medical grade touch screen monitor. 
5.2.2.3 Optical and acoustic radiation/emission and safety. 
During the review of the OCE system, it was noted, that when in use, the sample 
vibration system produced significant levels of acoustic noise. Acoustic absorbing 
material was fitted to the inside of the enclosure, to reduce these noise emissions. 
An initial risk assessment of the laser source was based on information obtained 
from the manufacturer. This information stated the source was ‘eye safe’, and, 
therefore no additional safety precautions (for example remote interlock or laser 
warning labels) were required. However, a risk assessment of the laser was 
undertaken by NHS Tayside’s non-ionising radiation protection officer, who found 
that there was a requirement for both the use of an interlock, as well as displaying 
appropriate hazard warning labels.  
5.2.2.4 Infection Control requirements. 
The infection control department of NHS Tayside carried out a review of the OCE 
system after the above remedial work was completed. This report stated, that the 
improvements made by upgrading the monitor and trunking, would allow the 
system to be easily cleaned and, therefore, comply with infection control 
requirements. 
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However, it was noted that cleaning and decontamination instructions would need 
to be produced, and if possible, to manufacture covers for the partially open base of 
the unit. In addition, a review of the area containing the actual sample and sample 
vibration system was carried out to prevent possible contamination from the biopsy 
sample or preserving fluids. Clear instructions on how to protect the biopsy sample 
during the scanning process would also need to be given in the user instructions. 
5.2.2.5 OCE System Documentation 
This was an area of concern for those reviewing the OCE system, as there was little, 
or no information, relating to the actual system. The documentation reviewed 
included numerous academic papers about the system but, vital documentation 
including the user guide, calibration status, hazard identification and construction 
guide, had not be written. As there was no ethically approved protocol for the 
proposed follow up clinical trial, any work involving patient samples, should not 
be undertaken until this had been completed and the required ethical approval, 
given. 
5.3 Rational for a Case Study  
This lack of documentation would prevent the system from being risk assessed, and, 
therefore, it could not be used within clinical areas.  As detailed in the aims of this 
thesis, the OCE system would be reviewed as a case study, to determine what 
documentation would be necessary to ensure that the OCE system would meet the 
requirements of the exemptions, detailed in the UK legislation(4) for any ‘in-house’ 
manufactured device.  
Following this review, guidelines would be produced for use by M&H or when 
working in collaboration with academics or third parties, during the design and 
manufacture of medical or in vitro diagnostic devices for ‘in-house’ use, so as to 
ensure that they are correctly controlled and documented. Further, by following 
these guidelines, the exemption requirements, detailed in UK law, for ‘in-house’ 
manufactured device, would be met. Any devices meeting these exemptions 
requirements would also meet the requirements of NHS Tayside. 
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5.3.1 Case study outline 
The outcome of this case study would be the drawing up of guidelines for those 
individuals, working on academic projects, to ensure they are correctly controlled 
and documented. These guidelines, if followed, would result in medical or in vitro 
diagnostic devices meeting the requirements of the exemptions detailed in the UK 
legislation(4) paragraphs 71 and 140 for ‘in-house’ manufactured devices. The 
guidelines would also ensure, that the documentation required to demonstrate that 
the exemption requirements have been met, is produced. To simplify matters, a 
device, by meeting these exemption requirements, should also meet the 
requirements of NHS Tayside. 
5.3.2 Case Study Plan 
To achieve the primary aim of this thesis the following actions were to be 
undertaken. 
• To review the exemptions contained in the UK legislation(4) relating to the 
‘in-house’ manufacture of medical and in vitro diagnostic devices, in order 
to determine what documentation needed to be produced and which actions 
were required, to  meet these exemption requirements.   
• To produce the documentation required to show that the OCE system met 
the legislative exemptions. 
• To draw up guidelines, for use by the University of Dundee Engineering 
School, to ensure that these documents were produced in future academic 
projects related to medical and in vitro diagnostic devices. 
• To have the documentation and design files of the OCE system reviewed by 
M&H QA auditors and, if possible, by external auditors. 
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5.4 UK Exemption for ‘In-House’ Manufacture  
The exemption requirements for the ‘in-house’ manufacture of medical and in vitro 
diagnostic are detailed at paragraph 71 and 140 of the UK legislation(4). The 
following is a synopsis of these exemptions. 
These exemptions relate to devices, manufactured, or modified, within a health care 
institution for ‘in-house’ use only. These devices must not be transferred to another 
body outside the manufacturing health care institution. 
Under these exemptions, the GSPRs apply to devices manufactured or modified for 
‘in-house’ use. 
The exemptions also require that:  
a. A justified reason be given for the need and manufacture or modification of 
such devices; 
b. Proof that these devices are designed and manufactured under a suitable 
quality system; 
c. A declaration, detailing that the device meets the requirements of the 
exemptions, must be drawn up, and confirms that device is manufactured in 
accordance to the manufacturing documentation detailed in point d below. 
The declaration must also detail how to identify the device and give the 
contact details of the manufacturing health institution. 
d. The documented details of the device, should state: the intended purpose and 
performance of the device, how it works or is to be used, how it is 
manufactured and maintained so as to be fit for use, and details given as to 
how it meets the relevant general safety and performance requirements. 
e. The details of how experience gained in clinical use will be gathered, 
evaluated and acted upon. 
Again, it must be noted, that these exemptions are not to be used to manufacture 
devices on an industrial scale. The term ‘industrial scale’ will be assessed on the 
basis of the number of ‘in-house’ devices produced in relation to the number of 
equivalent commercial devices which are produced. 
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5.4.1 Exemption Documentation.  
5.4.1.1 Justification  
The justification for the manufacture or modification of the device must detail why 
no other device, currently available for purchase, will provide the functionality or 
test required. The justification must inform as to the desired outcome of the device 
or device modification and why there is an important but significant unmet clinical 
or medical need. 
5.4.1.2 Proof of Quality System Used 
The evidence that the device has been manufactured under an appropriate quality 
system must be provided. This could be evidence of accreditation to an appropriate 
quality standard or a full description of the quality system used.  
5.4.1.3 Device details 
In the description of the device, the details should include, the purpose of the device, 
the intended users and patient group, how it functions and the performance criteria 
of the device. User instructions must be included and outline the maintenance of 
the device, appropriate cleaning instructions (including sterilisation instructions if 
applicable), calibration or quality checks required, troubleshooting advice and, in 
the event of a device failure, who to contact. 
Many of these details will/should be obtained from the evidence generated when 
addressing the General Safety and Performance Requirements (GSPR). 
5.4.1.4 General Safety and Performance Requirements 
Prior to addressing the GSPRs, the device type/class must be determined to ensure 
that the correct device risk classification is ascertained. Once the device type and 
its’ risk classification are known, then the GSPRs can be addressed.  
The risk classification rules which need to be followed will be dependent on 
whether the device is a medical device or an in vitro diagnostic device. The 
definitions given in the UK legislation(4) and the EU Regulations(2,3) can be used to 
determine if the device is a medical device or an in vitro diagnostic device.  
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As stated, once the device type is known then the risk classification of the device 
can be determined. This can be accomplished by following the appropriate 
classification rules. The rational for the final device classification must be 
documented. 
Evidence of how each GSPR, has been or will be met, must be documented The 
document must detail whether the requirement is applicable, details of how the 
requirement is to be fulfilled, or why it is not applicable, and the storage location 
of the evidence detailing how the requirement has been met. Table 5.1 is an extract 
of the draft GSPR document produced for the OCE system. The information 
contained in the documents produced to address the GSPRs will be used to address 
the exemption requirements. 
The draft GSPR matrix for the OCE system is given in Appendix 5.01 ‘OCE 
General Safety and Performance Requirements Matrix’. 
5.4.1.5 A manufacturing file 
Written instruction must be provided detailing how the device was manufactured, 
all acceptance testing undertaken, required labels and suitable packaging required 
to preserve the integrity of the device. This document should be detailed enough to 
allow future devices to be produced. 
5.4.1.6 Post manufacture and in use feedback 
These are the details of how the clinical and user experience will be gathered, 
evaluated and acted upon. This evidence is not only from the device user feedback, 
but from, for example, repair and service information, discussion with users and 
even continuing research in the field of the device leading to device improvements. 
This documentation must detail when to contact the relevant authorities, when to 
produce any required feedback reports and what actions are to be taken, if the device 
is involved in a serious incident. 
5.4.1.7 Declaration 
This is a declaration that the device meets the requirements of the exemptions. The 
declaration will contain a brief explanation of why the device or modification is 
required, how the device can be identified, and the details of the quality system used 
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to control the manufacture of the device. The declaration will state the location of 
the documentation to support this claim. The declaration will be signed by a 
responsible manager of the relevant health care institution, who will give their 
contact details and also the details of who should be contacted for further 
information or assistance, relating to the device, if required. Note that a responsible 
manager will need to be somebody with the legal authority to sign on behalf of the 
health care institution, the collaborating university or third party.  
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Table 5.1 Extract of the Draft General Safety and Performance Matrix for the OCE system. 
 
Essential Requirement  A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
6. The characteristics and performance of a device shall not be 
adversely affected to such a degree that the health or safety of 
the patient or the user and, where applicable, of other persons 
are compromised during the lifetime of the device, as 
indicated by the manufacturer, when the device is subjected to 
the stresses which can occur during normal conditions of use 
and has been properly maintained in accordance with the 
manufacturer's instructions. 
A EN ISO 14971:2012/2019 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-1:2016 
WIRD05 Risk Analysis 
Correct use details found in 
the user manual. 
OCE user manual held in Q-
Pulse . As this is a prototype 
device and under development 
this area needs to be reviewed 
after each modification or change 
both hardware and software. 
7. Devices shall be designed, manufactured and packaged in such 
a way that their characteristics and performance during their 
intended use are not adversely affected during transport and 
storage, for example, through fluctuations of temperature and 
humidity, taking account of the instructions and information 
provided by the manufacturer. 
A IVDR  
BS EN 60601-1 and BS EN 
61010 – and associated 
standards 
 
OCE Technical File  OCE technical file retained in –
Q-Pulse. 
8. All known and foreseeable risks, and any undesirable effects 
shall be minimised and be acceptable when weighed against 
the evaluated potential benefits to the patients and/or the user 
arising from the intended performance of the device during 
normal conditions of use. 
 EN ISO 14971:2012/2019 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-1:2016 
WIRD05 Risk Analysis. 
Residual risks detailed in the 
user manual.  
OCE user manual held in Q-
Pulse .  
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5.4.2 Publicly available information 
The exemption requirements detail the information which needs to be made 
available to the public. This information will include contact details of the 
institution, (and the relevant contact details of the department responsible for the 
device), details that are necessary to identify the device, a declaration that the device 
meets the GSPR and the rational for any of the requirements deemed not to be 
applicable. All of this information can be gleaned from the documentation referred 
to in section 5.4.1 ‘Exemption Documentation’. 
5.4.3 The OCE documentation Review and the Documentation Required. 
This review was undertaken to determine if any of the available OCE system 
documentation could be used to meet the exemption requirements of the UK law.  
5.4.3.1 Documentation review outcome 
The review determined that only academic papers had been produced for the OCE 
system. Some of these papers did have technical and user information relating to 
the device, but this information was not sufficient for the purposes of the exemption 
requirements.  
The classification of the OCE system was not stated in any of the academic papers 
– in short, was it a medical device or was it an in vitro diagnostic device? As 
previously stated, this basic, but important information determines which set of risk 
classification rules are to be followed and which of the GSPRs are to be reviewed 
and met. 
Further there was no documentation detailing how the OCE system was assembled 
or the parts used in its manufacture, nor were there any details of how to set up or 
calibrate the system. Also omitted, were the details of the maximum or minimum 
size or physical volume of the samples to be scanned, the resolution of the scanned 
image was not stated, no validation of the elastography results had been undertaken 
nor an understanding of the ability of the system to differentiate between the areas 
of different stiffness within the samples. If the device failed the published thesis, 
and supporting papers, did not contain enough detailed information to enable the 
device to be repaired. 
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In addition, there was no information as to how to use the device, how the data 
obtained from the analysis would be stored within the patient‘s medical file, nor 
how the analysis of the scanned images was undertaken. The only people with 
sufficient knowledge as to how to operate the OCE system, were the academic staff 
who had carried out the work on the system and those individuals supervising this 
work. If any other person was required to operate the OCE system then, in order to 
do so, they would have had to seek assistance from these members of staff. Without 
their assistance/input, the OCE system could not be operated by anyone else. 
It was also noted that no risk assessment nor hazard reduction analysis nor review 
had been undertaken to determine the safety of the OCE system.  This meant that 
essential data/information was unavailable, for example there was no indication of 
possible contra-indications to the use of the system, the hazards arising during the 
use of the system were unknown, the optical hazard from the laser used in the OCE 
system, had not been checked and the risk, associated with the contamination of the 
sample placement area, was also unknown.  
Lastly, there was no documentation detailing how the OCE system met the Essential 
Requirements of the old regulations.  
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5.5 OCE system - Exemption Requirements Documentation to be produced  
The following is the list of documents to be drawn up to directly address the 
exemption requirements or to enable these requirements to be met in respect of the 
OCE system. 
1. Justification that the OCE system provides a function not yet met by another 
device available on the market. 
2. Evidence of an appropriate quality system. 
3. Classification of the OCE system. 
4. Completed GSPR Matrix for the OCE system and documentation to support 
how the relevant requirements have been or will be fulfilled. 
5. A risk and hazard analysis which must detail any residual risks and 
contraindications to the use of the OCE system. This analysis must also have 
a formal statement confirming that the device is safe to use. 
6. The documentation must detail how the feedback, relating to the OCE system, 
is gathered, and how this feedback is analysed and reported.  
7. How the device is identified, its location tracked while in use and the actions 
to be taken if the device goes missing. 
8. Reports on the clinical and system tests to determine the operation limits of the 
OCE system e.g. scan resolution, elastography resolution (the ability of the 
system to differentiate between areas of different stiffness) and the results of 
clinical trials. 
9. Calibration instructions 
10. User and cleaning instructions 
11. The technical and manufacturing data required to meet the exemption 
requirements. 
12. A declaration that the device meets the UK exemptions. 
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5.5.1 OCE System Device Type and Risk Classification  
5.5.1.1 Device type 
During the review of the existing documentation relating to the OCE system, it was 
found that the device type of the OCE system had not been determined, in other 
words - was the OCE system a medical device or was it an in vitro diagnostic 
device? By answering this question, the area of the UK legislation required to be 
followed, would be determined. 
The definition of a medical or an in vitro diagnostic device used is that given by the 
Global Harmonisation Task Force (GHTF), (evolved into the International Medical 
Device Regulators Forum (IMDRF))(165) and echoed by the Food and Drug 
Administration (FDA)(166,167), the EU Regulations(2,3) (Article 2 Definitions 
Sections) and the UK legislation(4) (Scope and Definitions Sections New Part VIII 
and New Part IX). 
The OCE system requires that a biopsy sample is taken and then scanned to 
determine the pathology of this sample. This aligns with the definitions of an in 
vitro medical device. Hence, the risk classification of the device will be based on 
Schedule 23 Regulation 1A ‘Classification Rules for in vitro diagnostic medical 
devices’ of the UK legislation(4). 
5.5.1.2 OCE risk classification 
The risk classification is required to ensure that the device is designed and 
manufactured to meet the risk posed by the device during its intended use. The risk 
classification is also required when determining which of the GSPRs are applicable 
to the device. The type and level of control, and the reporting of post market 
feedback, is also dependent on the risk classification of the device. The risk 
classification for the OCE system can be determined by following WI-RD.07 
‘WIRD07 Classification Rules IVDR’(102). By using this work instruction, the OCE 
system risk classification is found to be Class C. This classification is derived as 
follows: 
1. Does not apply as the device is not used for the purposes of determining 
infection load or infection transmissibility. 
2. The devices is not used for compatibility checking.  
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3. The device is used for screening and in the diagnosis of cancer.  
Applicable – Class C 
4. Device is not intended for self-testing but near patient testing as per Rule 4 
point (5): Rule 3 still applies. 
5. Not one of these devices. 
6. Device is cover by Rule 3. 
7. Device is cover by Rule 3. 
See Appendix 5.02 Risk Classification For the OCE System. 
5.5.2 General Safety and Performance Requirements Review. 
As the OCE is a Class C in vitro diagnostic device, the General Safety and 
Performance Requirements detailed in SCHEDULE 17 Regulation 1A are to be 
reviewed, and the documentation produced, to detail how the applicable 
requirements are met. An explanation of any requirements which are not applicable, 
must also be provided. 
To facilitate this review the matrix, detailed in WI-RD.10 ‘IVDR General Safety 
and Performance Requirements Matrix’(102), was used. The completed matrix is 
given in Appendix 5.02. As this device is a prototype, all the documentation 
referenced in the GSPR matrix and GSPR matrix itself will need to be updated on 
a regular basis as the OCE system undergoes modifications and improvements. 
Points to note from the GSPR review given in Appendix 5.01 
Some of the GSPRs have been deemed not applicable. For example the OCE system 
is not for self-testing, the OCE system does not require packaging nor does it use 
any reagents to produce a test result. 
Due to the OCE system not being a traditional in vitro diagnostic device, the 
harmonised standards given for in vitro diagnostic devices were supplemented with 
more applicable standards. For example, the BS EN IEC 60601 family of standard 
for medical devices was deemed the best fit for the OCE system design and 
construction. The BS EN IEC 61010 family of standards for laboratory equipment 
was deemed appropriate to ensure the electrical and mechanical safety of the OCE 
system. 
Page 119 of 513 
 
 
5.5.3 Risk / Hazard Management and Analysis 
The GSPRs for in vitro diagnostic devices are given in UK legislation(4). In 
particular, paragraph 3 of Part 1 of Schedule 17 Regulation 1A requires that a risk 
management system is to be in operation to ensure that risks and hazards are 
analysed and reduced to an acceptable level prior to putting an in vitro diagnostic 
device into use. It was noted that no risk / hazard analysis had been carried out on 
the OCE system. 
The risk analysis for any medical or in vitro diagnostic device should start as soon 
as the device specification is known and agreed. This is to ensure that any risks 
noted, are taken into account at the start of the design and development phase, rather 
than trying to include changes, due to risk or hazards, at the end of this phase. Risk 
analysis reviews should be undertaken throughout the lifetime of a device from the 
concept phase through to the scrappage of the device. This will ensure that any 
hazards and /or risks found, no matter at what stage of the life of the device, are 
reviewed, analysed and reduced to an acceptable level. 
BS EN ISO 14971:2019(169) is the harmonised standard for risk in both medical and 
in vitro diagnostic devices. To enable the risk analysis to be undertaken and 
documented, M&H work instruction WIRD05 Risk Analysis(102) was followed. 
The initial risk analysis for the OCE system is given in Appendix 5.05. The final 
risk analysis of the system must contain a statement confirming that the use of the 
OCE system outweighs any residual risks or hazards associated with the OCE 
system when operated as intended. 
All changes to the OCE system must be reviewed to ensure that they do not 
introduce any new risk or hazard or exacerbate any existing risk or hazard. 
Similarly, the risk management system must, with respect to risks and hazards, 
review any feedback from users, patients or others obtained from the post-
production and in use phase of the OCE system. The result of all risk and hazard 
reviews are to be documented and any recommendations acted upon. If the 
recommendation is that ‘no action’ is required, then this too, must be documented.  
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5.5.4 Device Feedback and notification control 
Another requirement of the legislation to be taken into consideration is the Post 
Market Performance Follow-up, ‘PMPF’. This ‘follow-up’ requires that the 
performance of the OCE system is reviewed to ensure that it is functioning 
correctly, and that the results produced, are clinically correct and as expected. Post 
market surveillance will be controlled by four new M&H Work Instructions to be 
produced as a result of the work of this thesis. The work instructions will be: 
1. Post Market Surveillance; 
2. IVDD Post Market Performance Follow-up;  
3. MD Post Market Clinical Follow-up; and  
4. Generation of Periodic Safety Update Reports.  
5.5.5 Technical, Manufacturing and User Information  
The requirements for the technical file, for a fully compliant CE marked device, are 
detailed in WI-RD-01 ‘WIRD01 regulatory legislative technical file contents’ (102). 
Section 2 of this WI outlines the technical file contents for an IVDD. This work 
instruction is derived from Schedule 18 of the UK legislation(4) and Annex II of  EU 
IVDR regulation(3). As this is a prototype ‘in-house’ device, some of the 
requirements have been deemed not applicable, or the requirement is amended, to 
meet the requirements of the exemption. Table 5.2 is a list the documentation 
required by the exemptions to be produced for the OCE system. Once completed, 
this documentation will be held, either in the OCE system technical file retained in 
Q-Pulse, or its location will be given in this technical file. (Note Q-Pulse is a 
commercial application used within Medical Physics to control and manage 
documentation and activities associated with the M&H quality system.) 
As the OCE system is a device for ‘in-house’ use only, the certificate of conformity 
is not required, but a declaration, that the device meets the requirements of the 
exemptions, is required. 
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Table 5.2 Documentation required as proof the OCE system meets exemption requirements 
Requirement  Applicable 
YES/NO 
Reason for non-applicability or description of  
Title, Index and Certificate of Conformity. Yes Need a certificate to inform that the device meets the 
requirements of the exemptions. 
Device Description, Variants, Accessories and Specification Yes Outline of the function of the OCE and a device 
specification is required. 
Information supplied by the Manufacturer  Yes Full user instructions including labelling description, 
cleaning instructions, calibration details, residual 
risks/hazards related to OCE system use and safety 
information. 
Design and Manufacturing Information Yes A general description of the steps taken to design and 
develop the device. More detailed information on how 
the OCE system work.  
Full details of how to manufacture the OCE – parts 
lists, wiring diagrams, mechanical drawings, tests to be 
carried out, all software to be loaded and how tested, 
final test and calibration checks. 
General Safety and Performance Requirements Yes The General Safety and Performance Requirements 
Matrix 
Risk/Benefit Analysis and Risk Management Yes Output from WIRD.05 risk and hazard assessment 
Product Verification and Validation Yes This information contained in the design and 
manufacturing documentation. Also this information 
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not as extensive as this is still a prototype device and 
not all testing on the performance of the device is 
completed. 
Device Performance Yes The evolution of the device performance is still 
ongoing and hence this section can only detail the 
various comparisons carried out so far between 
biopsies scanned on the OCE and then sent to 
pathology for review. Work still to be carried out is to 
determine is the minimum dimension/volume of 
sample to be scanned and if the method used to 
obtain the sample affects the scanning result.  
Device Accuracy Yes Determination of device accuracy still ongoing. So can 
only detail the testing being carried out and the optical 
calibration using the calibrated test plate. 
Clinical Performance and Clinical Evidence Yes Details of testing methods and result evaluations of all 
tests carried out to determine the performance and 
efficacy of the OCE system. How these are reviewed 
and reported. 
Stability Yes  How was the OCE working life time determined and 
verified?  
Note For a chemical/biological based IVDD this will be 
the stability of the actual chemical/biological mix both 
in use and pre-use – storage, shipping and shelf life.  
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Software Validation and Verification Yes The information relating to the bespoke software and 
algorithms written to enable the OCE to operate and 
produce scan data. How this was tested and results 
verified.  
Additional Information No  
Quality System Yes A note in the certification to state the OCE system was 
designed and manufactured under a system 
complainant to 13485:2016 and aspects of the work, 
as defined, are as required by 15189:2012. 
Standards Yes A list of standards followed to be given on the 
certification.  
Self-testing Devices No This is not a self-testing device.  
Changes and additions Yes All changes and additions are controlled via QP.01 and 
logged in the Q-Pulse system 
Post Market Surveillance Plan Yes Reduced post market surveillance plan but it most 
include details of how all feedback, experienced 
gained from device use and incidents relating to the 
OCE system will be gathered and reviewed to 
determine if they are reportable to external 
authorities  
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5.5.6 User and cleaning instructions 
Two of the most important documents to be produced are the User Instruction and 
the Cleaning Instructions.  
The remit of those working on academic projects is to produce academic papers. 
The technical and scientific information contained relating to any device 
manufactured is often not complete, and the information as to how to use the device 
is either lacking, or non-existent. If projects developing devices are to be continued, 
then those working on these projects should pass on technical and scientific 
information to their successors. They should also instruct their successors on the 
operation of any devices made and how to interpret the information any such 
devices produce. In many cases this information is either not passed on, or is lost. 
Without this basic information the device is no longer usable, and time has to be 
spent, regaining the knowledge to use the device and interpret any output from the 
device. The details required to meet the GSPR will also outline details how to use 
a device, interpret the output from the device as well as, maintain, repair and clean 
the device. 
The draft user instructions, given in appendix 5.06, were drawn up following the 
requirements detailed in the GSPR relating to the information to be contained in the 
user instructions. 
Cleaning instructions must also be produced in respect to a device. Without these 
cleaning instructions the OCE system will not pass the inspection carried out by the 
NHS Tayside infection control team. The team will need to see and review the 
cleaning instructions to ensure users can clean, or if required, sterilise the devices. 
The team will determine if these instructions are sufficient. (As an aside, even if the 
device was only to be used in a laboratory setting, the method of cleaning the device 
must be validated and documented). 
The OCE system may be used to scan biopsy samples. In these cases, the cleaning 
instructions for the OCE system must include instructions on how to clean the area 
within the sample scanning area. These instructions are required in case a sample 
falls, or any sample fluid is spilt in this area. These cleaning instructions should be 
contained in the user instruction. 
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5.5.7 Calibration instructions 
The exemptions for devices manufactured ‘in-house’ require that these devices are 
safe and fit for use over the foreseen lifetime of the device. To ensure that the OCE 
system is fit for use, the output from the scanning system should be periodically 
checked to ensure that the image produced is correct and that the Elastography 
system is able to detect the small changes in stiffness required to highlight the 
difference between normal cell formations, and cancerous cell nodules. While 
reviewing the OCE system it was found, that there were no instructions for the 
calibration, or checking, of the device’s scanning function. The only check that 
could be found, was one relating to the scanning of human hair. This showed that 
the OCE system could scan very small objects but it did not inform as to the 
accuracy of the dimensional image produced, nor to the ability of the device to 
differentiate between differences in elasticity within a scanned sample. These 
checks of the OCE system are still to be determined and tested. 
5.5.8 Declaration that the device meets the UK exemptions. 
The information required in this declaration is set out in paragraph 140, of the UK 
legislation(4), ‘Placing on the market and putting into service’ part (5) subsection 
(f). The information required is set out in 5.4.2 ‘Publicly available information’ 
The declaration drawn up for the OCE system is shown in Appendix 5.01. Again it 
should be noted that this declaration is to be publicly available; possibly via the 
University of Dundee and / or NHS Tayside public web sites. 
5.5.9 Review of ongoing changes to the OCE System 
Those individuals working on this project, must ensure that any changes to the OCE 
system are reflected in the documentation produced, including the manufacturing 
data for changes to the hardware or software, updates to the risk and hazard review 
documentation, test reports, changes to device calibration and test methods and the 
user manual. 
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5.5.10 Conditions of use. 
This is not a requirement of the exemptions. These ‘conditions of use’ are there to 
inform the device users that the device is not to be transferred, or used outside of 
NHS Tayside. The conditions of use also detail the cleaning instructions, 
specifically the details on how to identify the device and as required user 
instructions. The conditions of use are authorised by the senior Clinical Engineering 
management, the senior clinical or medical staff responsible for the use of the 
device and the senior infection control staff. 
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5.6 Guidelines for academic and third party work 
After the work, to ensure that the OCE system met the exemption requirements of 
the UK legislation, was completed, it was determined that guidelines should be 
produced to ensure that devices resulting from academic, or other third party work 
would meet the exemption requirements of the UK legislation. These guidelines 
needed to be easy to follow, fitted in with the requirements of an academic thesis, 
resulted in the correct documentation being produced, and ensured that the devices 
produced, met all the safety and documentation requirements of the legislation. 
The usual content of a thesis consists of 4 key elements:  
1. an introduction to the work to be carried out,  
2. the background, including a literature review, to the science and engineering 
of the work to be carried out,  
3. a section detailing the actual work/research carried out and  
4. the final section giving a summary of the results of the project and any 
recommendations for future work. 
The exemptions required by the UK legislation to allow devices to be developed 
and manufactured, by those working in or for a health care institution, require a 
number of elements. In summary, the following are required: 
1. A full justification of why a device which carries out the function to be 
developed, cannot be purchased;  
2. Full details of how the device functions or operates, the evidence that the 
General Safety and Performance Requirements, where possible, have been 
met along with the supporting evidence, the manufacturing and production 
documentation and details of how the information relating to the device is 
gathered and analysed and:  
3. a declaration that the device meets the exemption requirements.  
5.6.1 Outline of the proposed guidelines 
The following is an outline of how the three main elements of the exemption 
requirements are included into the four elements/parts of a thesis and thus form the 
basis of the academic guidelines. 
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5.6.2 Thesis Introduction  
The introduction will need to be expanded – 
• to include a brief overview of the device being researched,  
• state whether this device is intended be used ‘in house’ within NHS Tayside,  
• specify the target patient group for the device; and  
• clarify whether the device is a medical device or an in vitro diagnostic 
device.  
If the thesis relates to a specific area or function of a device, an outline of how the 
work of the thesis will be used in the completed device should be given. 
5.6.3 Thesis Background/Literature Review 
For a thesis relating to a device to be manufactured for use within NHS Tayside this 
section will need to be expanded to include an analysis of the relevant medical or 
in vitro diagnostic device market to show that the device being developed meets a 
need not currently available. In the case of the OCE system, it has been shown that 
there are no devices on the market providing a similar function as the OCE system: 
- see section 2.3.6 ‘Optical Coherence Elastography commercial devices’. 
5.6.4 Thesis Main Body  
The main body of the thesis will need to include details of how each of the 
exemption requirements, relating to ‘in-house’ manufacture and use, have been 
addressed and documented. Any requirements not addressed, will need to be 
detailed in the conclusion section of the thesis.  
5.6.5 Thesis Conclusion 
The conclusion will need to indicate which of the exemption requirements been met 
and what documentation has been produced, to show compliance with these 
requirements. The conclusion must detail what further work is required to enable a 
device to meet the exemption requirements in full. 
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5.6.6 Storage of Documentation 
A large amount of documentation is normally produced to cover the exemption 
requirements of any medical or in vitro diagnostic device.  
M&H will need to retain a final copy of any thesis relating to devices manufactured 
for use within NHS Tayside. A copy of the documentation, referenced in these 
theses which are related to the exemptions requirements for ‘in-house’ manufacture, 
will also need to be retained by M&H within the M&H quality system. By retaining 
all the documentation relating to such devices, M&H will have the full knowledge 
of these devices and will, when required, be able to request that that documentation 
is reviewed and amended. As the documentation will be retained within the M&H 
quality system the retention period, accuracy, method, backup, and document 
control, for example, will also be fully controlled. 
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5.7 Proposed M&H documentation to control collaborative work with 
academic and third parties on medical and in vitro diagnostic devices 
The work of university academics related to the design and manufacture of medical 
or in vitro diagnostic devices must adhere to appropriate quality standards. The 
university may wish to implement a quality system. To achieve this requirement, 
such future projects could be undertaken in collaboration with an organisation 
which has operates an appropriate quality system. By doing this, the work would 
then be under the control of an appropriate quality system. The external 
organisation, in conjunction with the university, would need to draw up, the 
appropriate documentation to control such work.  
The following details the proposed Quality Documentation to be used by M&H to 
control work in collaboration with university academics and third parties. 
5.7.1 Documentation: Goals and Overview 
The proposed control documentation is required to ensure that the manufacture of 
devices, by an academic or third party meets the exemption requirements of the UK 
legislation related to medical and in vitro diagnostic devices(4). The relevant parts 
of such work must be undertaken under the auspices of a suitable quality system(4). 
The control documentation to be simple, effective, and not impair innovation or 
research. The documentation to be written in plain English – not technical, not ‘QA 
speak’. 
This documentation is to control the development of devices for use within NHS 
Tayside exclusively. For devices to be placed on the market, please refer to 
QP.03F(102). 
5.7.1.1 Responsibility  
M&H are to provide the expert supervisory overview of the development and 
design of the device, to ensure that the exemption requirements of the UK 
legislation relating to medical devices and in vitro diagnostic devices, are adhered 
to.  
M&H are to ensure that devices meet the required standards and requirements of 
the relevant UK law. 
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M &H will require the appropriate staff to ensure that the design and development 
in relation to these devices follow the industry standard processes and procedures 
for medical and in vitro device development and manufacture production.  
One point to note is the need to identify the senior staff who will be responsible for 
signing the declaration that the device meets the requirements of the exemptions. 
5.7.1.2 Documentation to be produced  
There will need to be a section detailing the documentation to be produced and how 
it will be reviewed to ensure it meets the exemption requirements. The following is 
a list of required documentation: 
1. Details of how to identify the device, 
2. Details of the manufacturing health institution 
3. A statement of why the function of the device cannot be met by currently 
available devices on the market.  
4. The intended purpose and performance of the device, how it functions, the 
user information, and how it is maintained and if necessary calibrated to 
ensure it is fit for use,  
5. Details of how the device meets the relevant general safety and performance 
requirements and an explanation of those not applicable. 
6. The manufacturing documentation and proof that the device is manufactured 
in accordance with these documents 
7. Details of how the clinical use experience will be gathered, evaluated and 
acted upon. 
This section will also detail how the documentation, and in particular, how all the 
elements of the ‘Technical File’ are to be retained. For work undertaken with 
academics the documentation may also include research theses. Details of these 
how these theses will be retained, and how to access the research associated with 
these theses will also need to be documentation. It must be emphasised that the 
theses will all need to be retained, and accessible for the lifetime of the device and 
possibly longer, depending on the type of device manufactured or produced. 
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5.7.1.3 Project control and review 
This section will need to detail the areas relating to planning, device specification, 
review, hazard and risk analysis, validation and verification testing, transfer of 
design to manufacture and change control. 
Appendix C5 6 is a draft copy of the proposed control documentation. 
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 CONCLUSIONS 
The work undertaken throughout this thesis has successfully addressed the main 
aim, which was, to produce guidelines that would ensure that academics and third 
parties, collaborating with M&H meet the legislative and regulatory requirements 
for the development and manufacture of medical or in vitro diagnostic devices to 
be used ‘in-house’ within NHS Tayside. 
It has been shown that, unless academics or third parties follow these guidelines, it 
will no longer be possible for them to manufacture such devices for use within 
health care institutions once the new UK legislation comes into force. 
To achieve the aim detailed above, a comprehensive review of the medical and in 
vitro diagnostic device legislation coming into force within the EU and UK was 
undertaken. The result of this review highlighted the changes required by the M&H 
QMS in order to comply with the requirements of this legislation.  
As detailed in the main body of this thesis, the development and manufacture of 
medical and in vitro diagnostic devices must adhere to an appropriate quality 
management system. The M&H accreditation to the BS EN ISO 13485 standard 
demonstrates that the work undertaken was controlled by such a quality 
management system. Significant work, as detailed within this thesis, was 
undertaken to maintain accreditation by achieving accreditation to the (BS EN ISO 
13485:2016). Thus ensuring that the development of ‘in-house’ medical and in vitro 
diagnostic devices by M&H and those collaborating with M&H could continue. 
By using information gained from the review of the medical and in vitro diagnostic 
device legislation, a comprehensive review of the University of Dundee OCE 
system was carried out to determine what modifications to the system were required 
to ensure that it was fit for use within a healthcare environment. Following this, the 
documentation to evidence that the OCE system met the exemption requirements, 
as detailed in the UK law for an ‘in-house’ manufactured in vitro diagnostic device, 
was identified. Draft copies of some of these documents are contained, and referred 
to within this thesis. 
The continuation of this project is detailed in the following chapter. 
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 FURTHER WORK 
The following points need to be addressed in the future: 
In order to allow the UOD project work to continue to be used within a health care 
environment, the proposed guidelines need to be reviewed and issued by the 
appropriate staff of the University of Dundee. These issued guidelines then need to 
be incorporated into the relevant / appropriate student handbooks to ensure that the 
requirements, relating to the design and manufacture of devices and which might 
be used within a healthcare institution, are detailed.  
It is necessary to continue developing the OCE system, and the associated 
documentation, to ensure that it meets the exemption requirements of the UK law 
to enable it to be used in the ongoing evaluation of this promising new diagnostic 
aid. 
As a result of the UK leaving the EU, the UK government is reviewing the current 
medical and in vitro diagnostic device legislation. Part of the further work, arising 
from this thesis, would be to monitor any proposals to the current legislation so as 
to determine how it may affect the exemption requirements related to ‘in-house’ 
design and manufacture of medical and in vitro diagnostic devices. 
Finally, as a result of the review of the medical and in vitro diagnostic device 
legislation and the work undertaken to gain accreditation to the latest revision of 
the BS EN ISO 13485 standard, a number of new quality documents have been 
proposed. This new documentation needs to be finalised and issued. Without these 
new quality documents, the accreditation will not be able to be maintained nor show 
that the department is compliant with the UK or EU legislation. Such inability to 
demonstrate compliance with the legislation or failure to maintain accreditation to 
BS EN ISO 13485, will significantly impact on the work to design and manufacture 
medical or in vitro diagnostic devices. 
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 APPENDIX 
Appendix C3 1 Template Differences between ISO 13485:2003/2012 and ISO 13485 2016 with comments on changes and interpretation. 
From https://elsmar.com/elsmarqualityforum/members/marmotte.50524 
ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
 0.1 General — Includes substantially more detail related to the nature of the 
organization covered by this International Standard’s requirements and 
the life-cycle stages covered. 
— Explains that the requirements can be used by suppliers or other 
external parties either voluntarily or as a result of contract 
arrangements. 
— Alerts organizations about their obligations related to regulatory 
requirements focused on quality management systems. 
— Alerts organizations about differences in local regulation definitions 
and their obligation to understand how these definitions will affect their 
quality management system. 
— Adds the obligation to meet the organization’s own quality 
management system requirements. 
— Specifically calls out the focus on the necessity to “meet customer 
and applicable regulatory requirements for safety and performance.” 
— Emphasizes that the product requirements that are important are 
those related to safety and performance. 
— Adds two influences on the nature of the quality management system 
that were not in the original listing (organizational environment and 
regulatory requirements). 
— Clarifies that the organization does not have to align its 
documentation to the clause structure of this International Standard. 
- No normative content; No impact. 
 0.2 Clarification of 
concepts 
— Adds two additional criteria associated with the description of 
appropriate requirements: 
— compliance with regulatory requirements; 
- No normative content; No impact. 
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
— the requirement is necessary for the organization to manage risks. 
— Limits application of risk to the safety or performance requirements 
of the medical device or meeting applicable regulatory requirements. 
— Clarifies that the term “documented” includes the need to establish, 
implement and maintain. 
— Clarifies that the term “product” applies to outputs that are intended 
for, or required by, a customer, or any intended output resulting from a 
product realization process. 
 0.3 Process approach Explanation of process approach extended. - No normative content ; No 
impact. 
 0.4 Relationship with 
ISO 9001 
— States the relationship between ISO 13485:2016 and ISO 9001. 
— Indicates the structural relationship between ISO 13485:2016 and 
ISO 9001:2015 will be outlined in Annex B. 
— The use of italic text within standard to indicate changes from ISO 
9001:2008 has been eliminated. 
- No normative content ; No 
impact. 
 1 Scope — Indicates the applicability of this International Standard to 
organizations that are involved in one or more stages of the life-cycle of 
a medical device. 
— Indicates that this International Standard can also be used by 
suppliers or external parties that provide product, including quality 
management system-related services to medical device organizations. 
— Specifically calls out the responsibilities for monitoring, 
maintaining, and controlling outsourced processes. 
— Expands requirements that can be not applicable to those in Clauses 
6 and 8. 
— Clarifies that the term “regulatory requirements” includes statutes, 
regulations, ordinances or directives and limits the scope of the 
“applicable regulatory requirements” to those requirements for the 
quality management system and the safety or performance of the 
medical device. 
- No Direct impact.  
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
 3 Terms and 
definitions 
— Several new definitions added and some existing definitions refined. - No Direct impact. 
4 Quality 
management 
system 
4.1 General 
requirements 
4 Quality 
management system 
4.1 General 
requirements 
— Added requirement to document the role(s) of the organization. 
— Requires the determination of processes “taking into account the 
roles undertaken by the organization.” 
— Requires the application of a “risk based approach to the control of 
the appropriate processes needed for the quality management system.” 
— Adds requirements related to changes to processes. 
— Added requirements related to validation of the application of 
computer software used in the quality management system. 
4.1.1. The organization shall 
document the role(s) undertaken 
by the organization under the 
applicable regulatory 
requirements. 
NOTE Roles undertaken by the 
organization can include 
manufacturer, authorized 
representative, importeror 
distributor. 
4.1.2. b) apply a risk based 
approach to the control of the 
appropriate processes needed 
for the quality management 
system; 
4.1.4[…]Changes to be made to 
these processes shall be: 
a) evaluated for their impact on 
the quality management system; 
b) evaluated for their impact on 
the medical devices produced 
under this quality management 
system; 
c) controlled in accordance with 
the requirements of this 
International Standard and 
applicable regulatory 
requirements. 
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
Also 4.1.5 “monitor outsourced 
processed” – e.g. consultant – 
require written agreement  
4.1.6 SW validation + 
revalidation after change  
4.2 
Documentation 
requirements 
4.2.1 General 
4.2 Documentation 
requirements 
4.2.1 General 
- No Change - No Change 
4.2.2 Quality 
manual 
4.2.2 Quality manual - No Change - No Change 
4.2.3 Control of 
documents 
4.2.4 Control of 
records 
4.2.3 Medical device 
file 
4.2.4 Control of 
documents 
4.2.5 Control of 
records 
Includes control of records within the document control requirements. 
Lists the documents that would be included in the medical device file. 
New requirement related to protection of confidential health 
information. 
New requirement related to deterioration and loss of documents 
-   
5 Management 
responsibility 
5.1 Management 
commitment 
5 Management 
responsibility 
5.1 Management 
commitment 
- No Change - No Change 
5.2 Customer 
focus 
5.2 Customer focus - No Change - No Change 
5.3 Quality 
policy 
5.3 Quality policy - No Change - No Change 
5.4 Planning 
5.4.1 Quality 
objectives 
5.4 Planning 
5.4.1 Quality 
objectives 
- No Change - No Change 
Page 139 of 513 
 
 
ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
5.4.2 Quality 
management 
system planning 
5.4.2 Quality 
management system 
planning 
- No Change - No Change 
5.5 
Responsibility, 
authority and 
communication 
5.5.1 
Responsibility 
and authority 
5.5 Responsibility, 
authority and 
communication 
5.5.1 Responsibility 
and authority 
- No Change - No Change 
5.5.2 
Management 
representative 
5.5.2 Management 
representative 
- No Change 
 
- No Change 
 
5.5.3 Internal 
communication 
5.5.3 Internal 
communication 
- No Change 
 
- No Change 
 
5.6 Management 
review 
5.6.1 General 
5.6.2 Review 
input 
5.6.3 Review 
output 
5.6 Management 
review 
5.6.1 General 
5.6.2 Review input 
5.6.3 Review output 
— Includes requirement for the documentation of one or more 
procedures for management review and the requirement for 
management reviews at “documented planned intervals”. 
— Lists of inputs and outputs of management review have been 
expanded. 
 Change from “management 
reviews at planned intervals” to 
“management reviews at 
documented planned intervals”. 
Lists expansions are more details 
but no real new content 
6. Resource 
management 
6.1 Provision of 
resources 
6. Resource 
management 
6.1 Provision of 
resources 
- No Change 
 
- No Change 
 
6.2 Human 
resources 
6.2.1 General 
6.2.2 
Competence, 
6.2 Human resources 
 
— New requirement for documentation processes of establishing 
competence, providing needed training and ensuring awareness of 
personnel. 
“The organization shall 
document the process(es) for 
establishing competence, 
providing needed training, and 
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
awareness and 
training 
ensuring awareness of 
personnel” 
6.3 Infrastructure 6.3 Infrastructure - Adds requirement that infrastructure prevents product mix-up and 
ensure orderly handling of product. 
- Adds information system to the listing of supporting services. 
- Besides of the two points on the 
left – there is now a requirement 
for the organization to 
DOCUMENT THE 
REQUIREMENTS. 
6.4 Work 
environment 
6.4 Work 
environment and 
contamination 
control 
6.4.1 Work 
environment 
6.4.2 Contamination 
control 
- Added documentation requirements for work environment. 
— Added requirement related to control of contamination with 
microorganism or particulate matter for sterile medical devices. 
- As above – new 
DOCUMENTAITON 
requirement  
7 Product 
realization 
7.1 Planning of 
product 
realization 
7 Product realization 
7.1 Planning of 
product realization 
— Added requirements to list.  new c) “required 
[…]measurement […], handling, 
storage, 
distribution and traceability […] 
7.2 Customer-
related processes 
7.2.1 
Determination of 
requirements 
related to the 
product 
7.2.2 Review of 
requirements 
related to the 
product 
7.2 Customer-related 
processes 
7.2.1 Determination 
of requirements 
related to the product 
7.2.2 Review of 
requirements related 
to the product 
 
- Added requirements to list :  
 
- 7.2.1 “d) any user training 
needed to ensure specified 
performance and safe use of the 
medical device;” 
- 7.2.2. 
c) applicable regulatory 
requirements are met; 
- d) any user training identified in 
accordance with 7.2.1 is 
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
 available or planned to be 
available; 
7.2.3 Customer 
communication 
7.2.3 Communication — New requirement related to communication with regulatory 
authorities. 
“The organization shall 
communicate with regulatory 
authorities in accordance with 
applicable regulatory 
requirements.”  Weird statement 
placement 
7.3 Design and 
development 
7.3.1 Design and 
development 
planning 
7.3 Design and 
development 
7.3.1 General 
7.3.2 Design and 
development 
planning 
- Added requirements to list. 
— Eliminated the requirement related to the management of the 
interfaces between different groups involved in design and 
development. 
7.3.2 e) the methods to ensure 
traceability of design and 
development outputs to design 
and 
development inputs; 
- f) the resources needed, 
including necessary competence 
of personnel. 
7.3.2 Design and 
development 
inputs 
7.3.3 Design and 
development inputs 
— Added requirements to list. 
— Added requirement that the requirements shall be able to be 
verified or validated. 
-  Added “usability”  + ref to 
IEC62366 
 
7.3.3 Design and 
development 
outputs 
7.3.4 Design and 
development outputs 
No Change - No Change 
7.3.4 Design and 
development 
review 
7.3.5 Design and 
development review 
Added details of the contents of records. “include the 
- identification of the design 
under review, the participants 
involved and the date of the 
review” 
7.3.5 Design and 
development 
verification 
7.3.6 Design and 
development 
verification 
Added requirement for documentation of verification plans and 
interface considerations. 
— Requirement added for records of verification. 
 New : “The organization shall 
document verification plans that 
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
include methods, acceptance 
criteria and, as 
appropriate, statistical 
techniques with rationale for 
sample size. 
If the intended use requires that 
the medical device be connected 
to, or have an interface with, 
other 
medical device(s), verification 
shall include confirmation that 
the design outputs meet design 
inputs 
- when so connected or 
interfaced.” 
Also added “Records of the 
- results AND CONCLUSIONS 
of […]” 
7.3.6 Design and 
development 
validation 
7.3.7 Design and 
development 
validation 
— Added requirement for documentation of validation plans, product to 
be used for validation 
and interface considerations. Requirement added for records of 
validation. 
New “The organization shall 
document validation plans that 
include methods, acceptance 
criteria and, as appropriate, 
statistical techniques with 
rationale for sample size.” New 
“A medical device used for 
clinical evaluation or 
performance evaluation is not 
considered to be released for use 
to the customer. If the intended 
use requires that the medical 
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
device be connected to, or have 
an interface with, other medical 
device(s), validation shall include 
confirmation that the 
requirements for the specified 
application or intended use have 
been met when so connected or 
interfaced” 
 7.3.8 Design transfer New Sub-clause added A medical device used for clinical 
evaluation or performance 
evaluation is not considered to 
be released for use to the 
customer. If the intended use 
requires that the medical device 
be connected to, or have an 
interface with, other medical 
device(s), validation shall include 
confirmation that the 
requirements for the specified 
- application or intended use 
have been met when so 
connected or interfaced 
7.3.7 Control of 
design and 
development 
changes 
7.3.9 Control of 
design and 
development changes 
Adds the requirement that the evaluation of the change effect should be 
made on products in process and on the outputs of risk management and 
product realization processes 
— Added detail to consider in the determination of the significance of a 
design and development changes 
New “:The organization shall 
determine the significance of the 
change to function, performance, 
usability, safety and applicable 
regulatory requirements for the 
medical device and its intended 
use.” 
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
- Also note the “products in process 
and on the outputs of risk 
management and product 
realization processes” as opposed 
to only released products + 
records of “changes, THEIR 
REVIEW […]”  
 7.3.10 Design and 
development files 
— New sub-clause added. - New but not really – i.e. DHF 
7.4 Purchasing 
7.4.1 Purchasing 
process 
7.4 Purchasing 
7.4.1 Purchasing 
process 
— Focuses the supplier selection criteria on the effect of the supplier 
performance on the quality of the medical device, the risk associated 
with the medical device, and the product meeting applicable regulatory 
requirements. 
— New requirements added related to monitoring and re-evaluation of 
suppliers, and action to be taken when purchasing requirements are not 
met. 
— Provides addition details related to the content of the records. 
- As explained 
7.4.2 Purchasing 
information 
7.4.2 Purchasing 
information 
— New requirement added to include notification of changes in 
purchased product. 
“Purchasing information shall 
include, as applicable, a written 
agreement that the supplier 
notify the organization of 
changes in the purchased 
product prior to implementation 
of any changes that affect 
- the ability of the purchased 
product to meet specified 
purchase requirements” 
7.4.3 Verification 
of purchased 
product 
7.4.3 Verification of 
purchased product 
New requirements added on the extent of verification activities and 
action to be taken when the organization becomes aware of any changes 
to the purchased product. 
Also new “The extent of 
verification activities shall be 
based on the supplier evaluation 
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
results and proportionate to the 
risks associated with the 
purchased product. When the 
organization becomes aware of 
any changes to the purchased 
product, the organization shall 
determine whether these 
changes affect the product 
realization process or the 
medical device.” 
7.5 Production 
and service 
provision 
7.5.1 Control of 
production and 
service provision 
7.5.1.1 General 
requirements 
 
7.5 Production and 
service provision 
7.5.1 Control of 
production and 
service provision 
 
7.5.1 - Adds details related to the controls for carrying out production 
and service provision. 
 
- Rewording but can’t find anything 
really different ? 
7.5.1.2 Control of 
production and 
service provision 
- Specific 
requirements 
7.5.1.2.1 
Cleanliness of 
product and 
contamination 
control 
 
7.5.2 Cleanliness of 
product 
 
7.5.2 - Added a requirement to the list. 
 
- New c) product cannot be 
cleaned prior to sterilization or 
its use, and its cleanliness is of 
significance in use; 
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ISO 13485:2003, 
EN ISO 
13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
7.5.1.2.2 
Installation 
activities 
 
7.5.3 Installation 
activities 
 
 - No Change 
7.5.1.2.3 
Servicing 
activities 
 
7.5.4 Servicing 
activities 
 
7.5.4 -— New requirement for analysis of records for servicing 
activities. 
 
New “The organization shall 
analyse records of servicing 
activities carried out by the 
organization or its 
supplier: 
a) to determine if the 
information is to be handled as a 
complaint; 
- b) as appropriate, for input to 
the improvement process.” 
7.5.1.3 Particular 
requirements for 
sterile medical 
devices 
 
7.5.5 Particular 
requirements for 
sterile medical 
devices 
 
 - No change 
7.5.2 Validation 
of processes for 
production and 
service provision 
7.5.2.1 General 
requirements 
 
7.5.6 Validation of 
processes for 
production and 
service provision 
 
-Added requirements to the list 
— Adds details related to situations requiring procedures. 
— Relates the specific approach to software validation to the risk 
associated with the use of 
the software. 
— Adds requirements related to the validation records. 
 
- d) as appropriate, statistical 
techniques with rationale for 
sample sizes; 
- f/criteria for revalidation; 
- g) approval of changes to the 
processes. 
The specific approach and 
activities associated with 
software validation and 
revalidation shall be 
proportionate to the risk 
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13485:2012 
ISO 13485:2016, EN 
ISO 13485:2016 
Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
associated with the use of the 
software, including the effect on 
the ability of the product to 
conform to specifications.  
 
Record of […]results and 
conclusion of validation and 
necessary actions[…] 
 
7.5.2.2 Particular 
requirements for 
sterile medical 
devices 
7.5.7 Particular 
requirements for 
validation of 
processes for 
sterilization and 
sterile barrier 
systems 
— Added requirements for sterile barrier systems. 
 
- As explained 
7.5.3 
Identification and 
traceability 
7.5.3.1 
Identification 
 
7.5.8 Identification 
 
Added requirement for unique device identification. 
— New requirement for a documented procedure for product 
identification and regarding identification and product status during 
production 
New “The organization shall 
identify product status with 
respect to monitoring and 
measurement requirements 
throughout product realization. 
Identification of product status 
shall be maintained throughout 
production, storage, installation 
and servicing of product to 
ensure that only product that has 
passed the required inspections 
and tests or released under an 
authorized concession is 
dispatched,used or installed. 
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- If required by applicable 
regulatory requirements, the 
organization” 
7.5.3.2 
Traceability 
7.5.3.2.1 General 
7.5.3.2.2 
Particular 
requirements for 
active 
implantable 
medical devices 
and implantable 
medical devices 
7.5.3.3 Status 
identification 
7.5.9 Traceability  - No Change 
7.5.4 Customer 
property 
7.5.10 Customer 
property 
 - No Change 
7.5.5 
Preservation of 
product 
7.5.11 Preservation 
of product 
Adds details as to how preservation can be accomplished. The organization shall protect 
product from alteration, 
contamination or damage when 
exposed to expected conditions 
and hazards during processing, 
storage, handling, and 
distribution by: a) designing and 
constructing suitable packaging 
and shipping containers; b) 
documenting requirements for 
special conditions needed if 
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Comments on change from ISO doc itself – Table A1 Personal interpretation   /details / 
extracts 
packaging alone cannot provide 
preservation 
7.6 Control of 
monitoring and 
measuring 
devices 
7.6 Control of 
monitoring and 
measuring equipment 
 - No change 
8 Measurement, 
analysis and 
improvement 
8.1 General 
8 Measurement, 
analysis and 
improvement 
8.1 General 
 - No Change 
8.2 Monitoring 
and measurement 
8.2.1 Feedback 
8.2 Monitoring and 
measurement 
8.2.1 Feedback 
 
Indicates that feedback should come from production and post-
production activities. 
— Adds a requirement to utilize feedback in risk management 
processes in order to monitor and maintain product requirements. 
New The organization shall 
document procedures for the 
feedback process. This feedback 
process shall include provisions 
to gather data from production 
as well as post-production 
activities. 
The information gathered in the 
feedback process shall serve as 
potential input into risk 
management for monitoring and 
maintaining the product 
requirements as well as the 
product realization or 
improvement processes 
Note that link to CAPArs 
disappeared 
 8.2.2 Complaint 
handling 
— New sub-clause. - New 
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 8.2.3 Reporting to 
regulatory authorities 
— New sub-clause. - New 
8.2.2 Internal 
audit 
8.2.4 Internal audit  - No change 
8.2.3 Monitoring 
and measurement 
of processes 
8.2.5 Monitoring and 
measurement of 
processes 
 -  No Change 
-  
8.2.4 Monitoring 
and measurement 
of product 
8.2.4.1 General 
requirements 
8.2.4.2 Particular 
requirement for 
active 
implantable 
medical devices 
and implantable 
medical devices 
8.2.6 Monitoring and 
measurement of 
product 
— Adds requirement to identify the test equipment used to perform 
measurement activities. 
As appropriate, records shall 
identify the test equipment used 
to perform measurement 
activities. 
8.3 Control of 
nonconforming 
product 
8.3 Control of 
nonconforming 
product 
8.3.1 General 
8.3.2 Actions in 
response to 
nonconforming 
product detected 
before delivery 
8.3.3 Actions in 
response to 
nonconforming 
— Added details related to kinds of controls that shall be documented. 
— Generalized the requirement to include any investigation and the 
rationale for decisions. 
— Adds requirements related to concessions. 
— Separated requirements for nonconformities detected before 
delivery, detected after delivery and rework. 
— Adds requirements for records related to the issuance of advisory 
notices. 
As explained 
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extracts 
product detected 
after delivery 
8.3.4 Rework 
8.4 Analysis of 
data 
8.4 Analysis of data Adds the requirement to include determination of appropriate methods, 
including statistical techniques and the extent of their use. 
— Adds detail to list of inputs. 
Stats as explained +  
e) audits; 
f) service reports, as appropriate. 
If the analysis of data shows that 
the quality management system 
is not suitable, adequate or 
effective, 
- the organization shall use this 
analysis as input for 
improvement as required in 8.5. 
8.5 Improvement 
8.5.1 General 
8.5 Improvement 
8.5.1 General 
 - No change 
-  
8.5.2 Corrective 
action 
 
8.5.2 Corrective 
action 
 
Adds the requirement to verify that the corrective action does not have 
an adverse effect. 
— Added requirement for corrective action to be taken without undue 
delay. 
- As explained 
8.5.3 Preventive 
action 
8.5.3 Preventive 
action 
- Adds the requirement to verify that the preventive action does not 
have an adverse effect. 
- As explained 
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Appendix C3 2 Template Differences between ISO 13485:2003/2012 and ISO 13485 2016 with space for individual comments. 
From https://elsmar.com/elsmarqualityforum/members/bjohnsonrli.278996/ 
 
ISO 13485:2003, EN ISO 13485:2012 ISO 13485:2016, EN ISO 13485:2016 Comments 
4 Quality management system 
4.1 General requirements 
4 Quality management system 
4.1 General requirements 
 
4.2 Documentation requirements 
4.2.1 General 
4.2 Documentation requirements 
4.2.1 General 
 
4.2.2 Quality manual 4.2.2 Quality manual  
4.2.3 Control of documents 
4.2.4 Control of records 
4.2.3 Medical device file 
4.2.4 Control of documents 
4.2.5 Control of records 
 
5 Management responsibility 
5.1 Management commitment 
5 Management responsibility 
5.1 Management commitment 
 
5.2 Customer focus 5.2 Customer focus  
5.3 Quality policy 5.3 Quality policy  
5.4 Planning 
5.4.1 Quality objectives 
5.4 Planning 
5.4.1 Quality objectives 
 
5.4.2 Quality management system planning 5.4.2 Quality management system planning  
5.5 Responsibility, authority and communication 
5.5.1 Responsibility and authority 
5.5 Responsibility, authority and communication 
5.5.1 Responsibility and authority 
 
5.5.2 Management representative 5.5.2 Management representative  
5.5.3 Internal communication 5.5.3 Internal communication  
Page 153 of 513 
 
 
5.6 Management review 
5.6.1 General 
5.6.2 Review input 
5.6.3 Review output 
5.6 Management review 
5.6.1 General 
5.6.2 Review input 
5.6.3 Review output 
 
6. Resource management 
6.1 Provision of resources 
6. Resource management 
6.1 Provision of resources 
 
6.2 Human resources 
6.2.1 General 
6.2.2 Competence, awareness and training 
6.2 Human resources 
6.2.1 General 
6.2.2 Competence, awareness and training 
 
6.3 Infrastructure 6.3 Infrastructure  
6.4 Work environment 6.4 Work environment and contamination control 
6.4.1 Work environment 
6.4.2 Contamination control 
 
7 Product realization 
7.1 Planning of product realization 
7 Product realization 
7.1 Planning of product realization 
 
7.2 Customer-related processes 
7.2.1 Determination of requirements related to the 
product 
7.2.2 Review of requirements related to the product 
7.2.3 Customer communication 
7.2 Customer-related processes 
7.2.1 Determination of requirements related to the 
product 
7.2.2 Review of requirements related to the product 
7.2.3 Communication 
 
7.3 Design and development 
7.3.1 Design and development planning 
7.3 Design and development 
7.3.1 General 
7.3.2 Design and development planning 
 
7.3.2 Design and development inputs 7.3.3 Design and development inputs  
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7.3.3 Design and development outputs 7.3.4 Design and development outputs  
7.3.4 Design and development review 7.3.5 Design and development review  
7.3.5 Design and development verification 7.3.6 Design and development verification  
7.3.6 Design and development validation 7.3.7 Design and development validation   
7.3.8 Design transfer  
7.3.7 Control of design and development changes 7.3.9 Control of design and development changes   
7.3.10 Design and development files  
7.4 Purchasing 
7.4.1 Purchasing process 
7.4 Purchasing 
7.4.1 Purchasing process 
 
7.4.2 Purchasing information 7.4.2 Purchasing information  
7.4.3 Verification of purchased product 7.4.3 Verification of purchased product  
7.5 Production and service provision 
7.5.1 Control of production and service provision 
7.5.1.1 General requirements 
7.5.1.2 Control of production and service provision 
- Specific requirements 
7.5.1.2.1 Cleanliness of product and contamination 
control 
7.5.1.2.2 Installation activities 
7.5.1.2.3 Servicing activities 
7.5.1.3 Particular requirements for sterile medical 
devices 
7.5.2 Validation of processes for production and 
service provision 
7.5.2.1 General requirements 
7.5 Production and service provision 
7.5.1 Control of production and service provision 
7.5.2 Cleanliness of product 
7.5.3 Installation activities 
7.5.4 Servicing activities 
7.5.5 Particular requirements for sterile medical 
devices 
7.5.6 Validation of processes for production and 
service provision 
7.5.7 Particular requirements for validation of 
processes for sterilization and sterile barrier systems 
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7.5.2.2 Particular requirements for sterile medical 
devices 
7.5.3 Identification and traceability 
7.5.3.1 Identification 
7.5.3.2 Traceability 
7.5.3.2.1 General 
7.5.3.2.2 Particular requirements for active 
implantable medical devices and implantable 
medical devices 
7.5.3.3 Status identification 
7.5.8 Identification 
7.5.9 Traceability 
 
7.5.4 Customer property 7.5.10 Customer property  
7.5.5 Preservation of product 7.5.11 Preservation of product  
7.6 Control of monitoring and measuring devices 7.6 Control of monitoring and measuring equipment  
8 Measurement, analysis and improvement 
8.1 General 
8 Measurement, analysis and improvement 
8.1 General 
 
8.2 Monitoring and measurement 
8.2.1 Feedback 
8.2 Monitoring and measurement 
8.2.1 Feedback 
8.2.2 Complaint handling 
 
 
8.2.3 Reporting to regulatory authorities  
8.2.2 Internal audit 8.2.4 Internal audit  
8.2.3 Monitoring and measurement of processes 8.2.5 Monitoring and measurement of processes  
8.2.4 Monitoring and measurement of product 
8.2.4.1 General requirements 
8.2.6 Monitoring and measurement of product  
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8.2.4.2 Particular requirement for active 
implantable medical devices and implantable 
medical devices 
8.3 Control of nonconforming product 8.3 Control of nonconforming product 
8.3.1 General 
8.3.2 Actions in response to nonconforming product 
detected before delivery 
8.3.3 Actions in response to nonconforming product 
detected after delivery 
8.3.4 Rework 
 
8.4 Analysis of data 8.4 Analysis of data  
8.5 Improvement 
8.5.1 General 
8.5 Improvement 
8.5.1 General 
 
8.5.2 Corrective action 
8.5.3 Preventive action 
8.5.2 Corrective action 
8.5.3 Preventive action 
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Appendix C3 3 Completed BSI Readiness Review 
 
Note Pictures in this appendix cropped to reduce document file size. 
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Appendix C3 4 Full review of the present management system against the 13485:2016 standard. (QM issue 10) 
 
For each clause and sub clause determine if the QM or relevant documents meet the requirements of the standard. If not indicate work to be 
undertaken. 
 
Clause number and title met 
yes/no, 
If yes which document inc 
para number meets this 
need. 
If no describe what needs to be added 
and to what document. 
Change or new document 
implemented/date. 
1 Scope No  Not all the exclusions / clauses that are 
not applicable are noted in the QM 
scope. Also need to update various non 
13485 scope entries.   
QM SCOPE  
2 Normative references No  Need to update the 13485 year number 
also check other standards year 
numbers. 
QM 3.1 
3 Terms and definitions No   Review the definitions especially for 
staff designations. Plus appendix 2 stuff  
QM 3.2 and Appendix 2 
and 3. 
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4 Quality management system     
4.1 General requirements No  Missing the points 4.1.1 to 4.1.6 Need to possibly added 
the breakdown 4.1.1, to 
4.1.6 to QM or something 
similar   
4.1.1 No  Need to point to QM Introduction and 
Scope which details what each area 
does. Maybe expand the 
Instrumentation bit re medical device 
manufacture. 
Review Introduction and 
Scope in QM 
4.1.2 No  No mention of risk based approach as 
required by 13495:2016 in relevant 
areas. Plus point to the flowcharts and 
management stuff in appendix 2 
Need to add risk based 
approached and review 
flowcharts appendix 5 
and appendix 2. 
4.1.3 No  Need to point to relevant areas of the 
QM which answer the points. 
Review QM sections 
related to these points to 
ensure they meet these 
requirements audit and 
action forms, resources,  
objectives and KPI. 
4.1.4 No  Again need to point to relevant areas of 
the QM which address these points. 
Changes are planned and 
documented via Action 
forms QM planning and 
action form sections. 
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4.1.5 Yes Subcontractors in purchasing 
and Supplier Performance -  
Might be an idea to review supplier 
performance to ensure it meets these 
requirements 
QP.11 not really QP.05 
4.1.6 No  Software Validation  Get WI or SOP for this – 
needs to cover both 
purchased and ‘in-house’ 
software. 
 
4.2 Documentation requirements Yes    
4.2.1 General YES 4.2.1 QM Need to double check the list of QP 
verses 13485 clauses  
Appendix 4 
4.2.2 Quality manual YES 4.2.2 QM Need to double check the flowcharts of 
document and process interactions 
Appendix 5 
4.2.3 Medical device file NO  Not got this at all. Need to add 4.2.3 
4.2.4 Control of documents YES 4.2.3  QM and QP.01 Double check QP.01 has available for 
users as required and also printed doc 
legible. External docs as per point F. Plus 
G . The end point under point H review 
QP.01 Possible change 
4.2.5 Control of records YES 4.2.4 and QP.24 Double check that 24 has legibility and 
retrievable.   
QP.24 Possible change 
5 Management responsibility     
5.1 Management commitment YES 5.1   
5.2 Customer focus NO 
Partial 
5.2 Partially met. Does not state need to 
meet applicable regulatory 
requirements 
Add to QM 5.2 about 
meeting stated and 
unstated regulatory needs 
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5.3 Quality policy NO 
Partial 
5.3 Partially met. Sections c and d need to 
check if these are mentioned in the 
policy. 
Check QM 5.3 for the 
requirements of parts c) 
and d). 
5.4 Planning     
5.4.1 Quality objectives NO 
Partial 
5.4.1 Review to ensure specifics relating to 
products are included 
Review 5.4.1 required 
5.4.2 Quality management 
system planning 
NO 
Partial 
5.4.2 Again review to ensure specifics related 
to products are included 
Review 5.4.2 required 
5.5 Responsibility, authority and 
communication 
    
5.5.1 Responsibility and authority NO 
Partial 
5.5.1 The word authority 
does not appear in this 
section 
Need to amend this section to include 
staff authority  
Need to review QM 5.5.1 
5.5.2 Management 
representative 
NO 
Partial 
5.5.2 partially addresses this 
clause 
Need to review and added in a few 
words to ensure section meets 
requriements 
Review and amend 5.5.2 
5.5.3 Internal communication No  QM 5.5.3 does not actually state that 
the points in the standard will be met or 
how 
Review 5.5.3 
5.6 Management review     
5.6.1 General     
5.6.2 Review input No 
Partial 
Some in QM 5.6.2 QM 5.6.2 review for  
c) reporting to regulatory authorities; 
These mentioned but should they be 
better highlighted – split up in 
agenda?? 
QM 5.6.2 review for 
completeness 
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e) monitoring and measurement of 
processes; 
f) monitoring and measurement of 
product; 
The following done but not specifically 
mentioned - 
g) corrective action; 
h) preventive action; 
5.6.3 Review output No 
Partial 
Some in 5.6.3 QM 5.6.3 the review minutes do not 
fully meet these requirements - are 
missing  
a) improvement needed to maintain 
the suitability, adequacy, and 
effectiveness of the quality 
management system and its processes; 
b) improvement of product related to 
customer requirements; 
c) changes needed to respond to 
applicable new or revised regulatory 
requirements; 
 
Review to ensure these 
are noted in the minutes. 
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6 Resource management     
6.1 Provision of resources NO 
Partial 
QM 6.1 Part of a) and all of b) QM 6.1 does it need to be modified or 
does it actually meet the statement a) a) 
implement the quality management 
system and to maintain its 
effectiveness; 
 
6.2 Human resources NO 
Partial 
QM 6.2 covers most aspects 
of the standard 
QM 6.2 does not cover - The 
organization shall document the 
process(es) for establishing 
competence, providing needed 
training, and ensuring awareness of 
personnel. 
Nor  
NOTE The methodology used to check 
effectiveness is proportionate to the risk 
associated with the work for which the 
training or other action is being provided. 
Qm 6.2 review and 
amend 
6.3 Infrastructure NO 
Partial 
QM 6.3 Bits are ok  Not all aspects of 6.3 discussed in QM 
6.3 
QM 6.3 review and 
amend. 
6.4 Work environment and 
contamination control 
NO  QM 6.4 needs to be fully revised and 
rewritten.  
QM 6.4 
6.4.1 Work environment     
6.4.2 Contamination control     
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7 Product realization No 
Partial 
 Parts of the introduction are mixed up 
with the requirements of 7.1 and vice 
versa 
Need to review Qm 7.1 
and Qm 7 to unmix intro 
from clause 7.1 
requriements 
7.1 Planning of product 
realization 
No 
Partial 
  Should this not point to 
qp.02 the project control 
procedure. Which should 
reiterate the relevant 
requirements of Section 
7. 
7.2 Customer-related processes NO 
Partial 
   
7.2.1 Determination of 
requirements related to product 
NO 
Partial 
 7.2.1 Points c) and d) missing. Review QM 7.2.1 and add 
in these points 
7.2.2 Review of requirements 
related to product 
NO 
Partial 
 7.2.2 Points c) and d) missing and also 
the word documented is missing. 
Review QM 7.2.2 and add 
in these points plus 
documented prior to 
commencement of work. 
7.2.3 Communication NO 
Partial 
 7.2.3 is point d) the same as standard 
7.2.3 a). The note at the end of 7.2.3 is 
missing. 
Review 7.2.3. 
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7.3 Design and development  Note that some of the QM 
heading change from ‘Design 
and Development’ to just 
‘design’ or just 
‘Development’.  
Need to keep heading the same please. All QM section 7 
7.3.1 General Yes Points to qp.02 but this 7.3.1 
not actually in the QM 
Review QP.02 to determine if all the 
points of clause 7 are included in it.  
Review QP.02 
7.3.2 Design and development 
planning 
No 
Partial 
This section QM 7.3.1 has all 
the requirements of 7.3.2 but 
not in same layout.  
Review QM 7.3.1 to see if using the a), b) 
etc layout for the points would be 
better? This will change to 7.3.2 once 
added in the 7.3.1 
Review Qm7.3.1 
7.3.3 Design and development 
inputs 
No 
Partial 
This section QM 7.3.2 has all 
the requirements of 7.3.3 but 
not in same layout. 
Review layout of QM 7.3.2. Also not all 
of the requirements of the last note in 
the clause seem to be in QM 7.3.2 
Review QM 7.3.2 
7.3.4 Design and development 
outputs 
No 
Partial 
Second sentence of 7.3.4 is 
not in QM 7.3.3.  
Add the requirements of first note 
sentence of 7.3.4 plus wording at start 
of QM 7.3.3 
Review QM 7.3.3. 
7.3.5 Design and development 
review 
No 
Partial 
QM 7.3.4 covers the basics 
but not the full extent of the 
new standard 7.3.5 
Review QM 7.3.4 to include all of the 
requirements  
Review QM 7.3.4 
7.3.6 Design and development 
verification 
No 
Partial 
QM 7.3.5 does not cover this 
fully 
Review QM7.3.5 to ensure it meets the 
requirements of 7.3.6 of the standard. 
Review QM 7.3.5 
7.3.7 Design and development 
validation 
NO  Review QM7.3.6 and amend as it does 
not cover 7.3.7 of the standard 
Full review of QM 7.3.6 if 
required add to QP.02. 
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7.3.8 Design and development 
transfer 
NO  This section does not exist in the QM.  
Add to QM 
Additional section to QM 
7.3.9 Control of design and 
development changes 
No 
Partial  
We have QP.20 but this not 
go into design change in any 
depth 
Review QM 7.3.7 and amend to include 
all of the requirements of the standard 
7.3.9 
Full review of QM 7.3.7 if 
required add to QP.02. 
7.3.10 Design and development 
files 
NO  This section does not exist in the QM.  
Add to QM 
Additional section to QM 
 
  
Page 173 of 513 
 
 
 
7.4 Purchasing     
7.4.1 Purchasing process No 
Partial 
Qm7.4.1 does not full 
address this clause 
No need to review risks. Also QM does 
not point to QP.11 or QP.20 or action 
forms 
Review QM 7.4.1 against 
standard. 
7.4.2 Purchasing information No 
Partial 
 Point c) missing and need to define 
traceability better. 
Review QM 7.4.2 and 
QP.05 (newest) agains 
standard. 
7.4.3 Verification of purchased 
product 
No 
Partial 
It is all there apart from the 
last sentence of the clause. 
No mention of documentation of 
certification activities. Might also be an 
idea to point to QP.05  
QM 7.4.3 
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7.5 Production and service 
provision 
No 
Partial 
This whole section needs to 
be reviewed. Number of new 
requirements added and 
need to be addressed in the 
QM 
Review all and amend as required  
7.5.1 Control of production and 
service provision 
  Has parts from the new sections mixed 
into it. 
 
7.5.2 Cleanliness of product No  New section but look in old QM 7.5.1  
7.5.3 Installation activities No  Not applicable do not do this  
7.5.4 Servicing activities No  Need new section and fully detaile.  
7.5.5 Particular requirements for 
sterile medical devices 
No  Needs a section  
7.5.6 Validation of processes for 
production and service provision 
No 
partial 
 Was in QM 7.5.2 and needs new section 
with correct controls 
 
7.5.7 Particular requirements for 
validation of processes for 
sterilization and 
sterile barrier systems 
No  Not applicable but should point to 
accredited services 
 
7.5.8 Identification No  This needs new section old QM 7.5.3 but 
mixed with new 7.5.9 
 
7.5.9 Traceability No 
Partial 
 Have it but mixed with new 7.5.8  
7.5.10 Customer property No 
Partial 
 Have it but needs reviewed against 
standard. We do not mention what to 
do if anything is wrong with the items 
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passed to us – this could be samples, 
material for a job, etc. 
7.5.11 Preservation of product No 
Partial 
 Have it but needs reviewed against 
standard. Does not really detail product 
packaging. 
 
7.6 Control of monitoring and 
measuring equipment 
No 
Partial 
 Have it but needs reviewed against 
standard – e.g. software validation 
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8 Measurement, analysis and 
improvement 
    
8.1 General NO 
Partial 
 QM 8.1 covers most of this clause but 
the word product is not really 
mentioned. Also need to add in changes 
to regulatory or relevant standards 
 
8.2 Monitoring and 
measurement 
No 
Partial 
 8.2 in QM is one section covering all of 
8.2.1, 8.2.2 and 8.2.3 in one lump. 
Maybe best to split it up and also add in 
the references to the various QPs also 
need to highlight QP names not 
complaint handling but customer 
feedback. 
 
8.2.1 Feedback   See 8.2  
8.2.2 Complaint handling   See 8.2  
8.2.3 Reporting to regulatory 
authorities 
  See 8.2  
8.2.4 Internal audit No 
Partial 
 Some of the key words are missing from 
8.2.2. For example planned, reviewed in 
light of precious findings and relevant to 
importance of activities. 
 
8.2.5 Monitoring and 
measurement of processes 
YES but  Might be an idea to point to things like 
NSD contracts with indicators and 
objectives. Also M&H general objectives. 
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8.2.6 Monitoring and 
measurement of product 
No 
Partial 
 QM 8.2.4 no mention of sign off for 
product release. Could be e-quip job 
closed or as in SCPS sign off for patient 
report. 
 
8.3 Control of nonconforming 
product 
No 
Partial 
 This is lumped in to 8.3 in the QM . 
Might be an idea to split up and also to 
point out that product includes test 
reports, completed repairs, patient 
treatment and etc. 
 
8.3.1 General   See 8.3  
8.3.2 Actions in response to 
nonconforming product detected 
before delivery 
  See 8.3  
8.3.3 Actions in response to 
nonconforming product detected 
after delivery 
  See 8.3  
8.3.4 Rework   See 8.3  
8.4 Analysis of data NO 
Patrial 
 Need to review 8.4 Qm against the 
standard and also areas such as SCPS do 
use statistics to monitor their test 
results so need to add this in. Also no 
mention of audits or trending of AFs stc. 
 
8.5 Improvement     
8.5.1 General YES but  Need to expand 8.1 QM to include the 
notion that training, audit  and action 
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form findings are part of preventative 
actions. 
8.5.2 Corrective action No 
Partial 
 Does answer the clause but could do 
better expecially in lloking at points a to 
f.  This would also make things better for 
the other standards 
 
8.5.3 Preventive action No 
Partial 
 No mention of embedded preventative 
actions – training competency auditing 
etc. It mainly looks at things that have 
been pointed out not that are in place to 
stop these things from happening,  Also 
any need to do the breakdown of a to e? 
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Appendix C3 5 Recommended changes to issue 10 of Quality Manual 
 
Please note that the document given in this appendix was written for use by 
M&H quality staff. IT is given in this thesis for completeness. It is reproduced 
in full without amendments. 
 
The procedure QP.03F was written to cover the specific requirements of the 
medical design and product standard 13485:2016 not correctly or fully included in 
Issue 10 Rev 0 of the M&H quality manual (The 2019 issue of this manual). 
This was achieved by reviewing each clause of 13485, determining how M&H 
would meet the requirement or requirements of each 13485 clause, and if these 
requirements were met in the M&H quality manual, if not what additional 
requirements would need to be stated in the new procedure being written. On 
occasion, the 13485 requirement were addressed in the M&H quality manual but 
in a manner not fully directed at the requirements of the 13485 standard. For 
example Section 8 of the M&H manual covers corrective and preventative action 
in depth but the actions detailed are not specific enough to the 13485 standard. 
The following details the gaps and required actions to ensure that the next issue of 
the M&H quality manual, Issue 11 Rev 0, better meets the requirements not just 
of the 13485 standard but the other standards M&H are certified or accredited to – 
9001, 17025 and 15189. 
 
General Changes: 
 
The name of Medical Physics Instrumentation has been change to Clinical 
Engineer. Update manual to reflect this change and also better define the work of 
this group in the introduction and scope sections.  
Review procedures referenced in the quality manual as some have had their title 
changed to better reflect the work or processes they control, some have been 
removed and a few new procedures, including QP.03F have been introduced. 
SCPS should have its own paragraph in scope? 
HMFUS are now part of Genetics – need to update this is rest of manual and also 
who they now report to. 
The introduction to the quality manual, senior staff responsibility and organisation 
chart requires amended to ensure the changes to SCPS, HMFUS and Clinical 
Engineering management structures are included. 
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Changes to specific Clauses.  
 
1 Introduction 
SCPS and UKCAL laboratory functions need more visability – maybe break the 
Photobiology paragraph into sub heading. 
Do same for Clinical Engineering. 
 
2. Scope 
2.2.4. No reference to HMFUS R&D work is against 13485 and 15189. Need to 
reference new MDR, IVDR and UK statue. 
 
3. References and Definitions 
Section 3.1 and 3.2 need review plus additions of documentation and corrective 
and add in some definitions for example preventative actions, risk review, 
avoidance and acceptable risk. 
 
4. Quality Management System for M&H, NHS Tayside 
4.1.2, 4.1.3 and 4.1.4 in 13485 should be addressed in QM as it will be of benefit 
to rest of system –  
1. Risk based approached to the procedures and process and ensure appropriate 
interaction. 
2.  Review procedures and process are achievable with the resources available.  
3.  Planning to achieve required results and maintain effectiveness.  
4. Reviewing document changes to ensure the changes do not adversely affect 
or interfere with other parts of the quality management system. 
4.2 Documentation Requirements 
More required as to the control of documentation given to or received from 
subcontractors. Needs to go into QP.01 – identification and control. 
E-Quip and Q-Pulse location sharing not in QP.01 plus control of external 
manuals for change control or review – they are not under our control so can only 
ask for staff to check they are the correct issue for the job. 
4.2.1 The management tree needs a review and update as mention of for example 
deputy quality manager role. 
4.2.2 Review this section as some of it seems redundant – e,g, is Appendix 1 
needed, The interaction appendix needs updated - new and removed documents.  
Missing - No mention of special documentation as required by regulatory or 
statutory requirements. Could be a new section?  
No mention of how subcontractors fit into the quality management system. 
  
Page 181 of 513 
 
 
4.2.3 No mention of change control and how this achieved. Also check QP.01 to 
determine if change control detailed fully.  
There is no mention of the control of documentation passed to or passed from 
subcontractors – check also QP.01 as to how subcontractors documentation (to or 
from) fits into our system. What about QP.24 for record retention in relation to 
subcontractors? 
4.2.4 No longer have QP.03 remove reference. 
4.4 Software Validation  
Beef up to meet 4.1.6 and double check qp.01 against 4.1.6 
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5. Management Responsibility 
 
5.1 Management Commitment 
5.1 Review list order as a bit haphazard. Plus check the content – e,g,  point g) 
seems ambiguous 
5.2 Customer Focus 
5.2 First list is missing the requirement to ensure we meet the needs of applicable 
regulatory or statutory requirements 
 
5.3 M&H Quality Policy 
5.3. The policy does not state that is communicated to staff nor reviewed for 
effectiveness. 
Also might it be an idea to detail the requirements of a policy statement.  
 
5.5 Responsibility, Authority and Communication 
5.5.1 Need to review sentence two of 13485 5.5.1 – ‘Top management shall 
document the interrelation of all personnel who manage, perform and verify work 
affecting quality and shall ensure the independence and authority necessary to 
perform these tasks.’ As the QM really does not do this and it is required for 
17025 and 15189. 
5.5.2 Need to add in statutory …. In fact review all QM to have ‘regulatory and 
statutory requirements’. 
5.6 Management Review 
5.6.2 Need to add in reporting to regulatory or statutory authorities to agenda.  
Need to look at point 3 of agenda to possibly add in how the complaint was dealt 
with – complaint handling…. 
5.6.3 It might be beneficial to include the requirements of the 13485 review 
minutes into this section of the quality manual. 
Also no mention of using action forms to recorded output of the reviews – things 
to be done or things to inform staff of – the good things and the not so good 
things…. 
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6. Resource Management 
 
6.1 Provisions of Resurces  
There is no mention in the introduction regarding the need to have sufficient and 
correct resources to implement the QMS and maintain its effectiveness.  
6.2 Human Resources 
6.2.2 Nothing about reviewing the risk re training – is trained, competency and 
ability of staff reviewed against the risk of failing to carry out a task or fulfilling 
an output. 
6.3 Infrastructure 
Need to review this against the needs of 13285 to see if adding any of the ideas 
contained would be of benefits to the quality system. 
6.4 Work Environment 
6.4 change titles to included contamination control as it is required by 15189 and 
have new 6.4.1 and 6.4.2 paragraphs as per 13485. 
 
7. Product & Service Provision 
 
Sections 7.1, 7.2, 7.3 and 7.4 is now contained in new QP.03F for work related to 
medical devices, patient tests and associated services. Need to add into 7.3 design 
transfer documentation into quality manual as it would seem sensible to detail 
how the handover of the results of general design and development work 
documentation and information to be manufactured is achieved. 
 
7.4 Purchasing 
7.4.2 There is no mention of regulatory or statutory requirements nor the quality 
of the required products. 
7.5 Production of Service Provision 
7.5.1 Missing SCPS and Clinical Areas. Also how much of the Clinical 
Engineering section have changed due to the introduction of e-Quip. 
7.5.3 Identification and traceability needs to be reviewed for need, in light of e-
Quip and the need of the various standards. 
7.5.4 Might be an idea to add in how customer supplied materials for 
incorporating into products are to be controlled. 
7.5.5 Review this section against the requirements of 13458 7.5.11 for non-
medical production work. 
13485 Clause 7.5.7 needs to be reference in the quality manual to state that only 
approved external sterilisation processes.  
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7.6 Control of Monitoring and Measuring Devices 
 
First sentence needs review as some parts do not seem to be correct. 
Also need to look at 
 
1. Ensure monitoring or calibrated equipment not inadvertently adjusted. 
2. Having calibration results, external or internal, document as found results.  
3. If monitoring or calibrated equipment is found to be in error or needs adjusted 
during calibration then need to determine how this error or adjustment has 
affected previous work and if rework or recall is required, 
 
8 Measurement, analysis and improvement 
 
8.2.1 Customer Satisfaction  
Should this section not mention complaint handling? 
8.3 Control of Non-Conformities 
Seems to be missing section number 8.3.1for this General Section. Also the 
general section does not mention the need to involve subcontractors in the 
investigation and control of non-conformities their work / product / materials 
involved in.  
Need to rectify other section numbering once 8.3.1 added. 
8.4 Analysis of Data 
The general outline of this section is not correct as SCPS have complex analysis 
of test result information – need to review this against 15189 and 17025 and 
13485 as each of these standards have requirements for statistical analysis of data. 
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Appendix C4 1 The EU and UK Exemption Requirements for ‘In-House’ 
Manufacture 
 
EU MDR(2) 
 
Article 5 
 
Placing on the market and putting into service 
1. A device may be placed on the market or put into service only if it complies 
with this Regulation when duly supplied and properly installed, maintained 
and used in accordance with its intended purpose. 
2. A device shall meet the general safety and performance requirements set out 
in Annex I which apply to it, taking into account its intended purpose. 
3. Demonstration of conformity with the general safety and performance 
requirements shall include a clinical evaluation in accordance with Article 
61. 
4. Devices that are manufactured and used within health institutions shall be 
considered as having been put into service. 
5. With the exception of the relevant general safety and performance 
requirements set out in Annex I, the requirements of this Regulation shall not 
apply to devices, manufactured and used only within health institutions 
established in the Union, provided that all of the following conditions are 
met: 
a) the devices are not transferred to another legal entity, 
b) manufacture and use of the devices occur under appropriate quality 
management systems, 
c) the health institution justifies in its documentation that the target patient 
group's specific needs cannot be met, or cannot be met at the 
appropriate level of performance by an equivalent device available on 
the market, 
d) the health institution provides information upon request on the use of 
such devices to its competent authority, which shall include a 
justification of their manufacturing, modification and use; 
e) the health institution draws up a declaration which it shall make 
publicly available, including: 
I) the name and address of the manufacturing health institution; 
II) the details necessary to identify the devices; 
III) a declaration that the devices meet the general safety and 
performance requirements set out in Annex I to this Regulation 
and, where applicable, information on which requirements are not 
fully met with a reasoned justification therefor, 
f) the health institution draws up documentation that makes it possible to 
have an understanding of the manufacturing facility, the manufacturing 
process, the design and performance data of the devices, including the 
intended purpose, and that is sufficiently detailed to enable the 
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competent authority to ascertain that the general safety and 
performance requirements set out in Annex I to this Regulation are met; 
g) the health institution takes all necessary measures to ensure that all 
devices are manufactured in accordance with the documentation 
referred to in point (f), and 
h) the health institution reviews experience gained from clinical use of the 
devices and takes all necessary corrective actions. 
Member States may require that such health institutions submit to the competent 
authority any further relevant information about such devices which have been 
manufactured and used on their territory. Member States shall retain the right to 
restrict the manufacture and the use of any specific type of such devices and shall 
be permitted access to inspect the activities of the health institutions. This 
paragraph shall not apply to devices that are manufactured on an industrial scale. 
6. In order to ensure the uniform application of Annex I, the Commission may 
adopt implementing acts to the extent necessary to resolve issues of divergent 
interpretation and of practical application. Those implementing acts shall be 
adopted in accordance with the examination procedure referred to in Article 
114(3). 
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EU IVDR(3) 
Article 5 
Placing on the market and putting into service 
1. A device may be placed on the market or put into service only if it complies 
with this Regulation when duly supplied and properly installed, maintained 
and used in accordance with its intended purpose. 
2. A device shall meet the general safety and performance requirements set out 
in Annex I which apply to it, taking into account its intended purpose. 
3. Demonstration of conformity with the general safety and performance 
requirements shall include a clinical evaluation in accordance with Article 
61. 
4. Devices that are manufactured and used within health institutions shall be 
considered as having been put into service. 
5. With the exception of the relevant general safety and performance 
requirements set out in Annex I, the requirements of this Regulation shall not 
apply to devices, manufactured and used only within health institutions 
established in the Union, provided that all of the following conditions are 
met: 
a) the devices are not transferred to another legal entity, 
b) manufacture and use of the devices occur under appropriate quality 
management systems, 
c) the health institution justifies in its documentation that the target patient 
group's specific needs cannot be met, or cannot be met at the 
appropriate level of performance by an equivalent device available on 
the market, 
d) the health institution provides information upon request on the use of 
such devices to its competent authority, which shall include a 
justification of their manufacturing, modification and use; 
e) the health institution draws up a declaration which it shall make 
publicly available, including: 
I) the name and address of the manufacturing health institution; 
II) the details necessary to identify the devices; 
III) a declaration that the devices meet the general safety and 
performance requirements set out in Annex I to this Regulation 
and, where applicable, information on which requirements are not 
fully met with a reasoned justification therefor, 
f) the health institution draws up documentation that makes it possible to 
have an understanding of the manufacturing facility, the manufacturing 
process, the design and performance data of the devices, including the 
intended purpose, and that is sufficiently detailed to enable the 
competent authority to ascertain that the general safety and 
performance requirements set out in Annex I to this Regulation are met; 
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g) the health institution takes all necessary measures to ensure that all 
devices are manufactured in accordance with the documentation 
referred to in point (f), and 
h) the health institution reviews experience gained from clinical use of the 
devices and takes all necessary corrective actions. 
Member States may require that such health institutions submit to the competent 
authority any further relevant information about such devices which have been 
manufactured and used on their territory. Member States shall retain the right to 
restrict the manufacture and the use of any specific type of such devices and shall 
be permitted access to inspect the activities of the health institutions. 
This paragraph shall not apply to devices that are manufactured on an industrial 
scale. 
6. In order to ensure the uniform application of Annex I, the Commission may 
adopt implementing acts to the extent necessary to resolve issues of divergent 
interpretation and of practical application. Those implementing acts shall be 
adopted in accordance with the examination procedure referred to in Article 
114(3). 
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UK Law (4) 
 
Placing on the market and putting into service 
 
71.— 
1. A device to which this Part applies may be placed on the market or put into 
service only if it complies with this Part when duly supplied and properly 
installed, maintained and used in accordance with its intended purpose. 
2. A device to which this Part applies must meet the general safety and 
performance requirements set out in Schedule 3 which apply to it, taking into 
account its intended purpose. 
3. Demonstration of the general safety and performance requirements must 
include a clinical evaluation in accordance with regulation 102. 
4. Devices that are manufactured and used within health institutions must be 
considered as having been put into service. 
5. With the exception of the relevant safety and performance requirements set 
out in Schedule 3, the requirements of this Part do not apply to a device 
which is manufactured and used only within health institutions provided 
that— 
a) the device is not transferred to another legal entity; 
b) manufacture and use of the device occurs under appropriate quality 
management systems; 
c) the health institution justifies in its documentation that the target patient 
group’s specific needs cannot be met, or cannot be met at the 
appropriate level of performance, by an equivalent device available on 
the market; 
d) on request from the Secretary of State, the health institution provides 
the Secretary of State with information (which must include 
justification for its manufacturing, modification and use of such 
devices) on the use of the devices; 
e) the health institution draws up and makes publically available a 
statement setting out— 
I) the name and address of the manufacturing health institution, 
II) the details necessary to identify the devices, 
III) a declaration that the devices meet the general safety and 
performance requirements set out in Schedule 3 or, where 
applicable, information on which requirements are not fully met 
and a reasoned justification for not meeting those requirements; 
f) the health institution draws up a document which makes it possible to 
have an understanding of the manufacturing facility, the manufacturing 
process, the design and performance data of the devices and the 
intended purpose, and which is sufficiently detailed to enable the 
Secretary of State to ascertain whether the general safety and 
performance requirements set out in Schedule 3 are met; 
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g) the health institution takes all necessary measures to ensure that the 
device is manufactured in accordance with the documentation referred 
to in sub-paragraph (f); 
h) the health institution reviews experience gained from the clinical use of 
the devices and takes all necessary corrective actions. 
6. The Secretary of State may require a health institution which has complied 
with paragraph (5) to provide the Secretary of State with any further 
information about the devices which it has manufactured or used. 
7. The Secretary of State may restrict the manufacture and the use of a specified 
type of device manufactured in accordance with paragraph (5) and, for the 
purpose of considering such a restriction, must be permitted access to inspect 
the activities of health institutions.  
8. Paragraph (5) does not apply to devices that are manufactured on an 
industrial scale. 
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Appendix C4 2 Side by side comparison of the exemption rules. 
 
MDR -Article 5 Placing on the market and 
putting into service 
1. A device may be placed on the 
market or put into service only if it 
complies with this Regulation when 
duly supplied and properly 
installed, maintained and used in 
accordance with its intended 
purpose. 
2. A device shall meet the general 
safety and performance 
requirements set out in Annex I 
which apply to it, taking into 
account its intended purpose. 
3. Demonstration of conformity with 
the general safety and performance 
requirements shall include a clinical 
evaluation in accordance with 
Article 61. 
4. Devices that are manufactured and 
used within health institutions shall 
be considered as having been put 
into service. 
IVDR Article 5 Placing on the market and 
putting into service 
1. A device may be placed on the 
market or put into service only if it 
complies with this Regulation when 
duly supplied and properly 
installed, maintained and used in 
accordance with its intended 
purpose. 
2. A device shall meet the general 
safety and performance 
requirements set out in Annex I 
which apply to it, taking into 
account its intended purpose. 
3. Demonstration of conformity with 
the general safety and performance 
requirements shall include a clinical 
evaluation in accordance with 
Article 61. 
4. Devices that are manufactured and 
used within health institutions shall 
be considered as having been put 
into service. 
UK Para 71 Placing on the market and 
putting into service 
1. A device to which this Part applies 
may be placed on the market or put 
into service only if it complies with 
this Part when duly supplied and 
properly installed, maintained and 
used in accordance with its intended 
purpose. 
2. A device to which this Part applies 
must meet the general safety and 
performance requirements set out in 
Schedule 3 which apply to it, taking 
into account its intended purpose. 
3. Demonstration of the general safety 
and performance requirements must 
include a clinical evaluation in 
accordance with regulation 102. 
4. Devices that are manufactured and 
used within health institutions must 
be considered as having been put into 
service. 
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5. With the exception of the relevant 
general safety and performance 
requirements set out in Annex I, 
the requirements of this Regulation 
shall not apply to devices, 
manufactured and used only within 
health institutions established in 
the Union, provided that all of the 
following conditions are met: 
a) the devices are not transferred to 
another legal entity, 
b) manufacture and use of the devices 
occur under appropriate quality 
management systems, 
c) the health institution justifies in its 
documentation that the target 
patient group's specific needs 
cannot be met, or cannot be met at 
the appropriate level of 
performance by an equivalent 
device available on the market, 
d) the health institution provides 
information upon request on the 
use of such devices to its 
competent authority, which shall 
include a justification of their 
5. With the exception of the relevant 
general safety and performance 
requirements set out in Annex I, 
the requirements of this Regulation 
shall not apply to devices, 
manufactured and used only within 
health institutions established in 
the Union, provided that all of the 
following conditions are met: 
a) the devices are not transferred to 
another legal entity, 
b) manufacture and use of the devices 
occur under appropriate quality 
management systems, 
c) the health institution justifies in its 
documentation that the target 
patient group's specific needs 
cannot be met, or cannot be met at 
the appropriate level of 
performance by an equivalent 
device available on the market, 
d) the health institution provides 
information upon request on the 
use of such devices to its 
competent authority, which shall 
include a justification of their 
5. With the exception of the relevant 
safety and performance requirements 
set out in Schedule 3, the 
requirements of this Part do not 
apply to a device which is 
manufactured and used only within 
health institutions provided that— 
a) the device is not transferred to 
another legal entity; 
b) manufacture and use of the device 
occurs under appropriate quality 
management systems; 
c) the health institution justifies in its 
documentation that the target 
patient group’s specific needs cannot 
be met, or cannot be met at the 
appropriate level of performance, by 
an equivalent device available on the 
market; 
d) on request from the Secretary of 
State, the health institution provides 
the Secretary of State with 
information (which must include 
justification for its manufacturing, 
modification and use of such devices) 
on the use of the devices; 
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manufacturing, modification and 
use; 
e) the health institution draws up a 
declaration which it shall make 
publicly available, including: 
I) the name and address of the 
manufacturing health institution; 
II) the details necessary to identify the 
devices; 
III) a declaration that the devices meet 
the general safety and performance 
requirements set out in Annex I to 
this Regulation and, where 
applicable, information on which 
requirements are not fully met with 
a reasoned justification therefor, 
f) the health institution draws up 
documentation that makes it 
possible to have an understanding 
of the manufacturing facility, the 
manufacturing process, the design 
and performance data of the 
devices, including the intended 
purpose, and that is sufficiently 
detailed to enable the competent 
authority to ascertain that the 
manufacturing, modification and 
use; 
e) the health institution draws up a 
declaration which it shall make 
publicly available, including: 
I) the name and address of the 
manufacturing health institution; 
II) the details necessary to identify the 
devices; 
III) a declaration that the devices meet 
the general safety and performance 
requirements set out in Annex I to 
this Regulation and, where 
applicable, information on which 
requirements are not fully met with 
a reasoned justification therefor, 
f) the health institution draws up 
documentation that makes it 
possible to have an understanding 
of the manufacturing facility, the 
manufacturing process, the design 
and performance data of the 
devices, including the intended 
purpose, and that is sufficiently 
detailed to enable the competent 
authority to ascertain that the 
e) the health institution draws up and 
makes publically available a 
statement setting out— 
I) the name and address of the 
manufacturing health institution, 
II) the details necessary to identify the 
devices, 
III) a declaration that the devices meet 
the general safety and performance 
requirements set out in Schedule 3 
or, where applicable, information on 
which requirements are not fully met 
and a reasoned justification for not 
meeting those requirements; 
f) the health institution draws up a 
document which makes it possible to 
have an understanding of the 
manufacturing facility, the 
manufacturing process, the design 
and performance data of the devices 
and the intended purpose, and which 
is sufficiently detailed to enable the 
Secretary of State to ascertain 
whether the general safety and 
performance requirements set out in 
Schedule 3 are met; 
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general safety and performance 
requirements set out in Annex I to 
this Regulation are met; 
g) the health institution takes all 
necessary measures to ensure that 
all devices are manufactured in 
accordance with the 
documentation referred to in point 
(f), and 
h) the health institution reviews 
experience gained from clinical use 
of the devices and takes all 
necessary corrective actions. 
Member States may require that such 
health institutions submit to the 
competent authority any further relevant 
information about such devices which 
have been manufactured and used on 
their territory. Member States shall retain 
the right to restrict the manufacture and 
the use of any specific type of such 
devices and shall be permitted access to 
inspect the activities of the health 
institutions. 
general safety and performance 
requirements set out in Annex I to 
this Regulation are met; 
g) the health institution takes all 
necessary measures to ensure that 
all devices are manufactured in 
accordance with the 
documentation referred to in point 
(f), and 
h) the health institution reviews 
experience gained from clinical use 
of the devices and takes all 
necessary corrective actions. 
Member States may require that such 
health institutions submit to the 
competent authority any further relevant 
information about such devices which 
have been manufactured and used on 
their territory. Member States shall retain 
the right to restrict the manufacture and 
the use of any specific type of such 
devices and shall be permitted access to 
inspect the activities of the health 
institutions. 
g) the health institution takes all 
necessary measures to ensure that 
the device is manufactured in 
accordance with the documentation 
referred to in sub-paragraph (f); 
h) the health institution reviews 
experience gained from the clinical 
use of the devices and takes all 
necessary corrective actions. 
6. The Secretary of State may require a 
health institution which has complied 
with paragraph (5) to provide the 
Secretary of State with any further 
information about the devices which 
it has manufactured or used. 
7. The Secretary of State may restrict 
the manufacture and the use of a 
specified type of device 
manufactured in accordance with 
paragraph (5) and, for the purpose of 
considering such a restriction, must 
be permitted access to inspect the 
activities of health institutions.  
8. Paragraph (5) does not apply to 
devices that are manufactured on an 
industrial scale. 
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This paragraph shall not apply to devices 
that are manufactured on an industrial 
scale. 
6. In order to ensure the uniform 
application of Annex I, the 
Commission may adopt 
implementing acts to the extent 
necessary to resolve issues of 
divergent interpretation and of 
practical application. Those 
implementing acts shall be adopted 
in accordance with the examination 
procedure referred to in Article 
114(3). 
This paragraph shall not apply to devices 
that are manufactured on an industrial 
scale. 
6. In order to ensure the uniform 
application of Annex I, the 
Commission may adopt 
implementing acts to the extent 
necessary to resolve issues of 
divergent interpretation and of 
practical application. Those 
implementing acts shall be adopted 
in accordance with the examination 
procedure referred to in Article 
114(3). 
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Appendix C4 3 Comparison: Medical Devices EU with UK General Safety and Performance Requirements. 
 
Regulation (EU) 2017/745 of the European Parliament and of the 
Council of 5 April 2017 on medical devices, amending Directive 
2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 
1223/2009 and repealing Council Directives 90/385/EEC and 
93/42/EEC, referenced as EU MDR 
 
 2019 No. 791 
EXITING THE EUROPEAN UNION CONSUMER PROTECTION 
The Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 
Made - 1st April 2019 
ANNEX I  
GENERAL SAFETY AND PERFORMANCE REQUIREMENTS  
 
Comparison 
 
Yes /NO  
Schedule 3 parts 1,2 and 3.  
General safety and performance requirements for general medical 
devices 
 
CHAPTER I 
GENERAL REQUIREMENTS 
 PART 1  
General requirements 
1. Devices shall  
achieve the performance intended by their manufacturer and  
shall be designed and manufactured in such a way that, during normal 
conditions of use, they are suitable for their intended purpose.  
They shall be safe and effective and shall not compromise the clinical 
condition or the safety of patients, or the safety and health of users or, 
where applicable, other persons, provided that any risks which may be 
 1. Devices must— 
(a) achieve the performance intended by their manufacturer; 
(b) be designed and manufactured in such a way that, during normal 
conditions of use, they are suitable for their intended purpose; 
(c) be safe and effective and not compromise the clinical condition or 
the safety of patients, or the safety and health of users or, where 
applicable, other persons, provided that any risks which may be 
associated with their use constitute acceptable risks when weighed 
against the benefits to the patient and are compatible with a high 
level of protection of health and safety, taking into account the 
generally acknowledged state of the art. 
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associated with their use constitute acceptable risks when weighed 
against the benefits to the patient and are compatible with a high level 
of protection of health and safety, taking into account the generally 
acknowledged state of the art. 
2.The requirement in this Annex to reduce risks as far as possible means 
the reduction of risks as far as possible without adversely affecting the 
benefit-risk ratio. 
 2. The requirement in this Schedule to reduce risks as far as possible 
means the reduction of risks as far as possible without adversely 
affecting the benefit-risk ratio. 
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3.Manufacturers shall establish, implement, document and maintain a 
risk management system. 
Risk management shall be understood as a continuous iterative process 
throughout the entire lifecycle of a device, requiring regular systematic 
updating. In carrying out risk management manufacturers shall: 
(a) establish and document a risk management plan for each device; 
(b)identify and analyse the known and foreseeable hazards associated 
with each device; 
(c)estimate and evaluate the risks associated with, and occurring during, 
the intended use and during reasonably foreseeable misuse; 
(d)eliminate or control the risks referred to in point (c) in accordance 
with the requirements of Section 4; 
(e)evaluate the impact of information from the production phase and, in 
particular, from the post-market surveillance system, on hazards and the 
frequency of occurrence thereof, on estimates of their associated risks, 
as well as on the overall risk, benefit-risk ratio and risk acceptability; 
and 
 3 - (1) Manufacturers must establish, implement, document and 
maintain a risk management system. 
(2) Risk management is to be understood as a continuous iterative 
process throughout the entire lifecycle of a device, which requires 
regular systematic updating and, in carrying out risk management, 
manufacturers must— 
(a) establish and document a risk management plan for each device; 
(b) identify and analyse the known and foreseeable hazards associated 
with each device; 
(c) estimate and evaluate the risks associated with, and occurring 
during, the intended use and during reasonably foreseeable misuse; 
(d) eliminate or control the risks referred to in sub-paragraph (c) in 
accordance with the requirements of paragraph 4; 
(e) evaluate the impact of information from the production phase and, 
in particular, from the post-market surveillance system, on hazards 
and the frequency of occurrence thereof, on estimates of their 
associated risks, as well as on the overall risk, benefit-risk ratio and 
risk acceptability; 
(f) based on the evaluation of the impact of the information referred to 
in paragraph (e), if necessary amend control measures in line with 
the requirements of paragraph 4. 
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(f)based on the evaluation of the impact of the information referred to 
in point (e), if necessary amend control measures in line with the 
requirements of Section 4. 
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4.Risk control measures adopted by manufacturers for the design and 
manufacture of the devices shall conform to safety principles, taking 
account of the generally acknowledged state of the art.  
To reduce risks, Manufacturers shall manage risks so that the residual 
risk associated with each hazard as well as the overall residual risk is 
judged acceptable. 
In selecting the most appropriate solutions, manufacturers shall, in the 
following order of priority: 
(a)eliminate or reduce risks as far as possible through safe design and 
manufacture; 
(b)where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated; and 
(c)provide information for safety (warnings/precautions/contra-
indications) and, where appropriate, training to users. 
Manufacturers shall inform users of any residual risks. 
 4 - (1) Risk control measures adopted by manufacturers for the design 
and manufacture of the devices must conform to safety principles, 
taking account of the generally acknowledged state of the art. 
(2) To reduce risks, manufacturers must manage risks so that the 
residual risk associated with each hazard as well as the overall 
residual risk is judged acceptable. 
(3) In selecting the most appropriate solutions, manufacturers must, in 
the following order of priority— 
(a) eliminate or reduce risks as far as possible through safe design and 
manufacture; 
(b) where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated;  
and 
(c) provide information for safety (warnings, precautions, contra-
indications) and, where appropriate, training to users; 
(d) inform users of any residual risks. 
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5.In eliminating or reducing risks related to use error, the manufacturer 
shall: 
(a)reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended to be 
used (design for patient safety), and 
(b)give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
 5. In eliminating or reducing risks related to use error, the manufacturer 
must— 
(a) reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended to 
be used (design for patient safety); 
(b) give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
6.The characteristics and performance of a device shall not be adversely 
affected to such a degree that the health or safety of the patient or the 
user and, where applicable, of other persons are compromised during 
the lifetime of the device, as indicated by the manufacturer, when the 
device is subjected to the stresses which can occur during normal 
conditions of use and has been properly maintained in accordance with 
the manufacturer's instructions. 
 6. The characteristics and performance of a device must not be 
adversely affected to such a degree that the health or safety of the 
patient or the user and, where applicable, of other persons are 
compromised during the lifetime of the device, as indicated by the 
manufacturer, when the device is subjected to the stresses which can 
occur during normal conditions of use and has been properly 
maintained in accordance with the manufacturer’s instructions. 
7.Devices shall be designed, manufactured and packaged in such a way 
that their characteristics and performance during their intended use are 
not adversely affected during transport and storage, for example, 
through fluctuations of temperature and humidity, taking account of the 
instructions and information provided by the manufacturer. 
 7. Devices must be designed, manufactured and packaged in such a 
way that their characteristics and performance during their intended 
use are not adversely affected during transport and storage, for 
example, through fluctuations of  temperature  and  humidity, taking 
account of the instructions and information provided by the 
manufacturer. 
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8.All known and foreseeable risks, and any undesirable side-effects, 
shall be minimised and be acceptable when weighed against the 
evaluated benefits to the patient and/or user arising from the achieved 
performance of the device during normal conditions of use. 
 8. All known and foreseeable risks, and any undesirable side-effects, 
must be minimised and be acceptable when weighed against the 
evaluated benefits to the patient or user arising from the achieved 
performance of the device during normal conditions of use. 
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9.For the devices referred to in Annex XVI, the general safety 
requirements set out in Sections 1 and 8 shall be understood to mean 
that the device, when used under the conditions and for the purposes 
intended, does not present a risk at all or presents a risk that is no more 
than the maximum acceptable risk related to the product's use which is 
consistent with a high level of protection for the safety and health of 
persons. 
 9. For the devices referred to in Schedule 16, the general safety 
requirements set out in paragraphs 1 and 8 must be understood to 
mean that the device, when used under the conditions and for the 
purposes intended, does not present a risk at all or presents a risk 
that is no more than the maximum acceptable risk related to the 
product’s use which is consistent with a high level of protection for 
the safety and health of persons. 
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 The information and requirements in this section need to be reviewed each time EU or UK legislation change as section 10.4 is liable to change. The 
changes may not be reflected between the two sets of requirements.  
CHAPTER II 
REQUIREMENTS REGARDING DESIGN AND MANUFACTURE 
 
PART 2 
Requirements regarding design and manufacture 
Essential Requirement 10. Chemical, physical and biological 
properties 
 
Chemical, physical and biological properties 
10.1Devices shall be designed and manufactured in such a way as to 
ensure that the characteristics and performance requirements referred to 
in Chapter I are fulfilled. Particular attention shall be paid to: 
(a)the choice of materials and substances used, particularly as regards 
toxicity and, where relevant, flammability; 
(b)the compatibility between the materials and substances used and 
biological tissues, cells and body fluids, taking account of the intended 
purpose of the device and, where relevant, absorption, distribution, 
metabolism and excretion; 
(c)the compatibility between the different parts of a device which 
consists of more than one implantable part; 
(d) the impact of processes on material properties; 
 10 .—(1) Devices must be designed and manufactured in such a way as 
to ensure that the characteristics and performance requirements 
referred to in paragraphs 1 to 9 are fulfilled. 
(2) Particular attention must be paid to— 
(a) the choice of materials and substances used, particularly as regards 
toxicity and, where relevant, flammability; 
(b) the compatibility between the materials and substances used and 
biological tissues, cells and body fluids, taking account of the 
intended purpose of the device and, where relevant, absorption, 
distribution, metabolism and excretion; 
(c) the compatibility between the different parts of a device which 
consists of more than one implantable part; 
(d) the impact of processes on material properties; 
(e) where appropriate, the results of biophysical or modelling research 
the validity of which has been demonstrated beforehand; 
(f) the mechanical properties of the materials used, reflecting, where 
appropriate, matters such as strength, ductility, fracture resistance, 
wear resistance and fatigue resistance; 
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(e)where appropriate, the results of biophysical or modelling research 
the validity of which has been demonstrated beforehand; 
(f)the mechanical properties of the materials used, reflecting, where 
appropriate, matters such as strength, ductility, fracture resistance, wear 
resistance and fatigue resistance; 
(g) surface properties; and 
(h)the confirmation that the device meets any defined chemical and/or 
physical specifications. 
(g) surface properties; 
(h) the confirmation that the device meets any defined chemical or 
physical specifications. 
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10.2.Devices shall be designed, manufactured and packaged in such a 
way as to minimise the risk posed by contaminants and residues to  
patients, taking account of the intended purpose of the device, 
 and to the persons involved in the transport, storage and use of the 
devices.  
Particular attention shall be paid to tissues exposed to those 
contaminants and residues and to the duration and frequency of 
exposure. 
 (3) Devices must be designed, manufactured and packaged in such a 
way as to minimise the risk posed by contaminants and residues to— 
(a) patients, taking account of the intended purpose of the device; 
 
(b) persons involved in the transport, storage and use of the device, 
and particular attention must be paid to tissues exposed to those 
contaminants and residues and to the duration and frequency of 
exposure. 
10.3.Devices shall be designed and manufactured in such a way that 
they can be used safely with the materials and substances, including 
gases, with which they enter into contact during their intended use;  
if the devices are intended to administer medicinal products they shall 
be designed and manufactured in such a way as to be compatible with 
the medicinal products concerned in accordance with the provisions and 
restrictions governing those medicinal products 
 (4) Devices must be designed and manufactured in such a way that they 
can be used safely with the materials and substances, including 
gases, with which they enter into contact during their intended use. 
(5) If the devices are intended to administer medicinal products they 
must— 
(a) be designed and manufactured in such a way as to be compatible 
with the medicinal products concerned in accordance with the 
provisions and restrictions governing those medicinal products; 
(b) ensure that the performance of both the medicinal products and of 
the devices is maintained in accordance with their respective 
indications and intended use. 
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and that the performance of both the medicinal products and of the 
devices is maintained in accordance with their respective indications 
and intended use. 
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10.4. Substances 
 
 Substances 
10.4.1.Design and manufacture of devices 
Devices shall be designed and manufactured in such a way as to reduce 
as far as possible the risks posed by substances or particles, including 
wear debris, degradation products and processing residues, that may be 
released from the device. 
 Design and manufacture of devices 
(6) Devices must be designed and manufactured in such a way as to 
reduce, as far as possible, the risks posed by substances or particles, 
including wear debris, degradation products and processing residues 
that may be released from the device. 
 Devices, or those parts thereof or those materials used therein that: 
 are invasive and come into direct contact with the human body, 
(re)administer medicines, body liquids or other substances, including 
gases, to/from the body, or 
transport or store such medicines, body fluids or substances, including 
gases, to be (re)administered to the body, 
 
 
This EU listing 
is the same as 
in UK (8) this 
section. See 
below UK (8) 
for 
comparison. 
 
(7) Devices, parts of those devices or materials used in those devices 
listed in sub- paragraph (8)  
 
 
 
 
may only contain the following substances in a concentration that is 
above 0.1% weight where that is justified in accordance with sub-
paragraph (9)— 
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shall only contain the following substances in a concentration that is 
above 0,1 % weight by weight (w/w) where justified pursuant to Section 
10.4.2: 
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(a) substances which are carcinogenic, mutagenic or toxic to 
reproduction (‘CMR’), of category 1A or 1B, in accordance with 
Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the 
European Parliament and of the Council (1), or 
 
 
 
(b)substances having endocrine-disrupting properties for which there is 
scientific evidence of probable serious effects to human health and 
which are identified either in accordance with 
 the procedure set out in Article 59 of Regulation (EC) No 1907/2006 
of the European Parliament and of the Council (2) or 
once a delegated act has been adopted by the Commission pursuant to 
the first subparagraph of Article 5(3) of Regulation (EU) No 528/2012 
of the European Parliament and the Council (3), in accordance with the 
criteria that are relevant to human health amongst the criteria 
established therein. 
UK (a) gives 
fuller details of 
the EU 
regulation to 
be applied. 
 
 
 
UK (b) (i) and 
(ii) gives fuller 
details of the 
EU regulation 
to be applied 
(a) substances which are carcinogenic, mutagenic or toxic to 
reproduction (‘CMR’), of category 1A or 1B, and on the UK 
mandatory classification and labelling list established and 
maintained in accordance with Article 38A(a) of Regulation (EC) 
No 1272/2008 of the European Parliament and of the Council of 16 
December 2008 on classification, labelling and packaging of 
substances and mixtures, amending and repealing Directives 
67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 
1907/2006; or 
(b) substances having endocrine-disrupting properties for which there is 
scientific evidence of probable serious effects to human health and 
which are identified in accordance with— 
(i) the procedure set out in Article 59 of Regulation (EC) No 1907/2006 
of the European Parliament and of the Council of 18 December 2006 
concerning the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH), establishing a European 
Chemicals Agency, amending Directive 1999/45/EC and repealing 
Council Regulation (EEC) No 793/93 and Commission Regulation 
(EC) No 1488/94 as well as Council Directive 76/769/EEC and 
Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 
2000/21/EC; or 
(ii) Commission Delegated Regulation (EU) 2017/2100 of 4 September 
2017 setting out the scientific criteria for the determination of 
endocrine-disrupting properties pursuant to Regulation (EU) 
528/2012 of the European Parliament and Council. 
Page 211 of 513 
 
 
 
  
Page 212 of 513 
 
 
 
 Devices, or those parts thereof or those materials used therein that: 
 are invasive and come into direct contact with the human body, 
(re)administer medicines, body liquids or other substances, including 
gases, to/from the body, or 
transport or store such medicines, body fluids or substances, including 
gases, to be (re)administered to the body, 
EU list from 
10.4.1 
reporduced 
here for 
comparison. 
(8) The devices (or parts or materials) to which sub-paragraph (7) 
relates are devices which— 
(a) are invasive and come into direct contact with the human body; 
(b) administer or re-administer medicines, body liquids or other 
substances, including gases, to the body; or 
(c) transport or store medicines, body fluids or substances, including 
gases, to be administered or re-administered to the body. 
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10.4.2. Justification regarding the presence of CMR and/or endocrine-
disrupting substances 
The justification for the presence of such substances shall be based 
upon: 
(a)an analysis and estimation of potential patient or user exposure to the 
substance; 
(b)an analysis of possible alternative substances, materials or designs, 
including, where available, information about independent research, 
peer-reviewed studies, scientific opinions from relevant scientific 
committees and an analysis of the availability of such alternatives; 
(c)argumentation as to why possible substance and/ or material 
substitutes, if available, or design changes, if feasible, are inappropriate 
in relation to maintaining the functionality, performance and the 
benefit-risk ratios of the product; including taking into account if the 
intended use of such devices includes treatment of children or treatment 
of pregnant or breastfeeding women or treatment of other patient groups 
considered particularly vulnerable to such substances and/or materials; 
and 
The wording 
differs 
between these 
two parts but 
are the same 
requirements. 
 
 
 
 
 
 
 
 
 
 
See below ** 
(9) The justification for the presence of the substances listed in sub-
paragraph (7) must be based upon— 
 
 
(a) an analysis and estimation of potential patient or user exposure to 
the substance; 
(b) an analysis of possible alternative substances, materials or  designs,  
including, where available, information about independent research, 
peer-reviewed studies, scientific opinions from relevant scientific 
committees and an analysis of the availability of such alternatives; 
(c) arguments as to why possible substance or material substitutes, if 
available, or design changes, if feasible, are inappropriate in relation 
to maintaining the functionality, performance and the benefit-risk 
ratios of the product; including, where relevant having regard to the 
intended use of the device, taking account of the vulnerability to 
such substances or materials of particular patient groups including 
children and pregnant or breastfeeding women; 
(d) where applicable and available, the latest scientific guidelines 
relating to the risks and benefits (including the availability of 
alterative substances, materials, designs or treatments) of phthalates 
and other CMR and endocrine-disrupting substances. 
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(d)where applicable and available, the latest relevant scientific 
committee guidelines in accordance with Sections 10.4.3. and 10.4.4. 
 
**Part EU and UK point (d) are different but point (d) EU when taken as a whole EU 10.4.3 and 10.4.4 mean the same as point (d) UK– get the most 
up to date evidence on their use. This point needs to be reviewed in the future when the EU committees report and when either EU or UK legislation is 
updated or amended. 
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** Need to review this section when EU or UK legislation is amended or updated. 
  
10.4.3.Guidelines on phthalates 
For the purposes of Section 10.4., the Commission shall, as soon as 
possible and by 26 May 2018, provide the relevant scientific committee 
with a mandate to prepare guidelines that shall be ready before 26 May 
2020. The mandate for the committee shall encompass at least a benefit-
risk assessment of the presence of phthalates which belong to either of 
the groups of substances referred to in points (a) and (b) of Section 
10.4.1. The benefit-risk assessment shall take into account the intended 
purpose and context of the use of the device, as well as any available 
alternative substances and alternative materials, designs or medical 
treatments. When deemed appropriate on the basis of the latest scientific 
evidence, but at least every five years, the guidelines shall be updated. 
10.4.4.Guidelines on other CMR and endocrine-disrupting substances 
Subsequently, the Commission shall mandate the relevant scientific 
committee to prepare guidelines as referred to in Section 10.4.3. also for 
other substances referred to in points (a) and (b) of Section 10.4.1., 
where appropriate. 
This area of 
EU legislation 
is the same as 
UK. The UK 
legislation 
informs to use 
best guidance 
while EU 
legislation 
refers to 
committees 
see below ** 
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10.4.5.Labelling 
Where devices, parts thereof or materials used therein as referred to in 
Section 10.4.1. contain substances referred to in points (a) or (b) of 
Section 10.4.1. in a concentration above 0,1 % weight by weight (w/w), 
the presence of those substances shall 
 be labelled on the device itself and/or on the packaging for each unit 
or, where appropriate, on the sales packaging, with the list of such 
substances.  
If the intended use of such devices includes treatment of children or 
treatment of pregnant or breastfeeding women or treatment of other 
patient groups considered particularly vulnerable to such substances 
and/or materials, information on residual risks for those patient groups 
and, if applicable, on appropriate precautionary measures shall be given 
in the instructions for use. 
 Labelling 
(10) Where the devices (parts or materials) referred to in sub-
paragraph (7) contain the substances in paragraph (a) and (b) of sub-
paragraph (7) in a concentration above 0.1% weight by weight (w/w), 
the presence of those substances must— 
(a) be labelled on the device itself or on the packaging for each unit 
or, where appropriate, on the sales packaging, with the list of such 
substances; 
(b) if the intended use of such devices includes treatment of 
particular patient groups (including children or pregnant or 
breastfeeding women) who are particularly vulnerable to those 
substances, be contained in information on residual risks for those 
patient groups and, if applicable, in appropriate precautionary measures 
in the instructions for use. 
10.5.Devices shall be designed and manufactured in such a way as to 
reduce as far as possible the risks posed by the unintentional ingress of 
substances into the device taking into account the device and the nature 
of the environment in which it is intended to be used. 
 (11) Devices must be designed and manufactured in such a way as to 
reduce, as far as possible, the risks posed by the unintentional ingress of 
substances into the device, taking into account the device and the nature 
of the environment in which it is intended to be used. 
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10.6.Devices shall be designed and manufactured in such a way as to 
reduce as far as possible the risks linked to the size and the properties 
of particles which are or can be released into the patient's or user's body, 
unless they come into contact with intact skin only. Special attention 
shall be given to nanomaterials. 
 (12) Unless they come into contact with intact skin only, devices 
must be designed and manufactured in such a way as to reduce, as far 
as possible, the risks linked to the size and the properties of particles 
which are or can be released into the patient’s or user’s body, and special 
attention must be given to nanomaterials. 
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Essential Requirement 11. Infection and microbial contamination 
 
Infection and microbial contamination 
11.1.Devices and their manufacturing processes shall be designed in 
such a way as to eliminate or to reduce as far as possible the risk of 
infection to patients, users and, where applicable, other persons. The 
design shall: 
(a)reduce as far as possible and appropriate the risks from unintended 
cuts and pricks, such as needle stick injuries, 
(b) allow easy and safe handling, 
(c)reduce as far as possible any microbial leakage from the device 
and/or microbial exposure during use, and 
(d)prevent microbial contamination of the device or its content such as 
specimens or fluids. 
 11 .—(1) Devices and their manufacturing processes must be 
designed in such a way as to eliminate or to reduce as far as possible the 
risk of infection to patients, users and, where applicable, other persons 
and the design must— 
(a) reduce as far as possible and appropriate the risks from 
unintended cuts and pricks, such as needle stick injuries; 
(b) allow easy and safe handling; 
(c) reduce as far as possible any microbial leakage from the device 
or microbial exposure during use; 
(d) prevent microbial contamination of the device or its content such 
as specimens or fluids. 
11.2.Where necessary devices shall be designed to facilitate their safe 
cleaning, disinfection, and/or re-sterilisation. 
 (2) Where necessary devices must be designed to facilitate their safe 
cleaning, disinfection or re-sterilisation. 
11.3.Devices labelled as having a specific microbial state shall be 
designed, manufactured and packaged to ensure that they remain in that 
 (3) Devices labelled as having a specific microbial state must be 
designed, manufactured and packaged to ensure that they remain in that 
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state when placed on the market and remain so under the transport and 
storage conditions specified by the manufacturer. 
state when placed on the market and remain so under the transport and 
storage conditions specified by the manufacturer. 
11.4. Devices delivered in a sterile state shall 
 be designed, manufactured and packaged in accordance with 
appropriate procedures, to ensure that they are sterile when placed on 
the market and that, unless the packaging which is intended to maintain 
their sterile condition is damaged, they remain sterile, under the 
transport and storage conditions specified by the manufacturer, until 
that packaging is opened at the point of use.  
It shall be ensured that the integrity of that packaging is clearly evident 
to the final user. 
 (4) Devices delivered in a sterile state must— 
(a) be designed, manufactured and packaged in accordance with 
appropriate procedures, to ensure that they are sterile when placed on 
the market and that, unless the packaging which is intended to maintain 
their sterile condition is damaged, they remain sterile, under the 
transport and storage conditions specified by the manufacturer, until that 
packaging is opened at the point of use; 
(b) ensure that the integrity of the packaging is clearly evident to the 
final user. 
 
11.5.Devices labelled as sterile shall be processed, manufactured, 
packaged and, sterilised by means of appropriate, validated methods. 
 (5) Devices labelled as sterile must be processed, manufactured, 
packaged and, sterilised by means of appropriate, validated methods. 
11.6.Devices intended to be sterilised shall be manufactured and 
packaged in appropriate and controlled conditions and facilities. 
 (6) Devices intended to be sterilised must be manufactured and 
packaged in appropriate and controlled conditions and facilities. 
11.7. Packaging systems for non-sterile devices shall   (7) Packaging systems for non-sterile devices must— 
(a) maintain the integrity and cleanliness of the product; 
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maintain the integrity and cleanliness of the product and,  
where the devices are to be sterilised prior to use, minimise the risk of 
microbial contamination;  
the packaging system shall be suitable taking account of the method of 
sterilisation indicated by the manufacturer. 
(b) where the devices are to be sterilised prior to use, minimise the 
risk of microbial contamination; 
(c) be  suitable  taking  account  of  the  method  of  sterilisation  
indicated  by  the manufacturer. 
11.8.The labelling of the device shall distinguish between identical or 
similar devices placed on the market in both a sterile and a non-sterile 
condition additional to the symbol used to indicate that devices are 
sterile. 
 (8) The labelling of the device must distinguish between identical 
or similar devices placed on the market in both a sterile and a non-sterile 
condition in addition to the symbol used to indicate that devices are 
sterile. 
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Essential Requirement 12. 
Devices incorporating a substance considered to be a medicinal 
product and devices that are composed of substances or of 
combinations of substances that are absorbed by or locally 
dispersed in the human body. 
 
Devices incorporating a substance considered to be a medicinal product 
and device that are composed of substances that are absorbed by or 
locally dispersed in the human body 
12.1.In the case of devices referred to in the first subparagraph of Article 
1(8), the quality, safety and usefulness of the substance which, if used 
separately, would be considered to be a medicinal product within the 
meaning of point (2) of Article 1 of Directive 2001/83/EC, shall be 
verified by analogy with the methods specified in Annex I to Directive 
2001/83/EC, as required by the applicable conformity assessment 
procedure under this Regulation. 
 12 - (1) In the case of devices referred to in regulation 68(8), the quality, 
safety and usefulness of the substance which, if used separately, 
would be considered to be a medicinal product within the meaning 
of regulation 2 of the Human Medicines Regulations 2002, must be 
verified by analogy with the methods specified in Annex I to 
Directive 2001/83/EC read subject to modifications made by the 
Human Medicines Regulations 2012, as required by the applicable 
conformity assessment procedure under Part VIII. 
12.2.Devices that are composed of substances or of combinations of 
substances that are intended to be introduced into the human body, and 
that are absorbed by or locally dispersed in the human body shall 
comply, where applicable and in a manner limited to the aspects not 
covered by this Regulation, with the relevant requirements laid down in 
Annex I to Directive 2001/83/EC for the evaluation of absorption, 
distribution, metabolism, excretion, local tolerance, toxicity, interaction 
with other devices, medicinal products or other substances and potential 
 (2) Devices that are composed of substances or of combinations of 
substances that are intended to be introduced into the human body, 
and that are absorbed by or  locally dispersed in the human body 
must comply, where applicable and in a manner limited to the 
aspects not covered by Part VIII, with the relevant requirements laid 
down in Annex I to Directive 2001/83/EC read subject to the 
modifications made by the Human Medicines Regulations 2012 for 
the evaluation of absorption, distribution, metabolism, excretion, 
local tolerance, toxicity, interaction with other devices, medicinal 
products or other substances and potential for adverse reactions, as 
required by the applicable conformity assessment procedure under 
Part VIII. 
Page 222 of 513 
 
 
for adverse reactions, as required by the applicable conformity 
assessment procedure under this Regulation. 
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Essential Requirement 13. Devices incorporating materials of 
biological origin 
 
Devices incorporating materials of biological origin 
13.1.For devices manufactured utilising derivatives of tissues or cells of 
human origin which are non-viable or are rendered non-viable covered 
by this Regulation in accordance with point (g) of Article 1(6), the 
following shall apply: 
(a)donation, procurement and testing of the tissues and cells shall be 
done in accordance with Directive 2004/23/EC; 
 
(b)processing, preservation and any other handling of those tissues and 
cells or their derivatives shall be carried out so as to provide safety for 
patients, users and, where applicable, other persons. In particular, safety 
with regard to viruses and other transmissible agents shall be addressed 
by appropriate methods of sourcing and by implementation of validated 
methods of elimination or inactivation in the course of the 
manufacturing process; 
(c)the traceability system for those devices shall be complementary and 
compatible with the traceability and data protection requirements laid 
down in Directive 2004/23/EC and in Directive 2002/98/EC. 
Must be 
careful here as 
EU states EU 
Legislation 
and UK states 
UK legislation  
13 - (1) For devices manufactured utilising derivatives of tissues or cells 
of human origin which are non-viable or are rendered non-viable 
which are covered by Part VIII in accordance with regulation 
68(6)(g), the following apply— 
(a) donation, procurement and testing of the tissues and cells must be 
done in accordance with Human Tissue (Quality and Safety for 
Human Application) Regulations 2007; 
(b) processing, preservation and any other handling of those tissues and 
cells or their derivatives must be carried out so as to provide safety 
for patients, users and, where applicable, other persons and, in 
particular, safety with regard to viruses and other transmissible 
agents must be addressed by appropriate methods of sourcing and 
by implementation of validated methods of elimination or 
inactivation in the course of the manufacturing process; 
(c) the traceability system for those devices must be complementary and 
compatible with the traceability and data protection requirements 
laid down in Human Tissue (Quality and Safety for Human 
Application) Regulations 2007 and in the Blood Safety and Quality 
Regulations 2005. 
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13.2.For devices manufactured utilising tissues or cells of animal origin, 
or their derivatives, which are non-viable or rendered non-viable the 
following shall apply: 
(a)where feasible taking into account the animal species, tissues and 
cells of animal origin, or their derivatives, shall originate from animals 
that have been subjected to veterinary controls that are adapted to the 
intended use of the tissues. Information on the geographical origin of 
the animals shall be retained by manufacturers; 
Wording is 
slightly 
different but 
means the 
same. 
(2) For devices manufactured utilising tissues or cells of animal origin, 
or their derivatives, which are non-viable or rendered non-viable the 
following apply— 
(a) where feasible taking into account the animal species, tissues and 
cells of animal origin, or their derivatives, the tissues or cells must 
originate from animals that have been subjected to veterinary 
controls that are adapted to the intended use of the tissues and 
information on the geographical origin of those animals must be 
retained by manufacturers; 
 
(b) sourcing, processing, preservation, testing and handling of tissues, 
cells and substances of animal origin, or their derivatives, shall be 
carried out so as to provide safety for patients, users and, where 
applicable, other persons.  
In particular safety with regard to viruses and other transmissible agents 
shall be addressed by implementation of validated methods of 
elimination or viral inactivation in the course of the manufacturing 
process, except when the use of such methods would lead to 
unacceptable degradation compromising the clinical benefit of the 
device; 
 (b) sourcing, processing, preservation, testing and handling of 
tissues, cells and substances of animal origin, or their derivatives, must 
be carried out so as to provide safety for patients, users and, where 
applicable, other persons; 
(c) safety with regard to viruses and other transmissible agents must 
be addressed by implementation of validated methods of elimination or 
viral inactivation in the course of the manufacturing process, except 
when the use of such methods would lead to unacceptable degradation 
compromising the clinical benefit of the device; 
 
(d) in the case of devices manufactured utilising tissues or cells of 
animal origin, or their derivatives, as referred to in the Regulation (EU) 
No 722/2012 the particular requirements laid down in that Regulation 
shall apply. 
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(c)in the case of devices manufactured utilising tissues or cells of animal 
origin, or their derivatives, as referred to in Regulation (EU) No 
722/2012 the particular requirements laid down in that Regulation shall 
apply. 
13.3.For devices manufactured utilising non-viable biological 
substances other than those referred to in Sections 13.1 and 13.2, the 
processing, preservation, testing and handling of those substances shall 
be carried out so as to provide safety for patients, users and, where 
applicable, other persons, including in the waste disposal chain. In 
particular, safety with regard to viruses and other transmissible agents 
shall be addressed by appropriate methods of sourcing and by 
implementation of validated methods of elimination or inactivation in 
the course of the manufacturing process. 
 (3) For devices manufactured utilising non-viable biological 
substances other than those referred to in sub-paragraphs (1) and (2), 
the processing, preservation, testing and handling of those substances 
must be carried out so as to provide safety for patients, users and, where 
applicable, other persons, including in the waste disposal chain and, 
safety with regard to viruses and other transmissible agents, must be 
addressed by appropriate methods of sourcing and by implementation 
of validated methods of elimination or inactivation in the course of the 
manufacturing process. 
Essential Requirement 14. Construction of devices and interaction 
with their environment 
 Construction of devices and interaction with the environment 
14.1.If the device is intended for use in combination with other devices 
or equipment 
 14 .—(1) If the device is intended for use in combination with other 
devices or equipment— 
(a) the whole combination, including the connection system must 
be safe and must not impair the specified performance of the devices; 
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the whole combination, including the connection system shall be safe 
and shall not impair the specified performance of the devices.  
Any restrictions on use applying to such combinations shall be indicated 
on the label and/or in the instructions for use.  
Connections which the user has to handle, such as fluid, gas transfer, 
electrical or mechanical coupling, shall be designed and constructed in 
such a way as to minimise all possible risks, such as misconnection. 
(b) any restrictions on use applying to such combinations must be 
indicated on the label or in the instructions for use; 
(c) connections which the user has to handle, such as fluid, gas 
transfer, electrical or mechanical coupling, must be designed and 
constructed in such a way as to minimise all possible risks, such as 
misconnection. 
14.2.Devices shall be designed and manufactured in such a way as to 
remove or reduce as far as possible: 
(a)the risk of injury, in connection with their physical features, 
including the volume/pressure ratio, dimensional and where appropriate 
ergonomic features; 
(b)risks connected with reasonably foreseeable external influences or 
environmental conditions, such as magnetic fields, external electrical 
and electromagnetic effects, electrostatic discharge, radiation associated 
with diagnostic or therapeutic procedures, pressure, humidity, 
temperature, variations in pressure and acceleration or radio signal 
interferences; 
 (2) Devices must be designed and manufactured in such a way 
as to remove or reduce as far as possible— 
(a) the risk of injury, in connection with their physical features, 
including the volume or pressure ratio, dimensional and where 
appropriate ergonomic features; 
(b) risks connected with reasonably foreseeable external 
influences or environmental conditions, such as magnetic fields, 
external electrical and electromagnetic effects, electrostatic discharge, 
radiation associated with diagnostic or therapeutic procedures, pressure, 
humidity, temperature, variations in pressure and acceleration or radio 
signal interferences; 
(c) the risks associated with the use of the device when it comes 
into contact with materials, liquids, and substances, including gases, to 
which it is exposed during normal conditions of use; 
(d) the risks associated with the possible negative interaction 
between software and the information technology environment within 
which it operates and interacts; 
(e) the risks of accidental ingress of substances into the device; 
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(c)the risks associated with the use of the device when it comes into 
contact with materials, liquids, and substances, including gases, to 
which it is exposed during normal conditions of use; 
(d)the risks associated with the possible negative interaction between 
software and the IT environment within which it operates and interacts; 
(e) the risks of accidental ingress of substances into the device; 
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(f)the risks of reciprocal interference with other devices normally used 
in the investigations or for the treatment given; and 
(g)risks arising where maintenance or calibration are not possible (as 
with implants), from ageing of materials used or loss of accuracy of any 
measuring or control mechanism. 
 (f) the risks of reciprocal interference with other devices normally 
used in the investigations or for the treatment given; 
(g) risks arising where maintenance or calibration are not possible 
(as with implants), from ageing of materials used or loss of accuracy of 
any measuring or control mechanism. 
14.3.Devices shall be designed and manufactured in such a way as to 
minimise the risks of fire or explosion during normal use and in single 
fault condition. Particular attention shall be paid to devices the intended 
use of which includes exposure to or use in association with flammable 
or explosive substances or substances which could cause combustion. 
 (3) Devices must be designed and manufactured in such a way as to 
minimise the risks of fire or explosion during normal use and in single 
fault condition and particular attention must be paid to devices the 
intended use of which includes exposure to or use in association with 
flammable or explosive substances or substances which could cause 
combustion. 
14.4.Devices shall be designed and manufactured in such a way that 
adjustment, calibration, and maintenance can be done safely and 
effectively. 
 (4) Devices must be designed and manufactured in such a way that 
adjustment, calibration and maintenance can be done safely and 
effectively. 
14.5.Devices that are intended to be operated together with other 
devices or products shall be designed and manufactured in such a way 
that the interoperability and compatibility are reliable and safe. 
 (5) Devices that are intended to be operate together with other 
devices or products must be designed and manufactured in such a way 
that the interoperability and compatibility are reliable and safe. 
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14.6.Any measurement, monitoring or display scale shall be designed 
and manufactured in line with ergonomic principles, taking account of 
the intended purpose, users and the environmental conditions in which 
the devices are intended to be used. 
 (6) Any measurement, monitoring or display scale must be designed 
and manufactured in line with ergonomic principles, taking account of 
the intended purpose, users and the environmental conditions in which 
the devices are intended to be used. 
14.7.Devices shall be designed and manufactured in such a way as to 
facilitate their safe disposal and the safe disposal of related waste 
substances by the user, patient or other person.  
To that end, manufacturers shall identify and test procedures and 
measures as a result of which their devices can be safely disposed after 
use. Such procedures shall be described in the instructions for use. 
These two in 
essence mean 
the same thing 
safe disposal 
of the device 
and related 
items by users, 
patients, etc. 
(7) In relation to the safe disposal of devices and related waste 
substances— 
(a) devices must be designed and manufactured in such a way as to 
facilitate their safe disposal and the safe disposal of related waste 
substances by the user, patient or other person; 
(b) manufacturers must identify and test procedures and measures 
as a result of which their devices can be safely disposed after use and 
such procedures must be described in the instructions for use. 
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Essential Requirement 15. Devices with a diagnostic or measuring 
function 
 
Devices with a diagnostic or measuring function 
15.1.Diagnostic devices and devices with a measuring function, shall be 
designed and manufactured in such a way as to provide sufficient 
accuracy, precision and stability for their intended purpose, based on 
appropriate scientific and technical methods. The limits of accuracy 
shall be indicated by the manufacturer. 
 15 - (1) Diagnostic devices and devices with a measuring function must 
be designed and manufactured in such a way as to provide sufficient 
accuracy, precision and stability for their intended purpose, based on 
appropriate scientific and technical methods and the limits of accuracy 
shall be indicated by the manufacturer. 
15.2.The measurements made by devices with a measuring function 
shall be expressed in legal units conforming to the provisions of Council 
Directive 80/181/EEC (4). 
Differing 
legislation 
referenced. 
(2) The measurements made by devices with a measuring function shall 
be expressed in legal units conforming to the provisions of Units of 
Measurement Regulations 1986(a). 
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Essential Requirement 16. Protection against radiation 
 
Protection against radiation 
16.1. General 
(a)Devices shall be designed, manufactured and packaged in such a way 
that exposure of patients, users and other persons to radiation is reduced 
as far as possible, and in a manner that is compatible with the intended 
purpose, whilst not restricting the application of appropriate specified 
levels for therapeutic and diagnostic purposes. 
(b)The operating instructions for devices emitting hazardous or 
potentially hazardous radiation shall contain 
 detailed information as to 
 the nature of the emitted radiation, the means of protecting the patient 
and the user, and  
on ways of avoiding misuse and of reducing the risks inherent to 
installation as far as possible and appropriate.  
Information regarding the acceptance and performance testing, the 
acceptance criteria, and the maintenance procedure shall also be 
specified. 
 16 –  
(1) Devices must be designed, manufactured and packaged in such a 
way that exposure of patients, users and other persons to radiation is 
reduced as far as possible, and in a manner that is compatible with the 
intended purpose, whilst not restricting the application of appropriate 
specified levels for therapeutic and diagnostic purposes. 
 
(2) The operating instructions for devices emitting hazardous or 
potentially hazardous radiation must contain— 
(a) detailed information as to— 
(i) the nature of the emitted radiation, the means of protecting the 
patient and the user, and; 
(ii) on ways of avoiding misuse and of reducing the risks inherent 
to installation as far as possible and appropriate; 
(b) information regarding the acceptance and performance testing, 
the acceptance criteria, and the maintenance procedure. 
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16.2. Intended radiation 
(a)Where devices are designed to emit hazardous, or potentially 
hazardous, levels of ionizing and/or non-ionizing radiation necessary 
for a specific medical purpose the benefit of which is considered to 
outweigh the risks inherent to the emission, 
 it shall be possible for the user to control the emissions. 
 Such devices shall be designed and manufactured to ensure 
reproducibility of relevant variable parameters within an acceptable 
tolerance. 
(b)Where devices are intended to emit hazardous, or potentially 
hazardous, ionizing and/or non-ionizing radiation, they shall be fitted, 
where possible, with visual displays and/or audible warnings of such 
emissions. 
The words are 
slightly 
different but 
the meaning is 
the same. 
(3) 
 Devices which are designed to emit hazardous, or potentially 
hazardous, levels of ionizing or non-ionizing radiation necessary for a 
specific medical purpose, the benefit of which is considered to outweigh 
the risks inherent to the emission, must— 
(a) make it possible for the user to control the emissions; 
(b) must be designed and manufactured to ensure reproducibility of 
relevant variable parameters within an acceptable tolerance; 
 
(c) be fitted, where possible, with visual displays or audible 
warnings of those emissions; 
 
16.3.Devices shall be designed and manufactured in such a way that 
exposure of patients, users and other persons to the emission of 
unintended, stray or scattered radiation is reduced as far as possible.  
 (d) be designed and manufactured in such a way that exposure of 
patients, users and other persons to the emission of unintended, stray or 
scattered radiation is reduced as far as possible; 
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Where possible and appropriate, methods shall be selected which reduce 
the exposure to radiation of patients, users and other persons who may 
be affected. 
(e) where possible and appropriate, ensure that methods are selected 
which reduce the exposure to radiation of patients, users and other 
persons who may be affected. 
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16.4. Ionising radiation 
(a)Devices intended to emit ionizing radiation shall be designed and 
manufactured taking into account the requirements of the Directive 
2013/59/Euratom laying down basic safety standards for protection 
against the dangers arising from exposure to ionising radiation. 
(b)Devices intended to emit ionising radiation shall be designed and 
manufactured in such a way as to ensure that, where possible, taking 
into account the intended use, the quantity, geometry and quality of the 
radiation emitted can be varied and controlled, and, if possible, 
monitored during treatment. 
(c)Devices emitting ionising radiation intended for diagnostic radiology 
shall be designed and manufactured in such a way as to achieve an 
image and/or output quality that are appropriate to the intended medical 
purpose whilst minimising radiation exposure of the patient and user. 
(d)Devices that emit ionising radiation and are intended for therapeutic 
radiology shall be designed and manufactured in such a way as to enable 
reliable monitoring and control of the delivered dose, the beam type, 
energy and, where appropriate, the quality of radiation. 
 (4) Devices intended to emit ionizing radiation must— 
(a) be designed and manufactured taking into account the 
requirements of any retained EU law which transposed Directive 
2013/59/Euratom laying down basic safety standards for 
protection against the dangers arising from exposure to ionising 
radiation; 
(b) be designed and manufactured in such a way as to ensure that, 
where possible, taking into account the intended use, the quantity, 
geometry and quality of the radiation emitted can be varied and 
controlled, and, if possible, monitored during treatment; 
(c) where the device is intended for diagnostic radiology, be designed 
and manufactured in such a way as to achieve an image or output 
quality that is appropriate to the intended medical purpose whilst 
minimising radiation exposure of the patient and user; 
 
(d) where the device is intended for therapeutic radiology, be designed 
and manufactured in such a way as to enable reliable monitoring 
and control of the delivered dose, the beam type, energy and, 
where appropriate, the quality of radiation 
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Essential Requirement 17.   Electronic programmable systems — 
devices that incorporate electronic 
programmable systems and software that 
are devices in themselves 
 
Electronic programmable systems — devices that incorporate 
electronic programmable systems and software that are devices in 
themselves 
17.1.Devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, shall  
be designed to ensure repeatability, reliability and performance in line 
with their intended use.  
In the event of a single fault condition, appropriate means shall be 
adopted to eliminate or reduce as far as possible consequent risks or 
impairment of performance. 
 17 .—(1) Devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
must— 
(a) be designed to ensure repeatability, reliability and performance in 
line with their intended use; 
(b) in the event of a single fault condition, be designed with appropriate 
means to eliminate or reduce as far as possible consequent risks or 
impairment of performance. 
17.2.For devices that incorporate software or for software that are 
devices in themselves, the software shall be developed and 
manufactured in accordance with the state of the art taking into account 
the principles of development life cycle, risk management, including 
information security, verification and validation. 
 (2) For devices that incorporate software or for software that are devices 
in themselves, the software must be developed and manufactured in 
accordance with the state of the art taking into account the principles 
of development life cycle, risk management, including information 
security, verification and validation. 
17.3.Software referred to in this Section that is intended to be used in 
combination with mobile computing platforms shall be designed and 
manufactured taking into account the specific features of the mobile 
 (3) Software referred to in this paragraph that is intended to be used in 
combination with mobile computing platforms must be designed 
and manufactured taking into account the specific features of the 
mobile platform (for example size and contrast ratio of the screen) 
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platform (e.g. size and contrast ratio of the screen) and the external 
factors related to their use (varying environment as regards level of light 
or noise). 
and the external factors related to their use (varying environment as 
regards level of light or noise). 
17.4.Manufacturers shall set out minimum requirements concerning 
hardware, IT networks characteristics and IT security measures, 
including protection against unauthorised access, necessary to run the 
software as intended. 
 (4) Manufacturers must set out minimum requirements concerning 
hardware, IT networks characteristics and IT security measures, 
including protection against unauthorised access, necessary to run 
the software as intended. 
Essential Requirement 18. Active devices and devices connected to 
them 
 Active devices and devices connected to them 
18.1.For non-implantable active devices, in the event of a single fault 
condition, appropriate means shall be adopted to eliminate or reduce as 
far as possible consequent risks. 
 18 .—(1) For non-implantable active devices, in the event of a single 
fault condition, appropriate means must be adopted to eliminate or 
reduce as far as possible consequent risks. 
18.2.Devices where the safety of the patient depends on an internal 
power supply shall be equipped with  
a means of determining the state of the power supply  
and an appropriate warning or indication for when the capacity of the 
power supply becomes critical. If necessary, such warning or indication 
shall be given prior to the power supply becoming critical. 
 (2) Devices, where the safety of the patient depends on an internal 
power supply, must be equipped with— 
(a) a means of determining the state of the power supply; 
(b) an appropriate warning or indication for when the capacity of the 
power supply becomes critical, if necessary, such warning or 
indication must be given prior to the power supply becoming 
critical. 
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18.3.Devices where the safety of the patient depends on an external 
power supply shall include an alarm system to signal any power failure. 
 (3) Devices where the safety of the patient depends on an external 
power supply must include an alarm system to signal any power 
failure. 
18.4.Devices intended to monitor one or more clinical parameters of a 
patient shall be equipped with appropriate alarm systems to alert the 
user of situations which could lead to death or severe deterioration of 
the patient's state of health. 
 (4) Devices intended to monitor one or more clinical parameters of a 
patient must be equipped with appropriate alarm systems to alert the 
user of situations which could lead to death or severe deterioration 
of the patient’s state of health. 
18.5.Devices shall be designed and manufactured in such a way as to 
reduce as far as possible the risks of creating electromagnetic 
interference which could impair the operation of the device in question 
or other devices or equipment in the intended environment. 
 (5) Devices must be designed and manufactured in such a way as to 
reduce as far as possible the risks of creating electromagnetic 
interference which could impair the operation of the device in 
question or other devices or equipment in the intended environment. 
18.6.Devices shall be designed and manufactured in such a way as to 
provide a level of intrinsic immunity to electromagnetic interference 
such that is adequate to enable them to operate as intended. 
 (6) Devices must be designed and manufactured in such a way as to 
provide a level of intrinsic immunity to electromagnetic interference 
that is adequate to enable them to operate as intended. 
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18.7.Devices shall be designed and manufactured in such a way as to 
avoid, as far as possible, the risk of accidental electric shocks to the 
patient, user or any other person, both during normal use of the device 
and in the event of a single fault condition in the device, provided the 
device is installed and maintained as indicated by the manufacturer. 
 (7) Devices must be designed and manufactured in such a way as to 
avoid, as far as possible, the risk of accidental electric shocks to the 
patient, user or any other person, both during normal use of the 
device and in the event of a single fault condition in the device, 
provided the device is installed and maintained as indicated by the 
manufacturer. 
18.8.Devices shall be designed and manufactured in such a way as to 
protect, as far as possible, against unauthorised access that could 
hamper the device from functioning as intended. 
 (8) Devices must be designed and manufactured in such a way as to 
protect, as far as possible, against unauthorised access that could 
hamper the device from functioning as intended. 
Essential Requirement 19. Particular requirements for active 
implantable devices 
 
Particular requirements for active implantable devices 
19.1.   Active implantable devices shall be designed and manufactured 
in such a way as to remove or minimize as far as possible: 
(a)risks connected with the use of energy sources with particular 
reference, where electricity is used, to insulation, leakage currents and 
overheating of the devices, 
(b)risks connected with medical treatment, in particular those resulting 
from the use of defibrillators or high-frequency surgical equipment, and 
 19 - (1) Active implantable devices must be designed and manufactured 
in such a way as to remove or minimize as far as possible— 
(a) risks connected with the use of energy sources with particular 
reference, where electricity is used, to insulation, leakage currents 
and overheating of the devices; 
(b) risks connected with medical treatment, in particular those resulting 
from the use of defibrillators or high- frequency surgical equipment; 
(c) risks  which  may  arise  where  maintenance  and  calibration  are  
impossible, including— 
(i) excessive increase of leakage currents; 
(ii) ageing of the materials used; 
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(c)risks which may arise where maintenance and calibration are 
impossible, including: 
— excessive increase of leakage currents, 
— ageing of the materials used, 
— excess heat generated by the device, 
— decreased accuracy of any measuring or control mechanism. 
(iii) excess heat generated by the device; 
(iv) decreased accuracy of any measuring or control mechanism. 
19.2.   Active implantable devices shall be designed and manufactured 
in such a way as to ensure 
—if applicable, the compatibility of the devices with the substances 
they are intended to administer, and 
— the reliability of the source of energy. 
 (2) Active implantable devices must be designed and manufactured in 
such a way as to ensure— 
(a) if applicable, the compatibility of the devices with the substances 
they are intended to administer; 
(b) the reliability of the source of energy. 
19.3.Active implantable devices and, if appropriate, their component 
parts shall be identifiable to allow any necessary measure to be taken 
following the discovery of a potential risk in connection with the 
devices or their component parts. 
 (3) Active implantable devices and, if appropriate, their component 
parts must be identifiable to allow any necessary measure to be taken 
following the discovery of a potential risk in connection with the 
devices or their component parts. 
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19.4.   Active implantable devices shall bear a code 
 by which they and their manufacturer can be unequivocally identified 
(particularly with regard to the type of device and its year of 
manufacture); 
 it shall be possible to read this code, if necessary, without the need for 
a surgical operation. 
 (4) Active implantable devices must bear a code— 
(a) by which they and their manufacturer can be unequivocally 
identified (particularly with regard to the type of device and its year 
of manufacture); and 
(b) which it is possible to read, if necessary, without the need for a 
surgical operation. 
Essential Requirement 20. Protection against mechanical and 
thermal risks 
 
Protection against mechanical and thermal risks 
20.1.Devices shall be designed and manufactured in such a way as to 
protect patients and users against mechanical risks connected with, for 
example, resistance to movement, instability and moving parts. 
 20 .—(1) Devices must be designed and manufactured in such a 
way as to protect patients and users against mechanical risks connected 
with, for example, resistance to movement, instability and moving parts. 
20.2.Devices shall be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from vibration 
generated by the devices, taking account of technical progress and of 
the means available for limiting vibrations, particularly at source, unless 
the vibrations are part of the specified performance. 
 (2) Devices must be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from vibration 
generated by the devices, taking account of technical progress and of 
the means available for limiting vibrations, particularly at source, unless 
the vibrations are part of the specified performance. 
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20.3.Devices shall be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from the noise 
emitted, taking account of technical progress and of the means available 
to reduce noise, particularly at source, unless the noise emitted is part 
of the specified performance. 
 (3) Devices must be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from the noise 
emitted, taking account of technical progress and of the means available 
to reduce noise, particularly at source, unless the noise emitted is part 
of the specified performance. 
20.4.Terminals and connectors to the electricity, gas or hydraulic and 
pneumatic energy supplies which the user or other person has to handle, 
shall be designed and constructed in such a way as to minimise all 
possible risks. 
 (4) Terminals and connectors to the electricity, gas or hydraulic and 
pneumatic energy supplies which the user or other person has to handle, 
must be designed and constructed in such a way as to minimise all 
possible risks. 
20.5.   Errors likely to be made when fitting or refitting certain parts 
which could be a source of risk 
 shall be made impossible by the design and construction of such parts 
or, failing this, by information given on the parts themselves and/or their 
housings. 
The same information shall be given on moving parts and/or their 
housings where the direction of movement needs to be known in order 
to avoid a risk. 
 (5) Errors likely to be made when fitting or refitting certain parts 
which could be a source of risk — 
(a) must be made impossible  by the design and construction of such 
parts or by information given on the parts themselves or their housings; 
and 
(b) must contain the same information on moving parts or their 
housings where the direction of movement needs to be known in order 
to avoid a risk. 
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20.6.Accessible parts of devices (excluding the parts or areas intended 
to supply heat or reach given temperatures) and their surroundings shall 
not attain potentially dangerous temperatures under normal conditions 
of use. 
 (6) Accessible parts of devices (excluding the parts or areas intended to 
supply heat or reach given temperatures) and their surroundings 
must not attain potentially dangerous temperatures under normal 
conditions of use. 
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Essential Requirement 21. Protection against the risks posed to the 
patient or user by devices supplying 
energy or substances 
 
Protection against the risks posed to the patient or user by devices 
supplying energy or substances 
21.1.Devices for supplying the patient with energy or substances shall 
be designed and constructed in such a way that the amount to be 
delivered can be set and maintained accurately enough to ensure the 
safety of the patient and of the user. 
 21 .—(1) Devices for supplying the patient with energy or substances 
must be designed and constructed in such a way that the amount to 
be delivered can be set and maintained accurately enough to ensure 
the safety of the patient and of the user. 
21.2. Devices shall  
be fitted with the means of preventing and/or indicating any 
inadequacies in the amount of energy delivered or substances delivered 
which could pose a danger. 
 Devices shall incorporate suitable means to prevent, as far as possible, 
the accidental release of dangerous levels of energy or substances from 
an energy and/or substance source. 
 (2) Devices must— 
(a) be fitted with the means of preventing or indicating any 
inadequacies in  the amount of energy delivered or substances 
delivered which could pose a danger; 
(b) incorporate suitable means to prevent, as far as possible, the 
accidental release of dangerous levels of energy or substances from 
an energy and/or substance source. 
 
21.3. The function of the controls and indicators 
 shall be clearly specified on the devices.  
 (3) The function of the controls and indicators— 
(a) must be clearly specified on devices; 
(b) where a device bears instructions required for its operation or 
indicates operating or adjustment parameters by means of a visual 
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Where a device bears instructions required for its operation or indicates 
operating or adjustment parameters by means of a visual system, such 
information shall be understandable to the user and, as appropriate, the 
patient. 
system, such information must be understandable to the user and, 
as appropriate, the patient. 
Essential Requirement 22. Protection against the risks posed by 
medical devices intended by the 
manufacturer for use by lay persons 
 Protection against the risks posed by medical devices intended by the 
manufacturer for use by lay persons 
22.1. Devices for use by lay persons shall 
 be designed and manufactured in such a way that they perform 
appropriately for their intended purpose taking into account the skills 
and the means available to lay persons and the influence resulting from 
variation that can be reasonably anticipated in the lay person's 
technique and environment.  
The information and instructions provided by the manufacturer shall 
be easy for the lay person to understand and apply. 
 22 .—(1) Devices for use by lay persons must— 
(a) be designed and manufactured in such a way that they perform 
appropriately for their intended purpose taking into account the 
skills and the means available to lay persons and the influence 
resulting from variation that can be reasonably anticipated in the 
lay person’s technique and environment; and 
(b) be provided by the manufacturer with information and instructions 
which are easy for the lay person to understand and apply. 
22.2.   Devices for use by lay persons shall be designed and 
manufactured in such a way as to: 
 (2) Devices for use by lay persons must be designed and manufactured 
in such a way as to— 
(a) ensure that the device can be used safely and accurately by the 
intended user at all stages of the procedure, if necessary after 
appropriate training or information; 
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—ensure that the device can be used safely and accurately by the 
intended user at all stages of the procedure, if necessary after 
appropriate training and/or information, 
—reduce, as far as possible and appropriate, the risk from unintended 
cuts and pricks such as needle stick injuries, and 
—reduce as far as possible the risk of error by the intended user in the 
handling of the device and, if applicable, in the interpretation of the 
results. 
(b) reduce, as far as possible and appropriate, the risk from unintended 
cuts and pricks such as needle stick injuries; and 
(c) reduce as far as possible the risk of error by the intended user in the 
handling of the device and, if applicable, in the interpretation of the 
results. 
22.3.   Devices for use by lay persons shall, where appropriate, include 
a procedure by which the lay person: 
—can verify that, at the time of use, the device will perform as intended 
by the manufacturer, and 
—if applicable, is warned if the device has failed to provide a valid 
result. 
 (3) Devices for use by lay persons must, where appropriate, include a 
procedure by which the lay person— 
(a) can verify that, at the time of use, the device will perform as 
intended by the manufacturer; 
(b) is warned if the device has failed to provide a valid result. 
 
 
CHAPTER III 
 RDING THE INFORMATION SUPPLIED WITH THE DEVICE 
 PART 3 
Requirements regarding instructions for use 
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Essential Requirement 23. Label and instructions for use 
 
Label and instructions for use 
23.1.General requirements regarding the information supplied by the 
manufacturer 
Each device shall be accompanied by the information needed to 
identify the device and its manufacturer, and by any safety and 
performance information relevant to the user, or any other person, as 
appropriate. Such information may appear on the device itself, on the 
packaging or in the instructions for use, and shall, if the manufacturer 
has a website, be made available and kept up to date on the website, 
taking into account the following: 
 23 .—(1) Each device must be accompanied by the information 
(which may appear on the device itself, on the packaging or in the 
instructions for use) needed to identify the device and its manufacturer, 
and by any safety and performance information relevant to the user, or 
any other person, as appropriate. 
(a)The medium, format, content, legibility, and location of the label 
and instructions for use shall be appropriate to the particular device, its 
intended purpose and the technical knowledge, experience, education 
or training of the intended user(s). In particular, instructions for use 
shall be written in terms readily understood by the intended user and, 
where appropriate, supplemented with drawings and diagrams. 
(b)The information required on the label shall be provided on the 
device itself. If this is not practicable or appropriate, some or all of the 
 (a) that the medium, format, content, legibility, and location of the 
label and instructions for use must be appropriate to the particular 
device, its  intended purpose and the technical knowledge, experience, 
education or training of the intended users and, in particular, 
instructions for use must be written in terms readily understood by the 
intended user and, where appropriate, supplemented with drawings and 
diagrams; 
(b) the information required on the label must be provided on the 
device itself or, if this is not practicable or appropriate, some or all of 
the information may appear on the packaging for each unit, or on the 
packaging of multiple devices; 
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information may appear on the packaging for each unit, and/or on the 
packaging of multiple devices. 
 
(c)Labels shall be provided in a human-readable format and may be 
supplemented by machine-readable information, such as radio-
frequency identification (‘RFID’) or bar codes. 
(d)Instructions for use shall be provided together with devices. By way 
of exception, instructions for use shall not be required for class I and 
class IIa devices if such devices can be used safely without any such 
instructions and unless otherwise provided for elsewhere in this 
Section. 
(e)Where multiple devices are supplied to a single user and/or location, 
a single copy of the instructions for use may be provided if so agreed 
by the purchaser who in any case may request further copies to be 
provided free of charge. 
(f)Instructions for use may be provided to the user in non-paper format 
(e.g. electronic) to the extent, and only under the conditions, set out in 
Regulation (EU) No 207/2012 or in any subsequent implementing 
rules adopted pursuant to this Regulation. 
 
 
 
 
 
 
 
 
Watch out for 
point F as this 
may vary in 
future EU 
and UK 
legislation 
 
 
 
 
This bit has a 
variation – 
(c) labels must be provided in a human-readable format and may be 
supplemented by machine-readable information, such as radio-
frequency identification (‘RFID’) or bar codes; 
(d) in general, instructions for use must be provided together with 
devices but, by way of exception, instructions for use are not 
required for Class I and Class IIa devices if such devices can be 
used safely without any such instructions and unless otherwise 
provided for elsewhere in this paragraph; 
(e) where multiple devices are supplied to a single user or location, a 
single copy of the instructions for use may be provided if so 
agreed by the purchaser who in any case may request further 
copies to be provided free of charge; 
(f) instructions for use may be provided to the user in non-paper 
format (for example electronic) to the extent, and only under the 
conditions, set out in Regulation (EU) No 207/2012; 
 
(g) residual risks which are required to be communicated to the user 
or other person must be included as limitations, contra-
indications, precautions or warnings in the information supplied 
by the manufacturer; 
(h) where appropriate, the information supplied by the manufacturer 
— 
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(g)Residual risks which are required to be communicated to the user 
and/or other person shall be included as limitations, contra-indications, 
precautions or warnings in the information supplied by the 
manufacturer. 
(h) Where appropriate, the information supplied by the manufacturer  
shall take the form of internationally recognised symbols. 
Any symbol or identification colour used shall conform to the 
harmonised standards or CS.  
In areas for which no harmonised standards or CS exist, the symbols 
and colours shall be described in the documentation supplied with the 
device. 
CS. In EU 
legislation 
this is 
Common 
specification
s. 
(i) must take the form of internationally recognised symbols; 
(ii) must conform, in terms of any symbol or identification colour 
used, to the relevant standards; and 
(iii) in areas for which no relevant standards exist, the symbols and 
colours must be described in the documentation supplied with the 
device. 
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23.2.   Information on the label 
The label shall bear all of the following particulars: 
(a) the name or trade name of the device; 
(b)the details strictly necessary for a user to identify the device, the 
contents of the packaging and, where it is not obvious for the user, the 
intended purpose of the device; 
(c)the name, registered trade name or registered trade mark of the 
manufacturer and the address of its registered place of business; 
(d)if the manufacturer has its registered place of business outside the 
Union, the name of the authorised representative and address of the 
registered place of business of the authorised representative; 
(e)where applicable, an indication that the device contains or 
incorporates: 
—a medicinal substance, including a human blood or plasma 
derivative, or 
— tissues or cells, or their derivatives, of human origin, or 
 Information on the label 
(4) The label must bear the following particulars— 
(a) the name or trade name of the device; 
(b) the details strictly necessary for a user to identify the device, the 
contents of the packaging and, where it is not obvious for the user, 
the intended purpose of the device; 
(c) the name, registered trade name or registered trade mark of the 
manufacturer and the address of its registered place of business; 
(d) if the manufacturer has its registered place of business outside the 
United Kingdom, the name and address of the person placing the 
device on the market; 
(e) where applicable, an indication that the device contains or 
incorporates— 
(i) a  medicinal substance,  including  a human  blood or plasma  
derivative,  or tissues or cells, or their derivatives, of human origin; 
or 
(ii) tissues  or  cells  of  animal  origin,  or  their  derivatives,  as  referred  
to  in Regulation (EU) No 722/2012; 
(f) where applicable, information labelled in accordance with 
paragraph 10(10); 
(g) the lot number or the serial number of the device preceded by the 
words LOT NUMBER or SERIAL NUMBER or an equivalent 
symbol, as appropriate; 
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—tissues or cells of animal origin, or their derivatives, as referred to in 
Regulation (EU) No 722/2012; 
(f)where applicable, information labelled in accordance with Section 
10.4.5.; 
(g)the lot number or the serial number of the device preceded by the 
words LOT NUMBER or SERIAL NUMBER or an equivalent 
symbol, as appropriate; 
(h)the UDI carrier referred to in Article 27(4) and Part C of Annex VII; 
(h) the UDI carrier referred to in regulation 91(4) and Part C of 
Schedule 8; 
(i)an unambiguous indication of t the time limit for using or implanting 
the device safely, expressed at least in terms of year and month, where 
this is relevant; 
(j)where there is no indication of the date until when it may be used 
safely, the date of manufacture. This date of manufacture may be 
included as part of the lot number or serial number, provided the date 
is clearly identifiable; 
(k)an indication of any special storage and/or handling condition that 
applies; 
 (i) an unambiguous indication of the time limit for using or implanting 
the device safely, expressed at least in terms of year and month, 
where this is relevant; 
(j) where there is no indication of the date until when it may be used 
safely, the date of manufacture and this date of manufacture may 
be included as part of the lot number or serial number, provided the 
date is clearly identifiable; 
(k) an indication of any special storage or handling condition that 
applies; 
(l) if the device is supplied sterile, an indication of its sterile state and 
the sterilisation method; 
(m) warnings or precautions to be taken that need to be brought to 
the immediate attention of the user of the device, and to any other 
person (this information may be kept to a minimum in which case, 
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(l)if the device is supplied sterile, an indication of its sterile state and 
the sterilisation method; 
(m)warnings or precautions to be taken that need to be brought to the 
immediate attention of the user of the device, and to any other person. 
This information may be kept to a minimum in which case more 
detailed information shall appear in the instructions for use, taking into 
account the intended users; 
(n)if the device is intended for single use, an indication of that fact. A 
manufacturer's indication of single use shall be consistent across the 
Union; 
(o)if the device is a single-use device that has been reprocessed, an 
indication of that fact, the number of reprocessing cycles already 
performed, and any limitation as regards the number of reprocessing 
cycles; 
(p) if the device is custom-made, the words ‘custom-made device’; 
more detailed information must appear in the instructions for use, 
taking into account the intended users); 
(n) if the device is intended for single use, an indication of that fact; 
(o) if the device is a single-use device that has been reprocessed, an 
indication of that fact, the number of reprocessing cycles already 
performed, and any limitation as regards the number of 
reprocessing cycles; 
(p) if the device is custom-made, the words ‘custom-made device’; 
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(q)an indication that the device is a medical device. If the device is 
intended for clinical investigation only, the words ‘exclusively for 
clinical investigation’; 
(r)in the case of devices that are composed of substances or of 
combinations of substances that are intended to be introduced into the 
human body via a body orifice or applied to the skin and that are 
absorbed by or locally dispersed in the human body, the overall 
qualitative composition of the device and quantitative information on 
the main constituent or constituents responsible for achieving the 
principal intended action; 
(s)for active implantable devices, the serial number, and for other 
implantable devices, the serial number or the lot number. 
 (q) an indication that the device is a medical device and, if the device 
is intended for clinical investigation only, the words ‘exclusively 
for clinical investigation’; 
(r) in the case of devices that are composed of substances or of 
combinations of substances that are intended to be introduced into 
the human body via a body orifice or applied to the skin and that 
are absorbed by or locally dispersed in the human body, the overall 
qualitative composition of the device and quantitative information 
on the main constituent or constituents responsible for achieving 
the principal intended action; 
(s) for active implantable devices, the serial number, and for other 
implantable devices, the serial number or the lot number. 
23.3.   Information on the packaging which maintains the sterile 
condition of a device (‘sterile packaging’) 
The following particulars shall appear on the sterile packaging: 
(a)an indication permitting the sterile packaging to be recognised as 
such, 
 (5) Where packaging maintains the sterile condition of the device 
(“sterile packaging”) t 
he following particulars must appear on that sterile packaging— 
(a) an indication permitting the sterile packaging to be recognised as 
such; 
(b) a declaration that the device is in a sterile condition; 
(c) the method of sterilisation; 
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(b) a declaration that the device is in a sterile condition, 
(c) the method of sterilisation, 
(d) the name and address of the manufacturer, 
(e) a description of the device, 
(f)if the device is intended for clinical investigations, the words 
‘exclusively for clinical investigations’, 
(g) if the device is custom-made, the words ‘custom-made device’, 
 
(d) the name and address of the manufacturer; 
(e) a description of the device; 
(f) if the device is intended for clinical investigations, the words 
‘exclusively for clinical investigations’; 
(g) if the device is custom-made, the words ‘custom-made device’; 
. 
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(h) the month and year of manufacture, 
(i)an unambiguous indication of the time limit for using or implanting 
the device safely expressed at least in terms of year and month, and 
(j)an instruction to check the instructions for use for what to do if the 
sterile packaging is damaged or unintentionally opened before use. 
 (h) the month and year of manufacture; 
(i) an unambiguous indication of the time limit for using or implanting 
the device safely expressed at least in terms of year and month; 
(j) an instruction to check the instructions for use for what to do if the 
sterile packaging is damaged or unintentionally opened before use 
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23.4.   Information in the instructions for use 
The instructions for use shall contain all of the following particulars: 
(a)the particulars referred to in points (a), (c), (e), (f), (k), (l), (n) and 
(r) of Section 23.2; 
(b)the device's intended purpose with a clear specification of 
indications, contra-indications, the patient target group or groups, and 
of the intended users, as appropriate; 
(c)where applicable, a specification of the clinical benefits to be 
expected. 
(d)where applicable, links to the summary of safety and clinical 
performance referred to in Article 32; 
(e) the performance characteristics of the device; 
(f)where applicable, information allowing the healthcare professional 
to verify if the device is suitable and select the corresponding software 
and accessories; 
 Information in instructions for use 
(6) The instructions for use must contain all the following particulars— 
(a) the particulars referred to in paragraphs (a), (c), (e), (f), (k), (l), (n) 
and (r) of paragraph 23(4); 
(b) the device’s intended purpose with a clear specification of 
indications, contra- indications, the patient target group or groups, 
and of the intended users, as appropriate; 
 (c) where applicable, a specification of the clinical benefits to be 
expected; 
(d) where applicable, links to the summary of safety and clinical 
performance referred to in regulation 96; 
(e) the performance characteristics of the device; 
(f) where applicable, information allowing the healthcare professional 
to verify if the device is suitable and select the corresponding 
software and accessories; 
(g) any residual risks, contra-indications and any undesirable side-
effects, including information to be conveyed to the patient in this 
regard; 
(h) specifications the user requires to use the device appropriately, for 
example if the device has a measuring function, the degree of 
accuracy claimed for it; 
(i) details of any preparatory treatment or handling of the device before 
it is ready for use or during its use, such as sterilisation, final 
assembly, calibration, including the levels of disinfection required 
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(g)any residual risks, contra-indications and any undesirable side-
effects, including information to be conveyed to the patient in this 
regard;  
(h)specifications the user requires to use the device appropriately, e.g. 
if the device has a measuring function, the degree of accuracy claimed 
for it; 
(i)details of any preparatory treatment or handling of the device before 
it is ready for use or during its use, such as sterilisation, final assembly, 
calibration, etc., including the levels of disinfection required to ensure 
patient safety and all available methods for achieving those levels of 
disinfection; 
to ensure patient safety and all available methods for achieving 
those levels of disinfection; 
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(j)any requirements for special facilities, or special training, or 
particular qualifications of the device user and/or other persons; 
(k)the information needed to verify whether the device is properly 
installed and is ready to perform safely and as intended by the 
manufacturer, together with, where relevant: 
—details of the nature, and frequency, of preventive and regular 
maintenance, and of any preparatory cleaning or disinfection, 
—identification of any consumable components and how to replace 
them, 
—information on any necessary calibration to ensure that the device 
operates properly and safely during its intended lifetime, and 
—methods for eliminating the risks encountered by persons involved 
in installing, calibrating or servicing devices; 
(l)if the device is supplied sterile, instructions in the event of the sterile 
packaging being damaged or unintentionally opened before use; 
(m)if the device is supplied non-sterile with the intention that it is 
sterilised before use, the appropriate instructions for sterilisation;  
 (j) any requirements for special facilities, or special training, or 
particular qualifications of the device user or other persons; 
(k) the information needed to verify whether the device is properly 
installed and is ready to perform safely and as intended by the 
manufacturer, together with, where relevant— 
(i) details of the nature, and frequency, of preventive and regular 
maintenance, and of any preparatory cleaning or disinfection; 
(ii) identification of any consumable components and how to 
replace them; 
(iii) information on any necessary calibration to ensure that the 
device operates properly and safely during its intended lifetime; 
(iv) methods for eliminating the risks encountered by persons 
involved in installing, calibrating or servicing devices; 
(l) if the device is supplied sterile, instructions in the event of the 
sterile packaging being damaged or unintentionally opened before use; 
(m) if the device is supplied non-sterile with the intention that it is 
sterilised before use, the appropriate instructions for sterilisation; 
(n) if the device is reusable, information must be provided— 
(i) on the appropriate processes for allowing reuse, including 
cleaning, disinfection, packaging and, where appropriate, the validated 
method of re- sterilisation; and 
(ii) to identify when the device should no longer be reused, for 
example signs of material degradation or the maximum number of 
allowable reuses; 
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(n) if the device is reusable, information  
on the appropriate processes for allowing reuse, including cleaning, 
disinfection, packaging and, where appropriate, the validated method 
of re-sterilisation appropriate to the Member State or Member States 
in which the device has been placed on the market. 
Information shall be provided to identify when the device should no 
longer be reused, e.g. signs of material degradation or the maximum 
number of allowable reuses; 
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(o)an indication, if appropriate, that a device can be reused only if it is 
reconditioned under the responsibility of the manufacturer to comply 
with the general safety and performance requirements; 
(p)if the device bears an indication that it is for single use, information 
on known characteristics and technical factors known to the 
manufacturer that could pose a risk if the device were to be re-used.  
This information shall be based on a specific section of the 
manufacturer's risk management documentation, where such 
characteristics and technical factors shall be addressed in detail.  
If in accordance with point (d) of Section 23.1. no instructions for use 
are required, this information shall be made available to the user upon 
request; 
(q)for devices intended for use together with other devices and/or 
general purpose equipment: 
—information to identify such devices or equipment, in order to obtain 
a safe combination, and/or 
 (o) an indication, if appropriate, that a device can be reused only if it 
is reconditioned under the responsibility of the manufacturer to 
comply with the general safety and performance requirements; 
(p) if the device bears an indication that it is for single use— 
(i) information on known characteristics and technical factors known 
to the manufacturer that could pose a risk if the device were to be 
re-used; 
(ii) the information must be based on a specific section of the 
manufacturer’s risk management documentation, where such 
characteristics and technical factors must be addressed in detail; 
(iii) if, in accordance with sub-paragraph (3)(d), no instructions for 
use are required, this information must be made available to the 
user upon request; 
(q) for devices intended for use together with other devices or general 
purpose equipment— 
(i) information to identify such devices or equipment, in order to 
obtain a safe combination; 
(ii) information on any known restrictions to combinations of devices 
and equipment; 
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—information on any known restrictions to combinations of devices 
and equipment; 
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(r) if the device emits radiation for medical purposes: 
—detailed information as to the nature, type and where appropriate, 
the intensity and distribution of the emitted radiation, 
—the means of protecting the patient, user, or other person from 
unintended radiation during use of the device; 
(s)information that allows the user and/or patient to be informed of any 
warnings, precautions, contra-indications, measures to be taken and 
limitations of use regarding the device. That information shall, where 
relevant, allow the user to brief the patient about any warnings, 
precautions, contra-indications, measures to be taken and limitations 
of use regarding the device. The information shall cover, where 
appropriate: 
—warnings, precautions and/or measures to be taken in the event of 
malfunction of the device or changes in its performance that may affect 
safety, 
—warnings, precautions and/or measures to be taken as regards the 
exposure to reasonably foreseeable external influences or 
environmental conditions, such as magnetic fields, external electrical 
 (r) if the device emits radiation for medical purposes— 
(i) detailed information as to the nature, type and where appropriate, 
the intensity and distribution of the emitted radiation; 
(ii) the means of protecting the patient, user, or other person from 
unintended radiation during use of the device; 
(s) information that allows the user or patient to be informed of, or as 
the case may be, briefed about any warnings, precautions, contra-
indications, measures to be taken and limitations of use regarding 
the device and this information must cover, where appropriate— 
 
 
(i) warnings, precautions or measures to be taken in the event of 
malfunction of the device or changes in its performance that may 
affect safety; 
(ii) warnings, precautions or measures to be taken as regards the 
exposure to reasonably foreseeable external influences or 
environmental conditions, such as magnetic fields, external 
electrical and electromagnetic effects, electrostatic discharge, 
radiation associated with diagnostic or therapeutic procedures, 
pressure, humidity, or temperature; 
(iii) warnings, precautions or measures to be taken as regards the 
risks of interference posed by the reasonably foreseeable presence 
of the device during specific diagnostic investigations, evaluations, 
or therapeutic treatment  or other procedures such as 
electromagnetic interference emitted by the device affecting other 
equipment; 
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and electromagnetic effects, electrostatic discharge, radiation 
associated with diagnostic or therapeutic procedures, pressure, 
humidity, or temperature, 
—warnings, precautions and/or measures to be taken as regards the 
risks of interference posed by the reasonably foreseeable presence of 
the device during specific diagnostic investigations, evaluations, or 
therapeutic treatment or other procedures such as electromagnetic 
interference emitted by the device affecting other equipment, 
—if the device is intended to administer medicinal products, tissues or 
cells of human or animal origin, or their derivatives, or biological 
substances, any limitations or incompatibility in the choice of 
substances to be delivered, 
—warnings, precautions and/or limitations related to the medicinal 
substance or biological material that is incorporated into the device as 
an integral part of the device; and 
—precautions related to materials incorporated into the device that 
contain or consist of CMR substances or endocrine-disrupting 
substances, or that could result in sensitisation or an allergic reaction 
by the patient or user; 
(iv) if the device is intended to administer medicinal products, 
tissues or cells of human or animal origin, or their derivatives, or 
biological substances, any limitations or incompatibility in the 
choice of substances to be delivered; 
(v) warnings, precautions or limitations related to the medicinal 
substance or biological material that is incorporated into the device 
as an integral part of the device; and 
(vi) precautions related to materials incorporated into the device 
that contain or consist of CMR substances or endocrine-disrupting 
substances, or that could result in sensitisation or an allergic 
reaction by the patient or user; 
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(t)in the case of devices that are composed of substances or of 
combinations of substances that are intended to be introduced into the 
human body and that are absorbed by or locally dispersed in the human 
body, warnings and precautions, where appropriate, related to 
 the general profile of interaction of the device and its products of 
metabolism with other devices, medicinal products and other 
substances  
as well as contra-indications, undesirable side-effects and risks relating 
to overdose; 
(u)in the case of implantable devices, the overall qualitative and 
quantitative information on the materials and substances to which 
patients can be exposed; 
(v)warnings or precautions to be taken in order to facilitate the safe 
disposal of the device, its accessories and the consumables used with 
it, if any. This information shall cover, where appropriate: 
 (t) in the case of devices that are composed of substances or of 
combinations of substances that are intended to be introduced into 
the human body and that are absorbed by or locally dispersed in the 
human body, warnings and precautions, where appropriate, related 
to— 
(i) the general profile of interaction of the device and its products of 
metabolism with other devices, medicinal products and other 
substances; 
(ii) contra-indications, undesirable side-effects and risks relating to 
overdose; 
(u) in the case of implantable devices, the overall qualitative and 
quantitative information on the materials and substances to which 
patients can be exposed; 
(v) warnings or precautions to be taken in order to facilitate the safe 
disposal of the device, its accessories and the consumables used 
with it, which must, where appropriate cover— 
(i) infection or microbial hazards such as explants, needles or surgical 
equipment contaminated with potentially infectious substances of 
human origin, and 
(ii) physical hazards such as from sharps; 
(iii) if, in accordance with the sub-paragraph (3)(d), no instructions 
for use are required, this information must be made available to the 
user upon request; 
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—infection or microbial hazards such as explants, needles or surgical 
equipment contaminated with potentially infectious substances of 
human origin, and 
— physical hazards such as from sharps. 
 
If in accordance with the point (d) of Section 23.1 no instructions for 
use are required, this information shall be made available to the user 
upon request; 
(w)for devices intended for use by lay persons, the circumstances in 
which the user should consult a healthcare professional; 
(x)for the devices covered by this Regulation pursuant to Article 1(2), 
information regarding the absence of a clinical benefit and the risks 
related to use of the device; 
(w) for devices intended for use by lay persons, the circumstances in 
which the user should consult a healthcare professional; 
(x) for the devices covered by Part VIII of these Regulations pursuant 
to regulation 68(2)(b), information regarding the absence of a 
clinical benefit and the risks related to use of the device; 
(y)date of issue of the instructions for use or, if they have been revised, 
date of issue and identifier of the latest revision of the instructions for 
use; 
(z)a notice to the user and/or patient that any serious incident that has 
occurred in relation to the device should be reported to the 
  (y)the date of issue of the instructions for use or, if they have been 
revised, the date of issue and the identifier of the latest revision of 
the instructions for use; 
(z) a notice to the user or patient that any serious incident that has 
occurred in relation to the device should be reported to the 
manufacturer and to the Secretary of State; 
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manufacturer and the competent authority of the Member State in 
which the user and/or patient is established; 
(aa)information to be supplied to the patient with an implanted device 
in accordance with Article 18; 
(ab)for devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
minimum requirements concerning hardware, IT networks 
characteristics and IT security measures, including protection against 
unauthorised access, necessary to run the software as intended. 
(aa) information to be supplied to the patient with an implanted device 
in accordance with regulation 83; 
(bb) for devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
minimum requirements concerning hardware, Information 
Technology networks characteristics and Information Technology 
security measures, including protection against unauthorised 
access, necessary to run the software as intended. 
 
(1)  Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of 
substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 ( OJ L 353, 
31.12.2008, p. 1). 
(2)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH) (OJ L 396, 30.12.2006, p. 1). 
(3)  Regulation (EU) No 528/2012 of the European Parliament and the Council of 22 May 2012 concerning the making available on the market of and 
use of biocidal products (OJ L 167, 27.6.2012, p. 1). 
(4)  Council Directive 80/181/EEC of 20 December 1979 on the approximation of the laws of the Member States relating to units of measurement and 
on the repeal of Directive 71/354/EEC (OJ L 39, 15.2.1980, p. 40). 
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Appendix C4 4 Comparison: In Vitro Diagnostic Devices EU with UK General Safety and Performance Requirements. 
REGULATION (EU) 2017/746 OF THE EUROPEAN 
PARLIAMENT AND OF THE COUNCIL 
of 5 April 2017 on in vitro diagnostic medical devices and repealing 
Directive 98/79/EC and Commission Decision 2010/227/EU 
 2019 No. 791 
EXITING THE EUROPEAN UNION CONSUMER PROTECTION 
The Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 
Made - 1st April 2019 
ANNEX I  
GENERAL SAFETY AND PERFORMANCE REQUIREMENTS  
CHAPTER I 
GENERAL REQUIREMENTS 
 SCHEDULE 17 Regulation 1A  
General safety and performance requirements- in vitro diagnostic 
medical devices  
PART 1 General requirements for in vitro diagnostic medical devices 
1. Devices shall achieve the performance intended by their 
manufacturer and shall be designed and manufactured in such a 
way that, during normal conditions of use, they are suitable for 
their intended purpose. They shall be safe and effective and shall 
not compromise the clinical condition or the safety of patients, or 
the safety and health of users or, where applicable, other persons, 
provided that any risks which may be associated with their use 
constitute acceptable risks when weighed against the benefits to the 
patient and are compatible with a high level of protection of health 
and safety, taking into account the generally acknowledged state of 
the art. 
 1. Devices must— (a)   achieve the performance intended by their 
manufacturer; (b)   be designed and manufactured in such a way 
that, during normal conditions of use, they are suitable for their 
intended purpose; (c)   be safe and effective; (d)   not  compromise  
the  clinical  condition  or  the  safety  of  patients,  or  the  safety  
and health  of  users  or,  where  applicable,  other  persons, 
provided  that  any  risks  which may be associated with their use 
constitute acceptable risks when weighed against the  benefits  to  
the  patient  and  are  compatible  with  a  high  level  of  protection  
of health and safety, taking into account the generally 
acknowledged state of the art. 
2. The requirement in this Annex to reduce risks as far as possible 
means the reduction of risks as far as possible without adversely 
affecting the benefit-risk ratio. 
 2. The requirement in this Schedule to reduce risks as far as possible 
means the reduction of risks as far as possible without adversely 
affecting the benefit-risk ratio. 
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3. Manufacturers shall establish, implement, document and maintain 
a risk management system. 
 Risk management shall be understood as a continuous iterative 
process throughout the entire lifecycle of a device, requiring 
regular systematic updating. In carrying out risk management 
manufacturers shall: 
(a) establish and document a risk management plan for each device; 
(b) identify and analyse the known and foreseeable hazards associated 
with each device; 
(c) estimate and evaluate the risks associated with, and occurring 
during, the intended use and during reasonably foreseeable misuse; 
(d) eliminate or control the risks referred to in point (c) in accordance 
with the requirements of Section 4; 
(e) evaluate the impact of information from the production phase and, 
in particular, from the post-market surveillance system, on hazards 
and the frequency of occurrence thereof, on estimates of their 
associated risks, as well as on the overall risk, the benefit-risk ratio 
and risk acceptability; and 
(f) based on the evaluation of the impact of the information referred to 
in point (e), if necessary amend control measures in line with the 
requirements of Section 4. 
 3.—(1) Manufacturers   must   establish,   implement,   document   and   
maintain   a   risk management system.  
(2) Risk management must be understood as a continuous iterative 
process throughout the entire  lifecycle  of  a  device,  requiring  
regular  systematic  updating  and  in  carrying  out  risk 
management manufacturers must—  
(a)   establish and document a risk management plan for each device;  
(b)   identify  and  analyse  the  known  and  foreseeable hazards  
associated  with  each device;  
(c)   estimate and evaluate the risks associated with, and occurring 
during, the intended use and during reasonably foreseeable misuse;  
(d)   eliminate  or  control  the  risks  referred  to  in  sub-paragraph  (c)  
in  accordance  with the requirements of paragraph 4; ( 
e)   evaluate  the  impact  of  information  from  the  production  phase  
and,  in  particular, from  the  post-market  surveillance  system,  
on  hazards  and  the  frequency  of occurrence thereof, on 
estimates of their associated risks, as well as on the overall risk, the 
benefit-risk ratio and risk acceptability;  
(f)    based on the evaluation of the impact of the information referred 
to in point (e), if necessary amend control measures in line with the 
requirements of paragraph 4. 
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4. Risk control measures adopted by manufacturers for the design and 
manufacture of the devices shall conform to safety principles, 
taking account of the generally acknowledged state of the art.  
To reduce risks, the manufacturers shall manage risks so that the 
residual risk associated with each hazard as well as the overall 
residual risk is judged acceptable. In selecting the most appropriate 
solutions, manufacturers shall, in the following order of priority: 
(a) eliminate or reduce risks as far as possible through safe design and 
manufacture; 
(b) where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated; 
and 
(c) provide information for safety (warnings/precautions/contra-
indications) and, where appropriate, training to users. 
Manufacturers shall inform users of any residual risks. 
 4.—(1) Risk control measures adopted by manufacturers for the design 
and manufacture of the devices must conform to safety principles, 
taking account of the generally acknowledged state of the art.  
(2) To reduce risks, the manufacturers must manage risks so that the 
residual risk associated with each hazard as well as the overall 
residual risk is judged acceptable. ( 
3) In selecting the most appropriate solutions, manufacturers must, in 
the following order of priority—  
(a) eliminate or reduce risks as far as possible through safe design and 
manufacture;  
(b) where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated; 
(c) provide information for safety (warnings, precautions, contra-
indications) and, where appropriate, training to users;  
(d) inform users of any residual risks. 
5.   In eliminating or reducing risks related to use error, the 
manufacturer shall: 
(a) reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended 
to be used (design for patient safety), and 
(b) give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
 5. In eliminating or reducing risks related to use error, the 
manufacturer must—  
(a) reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended 
to be used (design for patient safety);  
(b) give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
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6. The characteristics and performance of a device shall not be 
adversely affected to such a degree that the health or safety of the 
patient or the user and, where applicable, of other persons are 
compromised during the lifetime of the device, as indicated by the 
manufacturer, when the device is subjected to the stresses which 
can occur during normal conditions of use and has been properly 
maintained in accordance with the manufacturer's instructions. 
 6. The characteristics and performance of a device must not be 
adversely affected to such a degree that the health or safety of the 
patient or the user and, where applicable, of other persons are 
compromised during the lifetime of the device, as indicated by the 
manufacturer, when the device is subjected to the stresses which 
can occur during normal conditions of use and has been properly 
maintained in accordance with the manufacturer’s instructions. 
7. Devices shall be designed, manufactured and packaged in such a 
way that their characteristics and performance during their 
intended use are not adversely affected during transport and 
storage, for example, through fluctuations of temperature and 
humidity, taking account of the instructions and information 
provided by the manufacturer. 
 7. Devices must be designed, manufactured and packaged in such a 
way that their characteristics and performance during their 
intended use are not adversely affected during transport and 
storage, for example, through fluctuations of temperature and 
humidity, taking account of the instructions and information 
provided by the manufacturer. 
8. All known and foreseeable risks, and any undesirable effects shall 
be minimised and be acceptable when weighed against the 
evaluated potential benefits to the patients and/or the user arising 
from the intended performance of the device during normal 
conditions of use. 
 8. All known and foreseeable risks, and any undesirable effects must 
be minimised and be acceptable when weighed against the 
evaluated potential benefits to the patients or the user arising from 
the intended performance of the device during normal conditions 
of use. 
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CHAPTER II 
REQUIREMENTS REGARDING PERFORMANCE, DESIGN AND 
MANUFACTURE 
 PART 2  
Requirements regarding design and manufacture of in vitro diagnostic 
medical devices 
Essential Requirement 9 Performance characteristics 
 
Performance characteristics 
9.1. Devices shall be designed and manufactured in such a way that 
they are suitable for the purposes referred to in point (2) of 
Article 2, as specified by the manufacturer, and suitable with 
regard to the performance they are intended to achieve, taking 
account of the generally acknowledged state of the art. They shall 
achieve the performances, as stated by the manufacturer and in 
particular, where applicable: 
(a) the analytical performance, such as, analytical sensitivity, 
analytical specificity, trueness (bias), precision (repeatability and 
reproducibility), accuracy (resulting from trueness and precision), 
limits of detection and quantitation, measuring range, linearity, 
cut-off, including determination of appropriate criteria for 
specimen collection and handling and control of known relevant 
endogenous and exogenous interference, cross-reactions; and 
(b) the clinical performance, such as diagnostic sensitivity, 
diagnostic specificity, positive predictive value, negative 
predictive value, likelihood ratio, expected values in normal and 
affected populations. 
 9.—(1) Devices must— (a) be designed and manufactured in such a 
way that they are suitable for one or more of the purposes listed 
in the definition of “in vitro diagnostic medical device” in 
regulation 137, as specified by the manufacturer, and suitable 
with regard to the performance they are intended to achieve, 
taking account of the generally acknowledged state of the art; 
b) achieve the performances, as stated by the manufacturer and in 
particular, where applicable— (i) the analytical performance, 
such as, analytical sensitivity, analytical specificity, trueness 
(bias), precision (repeatability and reproducibility), accuracy 
(resulting from trueness and precision), limits of detection and 
quantitation, measuring range, linearity, cut-off, including 
determination of appropriate criteria for specimen collection and 
handling and control of known relevant endogenous and 
exogenous interference, cross- reactions; (ii) the clinical 
performance, such as diagnostic sensitivity, diagnostic specificity, 
positive predictive value, negative predictive value, likelihood 
ratio, expected values in normal and affected populations 
9.2. The performance characteristics of the device shall be maintained 
during the lifetime of the device as indicated by the 
manufacturer. 
 2) The performance characteristics of the device must be maintained 
during the lifetime of the device as indicated by the manufacturer. 
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9.3. Where the performance of devices depends on the use of 
calibrators and/or control materials, the metrological traceability 
of values assigned to calibrators and/or control materials shall be 
assured through suitable reference measurement procedures 
and/or suitable reference materials of a higher metrological order. 
Where available, metrological traceability of values assigned to 
calibrators and control materials shall be assured to certified 
reference materials or reference measurement procedures. 
 (3) Where the performance of devices depends on the use of 
calibrators or control materials— 
(a) the metrological traceability of values assigned to calibrators or 
control materials must be assured through suitable reference 
measurement procedures or suitable reference materials of a 
higher metrological order; 
(b) where available, metrological traceability of values assigned to 
calibrators and control materials must be assured to certified 
reference materials or reference measurement procedures. 
9.4. The characteristics and performances of the device shall be 
specifically checked in the event that they may be affected when 
the device is used for the intended use under normal conditions: 
(a) for devices for self-testing, performances obtained by laypersons; 
(b) for devices for near-patient testing, performances obtained in 
relevant environments (for example, patient home, emergency 
units, ambulances). 
 (4) The characteristics and performances of the device must be 
specifically checked in the event that they may be affected when 
the device is used for the intended use under normal conditions—  
(a) for devices for self-testing, performances obtained by laypersons;  
(b) for devices for near-patient testing, performances obtained in 
relevant environments (for example, patient home, emergency 
units, ambulances). 
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Essential Requirement 10 Chemical, physical and biological 
properties 
A 
NA 
Chemical physical and biological properties 
 
10.1. Devices shall be designed and manufactured in such a way as to 
ensure that the characteristics and performance requirements 
referred to in Chapter I are fulfilled. 
 Particular attention shall be paid to the possibility of impairment 
of analytical performance due to physical and/or chemical 
incompatibility between the materials used and the specimens, 
analyte or marker to be detected (such as biological tissues, cells, 
body fluids and micro-organisms), taking account of the intended 
purpose of the device. 
 10 (1) Devices must be designed and manufactured in such a way as 
to ensure that the characteristics and performance requirements 
referred to in Part 1 are fulfilled and, 
 in this regard, particular attention must be paid to the possibility 
of impairment of analytical performance due to physical or 
chemical incompatibility between the materials used and the 
specimens, analyte or marker to be detected (such as biological 
tissues, cells, body fluids and micro-organisms), taking account 
of the intended purpose of the device. 
10.2. Devices shall be designed, manufactured and packaged in such a 
way as to minimise the risk posed by contaminants and residues 
to patients, taking account of the intended purpose of the device, 
and to the persons involved in the transport, storage and use of 
the devices. Particular attention shall be paid to tissues exposed 
to those contaminants and residues and to the duration and 
frequency of exposure.10.3. Devices shall be designed and 
manufactured in such a way as to reduce to a level as low as 
reasonably practicable the risks posed by substances or particles, 
including wear debris, degradation products and processing 
residues, that may be released from the device. 
 Special attention shall be given to substances which are carcinogenic, 
mutagenic or toxic to reproduction (‘CMR’), in accordance with 
Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the 
European Parliament and of the Council (1), and to substances 
having endocrine disrupting properties for which there is 
scientific evidence of probable serious effects to human health 
Not the same 
words but the 
same meaning. 
(2) As regards substances or particles that may be released from the 
device— 
(a) devices must be designed and manufactured in such a way as to 
reduce to a level as low as reasonably practicable the risks posed 
by these substances or particles, including wear debris, 
degradation products and processing residues; 
 (b) special attention must be given to substances— 
(i) which are carcinogenic, mutagenic or toxic to reproduction 
(‘CMR’) and on the UK mandatory classification and labelling 
list established and maintained in accordance with Article 38A of 
Regulation (EC) No 1272/2008 of the European Parliament and 
of the Council; and 
(ii) with endocrine disrupting properties for which there is scientific 
evidence of probable serious effects to human health and which 
are identified in accordance with the procedure set out in Article 
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and which are identified in accordance with the procedure set out 
in Article 59 of Regulation (EC) No 1907/2006 of the European 
Parliament and of the Council (2). 
59 of Regulation (EC) No 1907/2006 of the European Parliament 
and of the Council. 
 
 
10.4. Devices shall be designed and manufactured in such a way as to 
reduce as far as possible the risks posed by the unintentional 
ingress of substances into the device, taking into account the 
device and the nature of the environment in which it is intended 
to be used. 
 (3) Devices must be designed and manufactured in such a way as to 
reduce as far as possible the risks posed by the unintentional 
ingress of substances into the device, taking into account the 
device and the nature of the environment in which it is intended 
to be used. 
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11.1. Devices and their manufacturing processes shall be designed in 
such a way as to eliminate or reduce as far as possible the risk of 
infection to the user or, where applicable, other persons. The 
design shall: 
(a) allow easy and safe handling; 
(b) reduce as far as possible any microbial leakage from the device 
and/or microbial exposure during use; 
 and, where necessary 
(c) prevent microbial contamination of the device during use and, in 
the case of specimen receptacles, the risk of contamination of the 
specimen. 
 11 - (1) Devices and their manufacturing processes must be designed 
in such a way as to eliminate or reduce as far as possible the risk 
of infection to the user or, where applicable, other persons and 
the design must— 
(a) allow easy and safe handling; 
(b) reduce, as far as possible, any microbial leakage from the device 
or microbial exposure during use; 
(c) where necessary, prevent microbial contamination of the device 
during use and, in the case of specimen receptacles, the risk of 
contamination of the specimen. 
 
11.2. Devices labelled either as sterile or as having a specific microbial 
state shall be designed, manufactured and packaged to ensure that 
their sterile condition or microbial state is maintained under the 
transport and storage conditions specified by the manufacturer 
until that packaging is opened at the point of use, unless the 
packaging which maintains their sterile condition or microbial 
state is damaged. 
 (2) Devices labelled either as sterile or as having a specific microbial 
state must be designed, manufactured and packaged to ensure 
that their sterile condition or microbial state is maintained under 
the transport and storage conditions specified by the 
manufacturer until that packaging is opened at the point of use, 
unless the packaging which maintains their sterile condition or 
microbial state is damaged. 
11.3. Devices labelled as sterile shall be processed, manufactured, 
packaged and, sterilised by means of appropriate, validated 
methods. 
 (3) Devices labelled as sterile must be processed, manufactured, 
packaged and, sterilised by means of appropriate, validated 
methods. 
11.4. Devices intended to be sterilised shall be manufactured and 
packaged in appropriate and controlled conditions and facilities. 
 (4) Devices intended to be sterilised must be manufactured and 
packaged in appropriate and controlled conditions and facilities. 
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11.5. Packaging systems for non-sterile devices  
 shall maintain the integrity and cleanliness of the product and, 
where the devices are to be sterilised prior to use, minimise the 
risk of microbial contamination;  
 the packaging system shall be suitable taking account of the 
method of sterilisation indicated by the manufacturer. 
 (5) Packaging systems for non-sterile devices must— 
(a) maintain the integrity and cleanliness of the product and, where 
the devices are to be sterilised prior to use, minimise the risk of 
microbial contamination; 
(b) be suitable taking account of the method of sterilisation indicated 
by the manufacturer. 
11.6. The labelling of the device shall distinguish between identical or 
similar devices placed on the market in both a sterile and a non-
sterile condition additional to the symbol used to indicate that 
devices are sterile. 
 (6) The labelling of the device must distinguish between identical or 
similar devices placed on the market in both a sterile and a non-
sterile condition additional to the symbol used to indicate that 
devices are sterile. 
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Essential Requirement 12 Devices incorporating materials of 
biological origin 
 
Devices incorporating materials of a biological origin 
Where devices include tissues, cells and substances of animal, human 
or microbial origin,  
the selection of sources, the processing, preservation, testing and 
handling of tissues, cells and substances of such origin and control 
procedures shall be carried out so as to provide safety for user or other 
person. 
 
In particular, safety with regard to microbial and other transmissible 
agents shall be addressed by implementation of validated methods of 
elimination or inactivation in the course of the manufacturing process. 
This might not apply to certain devices if the activity of the microbial 
and other transmissible agent are integral to the intended purpose of 
the device or when such elimination or inactivation process would 
compromise the performance of the device. 
 
 12. Where devices include tissues, cells and substances of animal, 
human or microbial origin— 
(a) the selection of sources, the processing, preservation, testing and 
handling  of tissues, cells and substances of such origin and 
control procedures must be carried out so as to provide safety for 
users or other persons; 
(b) safety with regard to microbial and other transmissible agents 
must be addressed by implementation of validated methods of 
elimination or inactivation  in  the course of the manufacturing 
process but this requirement would not apply to devices if the 
activity of the microbial and other transmissible agent are integral 
to the intended purpose of the device or when such elimination  
or  inactivation process would compromise the performance of 
the device. 
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Essential Requirement 13. Construction of devices and interaction 
with their environment 
 
Construction of devices and interaction with the environment 
13.1. If the device is intended for use in combination with other 
devices or equipment, the whole combination, including the 
connection system, shall be safe and shall not impair the 
specified performances of the devices. Any restrictions on use 
applying to such combinations shall be indicated on the label 
and/or in the instructions for use. 
 13 - (1) If the device is intended for use in combination with other 
devices or equipment, the whole combination, including the 
connection system, must be safe and must not impair the 
specified performances of the devices and any restrictions on use 
applying to such combinations must be indicated on the label 
and in the instructions for use. 
13.2. Devices shall be designed and manufactured in such a way as to 
remove or reduce as far as possible: 
(a) the risk of injury, in connection with their physical features, 
including the volume/pressure ratio, dimensional and where 
appropriate ergonomic features; 
(b) risks connected with reasonably foreseeable external influences 
or environmental conditions, such as magnetic fields, external 
electrical and electromagnetic effects, electrostatic discharge, 
radiation associated with diagnostic or therapeutic procedures, 
pressure, humidity, temperature, variations in pressure and 
acceleration or radio signal interferences; 
(c) the risks associated with the use of the device when it comes into 
contact with materials, liquids, and substances, including gases, 
to which it is exposed during normal conditions of use; 
(d) the risks associated with the possible negative interaction 
between software and the IT environment within which it 
operates and interacts; 
(e) the risks of accidental ingress of substances into the device; 
(f) the risk of incorrect identification of specimens and the risk of 
erroneous results due to, for example, confusing colour and/or 
numeric and/or character codings on specimen receptacles, 
 (2) Devices must be designed and manufactured in such a way as to 
remove or reduce as far as possible— 
(a) the risk of injury, in connection with their physical features, 
including the volume/pressure ratio, dimensional and where 
appropriate ergonomic features; 
(b) risks connected with reasonably foreseeable external influences 
or environmental conditions, such as magnetic fields, external 
electrical and electromagnetic effects, electrostatic discharge, 
radiation associated with diagnostic or therapeutic procedures, 
pressure, humidity, temperature, variations in pressure and 
acceleration or radio signal interferences; 
(c) the risks associated with the use of the device when it comes into 
contact with materials, liquids, and substances, including gases, 
to which it is exposed during normal conditions of use; 
(d) the risks associated with the possible negative interaction 
between software and the IT environment within which it 
operates and interacts; 
(e) the risks of accidental ingress of substances into the device; 
(f) the risk of incorrect identification of specimens and the risk of 
erroneous results due to, for example, confusing colour or 
numeric or character codings on specimen receptacles, 
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removable parts and/or accessories used with devices in order to 
perform the test or assay as intended; 
(g) the risks of any foreseeable interference with other devices. 
removable parts or accessories used with devices in order to 
perform the test or assay as intended; 
(g) the risks of any foreseeable interference with other devices. 
 
 
13.3. Devices shall be designed and manufactured in such a way as to 
minimise the risks of fire or explosion during normal use and in 
single fault condition. Particular attention shall be paid to 
devices the intended use of which includes exposure to or use in 
association with flammable or explosive substances or 
substances which could cause combustion. 
 (3) Devices must be designed and manufactured in such a way as to 
minimise the risks of fire or explosion during normal use and in 
single fault condition and, in this regard, particular attention 
must be paid to devices the intended use of which includes 
exposure to or use in association with flammable or explosive 
substances or substances which could cause combustion. 
13.4. Devices shall be designed and manufactured in such a way that 
adjustment, calibration, and maintenance can be done safely and 
effectively. 
 (4) Devices must be designed and manufactured in such a way that 
adjustment, calibration, and maintenance can be done safely and 
effectively. 
13.5.   Devices that are intended to be operated together with other 
devices or products shall be designed and manufactured in such 
a way that the interoperability and compatibility are reliable and 
safe. 
 (5) Devices that are intended to be operated together with other 
devices or products must be designed and manufactured in such 
a way that the interoperability and compatibility are reliable and 
safe. 
13.6. Devices shall be designed and manufactured in such a way as to 
facilitate their safe disposal and the safe disposal of related waste 
substances by users, or other person. To that end, manufacturers 
shall  
identify and test procedures and measures as a result of which their 
devices can be safely disposed after use. 
 Such procedures shall be described in the instructions for use. 
 (6) Devices must be designed and manufactured in such a way as to 
facilitate their safe disposal and the safe disposal of related waste 
substances by users, or other persons and, in doing so 
manufacturers must— 
(a) identify and test procedures and measures as a result of which 
their devices can be safely disposed after use; 
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(b) ensure that such test procedures are described in the instructions 
for use. 
13.7 The measuring, monitoring or display scale (including colour 
change and other visual indicators) shall be designed and 
manufactured in line with ergonomic principles, taking account 
of the intended purpose, users and the environmental conditions 
in which the devices are intended to be used. 
 (7) The measuring, monitoring or display scale (including colour 
change and other visual indicators) must be designed and 
manufactured in line with ergonomic principles, taking account 
of the intended purpose, users and the environmental conditions 
in which the devices are intended to be used. 
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Essential Requirement 14. Devices with a measuring function A 
NA 
Devices with a measuring function 
14.1. Devices having a primary analytical measuring function shall be 
designed and manufactured in such a way as to provide 
appropriate analytical performance in accordance with point (a) 
of Section 9.1 of Annex I, taking into account the intended 
purpose of the device. 
 14 .—(1) Devices having a primary analytical measuring function 
must be designed and manufactured in such a way as to provide 
appropriate analytical performance in accordance with paragraph 
9(1), taking into account the intended purpose of the device. 
14.2. The measurements made by devices with a measuring function 
shall be expressed in legal units conforming to the provisions of 
Council Directive 80/181/EEC (3). 
 (2) The measurements made by devices with a measuring function 
must be expressed in legal units conforming to the provisions of 
the Units of Measurement Regulations 1986. 
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Essential Requirement 15. Protection against radiation 
 
 
Protection against radiation 
15.1. Devices shall be designed, manufactured and packaged in such 
a way that exposure of users or other persons to radiation 
(intended, unintended, stray or scattered) is reduced as far as 
possible and in a manner that is compatible with the intended 
purpose, whilst not restricting the application of appropriate 
specified levels for diagnostic purposes. 
 15 - (1) Devices must be designed, manufactured and packaged in 
such a way that exposure of users or other persons to radiation 
(intended, unintended, stray or scattered) is reduced as far as 
possible and in a manner that is compatible with the intended 
purpose, whilst not restricting the application of appropriate 
specified levels for diagnostic purposes. 
15.2. When devices are intended to emit hazardous, or potentially 
hazardous, ionizing and/or non-ionizing radiation, they shall as 
far as possible be: 
(a) designed and manufactured in such a way as to ensure that the 
characteristics and the quantity of radiation emitted can be 
controlled and/or adjusted; and 
(b) fitted with visual displays and/or audible warnings of such 
emissions. 
 (2) When devices are intended to emit hazardous, or potentially 
hazardous, ionizing or non-ionizing radiation, they must as far as 
possible be— 
(a) designed and manufactured in such a way as to ensure that the 
characteristics and the quantity of radiation emitted can be 
controlled or adjusted; 
(b) fitted with visual displays or audible warnings of such emissions. 
15.3. The operating instructions for devices emitting hazardous or 
potentially hazardous radiation shall contain  
detailed information as to the nature of the emitted radiation, the 
means of protecting the user, and on ways of avoiding misuse 
and of reducing the risks inherent to installation as far as 
possible and appropriate.  
Information regarding the acceptance and performance testing, the 
acceptance criteria, and the maintenance procedure shall also be 
specified. 
 (3) The operating instructions for devices emitting hazardous or 
potentially hazardous radiation must contain— 
(a) detailed information as to the nature of the emitted radiation, the 
means of protecting the user, and on ways of avoiding misuse 
and of reducing the risks inherent to installation as far as 
possible and appropriate; 
(b) information regarding the acceptance and performance testing, 
the acceptance criteria, and the maintenance procedure. 
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Essential Requirement 16. Electronic programmable systems — 
devices that incorporate electronic programmable systems and 
software that are devices in themselves. 
 
Electronic programmable systems- devices that incorporate 
programmable systems and software that are devices in themselves 
16.1. Devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
shall be  
designed to ensure repeatability, reliability and performance in line 
with their intended use.  
In the event of a single fault condition, appropriate means shall be 
adopted to eliminate or reduce as far as possible consequent risks 
or impairment of performance. 
 16 - (1) Devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
must— 
(a) be designed to ensure repeatability, reliability and performance 
in line with their intended use; 
(b) in the event of a single fault condition, appropriate means must 
be adopted to eliminate or reduce as far as possible consequent 
risks or impairment of performance. 
16.2. For devices that incorporate software or for software that are 
devices in themselves, the software shall be developed and 
manufactured in accordance with the state of the art taking into 
account the principles of development life cycle, risk 
management, including information security, verification and 
validation. 
 (2) For devices that incorporate software or for software that is a 
device in itself , the software must be developed and 
manufactured in accordance with the state of the art taking into 
account the principles of development life cycle, risk 
management, including information security, verification and 
validation. 
16.3. Software referred to in this Section that is intended to be used in 
combination with mobile computing platforms shall be designed 
and manufactured taking into account the specific features of the 
mobile platform (e.g. size and contrast ratio of the screen) and 
the external factors related to their use (varying environment as 
regards level of light or noise). 
 (3) Software referred to in this paragraph that is intended to be used 
in combination with mobile computing platforms must be 
designed and manufactured taking into account the specific 
features of the mobile platform (e.g. size and contrast ratio of the 
screen) and the external factors related to their use (varying 
environment as regards level of light or noise). 
16.4. Manufacturers shall set out minimum requirements concerning 
hardware, IT networks characteristics and IT security measures, 
including protection against unauthorised access, necessary to 
run the software as intended. 
 (4) Manufacturers must set out minimum requirements concerning 
hardware, IT networks characteristics and IT security measures, 
including protection against unauthorised access, necessary to 
run the software as intended. 
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Essential Requirement. 17. Devices connected to or equipped with 
an energy source 
 
Devices connected to or equipped with an energy source 
17.1. For devices connected to or equipped with an energy source, in 
the event of a single fault condition, appropriate means shall be 
adopted to eliminate or reduce as far as possible consequent 
risks. 
 17 - (1) For devices connected to or equipped with an energy source, 
in the event of a single fault condition, appropriate means must 
be adopted to eliminate or reduce as far as possible consequent 
risks. 
17.2. Devices where the safety of the patient depends on an internal 
power supply shall be equipped with a means of determining the 
state of the power supply and an appropriate warning or 
indication for when the capacity of the power supply becomes 
critical. If necessary, such warning or indication shall be given 
prior to the power supply becoming critical. 
 (2) Devices where the safety of the patient depends on an internal 
power supply must be equipped with a means of determining the 
state of the power supply and an appropriate warning or 
indication for when the capacity of the power supply becomes 
critical and if necessary, such warning or indication shall be 
given prior to the power supply becoming critical. 
17.3. Devices shall be designed and manufactured in such a way as to 
reduce as far as possible the risks of creating electromagnetic 
interference which could impair the operation of the device in 
question or other devices or equipment in the intended 
environment. 
 (3) Devices must be designed and manufactured in such a way as to 
reduce as far as possible the risks of creating electromagnetic 
interference which could impair the operation of the device in 
question or other devices or equipment in the intended 
environment. 
17.4. Devices shall be designed and manufactured in such a way as to 
provide a level of intrinsic immunity to electromagnetic 
interference such that is adequate to enable them to operate as 
intended. 
 (4) Devices must be designed and manufactured in such a way as to 
provide a level of intrinsic immunity to electromagnetic 
interference such that is adequate to enable them to operate as 
intended. 
17.5. Devices shall be designed and manufactured in such a way as to 
avoid as far as possible the risk of accidental electric shocks to 
the user, or other person both during normal use of the device 
and in the event of a single fault condition in the device, 
provided the device is installed and maintained as indicated by 
the manufacturer. 
 (5) Devices must be designed and manufactured in such a way as to 
avoid as far as possible the risk of accidental electric shocks to 
the user, or other person both during normal use of the device 
and in the event of a single fault condition in the device, 
provided the device is installed and maintained as indicated by 
the manufacturer. 
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Essential Requirement. 18. Protection against mechanical and 
thermal risks 
 
Protection against mechanical and thermal risks 
18.1. Devices shall be designed and manufactured in such a way as to 
protect users and other persons against mechanical risks. 
 18 .—(1) Devices must be designed and manufactured in such a 
way as to protect users and other persons against mechanical 
risks. 
18.2. Devices shall be  
sufficiently stable under the foreseen operating conditions.  
They shall be suitable to withstand stresses inherent to the foreseen 
working environment, and to retain this resistance during the 
expected lifetime of the devices, subject to any inspection and 
maintenance requirements as indicated by the manufacturer. 
 (2) Devices must— 
(a) be sufficiently stable under the foreseen operating conditions; 
(b) be suitable to withstand stresses inherent to the foreseen working 
environment, and to retain this resistance during the expected 
lifetime of the devices, subject to any inspection and 
maintenance requirements as indicated by the manufacturer. 
 
18.3. Where there are risks due to the presence of moving parts, risks 
due to break-up or detachment, or leakage of substances, then 
appropriate protection means shall be incorporated.  
 Any guards or other means included with the device to provide 
protection, in particular against moving parts, shall be secure and 
shall not interfere with access for the normal operation of the 
device, or restrict routine maintenance of the device as intended 
by the manufacturer. 
 (3) Where there are risks due to the presence of moving parts, risks 
due to break-up or detachment, or leakage of substances, then 
appropriate protection means must be incorporated. 
 (4) Any guards or other means included with the device to provide 
protection, in particular against moving parts, must be secure and 
must not interfere with access for the normal operation of the 
device, or restrict routine maintenance of the device as intended 
by the manufacturer. 
18.4. Devices shall be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from 
vibration generated by the devices, taking account of technical 
progress and of the means available for limiting vibrations, 
particularly at source, unless the vibrations are part of the 
specified performance. 
 (5) Devices must be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from 
vibration generated by the devices, taking account of technical 
progress and of the means available for limiting vibrations, 
particularly at source, unless the vibrations are part of the 
specified performance. 
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18.5. Devices shall be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from the 
noise emitted, taking account of technical progress and of the 
means available to reduce noise, particularly at source, unless the 
noise emitted is part of the specified performance. 
 (6) Devices must be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from the 
noise emitted, taking account of technical progress and of the 
means available to reduce noise, particularly at source, unless the 
noise emitted is part of the specified performance. 
18.6. Terminals and connectors to the electricity, gas or hydraulic and 
pneumatic energy supplies which the user or other person has to 
handle, shall be designed and constructed in such a way as to 
minimise all possible risks. 
 (7) Terminals and connectors to the electricity, gas or hydraulic and 
pneumatic energy supplies which the user or other person has to 
handle, must be designed and constructed in such a way as to 
minimise all possible risks. 
18.7. Errors likely to be made when fitting or refitting certain parts 
which could be a source of risk shall be made impossible by the 
design and construction of such parts or, failing this, by 
information given on the parts themselves and/or their housings. 
 The same information shall be given on moving parts and/or their 
housings where the direction of movement needs to be known in 
order to avoid a risk. 
 (8) Errors likely to be made when fitting or refitting certain parts 
which could be a source of risk must be made impossible by the 
design and construction of such parts or, failing this, by 
information given on the parts themselves or their housings. 
(9) Information must be given on moving parts or their housings 
where the direction of movement needs to be known in order to 
avoid a risk. 
18.8. Accessible parts of devices (excluding the parts or areas 
intended to supply heat or reach given temperatures) and their 
surroundings shall not attain potentially dangerous temperatures 
under normal conditions of use. 
 (10) Accessible parts of devices (excluding the parts or areas intended 
to supply heat or reach given temperatures) and their 
surroundings must not attain potentially dangerous temperatures 
under normal conditions of use. 
 
  
Page 290 of 513 
 
 
Essential Requirement. 19. Protection against the risks posed by 
devices intended for self-testing or 
near-patient testing 
 
Protection against the risks posed by devices intended for self-testing 
or near-patient testing 
19.1. Devices intended for self-testing or near-patient testing shall be  
designed and manufactured in such a way that they perform 
appropriately for their intended purpose taking into account the 
skills and the means available to the intended user and the 
influence resulting from variation that can be reasonably 
anticipated in the intended user's technique and environment.  
The information and instructions provided by the manufacturer shall 
be easy for the intended user to understand and apply in order to 
correctly interpret the result provided by the device and to avoid 
misleading information. 
 In the case of near-patient testing, the information and the 
instructions provided by the manufacturer shall make clear the 
level of training, qualifications and/or experience required by the 
user. 
 19 .—(1) Devices intended for self-testing or near-patient testing— 
(a) must be designed and manufactured in such a way that they 
perform appropriately for their intended purpose taking into 
account the skills and the means available to the intended user and 
the influence resulting from variation that can be reasonably 
anticipated in the intended user’s technique and environment; 
(b) the information and instructions provided by the manufacturer 
must be easy for the intended user to understand and apply in 
order to correctly interpret the result provided by the device and 
to avoid misleading information; 
(c) in the case of near-patient testing, the information and the 
instructions provided by the manufacturer must make clear the 
level of training, qualifications or experience required by the user. 
19.2. Devices intended for self-testing or near-patient testing shall be 
designed and manufactured in such a way as to: 
(a) ensure that the device can be used safely and accurately by the 
intended user at all stages of the procedure if necessary after 
appropriate training and/or information; and 
(b) reduce as far as possible the risk of error by the intended user in 
the handling of the device and, if applicable, the specimen, and 
also in the interpretation of the results. 
 (2) Devices intended for self-testing or near-patient testing must be 
designed and manufactured in such a way as to— 
(a) ensure that the device can be used safely and accurately by the 
intended user at all stages of the procedure if necessary after 
appropriate training or information; 
(b) reduce as far as possible the risk of error by the intended user in 
the handling of the device and, if applicable, the specimen, and 
also in the interpretation of the results. 
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19.3. Devices intended for self-testing and near-patient testing shall, 
where feasible, include a procedure by which the intended user: 
(a) can verify that, at the time of use, the device will perform as 
intended by the manufacturer; and 
(b) be warned if the device has failed to provide a valid result. 
 (3) Devices intended for self-testing and near-patient testing must, 
where feasible, include a procedure by which the intended user— 
(a) can verify that, at the time of use, the device will perform as 
intended by the manufacturer; 
(b) be warned if the device has failed to provide a valid result. 
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.  
CHAPTER III 
REQUIREMENTS REGARDING INFORMATION SUPPLIED 
WITH THE DEVICE  
 PART 3 
Requirements regarding information supplied with the device 
 
Essential Requirement. 20. Label and instructions for use 
 
Labels and instructions for use 
 
20.1. General requirements regarding the information supplied by the 
manufacturer 
 Each device shall be accompanied by the information needed to 
identify the device and its manufacturer, and by any safety and 
performance information relevant to the user or any other person, 
as appropriate. Such information may appear on the device itself, 
on the packaging or in the instructions for use, and shall, if the 
manufacturer has a website, be made available and kept up to date 
on the website, taking into account the following: 
(a) The medium, format, content, legibility, and location of the label 
and instructions for use shall be appropriate to the particular 
device, its intended purpose and the technical knowledge, 
experience, education or training of the intended user(s). In 
particular, instructions for use shall be written in terms readily 
understood by the intended user and, where appropriate, 
supplemented with drawings and diagrams. 
(b) The information required on the label shall be provided on the 
device itself. If this is not practicable or appropriate, some or all 
of the information may appear on the packaging for each unit. If 
individual full labelling of each unit is not practicable, the 
information shall be set out on the packaging of multiple devices. 
 General requirements regarding the information supplied by the 
manufacturer 
20 - (1) Each device must be accompanied— 
(a) by the information needed to identify the device and its 
manufacturer;  
(b) by any safety and performance information relevant to the 
user or any other person, as appropriate. 
(2) The information in paragraph (1) may appear on the device 
itself, on the packaging or in the instructions for use, and must, if the 
manufacturer has a website, be made available and kept up to date on 
the website, taking into account the following— 
(a) the medium, format, content, legibility, and location of the 
label and instructions for use must be appropriate to the particular 
device, its intended purpose and the technical knowledge, experience, 
education or training of the intended user and, in particular, 
instructions for use must be written in terms readily understood by 
the intended user and, where appropriate, supplemented with 
drawings and diagrams; 
(b) the information required on the label must be provided on the 
device itself or if this is not practicable or appropriate, some or all of 
the information may appear on the packaging for each unit and, if 
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individual full labelling of each unit is not practicable, the 
information must be set out on the packaging of multiple devices; 
 
(c) Labels shall be provided in a human-readable format and may be 
supplemented by machine-readable information, such as radio-
frequency identification or bar codes. 
(d) Instructions for use shall be provided together with devices. 
However, in duly justified and exceptional cases instructions for 
use shall not be required or may be abbreviated if the device can 
be used safely and as intended by the manufacturer without any 
such instructions for use. 
(e) Where multiple devices, with the exception of devices intended 
for self-testing or near-patient testing, are supplied to a single user 
and/or location, a single copy of the instructions for use may be 
provided if so agreed by the purchaser who in any case may 
request further copies to be provided free of charge. 
(f) When the device is intended for professional use only, instructions 
for use may be provided to the user in non-paper format (e.g. 
electronic), except when the device is intended for near-patient 
testing. 
(g) Residual risks which are required to be communicated to the user 
and/or other person shall be included as limitations, contra-
indications, precautions or warnings in the information supplied 
by the manufacturer. 
 
 (c) labels must be provided in a human-readable format and may be 
supplemented by machine-readable information, such as radio-
frequency identification or bar codes; 
(d) instructions for use must be provided together with devices but, in 
duly justified and exceptional cases, instructions for use are not 
required, or may be abbreviated, if the device can be used safely 
and as intended by the manufacturer without any such instructions 
for use; 
(e) where multiple devices, with the exception of devices intended for 
self-testing or near-patient testing, are supplied to a single user or 
location, a single copy of the instructions for use may be provided 
if so agreed by the purchaser who in any case may request further 
copies to be provided free of charge; 
(f) when the device is intended for professional use only, instructions 
for use may be provided to the user in non-paper format (e.g. 
electronic), except when the device is intended for near-patient 
testing; 
(g) residual risks which are required to be communicated to the user 
or other person shall be included as limitations, contra-
indications, precautions or warnings in the information supplied 
by the manufacturer; 
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(h) Where appropriate, the information supplied by the manufacturer  
shall take the form of internationally recognised symbols, taking into 
account the intended users. 
 Any symbol or identification colour used shall conform to the 
harmonised standards or CS.  
In areas for which no harmonised standards or CS exist, the symbols 
and colours shall be described in the documentation supplied with 
the device. 
(h) where appropriate, the information supplied by the 
manufacturer— 
(i) must take the form of internationally recognised symbols, taking 
into account the intended users; 
(ii) must conform, in terms of any symbols or identification colour 
used, to the designated standards or CS; 
(iii) in areas for which no designated standards or CS exist, the 
symbols and colours must be described in the documentation 
supplied with the device; 
(i) In the case of devices containing a substance or a mixture 
which may be considered as being dangerous, taking 
account of the nature and quantity of its constituents and 
the form under which they are present,  
(ii) relevant hazard pictograms and labelling requirements of 
Regulation (EC) No 1272/2008 shall apply. 
(iii)  Where there is insufficient space to put all the 
information on the device itself or on its label, the relevant 
hazard pictograms shall be put on the label and the other 
information required by Regulation (EC) No 1272/2008 
shall be given in the instructions for use. 
(j) The provisions of Regulation (EC) No 1907/2006 on the safety 
data sheet shall apply, unless all relevant information, as 
appropriate, is already made available in the instructions for use. 
 (i) in the case of devices containing a substance or a mixture which 
may be considered as being dangerous, taking account of the 
nature and quantity of its constituents and the form under which 
they are present— 
(i) relevant hazard pictograms and labelling requirements of 
Regulation (EC) No 1272/2008 apply; or 
(ii) where there is insufficient space to put all the information on the 
device itself or on its label, the relevant hazard pictograms must 
be put on the label and the other information required by 
Regulation (EC) No 1272/2008 must be given in the instructions 
for use; 
(j) the provisions of Regulation (EC) No 1907/2006 on the safety 
data sheet must apply, unless all relevant information, as 
appropriate, is already made available in the instructions for use. 
20.2. Information on the label 
The label shall bear all of the following particulars: 
 Information on the label 
(3) The label must bear all of the following particulars— 
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(a) the name or trade name of the device; 
(b) the details strictly necessary for a user to identify the device and, 
where it is not obvious for the user, the intended purpose of the 
device; 
(c) the name, registered trade name or registered trade mark of the 
manufacturer and the address of its registered place of business; 
(d) if the manufacturer has its registered place of business outside the 
Union, the name of its authorised representative and the address 
of the registered place of business of the authorised 
representative; 
(e) an indication that the device is an in vitro diagnostic medical 
device, or if the device is a ‘device for performance study’, an 
indication of that fact; 
(f) the lot number or the serial number of the device preceded by the 
words LOT NUMBER or SERIAL NUMBER or an equivalent 
symbol, as appropriate; 
(g) the UDI carrier as referred to in Article 24 and Part C of Annex 
VI; 
(h) an unambiguous indication of the time limit for using the device 
safely, without degradation of performance, expressed at least in 
terms of year and month and, where relevant, the day, in that 
order; 
(i) where there is no indication of the date until when it may be used 
safely, the date of manufacture. This date of manufacture may be 
included as part of the lot number or serial number, provided the 
date is clearly identifiable; 
(a) the name or trade name of the device; 
(b) the details strictly necessary for a user to identify the device and, 
where it is not obvious for the user, the intended purpose of the 
device; 
(c) the name, registered trade name or registered trade mark of the 
manufacturer and the address of its registered place of business; 
(d) if the manufacturer has its registered place of business outside the 
United Kingdom, the name and address of the person placing the 
device on the market; 
(e) an indication that the device is an in vitro diagnostic medical 
device, or if the device is a ‘device for performance study’, an 
indication of that fact; 
(f) the lot number or the serial number of the device preceded by the 
words LOT NUMBER or SERIAL NUMBER or an equivalent 
symbol, as appropriate; 
(g) the UDI carrier as referred to in regulation 157 and Part C of 
Schedule 22; 
(h) an unambiguous indication of the time limit for using the device 
safely, without degradation of performance, expressed at least in 
terms of year and month and, where relevant, the day, in that 
order; 
(i) where there is no indication of the date until when it may be used 
safely, the date of manufacture and this date of manufacture may 
be included as part of the lot number or serial number, provided 
the date is clearly identifiable; 
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(j) where relevant, an indication of the net quantity of contents, 
expressed in terms of weight or volume, numerical count, or any 
combination of thereof, or other terms which accurately reflect the 
contents of the package; 
(k) an indication of any special storage and/or handling condition that 
applies; 
(l) where appropriate, an indication of the sterile state of the device 
and the sterilisation method, or a statement indicating any special 
microbial state or state of cleanliness; 
(m) warnings or precautions to be taken that need to be brought to 
the immediate attention of the user of the device or to any other 
person. This information may be kept to a minimum in which case 
more detailed information shall appear in the instructions for use, 
taking into account the intended users; 
(n) if the instructions for use are not provided in paper form in 
accordance with point (f) of Section 20.1, a reference to their 
accessibility (or availability), and where applicable the website 
address where they can be consulted; 
(o) where applicable, any particular operating instructions; 
(p) if the device is intended for single use, an indication of that fact. A 
manufacturer's indication of single use shall be consistent across 
the Union; 
(q) if the device is intended for self-testing or near-patient testing, an 
indication of that fact; 
(r) where rapid assays are not intended for self-testing or near-patient 
testing, the explicit exclusion hereof; 
Note how the 
UK 
legislation 
does not look 
outside of UK 
– see point (p) 
(j) where relevant, an indication of the net quantity of contents, 
expressed in terms of weight or volume, numerical count, or any 
combination of thereof, or other terms which accurately reflect the 
contents of the package; 
(k) an indication of any special storage or handling condition that 
applies; 
(l) where appropriate, an indication of the sterile state of the device 
and the sterilisation method, or a statement indicating any special 
microbial state or state of cleanliness; 
(m) warnings or precautions to be taken that need to be brought to 
the immediate attention of the user of the device or to any other 
person (this information may be kept to a minimum in which case 
more detailed information must appear in the instructions for use, 
taking into account the intended users); 
(n) if the instructions for use are not provided in paper form in 
accordance with paragraph 20(2)(f), a reference to their 
accessibility (or availability), and where applicable the website 
address where they can be consulted; 
(o) where applicable, any particular operating instructions; 
(p) if the device is intended for single use, an indication of that fact; 
(q) if the device is intended for self-testing or near-patient testing, an 
indication of that fact; 
(r) where rapid assays are not intended for self-testing or near-patient 
testing, the explicit exclusion thereof; 
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(s) where device kits include individual reagents and articles that are 
made available as separate devices, each of those devices shall 
comply with the labelling requirements contained in this Section 
and with the requirements of this Regulation; 
(t) the devices and separate components shall be identified, where 
applicable in terms of batches, to allow all appropriate action to 
detect any potential risk posed by the devices and detachable 
components. As far as practicable and appropriate, the 
information shall be set out on the device itself and/or, where 
appropriate, on the sales packaging; 
(u) the label for devices for self-testing shall bear the following 
particulars: 
(i) the type of specimen(s) required to perform the test (e.g. blood, 
urine or saliva); 
(ii) the need for additional materials for the test to function properly; 
(iii) contact details for further advice and assistance. 
 The name of devices for self-testing shall not reflect an intended 
purpose other than that specified by the manufacturer. 
 (4) The following additional labelling requirements apply to these 
specific devices— 
(a) for device kits which include individual reagents and articles 
that are made available as separate devices, the labelling 
requirements contained in sub- paragraph (3) and requirements of 
Part IX apply to each device; 
(b) devices and separate components must be identified, where 
applicable in terms of batches, to allow all appropriate action to 
detect any potential risk posed by the devices and detachable 
components and, as far as practicable and appropriate, the 
information must be set out on the device itself and, where 
appropriate, on the sales packaging; 
(c) the label for devices for self-testing must bear the following 
particulars— 
(i) the type of specimens required to perform the test (for 
example blood, urine or saliva); 
(ii) the need for additional materials for the test to function 
properly; 
(iii) contact details for further advice and assistance; 
(d) the name of devices for self-testing must not reflect an 
intended purpose other than that specified by the manufacturer. 
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20.3. Information on the packaging which maintains the sterile 
condition of a device (‘sterile packaging’): 
The following particulars shall appear on the sterile packaging: 
(a) an indication permitting the sterile packaging to be recognised as 
such, 
(b) a declaration that the device is in a sterile condition, 
(c) the method of sterilisation, 
(d) the name and address of the manufacturer, 
(e) a description of the device, 
(f) the month and year of manufacture, 
(g) an unambiguous indication of the time limit for using the device 
safely, expressed at least in terms of year and month and, where 
relevant, the day, in that order, 
(h) an instruction to check the instructions for use for what to do if 
the sterile packaging is damaged or unintentionally opened before 
use. 
 Information on the packaging which maintains the sterile condition of 
a device (‘sterile packaging’) 
(5) The following particulars must appear on the sterile packaging— 
(a) an indication permitting the sterile packaging to be recognised as 
such; 
(b) a declaration that the device is in a sterile condition; 
(c) the method of sterilisation; 
(d) the name and address of the manufacturer; 
(e) description of the device; 
(f) the month and year of manufacture; 
(g) an unambiguous indication of the time limit for using the device 
safely, expressed at least in terms of year and month and, where 
relevant, the day, in that order. 
20.4. Information in the instructions for use 
20.4.1. The instructions for use shall contain all of the following 
particulars: 
(a) the name or trade name of the device; 
(b) the details strictly necessary for the user to uniquely identify the 
device; 
(c) the device's intended purpose: 
(i) what is detected and/or measured; 
 Information in the instructions for use 
(6) The instructions for use must contain all of the following 
particulars— 
(a) the name or trade name of the device; 
(b) the details strictly necessary for the user to uniquely identify the 
device; 
(c) the device’s intended purpose in terms of— 
(i) what is detected or measured; 
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(ii) its function (e.g. screening, monitoring, diagnosis or aid to 
diagnosis, prognosis, prediction, companion diagnostic); 
(iii) the specific information that is intended to be provided in the 
context of: 
— a physiological or pathological state; 
— congenital physical or mental impairments; 
— the predisposition to a medical condition or a disease; 
— the determination of the safety and compatibility with potential 
recipients; 
— the prediction of treatment response or reactions; 
— the definition or monitoring of therapeutic measures; 
(iv) whether it is automated or not; 
(v) whether it is qualitative, semi-quantitative or quantitative; 
(vi) the type of specimen(s) required; 
(vii) where applicable, the testing population; and 
(viii) for companion diagnostics, the International Non-proprietary 
Name (INN) of the associated medicinal product for which it is a 
companion test. 
(d) an indication that the device is an in vitro diagnostic medical 
device, or, if the device is a ‘device for performance study’, an 
indication of that fact; 
(ii) its function (for example screening, monitoring, diagnosis or aid 
to diagnosis, prognosis, prediction, companion diagnostic); 
(iii) the specific information that is intended to be provided in the 
context of— (aa) a physiological or pathological state; 
(bb) congenital physical or mental impairments; 
(cc) the predisposition to a medical condition or a disease; 
(dd) the  determination  of  the  safety  and  compatibility  with  
potential recipients; 
(ee) the prediction of treatment response or reactions; 
(ff) the definition or monitoring of therapeutic measures; 
(iv) whether it is automated or not; 
(v) whether it is qualitative, semi-quantitative or quantitative; 
(vi) the type of specimens required; 
(vii) where applicable, the testing population; 
(viii) for companion diagnostics, the International Non-proprietary 
Name (INN) of the associated medicinal product for which it is a 
companion test; 
(d) an indication that the device is an in vitro diagnostic medical 
device, or, if the device is a ‘device for performance study’, an 
indication of that fact; 
(e) the intended user, as appropriate (e.g. self-testing, near patient and 
laboratory professional use, healthcare professionals); 
(f) the test principle; 
(g) a description of the calibrators and controls and any limitation 
upon their use (e.g. suitable for a dedicated instrument only); 
(h) a description of the reagents and any limitation upon their use 
(e.g. suitable for a dedicated instrument only) and the composition 
 (e) the  intended  user,  as  appropriate  (for  example  self-testing,  
near  patient  and laboratory professional use, healthcare 
professionals); 
(f) the test principle; 
(g) a description of the calibrators and controls and any limitation 
upon their use (for example suitable for a dedicated instrument 
only); 
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of the reagent product by nature and amount or concentration of 
the active ingredient(s) of the reagent(s) or kit as well as a 
statement, where appropriate, that the device contains other 
ingredients which might influence the measurement; 
(i) a list of materials provided and a list of special materials required 
but not provided; 
(j) for devices intended for use in combination with or installed with 
or connected to other devices and/or general purpose equipment: 
— information to identify such devices or equipment, in order to 
obtain a validated and safe combination, including key 
performance characteristics, and/or 
— information on any known restrictions to combinations of devices 
and equipment. 
(k) an indication of any special storage (e.g. temperature, light, 
humidity, etc.) and/or handling conditions which apply; 
(l) in-use stability which may include the storage conditions, and 
shelf life following the first opening of the primary container, 
together with the storage conditions and stability of working 
solutions, where this is relevant; 
(h) a description of the reagents and any limitation upon their use  
(for  example suitable for a dedicated instrument only) and the 
composition of the  reagent product by nature and amount or 
concentration of the active ingredient of the reagent or kit as well 
as a statement, where appropriate, that the device contains other 
ingredients which might influence the measurement; 
(i) a list of materials provided and a list of special materials required 
but not provided; 
(j) for devices intended for use in combination with or installed with 
or connected to other devices or general purpose equipment— 
(i) information to identify such devices or equipment, in order to 
obtain a validated and safe combination, including key 
performance characteristics; 
(ii) information on any known restrictions to combinations of devices 
and equipment; 
(k) an indication of any special storage (for example temperature, 
light, humidity, etc.) or handling conditions which apply; 
(l) in-use stability which may include the storage conditions, and 
shelf life following the first opening of the primary container, 
together with the storage conditions and stability of working 
solutions, where this is relevant; 
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(m) if the device is supplied as sterile, an indication of its sterile 
state, the sterilisation method and instructions in the event of the 
sterile packaging being damaged before use; 
(n) information that allows the user to be informed of any warnings, 
precautions, measures to be taken and limitations of use regarding 
the device. That information shall cover, where appropriate: 
(i) warnings, precautions and/or measures to be taken in the event of 
malfunction of the device or its degradation as suggested by 
changes in its appearance that may affect performance, 
(ii) warnings, precautions and/or measures to be taken as regards the 
exposure to reasonably foreseeable external influences or 
environmental conditions, such as magnetic fields, external 
electrical and electromagnetic effects, electrostatic discharge, 
radiation associated with diagnostic or therapeutic procedures, 
pressure, humidity, or temperature, 
(iii) warnings, precautions and/or measures to be taken as regards 
the risks of interference posed by the reasonably foreseeable 
presence of the device during specific diagnostic investigations, 
evaluations, therapeutic treatment or other procedures such as 
electromagnetic interference emitted by the device affecting other 
equipment, 
(iv) precautions related to materials incorporated into the device 
that contain or consist of CMR substances, or endocrine 
disrupting substances or that could result in sensitisation or an 
allergic reaction by the patient or user, 
 (m) if the device is supplied as sterile, an indication of its sterile 
state, the sterilisation method and instructions in the event of the 
sterile packaging being damaged before use; 
(n) information that allows the user to be informed of any warnings, 
precautions, measures to be taken and limitations of use regarding 
the device, that information must, where appropriate, cover— 
(i) warnings, precautions or measures to be taken in the event of 
malfunction of the device or its degradation as suggested by 
changes in its appearance that may affect performance; 
(ii) warnings, precautions or measures to be taken as regards the 
exposure to reasonably foreseeable external influences or 
environmental conditions, such as magnetic fields, external 
electrical and electromagnetic effects, electrostatic discharge, 
radiation associated with diagnostic or therapeutic procedures, 
pressure, humidity, or temperature, 
(iii) warnings, precautions or measures to be taken as regards the 
risks of interference posed by the reasonably foreseeable presence 
of the device during specific diagnostic investigations, 
evaluations, therapeutic treatment or other procedures such as 
electromagnetic interference emitted by the device affecting other 
equipment; 
(iv) precautions related to materials incorporated into the device 
that contain or consist of CMR substances, or endocrine 
disrupting substances or that could result in sensitisation or an 
allergic reaction by the patient or user; 
(v) if the device is intended for single use, an indication of that fact; 
 
Page 302 of 513 
 
 
(v) if the device is intended for single use, an indication of that fact. A 
manufacturer's indication of single use shall be consistent across 
the Union, 
 
 
(vi) if the device is reusable, 
 information on the appropriate processes to allow reuse, including 
cleaning, disinfection, decontamination, packaging and, where 
appropriate, the validated method of re-sterilisation.  
Information shall be provided to identify when the device should no 
longer be reused, such as signs of material degradation or the 
maximum number of allowable reuses; 
(o) any warnings and/or precautions related to potentially infectious 
material that is included in the device; 
(p) where relevant, requirements for special facilities, such as a clean 
room environment, or special training, such as on radiation safety, 
or particular qualifications of the intended user; 
(q) conditions for collection, handling, and preparation of the 
specimen; 
(r) details of any preparatory treatment or handling of the device 
before it is ready for use, such as sterilisation, final assembly, 
calibration, etc., for the device to be used as intended by the 
manufacturer; 
(s) the information needed to verify whether the device is properly 
installed and is ready to perform safely and as intended by the 
manufacturer, together with, where relevant: 
 (vi) if the device is reusable— 
(aa) information on the appropriate processes to allow reuse, 
including cleaning, disinfection, decontamination, packaging and, 
where appropriate, the validated method of re-sterilisation, 
(bb)   information on when the device should no longer be used such 
as signs of material degradation or the maximum number of 
allowable reuses; 
(o) any warnings or precautions related to potentially infectious 
material that is included in the device; 
(p) where relevant, requirements for special facilities, such as a clean 
room environment, or special training, such as on radiation safety, 
or particular qualifications of the intended user; 
(q) conditions for collection, handling, and preparation of the 
specimen; 
(r) details of any preparatory treatment or handling of the device 
before it is ready for use, such as sterilisation, final assembly, 
calibration, etc., for the device to be used as intended by the 
manufacturer; 
(s) the information needed to verify whether the device is properly 
installed and is ready to perform safely and as intended by the 
manufacturer, together with, where relevant— 
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— details of the nature, and frequency, of preventive and regular 
maintenance, including cleaning and disinfection; 
— identification of any consumable components and how to replace 
them; 
— information on any necessary calibration to ensure that the device 
operates properly and safely during its intended lifetime; 
— methods for mitigating the risks encountered by persons involved 
in installing, calibrating or servicing devices. 
(t) where applicable, recommendations for quality control 
procedures; 
 
(i) details of the nature, and frequency, of preventive and regular 
maintenance, including cleaning and disinfection; 
(ii) identification of any consumable components and how to replace 
them; 
(iii) information on any necessary calibration to ensure that the 
device operates properly and safely during its intended lifetime; 
(iv) methods for mitigating the risks encountered by persons 
involved in installing, calibrating or servicing devices; 
(t) where applicable, recommendations for quality control 
procedures; 
(u) the metrological traceability of values assigned to calibrators and 
control materials, including identification of applied reference 
materials and/or reference measurement procedures of higher 
order and information regarding maximum (self-allowed) batch to 
batch variation provided with relevant figures and units of 
measure; 
(v) assay procedure including calculations and interpretation of 
results and where relevant if any confirmatory testing shall be 
considered; where applicable, the instructions for use shall be 
accompanied by information regarding batch to batch variation 
provided with relevant figures and units of measure; 
(w) analytical performance characteristics, such as analytical 
sensitivity, analytical specificity, trueness (bias), precision 
(repeatability and reproducibility), accuracy (resulting from 
trueness and precision), limits of detection and measurement 
range, (information needed for the control of known relevant 
 (u) the metrological traceability of values assigned to calibrators and 
control materials, including identification of applied reference 
materials or reference measurement procedures of higher order 
and information regarding maximum (self-allowed) batch to batch 
variation provided with relevant figures and units of measure; 
(v) assay procedure including calculations and interpretation of 
results and where relevant if any confirmatory testing is to be 
considered; 
(w) where applicable, the instructions for use shall be accompanied by 
information regarding batch to batch variation provided with 
relevant figures and units of measure; 
(x) analytical performance characteristics, such as analytical 
sensitivity, analytical specificity, trueness (bias), precision 
(repeatability and reproducibility), accuracy (resulting from 
trueness and precision), limits of detection and measurement 
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interferences, cross-reactions and limitations of the method), 
measuring range, linearity and information about the use of 
available reference measurement procedures and materials by the 
user; 
(x) clinical performance characteristics as defined in Section 9.1 of 
this Annex; 
(y) the mathematical approach upon which the calculation of the 
analytical result is made; 
 
range, (information needed for the control of known relevant 
interferences, cross- reactions and limitations of the method), 
measuring range, linearity and information about the use of 
available reference measurement procedures and materials by the 
user; 
(y) clinical performance characteristics as defined in paragraph 9(1) 
of this Schedule; 
(z) the mathematical approach upon which the calculation of the 
analytical result is made; 
(z) where relevant, clinical performance characteristics, such as 
threshold value, diagnostic sensitivity and diagnostic specificity, 
positive and negative predictive value;  
(aa) where relevant, reference intervals in normal and affected 
populations; 
(ab) information on interfering substances or limitations (e.g. visual 
evidence of hyperlipidaemia or haemolysis, age of specimen) that 
may affect the performance of the device; 
(ac) warnings or precautions to be taken in order to facilitate the safe 
disposal of the device, its accessories, and the consumables used 
with it, if any. This information shall cover, where appropriate: 
(i) infection or microbial hazards, such as consumables contaminated 
with potentially infectious substances of human origin; 
(ii) environmental hazards such as batteries or materials that emit 
potentially hazardous levels of radiation); 
(iii) physical hazards such as explosion. 
 (aa) where relevant, clinical performance characteristics, such as 
threshold value, diagnostic sensitivity and diagnostic specificity, 
positive and negative predictive value; 
(bb) where relevant, reference intervals in normal and affected 
populations; 
(cc) information on interfering substances or limitations (for example 
visual evidence of hyperlipidaemia or haemolysis, age of 
specimen) that may affect the performance of the device; 
(dd) warnings or precautions to be taken in order to facilitate the safe 
disposal of the device, its accessories, and the consumables used 
with it, if any which, where appropriate, must cover— 
(i) infection  or  microbial  hazards,  such  as  consumables  
contaminated  with potentially infectious substances of human 
origin; 
(ii) environmental  hazards  such  as  batteries  or  materials that emit 
potentially hazardous levels of radiation); 
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(ad) the name, registered trade name or registered trade mark of 
the manufacturer and the address of its registered place of 
business at which he can be contacted and its location be 
established, together with a telephone number and/or fax number 
and/or website address to obtain technical assistance; 
(ae) date of issue of the instructions for use or, if they have been 
revised, date of issue and identifier of the latest revision of the 
instructions for use, with a clear indication of the introduced 
modifications; 
(af) a notice to the user that any serious incident that has occurred 
in relation to the device shall be reported to the manufacturer and 
the competent authority of the Member State in which the user 
and/or the patient is established; 
(iii) physical hazards such as explosion; 
(ee) the name, registered trade name or registered trade mark of the 
manufacturer and the address of their registered place of business 
at which they can be contacted and their location be established, 
together with a telephone number or fax number or website 
address to obtain technical assistance; 
(ff) date of issue of the instructions for use or, if they have been 
revised, date of issue and identifier of the latest revision of the 
instructions for use, with a clear indication of the introduced 
modifications; 
(gg) a notice to the user that any serious incident that has occurred in 
relation to the device must be reported to the manufacturer and to 
the Secretary of State; 
 
 
 
(ag) where device kits include individual reagents and articles that 
may be made available as separate devices, each of these devices 
shall comply with the instructions for use requirements contained 
in this Section and with the requirements of this Regulation; 
 
(ah) for devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
minimum requirements concerning hardware, IT networks 
characteristics and IT security measures, including protection 
against unauthorised access, necessary to run the software as 
intended. 
EU 
legislation  
paragraphs 
20.4.1 (ag) 
and (ah) are 
noted in UK 
legislation 
point 20 – 7 
(a) and 20 – 7 
(b)  
(7) The following additional requirements relating to the instructions 
for use apply to these specific devices— 
 
(a) for device kits which include individual reagents and articles that 
may be made available as separate devices, each of these devices 
must comply with the instructions for use requirements contained 
in this sub-paragraph (6) and with the requirements of Part IX; 
 
(b) for devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
minimum requirements concerning hardware, IT networks 
characteristics and IT security measures, including protection 
against unauthorised access, necessary to run the software as 
intended. 
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20.4.2   In addition, 
 
 
 
 
   
 
 
the instructions for use for devices intended for self-testing shall 
comply with all of the following principles: 
(a) details of the test procedure shall be given, including any 
reagent preparation, specimen collection and/or preparation and 
information on how to run the test and interpret the results; 
(b) specific particulars may be omitted provided that the other 
information supplied by the manufacturer is sufficient to enable 
the user to use the device and to understand the result(s) 
produced by the device; 
(c) the device's intended purpose shall provide sufficient 
information to enable the user to understand the medical context 
and to allow the intended user to make a correct interpretation of 
the results; 
(d) the results shall be expressed and presented in a way that is 
readily understood by the intended user; 
(e) information  
UK legislation 
point 20 – 7 (a) 
and 20 – 7 (b) 
are noted in 
EU legislation  
paragraphs 
20.4.1 (ag) and 
(ah) 
(7) The following additional requirements relating to the instructions 
for use apply to these specific devices— 
(a) for device kits which include individual reagents and articles that 
may be made available as separate devices, each of these devices 
must comply with the instructions for use requirements contained 
in this sub-paragraph (6) and with the requirements of Part IX; 
(b) for devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
minimum requirements concerning hardware, IT networks 
characteristics and IT security measures, including protection 
against unauthorised access, necessary to run the software as 
intended. 
(c) the instructions for use for devices intended for self-testing must 
comply with all of the following principles— 
(i) details of the test procedure shall be given, including any reagent 
preparation, specimen collection or preparation and information 
on how to run the test and interpret the results; 
(ii) specific particulars may be omitted provided that the other 
information supplied by the manufacturer is sufficient to enable 
the user to use the device and to understand the results produced 
by the device; 
(iii) the device’s intended purpose must provide sufficient 
information to enable the user to understand the medical context 
and to allow the intended user to make a correct interpretation of 
the results; 
(iv) the results must be expressed and presented in a way that is 
readily understood by the intended user; 
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shall be provided with advice to the user on action to be taken (in 
case of positive, negative or indeterminate result), on the test 
limitations and on the possibility of false positive or false 
negative result. 
Information shall also be provided as to any factors that can affect 
the test result such as age, gender, menstruation, infection, 
exercise, fasting, diet or medication; 
(f) the information provided shall include a statement clearly 
directing that the user should not take any decision of medical 
relevance without first consulting the appropriate healthcare 
professional, information on disease effects and prevalence, and, 
where available, information specific to the Member State(s) 
where the device is placed on the market on where a user can 
obtain further advice such as national helplines, websites;  
(g) for devices intended for self-testing used for the monitoring of a 
previously diagnosed existing disease or condition, the 
information shall specify that the patient should only adapt the 
treatment if he has received the appropriate training to do so. 
(v) information— 
(aa)   must be provided with advice to the user on action to be taken 
(in case of positive, negative or indeterminate result), on the test 
limitations and on the possibility of false positive or false negative 
result; 
(bb) must also be provided as to any factors that can affect the test 
result such as age, gender, menstruation, infection, exercise, 
fasting, diet or medication; 
(vi) the information provided must include a statement clearly 
directing that the user should not take any decision of medical 
relevance without first consulting the appropriate healthcare 
professional, information on disease effects and prevalence, and, 
where available, information on where a user can obtain further 
advice such as helplines, websites; 
 
(d) for devices intended for self-testing used for the monitoring of a 
previously diagnosed existing disease or condition, the 
information must specify that the patient should only adapt the 
treatment if he has received the appropriate training to do so. 
(1)  Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of 
substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (OJ L 353, 
31.12.2008, p. 1). 
(2)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH) (OJ L 136, 29.5.2007, p. 3). 
(3)  Council Directive 80/181/EEC of 20 December 1979 on the approximation of the laws of the Member States relating to units of measurement and 
on the repeal of Directive 71/354/EEC (OJ L 39, 15.2.1980, p. 40).   
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Appendix C4 5 Comparison: Technical Documentation Requirements EU with UK  
 
In Vitro Diagnostic Devices. 
 
REGULATION (EU) 2017/746 OF THE EUROPEAN 
PARLIAMENT AND OF THE COUNCIL 
of 5 April 2017 on in vitro diagnostic medical devices and repealing 
Directive 98/79/EC and Commission Decision 2010/227/EU 
 2019 No. 791 
EXITING THE EUROPEAN UNION CONSUMER PROTECTION 
The Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 
Made - 1st April 2019 
Annex II  SCHEDULE 18 Regulation 1A 
TECHNICAL DOCUMENTATION  
The technical documentation and, if applicable, the summary thereof 
to be drawn up by the manufacturer shall be presented in a clear, 
organised, readily searchable and unambiguous manner and shall 
include in particular the elements listed in this Annex. 
 Technical documentation- in vitro diagnostic medical devices 
1. The technical documentation and, if applicable, the summary 
thereof to be drawn up by the manufacturer must be presented in a 
clear, organised, readily searchable and unambiguous manner and 
must include in particular the elements listed in this Schedule. 
1.Device description and specification, including variants and 
accessories 
 Device description and specification, including variants and 
accessories 
1.1.   Device description and specification 
 
 
(a) product or trade name and a general description of the device 
including its intended purpose and intended users;  
Device description and specification 
2.—(1) The description and specification of the device must contain 
the following— 
(a) product or trade name and a general description of the device 
including  its intended purpose and intended users; 
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(b) the Basic UDI-DI as referred to in Part C of Annex VI assigned 
by the manufacturer to the device in question, as soon as identification 
of this device becomes based on a UDI system, or otherwise a clear 
identification by means of product code, catalogue number or other 
unambiguous reference allowing traceability; 
(b) the Basic UDI-DI as referred to in Part C of Schedule 22 
assigned by the manufacturer to the device in question, as soon as 
identification of this device becomes based on a UDI system, or 
otherwise a clear identification by means of product code, catalogue 
number or other unambiguous reference allowing traceability; 
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(c) the intended purpose of the device which may include 
information on: 
(i) what is to be detected and/or measured; 
(ii) its function such as screening, monitoring, diagnosis or aid to 
diagnosis, prognosis, prediction, companion diagnostic; 
(iii) the specific disorder, condition or risk factor of interest that it 
is intended to detect, define or differentiate; 
(iv) whether it is automated or not; 
(v) whether it is qualitative, semi-quantitative or quantitative; 
(vi) the type of specimen(s) required; 
(vii) where applicable, the testing population; 
(viii) the intended user; 
(ix) in addition, for companion diagnostics, the relevant target 
population and the associated medicinal product(s). 
(d) the description of the principle of the assay method or the 
principles of operation of the instrument; 
(e) the rationale for the qualification of the product as a device; 
(f) the risk class of the device and the justification for the 
classification rule(s) applied in accordance with Annex VIII; 
 
 
(c) the intended purpose of the device which may include 
information on— 
(i) what is to be detected or measured; 
(ii) its  function  such  as  screening,  monitoring,  diagnosis  or  
aid  to  diagnosis, prognosis, prediction, companion diagnostic; 
(iii) the specific disorder, condition or risk factor of interest that it 
is intended to detect, define or differentiate; 
(iv) whether it is automated or not; 
(v) whether it is qualitative, semi-quantitative or quantitative; 
(vi) the type of specimen required; 
(vii) where applicable, the testing population; 
(viii) the intended user; 
(ix) in addition, for companion diagnostics, the relevant target 
population and the associated medicinal products; 
(d) the description of the principle of the assay method or the 
principles of operation of the instrument; 
(e) the rationale for the qualification of the product as a device; 
(f) the risk class of the device and the justification for the 
classification rules applied in accordance with Schedule 23; 
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(g) the description of the components and where appropriate, the 
description of the reactive ingredients of relevant components such as 
antibodies, antigens, nucleic acid primers; 
and where applicable: 
(h) the description of the specimen collection and transport materials 
provided with the device or descriptions of specifications 
recommended for use; 
(i) for instruments of automated assays: the description of the 
appropriate assay characteristics or dedicated assays; 
(j) for automated assays: a description of the appropriate 
instrumentation characteristics or dedicated instrumentation; 
 
(k) a description of any software to be used with the device; 
 
(l) a description or complete list of the various 
configurations/variants of the device that are intended to be made 
available on the market; 
(m) a description of the accessories for a device, other devices and 
other products that are not devices, which are intended to be used in 
combination with the device. 
 (g) the description of the components and where appropriate, the 
description of the reactive ingredients of relevant components such as 
antibodies, antigens, nucleic acid primers; 
 
(h) where applicable, the description of the specimen collection and 
transport materials provided with the device or descriptions of 
specifications recommended for use; 
(i) where applicable, for instruments of automated assays, the 
description of the appropriate assay characteristics or dedicated assays; 
(j) where applicable, for automated assays, a description of the 
appropriate instrumentation characteristics or dedicated 
instrumentation; 
k) where applicable, a description of any software to be used with the 
device; 
(l) where applicable, a description or complete list of the various 
configurations or variants of the device that are intended to be made 
available on the market; 
(m) where applicable, a description of the accessories for a device, 
other devices and other products that are not devices, which are 
intended to be used in combination with the device. 
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1.2.   Reference to previous and similar generations of the device 
 
(a) an overview of the previous generation or generations of the 
device produced by the manufacturer, where such devices exist; 
(b) an overview of identified similar devices available on the 
Union or international markets, where such devices exist. 
 Reference to previous and similar generations of the device 
(2) Where applicable the technical documentation must contain— 
(a) an overview of the previous generation or generations of the 
device produced by the manufacturer, where such devices exist; 
(b) an overview of identified similar devices available on 
international markets, where such devices exist. 
 
  
Page 313 of 513 
 
 
 
2.   INFORMATION TO BE SUPPLIED BY THE 
MANUFACTURER 
 Information to be supplied by the manufacturer 
A complete set of 
(a) the label or labels on the device and on its packaging, such as 
single unit packaging, sales packaging, transport packaging in the case 
of specific management conditions, in the languages accepted in the 
Member States where the device is envisaged to be sold; 
(b) the instructions for use in the languages accepted in the 
Member States where the device is envisaged to be sold. 
 
3. The manufacturer must supply a complete set of— 
(a) the label or labels on the device and on its packaging, such as 
single unit packaging, sales packaging, transport packaging in the case 
of specific management conditions, in English; 
 
(b) the instructions for use in English. 
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3.   DESIGN AND MANUFACTURING INFORMATION  Design and manufacturing information 
3.1.   Design information 
Information to allow the design stages applied to the device to be 
understood shall include: 
(a) a description of the critical ingredients of the device such as 
antibodies, antigens, enzymes and nucleic acid primers provided or 
recommended for use with the device; 
(b) for instruments, a description of major subsystems, analytical 
technology such as operating principles and control mechanisms, 
dedicated computer hardware and software; 
(c) for instruments and software, an overview of the entire system; 
(d) for software, a description of the data interpretation 
methodology, namely the algorithm; 
(e) for devices intended for self-testing or near-patient testing, a 
description of the design aspects that make them suitable for self-
testing or near-patient testing. 
 Design information 
4. - (1) Information to allow the design stages applied to the device to 
be understood must include— 
(a) a description of the critical ingredients of the device such as 
antibodies, antigens, enzymes and nucleic acid primers provided or 
recommended for use with the device; 
(b) for instruments, a description of major subsystems, analytical 
technology such as operating principles and control mechanisms, 
dedicated computer hardware and software; 
(c) for instruments and software, an overview of the entire system; 
(d) for software, a description of the data interpretation 
methodology, namely the algorithm; 
(e) for devices intended for self-testing or near-patient testing, a 
description of the design aspects that make them suitable for self-
testing or near-patient testing. 
3.2.   Manufacturing information 
 
(a) information to allow the manufacturing processes such as 
production, assembly, final product testing, and packaging of the 
finished device to be understood. More detailed information shall be 
provided for the audit of the quality management system or other 
applicable conformity assessment procedures; 
(b) identification of all sites, including suppliers and sub-
contractors, where manufacturing activities are performed. 
 Manufacturing information 
(2) Manufacturing information must include— 
(a) information to allow the manufacturing processes such as 
production, assembly, final product testing, and packaging of the 
finished device to be understood (more detailed information must be 
provided for the audit of the quality management system or other 
applicable conformity assessment procedures); 
(b) identification of all sites, including suppliers and sub-
contractors, where manufacturing activities are performed. 
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4.   GENERAL SAFETY AND PERFORMANCE REQUIREMENTS  General safety and performance requirements 
The documentation shall contain information for the demonstration of 
conformity with the general safety and performance requirements set 
out in Annex I that are applicable to the device taking into account its 
intended purpose, and shall include a justification, validation and 
verification of the solutions adopted to meet those requirements.  
 
The demonstration of conformity shall also include: 
(a) the general safety and performance requirements that apply to 
the device and an explanation as to why others do not apply; 
(b) the method or methods used to demonstrate conformity with 
each applicable general safety and performance requirement; 
(c) the harmonised standards, CS or other solutions applied; 
(d) the precise identity of the controlled documents offering 
evidence of conformity with each harmonised standard, CS or other 
method applied to demonstrate conformity with the general safety and 
performance requirements. 
The information referred to under this point shall incorporate a cross-
reference to the location of such evidence within the full technical 
documentation and, if applicable, the summary technical 
documentation. 
 
5 .—(1) The documentation must contain information for the 
demonstration of conformity with the general safety and performance 
requirements set out in Schedule 17 that are applicable to the device 
taking into account its intended purpose, and must include a 
justification, validation and verification of the solutions adopted to 
meet  those requirements. 
(2) The demonstration of conformity must also include— 
(a) the general safety and performance requirements that apply to the 
device and an explanation as to why others do not apply; 
(b) the method or methods used to demonstrate conformity with each  
applicable general safety and performance requirement; 
(c) the designated standards, CS or other solutions applied; 
(d) the precise identity of the controlled documents offering evidence 
of conformity with each designated standard, CS or other method 
applied to demonstrate conformity with the general safety and 
performance requirements. 
(e) the information referred to in paragraph (d) must incorporate a 
cross-reference to the location of such evidence within the full 
technical documentation and, if applicable, the summary technical 
documentation. 
CS – Common Specification 
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5.   BENFIT-RISK ANALYSIS AND RISK MANAGEMENT  Benefit-risk analysis and risk management 
 
The documentation shall contain information on: 
(a) the benefit-risk analysis referred to in Sections 1 and 8 of 
Annex I, and 
(b) the solutions adopted and the results of the risk management 
referred to in Section 3 of Annex I.  
6. The documentation must contain information on— 
(a) the benefit-risk analysis referred to in paragraphs 1 and 8 of 
Schedule 17, 
(b) the solutions adopted and the results of the risk management 
referred to in paragraph 3 of Schedule 17. 
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6.   PRODUCT VERIFICATION AND VALIDATION  Product verification and validation 
 
The documentation shall contain the results and critical analyses of all 
verifications and validation tests and/or studies undertaken to 
demonstrate conformity of the device with the requirements of this 
Regulation and in particular the applicable general safety and 
performance requirements. 
This includes: 
6.1.   Information on analytical performance of the device 
6.1.1.   Specimen type 
This Section shall describe the different specimen types that can be 
analysed, including their stability such as storage, where applicable 
specimen transport conditions and, with a view to time-critical 
analysis methods, information on the timeframe between taking the 
specimen and its analysis and storage conditions such as duration, 
temperature limits and freeze/thaw cycles. 
 
7. The documentation must contain the results and critical 
analyses of all verifications and validation tests or studies undertaken 
to demonstrate conformity of the device with the requirements Part IX 
and Schedules 17 to 28 and in particular the applicable general safety 
and performance requirements in Schedule 17. 
 
8.—(1) The documentation must include the information on the 
performance of the device listed in sub-paragraphs (2) and (3). 
(2) The specimen type which must describe the different specimen 
types that can be analysed, including their stability such as storage, 
where applicable specimen transport conditions and, with a view to 
time-critical analysis methods, information on the timeframe between 
taking the specimen and its analysis and storage conditions such as 
duration, temperature limits and freeze/thaw cycles; 
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6.1.2.   Analytical performance characteristics 
6.1.2.1.   Accuracy of measurement 
(a) Trueness of measurement 
This Section shall provide information on the trueness of the 
measurement procedure and summarise the data in sufficient detail to 
allow an assessment of the adequacy of the means selected to establish 
the trueness. Trueness measures apply to both quantitative and 
qualitative assays only when a certified reference material or certified 
reference method is available. 
(b) Precision of measurement 
This Section shall describe repeatability and reproducibility studies. 
 
6.1.2.2.   Analytical sensitivity 
This Section shall include information about the study design and 
results.  
It shall provide a description of specimen type and preparation 
including matrix, analyte levels, and how levels were established. 
The number of replicates tested at each concentration shall also be 
provided as well as a description of the calculation used to determine 
assay sensitivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
temperature limits and freeze/thaw cycles; 
(3) The accuracy of the measurement consisting of— 
 
(a) the trueness of the measurement which must provide information 
on the trueness of the measurement procedure and summarise the data 
in sufficient detail to allow an assessment of the adequacy of the 
means selected to establish the trueness whilst noting that trueness 
measures apply to both quantitative and qualitative assays only when a 
certified reference material or certified reference method is available; 
(b) the precision of the measurement which must describe the 
repeatability and reproducibility studies; 
 
(c) the analytical sensitivity which must include— 
 
(i) information about the study design and results; 
(ii) a description of specimen type and preparation including matrix, 
analyte levels, and how levels were established; 
(ii) the number of replicates tested at each concentration must also be 
provided as well as a description of the calculation used to determine 
assay sensitivity; 
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6.1.2.3.   Analytical specificity 
This Section shall describe interference and cross reactivity studies 
performed to determine the analytical specificity in the presence of 
other substances/agents in the specimen. 
Information shall be provided on the evaluation of potentially 
interfering and cross-reacting substances or agents on the assay, on the 
tested substance or agent type and its concentration, specimen type, 
analyte test concentration, and results. 
Interferents and cross-reacting substances or agents, which vary 
greatly depending on the assay type and design, could derive from 
exogenous or endogenous sources such as: 
(a) substances used for patient treatment such as medicinal 
products; 
(b) substances ingested by the patient such as alcohol, foods; 
(c) substances added during specimen preparation such as 
preservatives, stabilisers; 
(d) substances encountered in specific specimen types such as 
haemoglobin, lipids, bilirubin, proteins; 
(e) analytes of similar structure such as precursors, metabolites or 
medical conditions unrelated to the test condition including specimens 
negative for the assay but positive for a condition that can mimic the 
test condition. 
 (d) analytical specificity which must include— 
(i) a description of interference and cross reactivity studies performed 
to determine the analytical specificity in the presence of other 
substances/agents in the specimen; 
(ii) information on the evaluation of potentially interfering and cross-
reacting substances or agents on the assay, on the tested substance or 
agent type and its concentration, specimen type, analyte test 
concentration, and results; 
(iii) information on interferents and cross-reacting substances or 
agents, which vary greatly depending on the assay type and design and 
could derive from exogenous or endogenous sources such as— 
(aa) substances used for patient treatment such as medicinal products; 
(bb) substances ingested by the patient such as alcohol, foods; 
(cc) substances added during specimen preparation such as 
preservatives, stabilisers; 
(dd) substances encountered in specific specimen types such as 
haemoglobin, lipids, bilirubin, proteins; 
(ee) analytes of similar structure such as precursors, metabolites or 
medical conditions unrelated to the test condition including specimens 
negative for the assay but positive for a condition that can mimic the 
test condition; 
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6.1.2.4.   Metrological traceability of calibrator and control material 
values 
 
6.1.2.5.   Measuring range of the assay 
This Section shall include information 
 
 on the measuring range regardless of whether the measuring systems 
are linear or non-linear, including the limit of detection and describe 
information on how the range and detection limit were established. 
 
This information shall include a description of specimen type, number 
of specimens, number of replicates, and specimen preparation 
including information on the matrix, analyte levels and how levels 
were established. 
 
If applicable, a description of any high dose hook effect and the data 
supporting the mitigation such as dilution steps shall be added. 
 
6.1.2.6.   Definition of assay cut-off 
This Section shall provide a summary of analytical data with a 
description of the study design including methods for determining the 
assay cut-off, such as: 
 
(a) the population(s) studied: demographics, selection, inclusion 
and exclusion criteria, number of individuals included; 
 
(b) method or mode of characterisation of specimens; and 
 
 
 
(iv) the metrological traceability of calibrator and control material 
values; 
 
(v) the measuring range of the assay which must include 
information— 
 
(vi) on the measuring range regardless of whether the measuring 
systems are linear or non-linear, including the limit of detection and 
describe information on how the range and detection limit were 
established; 
 
(vii) including a description of specimen type, number of specimens, 
number of replicates, and specimen preparation including information 
on the matrix, analyte levels and how levels were established; 
 
(viii) applicable, a description of any high dose hook effect and the 
data supporting the mitigation such as dilution steps shall be added; 
 
(ix) a definition of the assay cut-off including— 
 
(x) a summary of analytical data with a description of the study design 
including methods for determining the assay cut-off, such as— 
 
(aa) the populations studied including demographics, selection, 
inclusion and exclusion criteria, number of individuals included; 
 
(bb) the method or mode of characterisation of specimens; 
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(c) statistical methods such as Receiver Operator Characteristic 
(ROC) to generate results and if applicable, define grey-
zone/equivocal zone. 
 
6.1.3.   The analytical performance report referred to in Annex XIII. 
(cc) statistical methods such as Receiver Operator Characteristic 
(ROC) to generate results and if applicable, define grey-
zone/equivocal zone; 
 
(xi) the analytical performance report referred to in Schedule 27. 
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6.2.   Information on clinical performance and clinical evidence. 
Performance Evaluation Report 
The documentation shall contain the performance evaluation report, 
which includes the reports on the scientific validity, the analytical and 
the clinical performance, as referred to in Annex XIII, together with an 
assessment of those reports. 
The clinical performance study documents referred to in Section 2 of 
Part A of Annex XIII shall be included and/or fully referenced in the 
technical documentation. 
 
9. The documentation— 
(a) must contain the performance evaluation report, which includes the 
reports on the scientific validity, the analytical and the clinical 
performance, as referred to in Schedule 27, together with an 
assessment of those reports; 
 
(b) must include, or fully reference, the clinical performance study 
documents referred to in paragraph 2 of Part A of Schedule 27. 
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6.3.   Stability (excluding specimen stability) 
This Section shall describe claimed shelf life, in use stability and 
shipping stability studies. 
6.3.1.   Claimed shelf-life 
This Section shall provide information on stability testing studies to 
support the shelf life that is claimed for the device.  
Testing shall be performed on at least three different lots manufactured 
under conditions that are essentially equivalent to routine production 
conditions. The three lots do not need to be consecutive.  
Accelerated studies or extrapolated data from real time data are 
acceptable for initial shelf life claims but shall be followed up with 
real time stability studies. 
Such detailed information shall include: 
 
(a) the study report including the protocol, number of lots, 
acceptance criteria and testing intervals; 
(b)  where accelerated studies have been performed in 
anticipation of the real time studies, the method used for accelerated 
studies shall be described; 
(c) the conclusions and claimed shelf life. 
 Shelf life, in-use stability and shipping stability studies 
10. The documentation must describe claimed shelf life, in use 
stability and shipping stability studies. 
11. For claimed shelf life the documentation must— 
(a) provide information on stability testing studies to support the shelf 
life that is claimed for the device; 
(b) confirm that testing has been performed on at least 3 different (but 
not necessarily consecutive) lots manufactured under conditions that 
are essentially equivalent to routine production conditions; 
(c) describe whether accelerated studies or extrapolated data from real 
time data are used for initial shelf life claims and that these studies will 
be followed up with real time stability studies; 
(d) include the detailed information in paragraphs (b) to (c) which 
must include— 
(i) the study report including the protocol, number of lots, acceptance 
criteria and testing intervals; 
(ii) where accelerated studies have been performed in anticipation of 
the real time studies, the method used for accelerated studies must be 
described; 
(iii) the conclusions and claimed shelf life. 
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6.3.2.   In-use stability 
This Section shall provide information on in-use stability studies for 
one lot reflecting actual routine use of the device, regardless of 
whether real or simulated. This may include open vial stability and/or, 
for automated instruments, on board stability. 
In the case of automated instrumentation, if calibration stability is 
claimed, supporting data shall be included. 
Such detailed information shall include: 
(a) the study report (including the protocol, acceptance criteria and 
testing intervals); 
(b) the conclusions and claimed in-use stability. 
 12. For in-use stability the documentation must— 
(a) provide information on in-use stability studies for one lot reflecting 
actual routine use of the device, regardless of whether real or 
simulated which may include open vial stability or, for automated 
instruments, on board stability; 
(b) provide supporting data in cases of automated instrumentation 
where calibration stability is claimed; 
(c) include— 
(i) the study report (including the protocol, acceptance criteria and 
testing intervals); 
(ii) the conclusions and claimed in-use stability. 
6.3.3.   Shipping stability 
This Section shall provide information on shipping stability studies for 
one lot of devices to evaluate the tolerance of devices to the 
anticipated shipping conditions. 
Shipping studies may be done under real and/or simulated conditions 
and shall include variable shipping conditions such as extreme heat 
and/or cold. 
Such information shall describe: 
(a) the study report (including the protocol, acceptance criteria); 
(b) the method used for simulated conditions; 
(c) the conclusion and recommended shipping conditions. 
 13. For shipping stability the documentation must— 
(a) provide information on shipping stability studies for one lot of 
devices to evaluate the tolerance of devices to the anticipated shipping 
conditions; 
(b) provide information on whether the shipping studies were done 
under real or simulated conditions and must include variable shipping 
conditions such as extreme heat and/or cold; 
(c) include— 
(i) the study report (including the protocol, acceptance criteria); 
(ii) the method used for simulated conditions; 
(iii) conclusion and recommended shipping conditions. 
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6.4.   Software verification and validation 
 
The documentation shall contain evidence of the validation of the 
software, as it is used in the finished device.  
Such information shall typically include the summary results of all 
verification, validation and testing performed in-house and applicable 
in an actual user environment prior to final release. 
It shall also address all of the different hardware configurations and, 
where applicable, operating systems identified in the labelling 
 
 
Software verification and validation 
14. The documentation must— 
(a) contain evidence of the validation of the software, as it is used 
in the finished device; 
(b) typically include the summary results of all verification, 
validation and testing performed in-house and applicable in an actual 
user environment prior to final release; 
(c) also address all of the different hardware configurations and, 
where applicable, operating systems identified in the labelling. 
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6.5.   Additional information required in specific cases 
 
 
(a) In the case of devices placed on the market in a sterile or 
defined microbiological condition, a description of the environmental 
conditions for the relevant manufacturing steps.  
In the case of devices placed on the market in a sterile condition, a 
description of the methods used, including the validation reports, with 
regard to packaging, sterilisation and maintenance of sterility. The 
validation report shall address bioburden testing, pyrogen testing and, 
if applicable, testing for sterilant residues. 
(b) In the case of devices containing tissues, cells and 
substances of animal, human or microbial origin, information on the 
origin of such material and on the conditions in which it was collected. 
(c) In the case of devices placed on the market with a 
measuring function, a description of the methods used in order to 
ensure the accuracy as given in the specifications. 
(d) If the device is to be connected to other equipment in order 
to operate as intended, a description of the resulting combination 
including proof that it conforms to the general safety and performance 
requirements set out in Annex I when connected to any such 
equipment having regard to the characteristics specified by the 
manufacturer. 
 
Additional information required in specific cases 
15. The additional information required in specific cases is as 
follows— 
(a) in the case of devices placed on the market in a sterile or 
defined microbiological condition, a description of the environmental 
conditions for the relevant manufacturing steps; 
(b) in the case of devices placed on the market in a sterile 
condition, a description of the methods used, including the validation 
reports, with regard to packaging, sterilisation and maintenance of 
sterility and the validation report must address bioburden testing, 
pyrogen testing and, if applicable, testing for sterilant residues; 
(c) in the case of devices containing tissues, cells and substances 
of animal, human or microbial origin, information on the origin of 
such material and on the conditions in which it was collected; 
(d) in the case of devices placed on the market with a measuring 
function, a description of the methods used in order to ensure the 
accuracy as given in the specifications; 
(e) if the device is to be connected to other equipment in order to 
operate as intended, a description of the resulting combination 
including proof that it conforms to the general safety and performance 
requirements set out in Schedule 17 when connected to any such 
equipment having regard to the characteristics specified by the 
manufacturer. 
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ANNEX III - TECHNICAL DOCUMENTATION ON POST-
MARKET SURVEILLANCE  
 SCHEDULE 19 Regulation 1A - Technical documentation on post-
market surveillance for in vitro diagnostic medical devices 
The technical documentation on post-market surveillance to be drawn 
up by the manufacturer in accordance with Articles 78 to 81 shall be 
presented in a clear, organised, readily searchable and unambiguous 
manner and shall include in particular the elements described in this 
Annex. 
 
1. The technical documentation on post-market surveillance to be 
drawn up by the manufacturer in accordance with regulations 186 to 
189 must be presented in a clear, organised, readily searchable and 
unambiguous manner and must include in particular the elements 
described in this Schedule. 
1.   The post-market surveillance plan drawn up in accordance with 
Article 79. 
The manufacturer shall prove in a post-market surveillance plan that it 
complies with the obligation referred to in Article 78. 
(a) The post-market surveillance plan shall address the collection and 
utilisation of available information, in particular: 
— information concerning serious incidents, including information 
from periodic safety update report (‘PSUR’), and field safety 
corrective actions, 
— records referring to non-serious incidents and data on any 
undesirable side-effects, 
— information from trend reporting, 
— relevant specialist or technical literature, databases and/or 
registers, 
— information, including feedbacks and complaints, provided by 
users, distributors and importers, and 
— publicly-available information about similar medical devices. 
2. In the post market surveillance plan drawn up in accordance with 
regulation 187 the manufacturer must prove that the plan complies 
with the obligation in regulation 186. 
 
3. The post-market surveillance plan must address the collection and 
utilisation of available information, in particular— 
(a) information concerning serious incidents, including information 
from periodic safety update report (‘PSUR’), and field safety 
corrective actions; 
(b) records referring to non-serious incidents and data on any 
undesirable side-effects, 
(c) information from trend reporting; 
(d) relevant specialist or technical literature, databases and/or registers; 
 
(e) information, including feedbacks and complaints, provided by 
users, distributors and importers; 
(f) publicly-available information about similar medical devices. 
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(b) The post-market surveillance plan shall cover at least: 
— a proactive and systematic process to collect any information 
referred to in point (a). The process shall allow a correct 
characterisation of the performance of the devices and shall also allow 
a comparison to be made between the device and similar products 
available on the market; 
— effective and appropriate methods and processes to assess the 
collected data; 
— suitable indicators and threshold values that shall be used in the 
continuous reassessment of the benefit-risk analysis and of the risk 
management as referred to in Section 3 of Annex I; 
— effective and appropriate methods and tools to investigate 
complaints and analyse market-related experience collected in the 
field; 
— methods and protocols to manage the events subject to the trend 
report as provided for in Article 83, including the methods and 
protocols to be used to establish any statistically significant increase in 
the frequency or severity of incidents as well as the observation 
period; 
— methods and protocols to communicate effectively with competent 
authorities, notified bodies, economic operators and users; 
— reference to procedures to fulfil the manufacturers obligations laid 
down in Articles 78, 79 and 81; 
— systematic procedures to identify and initiate appropriate measures 
including corrective actions; 
4. The post-market surveillance plan must cover at least— 
(a) a proactive and systematic process to collect any information 
referred to in paragraph 3 which must allow a correct characterisation 
of the performance of the devices and must also allow a comparison to 
be made between the device and similar products available on the 
market; 
(b) effective and appropriate methods and processes to assess the 
collected data; 
(c) suitable indicators and threshold values that must be used in the 
continuous reassessment of the benefit-risk analysis and of the risk 
management as referred to in paragraph 3 of Schedule 3; 
(d) effective and appropriate methods and tools to investigate 
complaints and analyse market-related experience collected in the 
field; 
(e) methods and protocols to manage the events subject to the trend 
report as provided for in regulation 191, including the methods and 
protocols to be used to establish any statistically significant increase in 
the frequency or severity of incidents as well as the observation 
period; 
(f) methods and protocols to communicate effectively with the 
Secretary of State, notified bodies, economic operators and users; 
(g) reference to procedures to fulfil the manufacturers obligations laid 
down in regulations 186, 187 and 189; 
(h) systematic procedures to identify and initiate appropriate measures 
including corrective actions; 
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— effective tools to trace and identify devices for which corrective 
actions might be necessary; and 
— a PMPF plan as referred to in Part B of Annex XIII, or a 
justification as to why a PMPF is not applicable. 
(i) effective tools to trace and identify devices for which corrective 
actions might be necessary; and 
(j) PMPF plan as referred to in Part B of Schedule 27 or a justification 
as to why a PMPF is not applicable. 
2.   The PSUR referred to in Article 81 and the post-market 
surveillance report referred to in Article 80. 
 5. The PSUR referred to in Article 81 and the post-market surveillance 
report referred to in Article 80. 
 
PSUR - Periodic Safety Update Report 
PMPF - Post-Market Performance Follow-up 
PMCF – Post Market clinical Follow-up 
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For Medical Devices 
 
Medical Device Regulation MDR REGULATION (EU) 2017/746 
Annex II and Annex III 
 2019 No. 791 Exiting the European Union Consumer Protection, The 
Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 
Schedule 4 and Schedule 5 of the act. 
TECHNICAL DOCUMENTATION  
The technical documentation and, if applicable, the summary thereof 
to be drawn up by the manufacturer shall be presented in a clear, 
organised, readily searchable and unambiguous manner and shall 
include in particular the elements listed in this Annex. (II)  
SCHEDULE 4 Regulation 1A Technical Documentation 
1. The technical documentation and, if applicable, the summary of that 
documentation drawn up by the manufacturer must be presented in 
clear, organised, readily searchable and unambiguous manner and 
must include the elements listed in this Schedule. (4) 
1. Device description and specification including, variants and 
accessories 
 Device description and specification including variants and accessories 
1.1.   Device description and specification 
 
 
(a) product or trade name and a general description of the device 
including its intended purpose and intended users; 
(b) the Basic UDI-DI as referred to in Part C of Annex VI assigned by 
the manufacturer to the device in question, as soon as identification of 
this device becomes based on a UDI system, or otherwise a clear 
identification by means of product code, catalogue number or other 
unambiguous reference allowing traceability; 
(c) the intended patient population and medical conditions to be 
diagnosed, treated and/or monitored and other considerations such as 
patient selection criteria, indications, contra-indications, warnings; 
(d) principles of operation of the device and its mode of action, 
scientifically demonstrated if necessary; 
 
 
 
 
 
 
 
Device description and specification 
2.—(1) The description and specification of a device must contain the 
following— 
(a) the product or trade name and a general description of the device 
including its intended purpose and intended users; 
(b) the Basic UDI-DI as referred to in Part C of Schedule 8 assigned 
by the manufacturer to the device in question, as soon as identification 
of this device becomes based on a UDI system, or otherwise a clear 
identification by means of product code, catalogue number or other 
unambiguous reference allowing traceability; 
(c) the intended patient population and medical conditions to be 
diagnosed, treated or monitored and other considerations such as 
patient selection criteria, indications, contra-indications, warnings; 
(d) principles of operation of the device and its mode of action, 
scientifically demonstrated if necessary; 
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(e) the rationale for the qualification of the product as a device; (e) the rationale for the qualification of the product as a device; 
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(f) the risk class of the device and the justification for the 
classification rule(s) applied in accordance with Annex VIII; 
(g) an explanation of any novel features; 
(h) a description of the accessories for a device, other devices and 
other products that are not devices, which are intended to be used in 
combination with it; 
(i) a description or complete list of the various 
configurations/variants of the device that are intended to be made 
available on the market; 
(j) a general description  
of the key functional elements, e.g. its parts/components (including 
software if appropriate), its formulation, its composition, its 
functionality and, where relevant, its qualitative and quantitative 
composition.  
Where appropriate, this shall include labelled pictorial representations 
(e.g. diagrams, photographs, and drawings), clearly indicating key 
parts/components, including sufficient explanation to understand the 
drawings and diagrams; 
(k) a description of the raw materials incorporated into key functional 
elements and those making either direct contact with the human body 
or indirect contact with the body, e.g., during extracorporeal 
circulation of body fluids; 
 
(f) the risk class of the device and the justification for the 
classification rules applied in accordance with Schedule 9; 
(g) an explanation of any novel features; 
(h) a description of the accessories for the device, other devices and 
other products that are not devices, which are intended to be used in 
combination with it; 
(i) a description or complete list of the various configurations or 
variants of the device that are intended to be made available on the 
market; 
(j) a general description— 
(i) of the key functional elements, for example its parts or 
components (including software if appropriate), its formulation, its 
composition, its functionality and, where relevant, its qualitative and 
quantitative composition; and 
(ii) which, where appropriate, must include labelled pictorial 
representations (for example diagrams, photographs, and drawings), 
clearly indicating key parts or components, including sufficient 
explanation to understand the drawings and diagrams; 
(k) a description of the raw materials incorporated into key functional 
elements and those making either direct contact with the human body 
or indirect contact with the body, for example during extracorporeal 
circulation of body fluids; 
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(l) technical specifications, such as features, dimensions and 
performance attributes, of the device and any variants/configurations 
and accessories that would typically appear in the product 
specification made available to the user, for example in brochures, 
catalogues and similar publications. 
 (l) technical specifications, such as features, dimensions and 
performance attributes, of the device and any variants or 
configurations and accessories that would typically appear in the 
product specification made available to the user, for example in 
brochures, catalogues and similar publications. 
1.2.   Reference to previous and similar generations of the device 
 
(a) an overview of the previous generation or generations of the 
device produced by the manufacturer, where such devices exist; 
(b) an overview of identified similar devices available on the Union 
or international markets, where such devices exist. 
 Reference to previous and similar generations of the device 
(2) Where applicable the technical documentation must contain— 
(a) an overview of the previous generation or generations of the 
device produced by the manufacturer, where such devices exist; 
(b) an overview of identified similar devices available on the 
international markets, where such devices exist. 
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2.   Information to be supplied by the manufacturer  Information to be supplied by the manufacturer 
A complete set of: 
- the label or labels on the device and on its packaging, such as 
single unit packaging, sales packaging, transport packaging in case of 
specific management conditions, in the languages accepted in the 
Member States where the device is envisaged to be sold; and 
- the instructions for use in the languages accepted in the Member 
States where the device is envisaged to be sold. 
 
3. The manufacturer must supply a complete set of— 
(a) the label or labels on the device and on its packaging, such as 
single unit packaging, sales packaging, transport packaging in case of 
specific management conditions in English; and 
(b) the instructions for use in English. 
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3.   DESIGN AND MANUFACTURING INFORMATION  Design and manufacturing information 
(a) information to allow the design stages applied to the device to be 
understood; 
(b) complete information and specifications, including the 
manufacturing processes and their validation, their adjuvants, the 
continuous monitoring and the final product testing. Data shall be fully 
included in the technical documentation; 
(c) identification of all sites, including suppliers and sub-contractors, 
where design and manufacturing activities are performed. 
. 
 
4. The following design and manufacturing information must be 
supplied— 
(a) information (including full data) to allow the design stages 
applied to the device to be understood; 
 
(b) complete information (including full data) and specifications, 
including the manufacturing processes and their validation, their 
adjuvants, the continuous monitoring and the final product testing. 
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4.   General safety and performance requirements  General safety and performance requirements 
The documentation shall contain information for the demonstration of 
conformity with the general safety and performance requirements set 
out in Annex I that are applicable to the device taking into account its 
intended purpose, and shall include a justification, validation and 
verification of the solutions adopted to meet those requirements. 
 
The demonstration of conformity shall include: 
 
(a) the general safety and performance requirements that apply to the 
device and an explanation as to why others do not apply; 
(b) the method or methods used to demonstrate conformity with each 
applicable general safety and performance requirement; 
(c) the harmonised standards, CS or other solutions applied; and 
(d) the precise identity of the controlled documents offering evidence 
of conformity with each harmonised standard, CS or other method 
applied to demonstrate conformity with the general safety and 
performance requirements.  
The information referred to under this point shall incorporate a cross-
reference to the location of such evidence within the full technical 
documentation and, if applicable, the summary technical 
documentation. 
 
5.—(1) The documentation must contain information for the 
demonstration of conformity with the general safety and performance 
requirements set out in Schedule 3 that are applicable to the device 
taking into account its intended purpose, and must include a 
justification, validation and verification of the solutions adopted to 
meet those requirements. 
(2) The demonstration of conformity in sub-paragraph (1) must 
include— 
(a) the general safety and performance requirements that apply to the 
device and an explanation as to why others do not apply; 
(b) the method or methods used to demonstrate conformity with each  
applicable general safety and performance requirement; 
(c) the standards or other solutions applied; 
(d) the precise identity of the controlled documents offering evidence 
of conformity with each standard, or other method applied to 
demonstrate conformity with the general safety and performance 
requirements; and 
(e) the information referred to paragraph (d) must incorporate a cross-
reference to the location of such evidence within the full technical 
documentation and, if applicable, the summary technical 
documentation. 
CS - common specifications 
 
5.   Benefit-risk analysis and risk management  Benefit-risk analysis and risk management 
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The documentation shall contain information on: 
(a) the benefit-risk analysis referred to in Sections 1 and 8 of Annex I, 
and 
(b) the solutions adopted and the results of the risk management 
referred to in Section 3 of Annex I. 
 
6. The technical documentation must contain information on— 
(a) the benefit-risk analysis referred to in paragraphs 1 and 8 of 
Schedule 3; 
(b) the solutions adopted and the results of the risk management 
referred to in paragraph 3 of Schedule 3. 
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6.   PRODUCT VERIFICATION AND VALIDATION  Product verification and validation 
The documentation shall contain the results and critical analyses of all 
verifications and validation tests and/or studies undertaken to 
demonstrate conformity of the device with the requirements of this 
Regulation and in particular the applicable general safety and 
performance requirements. 
 
6.1.   Pre-clinical and clinical data 
 
 
(a) results of tests, such as engineering, laboratory, simulated use and 
animal tests, and evaluation of published literature applicable to the 
device, taking into account its intended purpose, or to similar devices, 
regarding the pre-clinical safety of the device and its conformity with 
the specifications; 
(b) detailed information regarding test design, complete test or study 
protocols, methods of data analysis, in addition to data summaries and 
test conclusions regarding in particular: 
- the biocompatibility of the device including the identification of 
all materials in direct or indirect contact with the patient or user; 
- physical, chemical and microbiological characterisation; 
- electrical safety and electromagnetic compatibility; 
 
 
Product verification and validation 
7.—(1) The documentation must contain the results and critical 
analyses of all verifications and validation tests or studies undertaken 
to demonstrate conformity of the device with the requirements of Part 
VIII and in particular the applicable general safety and performance 
requirements. 
Pre-clinical and clinical data. 
(2) The documentation must contain the following pre-clinical and 
clinical data— 
(a) results of tests, such as engineering, laboratory, simulated use and 
animal tests, and evaluation of published literature applicable to the 
device, taking into account its intended purpose, or to similar devices, 
regarding the pre-clinical safety of the device and its conformity with 
the specifications; 
(b) detailed information regarding test design, complete test or study 
protocols, methods of data analysis, in addition to data summaries and 
test conclusions regarding in particular— 
(i) the biocompatibility of the device including the identification of all 
materials in direct or indirect contact with the patient or user; 
(ii) physical, chemical and microbiological characterisation; 
(iii) electrical safety and electromagnetic compatibility; 
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- software verification and validation  
(describing the software design and development process and evidence 
of the validation of the software, as used in the finished device.  
 
This information shall typically include the summary results of all 
verification, validation and testing performed both in-house and in a 
simulated or actual user environment prior to final release.  
It shall also address all of the different hardware configurations and, 
where applicable, operating systems identified in the information 
supplied by the manufacturer); 
- stability, including shelf life; and 
- performance and safety. 
Where applicable, conformity with the provisions of Directive 
2004/10/EC of the European Parliament and of the Council (1) shall 
be demonstrated. 
Where no new testing has been undertaken, the documentation shall 
incorporate a rationale for that decision. An example of such a 
rationale would be that biocompatibility testing on identical materials 
was conducted when those materials were incorporated in a previous 
version of the device that has been legally placed on the market or put 
into service; 
( 
 
 
 
 
 
 
 
 
(iv) software verification and validation which must— 
(aa) describe the software design and development process and 
provide evidence of the validation of the software, as used in the 
finished device; 
(bb) typically include the summary results of all verification, 
validation and testing performed both in-house and in a simulated or 
actual user environment prior to final release; and 
(cc) address all of the different hardware configurations and, where 
applicable, operating systems identified in the information supplied by 
the manufacturer; 
(v) stability, including shelf life; and 
(vi) performance and safety. 
(3) Where applicable, conformity with the Good Laboratory 
Practice Regulations 1999(a) must be demonstrated. 
 
(4) Where no new testing has been undertaken, the documentation 
must incorporate a rationale for that decision (for example, a rationale 
would be that biocompatibility testing on identical materials was 
conducted when those materials were incorporated in a previous 
version of the device that has been legally placed on the market or put 
into service). 
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c) the clinical evaluation report and its updates and the clinical 
evaluation plan referred to in Article 61(12) and Part A of Annex XIV; 
(d) the PMCF plan and PMCF evaluation report referred to in Part B 
of Annex XIV or a justification why a PMCF is not applicable. 
(5) The documentation must also include— 
(a) the clinical evaluation report and its updates and the clinical 
evaluation  plan referred to in regulation 102(14) and Part A of 
Schedule 14; 
(b) the PMCF plan and PMCF evaluation report referred to in Part 
B of Schedule 14 or a justification why a PMCF is not applicable. 
PMCF - POST-MARKET CLINICAL FOLLOW-UP 
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6.2.   Additional information required in specific cases 
 
 
(a) Where a device incorporates, as an integral part, a substance 
which, if used separately, may be considered to be a medicinal product 
within the meaning of point 2 of Article 1 of Directive 2001/83/EC, 
including a medicinal product derived from human blood or human 
plasma, as referred to in the first subparagraph of Article 1(8),  
a statement indicating this fact.  
In this case, the documentation shall identify the source of that 
substance and contain the data of the tests conducted to assess its 
safety, quality and usefulness, taking account of the intended purpose 
of the device. 
(b) Where a device is manufactured utilising tissues or cells of human 
or animal origin, or their derivatives, and is covered by this Regulation 
in accordance with points (f) and (g) of Article 1(6, and where a device 
incorporates, as an integral part, tissues or cells of human origin or 
their derivatives that have an action ancillary to that of the device and 
is covered by this Regulation in accordance with the first subparagraph 
of Article 1(10), 
a statement indicating this fact.  
In such a case, the documentation shall identify all materials of human 
or animal origin used and provide detailed information concerning the 
conformity with Sections 13.1. or 13.2., respectively, of Annex I. 
 
Additional information required in specific cases 
(6) The additional information specified is required as part of the 
technical documentation in the following cases— 
(a) where a device incorporates, as an integral part, a substance 
which, if used separately, may be considered to be a medicinal product 
within the meaning of regulation 2(1) of the Human Medicines 
Regulations 2012 including a medicinal product derived from human 
blood or human plasma, as referred to in regulation 68(8)— 
(i) a statement indicating this fact; and 
(ii) documentation sufficient to identify the source of that 
substance and contain the data of the tests conducted to assess its 
safety, quality and usefulness, taking account of the intended purpose 
of the device; 
(b) where a device is manufactured utilising tissues or cells of 
human or animal origin, or their derivatives, and is covered by Part 
VIII in accordance with sub-paragraphs (g) and (h) of regulation 68(6), 
and where a device incorporates, as an integral part, tissues or cells of 
human origin or their derivatives that have an action ancillary to that 
of the device and is covered by Part VIII in accordance with regulation 
68(14), 
(i) a statement indicating this fact; and 
(ii) documentation sufficient to identify all materials of human or 
animal origin used and provide detailed information concerning the 
conformity with sub- paragraphs (1) and (2) of paragraph 13 of 
Schedule 3; 
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(c) In the case of devices that are composed of substances or 
combinations of substances that are intended to be introduced into the 
human body and that are absorbed by or locally dispersed in the 
human body, detailed information, including test design, complete test 
or study protocols, methods of data analysis, and data summaries and 
test conclusions, regarding studies in relation to: 
- absorption, distribution, metabolism and excretion; 
- possible interactions of those substances, or of their products of 
metabolism in the human body, with other devices, medicinal products 
or other substances, considering the target population, and its 
associated medical conditions; 
- local tolerance; and 
- toxicity, including single-dose toxicity, repeat-dose toxicity, 
genotoxicity, carcinogenicity and reproductive and developmental 
toxicity, as applicable depending on the level and nature of exposure to 
the device. 
In the absence of such studies, a justification shall be provided. 
(d) In the case of devices containing CMR or endocrine-disrupting 
substances referred to in Section 10.4.1 of Annex I, the justification 
referred to in Section 10.4.2 of that Annex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) in the case of devices that are composed of substances or 
combinations of substances that are intended to be introduced into the 
human body and that are absorbed by or locally dispersed in the 
human body, detailed information, including test design, complete test 
or study protocols, methods of data analysis, and data summaries and 
test conclusions, regarding studies in relation to— 
(i) absorption, distribution, metabolism and excretion; 
(ii) possible interactions of those substances, or of their products of 
metabolism in the human body, with other devices, medicinal products 
or other substances, considering the target population, and its 
associated medical conditions; 
(iii) local tolerance; 
(iv) toxicity, including single-dose toxicity, repeat-dose toxicity, 
genotoxicity, carcinogenicity and reproductive and developmental 
toxicity, as applicable depending on the level and nature of exposure to 
the device and in the absence of such studies, a justification shall be 
provided; 
(d) in the case of devices containing CMR or endocrine-disrupting 
substances referred to in paragraph 10(7) of Schedule 3, the 
justification referred to in paragraph 10(9) of that Schedule; 
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(e) In the case of devices placed on the market in a sterile or defined 
microbiological condition, a description of the environmental 
conditions for the relevant manufacturing steps.  
In the case of devices placed on the market in a sterile condition,  
a description of the methods used,  
including the validation reports, with respect to packaging, sterilisation 
and maintenance of sterility. The validation report shall address 
bioburden testing, pyrogen testing and, if applicable, testing for 
sterilant residues. 
(f) In the case of devices placed on the market with a measuring 
function, a description of the methods used in order to ensure the 
accuracy as given in the specifications. 
(g) If the device is to be connected to other device(s) in order to 
operate as intended, a description of this combination/configuration 
including proof that it conforms to the general safety and performance 
requirements when connected to any such device(s) having regard to 
the characteristics specified by the manufacturer. 
 
(e) in the case of devices placed on the market in a sterile or 
defined microbiological condition, a description of the environmental 
conditions for the relevant manufacturing steps; 
(f) in the case of devices placed on the market in a sterile 
condition— 
(i) a description of the methods used; and 
(ii) validation reports, with respect to packaging, sterilisation and 
maintenance of sterility which must address bioburden testing, 
pyrogen testing and, if applicable, testing for sterilant residues; 
(g) in the case of devices placed on the market with a measuring 
function, a description of the methods used in order to ensure the 
accuracy as given in the specifications; 
(h) if the device is to be connected to other devices in order to 
operate as intended, a description of this combination or configuration 
including proof that it conforms to the general safety and performance 
requirements when connected to any such devices having regard to the 
characteristics specified by the manufacturer. 
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ANNEX III - Technical documentation on post-market surveillance  SCHEDULE 5 Regulation 1A - Technical documentation on post-
market surveillance 
The technical documentation on post-market surveillance to be drawn 
up by the manufacturer in accordance with Articles 83 to 86 shall be 
presented in a clear, organised, readily searchable and unambiguous 
manner and shall include in particular the elements described in this 
Annex. 
1.1.   The post-market surveillance plan drawn up in accordance with 
Article 84.  
The manufacturer shall prove in a post-market surveillance plan that it 
complies with the obligation referred to in Article 83. 
(a) The post-market surveillance plan shall address the collection and 
utilization of available information, in particular: 
- information concerning serious incidents, including information 
from PSURs, and field safety corrective actions; 
- records referring to non-serious incidents and data on any 
undesirable side-effects; 
- information from trend reporting; 
- relevant specialist or technical literature, databases and/or registers; 
- information, including feedbacks and complaints, provided by users, 
distributors and importers; and 
- publicly available information about similar medical devices. 
This is not 
present in the 
UK 
legislation.
 
1.—(1) The technical documentation on post-market surveillance 
drawn up by the manufacturer in accordance with regulations 121 to 
123 must be presented in a clear, organised, readily searchable and 
unambiguous manner and must include in particular the elements 
described in sub-paragraphs (2) to (4) this Schedule. 
(2) In the post-market surveillance plan drawn up in accordance with 
regulation 122, the manufacturer must prove that the requirements of 
regulation 121 have been met. 
(3) The post-market surveillance plan must— 
(a) address the collection and utilization of available information, in 
particular— 
(i) information concerning serious incidents, including information 
from PSURs, and field safety corrective actions; 
(ii) records referring to non-serious incidents and data on any 
undesirable side- effects; 
(iii) information from trend reporting; 
 
(iv) information, including feedbacks and complaints, provided by 
users, distributors and importers; 
(v) publicly available information about similar medical devices; 
 
(b) The post-market surveillance plan shall cover at least:  (b) cover at least— 
Page 345 of 513 
 
 
- a proactive and systematic process to collect any information 
referred to in point (a). The process shall allow a correct 
characterisation of the performance of the devices and shall also allow 
a comparison to be made between the device and similar products 
available on the market; 
- effective and appropriate methods and processes to assess the 
collected data; 
- suitable indicators and threshold values that shall be used in the 
continuous reassessment of the benefit-risk analysis and of the risk 
management as referred to in Section 3 of Annex I; 
- effective and appropriate methods and tools to investigate 
complaints and analyse market-related experience collected in the 
field; 
- methods and protocols to manage the events subject to the trend 
report as provided for in Article 88, including the methods and 
protocols to be used to establish any statistically significant increase in 
the frequency or severity of incidents as well as the observation 
period; 
 
 
(i) a proactive and systematic process to collect any information 
referred to in sub-paragraph 1(2). The process must allow a correct 
characterisation of the performance of the devices and must also allow 
a comparison to be made between the device and similar products 
available on the market; 
(ii) effective and appropriate methods and processes to assess the 
collected data; 
(iii) suitable indicators and threshold values that must be used in 
the continuous reassessment of the benefit-risk analysis and of the risk 
management as referred to in paragraph 3 of Schedule 3; 
(iv) effective and appropriate methods and tools to investigate 
complaints and analyse market-related experience collected in the 
field; 
(v) methods and protocols to manage the events subject to the 
trend report as provided for in regulation 126, including the methods 
and protocols to be used to establish any statistically significant 
increase in the frequency or severity of incidents as well as the 
observation period; 
( 
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- methods and protocols to communicate effectively with competent 
authorities, notified bodies, economic operators and users; 
- reference to procedures to fulfil the manufacturers obligations laid 
down in Articles 83, 84 and 86; 
- systematic procedures to identify and initiate appropriate measures 
including corrective actions; 
- effective tools to trace and identify devices for which corrective 
actions might be necessary; and 
- a PMCF plan as referred to in Part B of Annex XIV, or a 
justification as to why a PMCF is not applicable. 
1.2.   The PSUR referred to in Article 86 and the post-market 
surveillance report referred to in Article 85. 
 
vi) methods and protocols to communicate effectively to the 
Secretary of State, economic operators and users; 
(vii) reference to procedures to fulfil the manufacturers obligations 
laid down in regulations 121, 122 and 124; 
(viii) systematic procedures to identify and initiate appropriate 
measures including corrective actions; 
(ix) effective tools to trace and identify devices for which 
corrective actions might be necessary; 
(x) a PMCF plan as referred to in Part B of Schedule 14, or a 
justification as to why a PMCF is not applicable. 
(4) The  PSUR  referred  to  in  regulation  124  and  the  post-
market  surveillance  report referred to in regulation 123. 
PSUR - Periodic Safety Update Report 
PMPF - Post-Market Performance Follow-up 
PMCF – Post Market Clinical Follow-up. 
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Appendix C4 6 Comparisons of the requirements of all three sets of legislation hazard and risk – IVDR with MDR with UK Law. 
 
The review of the differences between the risk management requirements of the MDR and the IVDR and then to compare these to the UK requirements 
This review will include determining if any definitions given or requirements relating to risk management are the same. If not highlight these so that any QA documentation relating to risk management reflects these differences.  
 
Note the comparison of the EU legislation was been carried out using the consolidated text of the regulations given at  
1. MDR with consolidated text from 2019 - https://eur-lex.europa.eu/eli/reg/2017/745/2017-05-05 and using the PDF version of the text. 
2. IVDR with consolidated text from 2019 https://eur-lex.europa.eu/eli/reg/2017/746/2017-05-05 and using the PDF version of the text. 
 
Both of these documents and also be found by following the links given in from the EU page  
https://ec.europa.eu/growth/sectors/medical-devices/new-regulations_en New regulations’ which gives summary details of the new regulations. 
 
The UK legislation used to compare the UK and EU legislation used the above EU legislation and the following UK legislation: 
https://www.legislation.gov.uk/uksi/2019/791/contents/made 
 
The main problem is the different way of referencing the requirements in the two EU regulations and the one UK statutory instrument..  
 
 
PSUR - Periodic Safety Update Report 
PMPF - Post-Market Performance Follow-up 
PMCF – Post Market clinical Follow-up 
Application of Parts II and III on and after 26th May 2020, the related transitional provisions and the revocation of Parts II and III on 26th May 2025 
4F.(7) The requirements of Part VIII in respect of post-market surveillance, market surveillance, vigilance and registration of economic operators and of devices apply in place of the corresponding requirements of Parts II and III 
(although regulations 7A and 21A may continue to apply, subject to paragraphs (3) and (4)). Need to look at this transition point in detail to figure out what it actually means, 
 
 
 
 
The columns headings are: 
 
IVDR Comparison 
IVDR to MDR 
MDR Comparison 
MDR TO UK 
UK 
 
If the IVDR and MDR are then same then the comparison MDR to UK is valid for both. 
IF the either the IVDR or MDR clauses are not shown then the comparison MDR to UK is for the relevant clause showing – IVDR or MDR.. 
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CHAPTER I 
INTRODUCTORY PROVISIONS 
 
 CHAPTER I 
SCOPE AND DEFINITIONS 
 PART VIII 
Scope and Definitions 
  Article 1 
Subject matter and scope 
2. This Regulation shall also apply, as from the date of application of 
common specifications adopted pursuant to Article 9, to the groups of 
products without an intended medical purpose that are listed in Annex 
XVI, taking into account the state of the art, and in particular existing 
harmonised standards for analogous devices with a medical purpose, 
based on similar technology. The common specifications for each of 
the groups of products listed in Annex XVI shall address, at least, 
application of risk management as set out in Annex I for the group of 
products in question and, where necessary, clinical evaluation 
regarding safety. 
  
CHAPTER II 
MAKING AVAILABLE ON THE MARKET AND PUTTING INTO 
SERVICE OF DEVICES, OBLIGATIONS OF ECONOMIC 
OPERATORS, CE MARKING, FREE MOVEMENT 
 CHAPTER II 
MAKING AVAILABLE ON THE MARKET AND PUTTING INTO 
SERVICE OF DEVICES, OBLIGATIONS OF ECONOMIC 
OPERATORS, REPROCESSING, CE MARKING, FREE 
MOVEMENT 
  
Article 8 
Use of harmonised standards 
1. Devices that are in conformity with the relevant harmonised 
standards, or the relevant parts of those standards, the references of 
which have been published in the Official Journal of the European 
Union, shall be presumed to be in conformity with the requirements of 
this Regulation covered by those standards or parts thereof. 
The first subparagraph shall also apply to system or process 
requirements to be fulfilled in accordance with this Regulation by 
economic operators or sponsors, including those relating to quality 
management systems, risk management, post-market surveillance 
systems, performance studies, clinical evidence or post-market 
performance follow-up (‘PMPF’). 
 Article 8 
Use of harmonised standards 
1. Devices that are in conformity with the relevant harmonised 
standards, or the relevant parts of those standards, the references of 
which have been published in the Official Journal of the European 
Union, shall be presumed to be in conformity with the requirements of 
this Regulation covered by those standards or parts thereof. 
The first subparagraph shall also apply to system or process 
requirements to be fulfilled in accordance with this Regulation by 
economic operators or sponsors, including those relating to quality 
management systems, risk management, post-market surveillance 
systems, clinical investigations, clinical evaluation or post-market 
clinical follow-up (‘PMCF’) 
 Use of designated standards 
74.—(1) Devices that are in conformity with the designated standards, 
or the relevant parts of those standards, are presumed to be in 
conformity with the requirements of this Part covered by those 
standards or relevant parts of those standards. 
 
(2) Paragraph (1) also applies to system or process requirements to be 
fulfilled in accordance with this Part by economic operators or 
sponsors, including those relating to quality management systems, risk 
management, post market surveillance systems, clinical investigations, 
clinical evaluation or post-market clinical follow up (‘PMCF’). 
 
Article 10 
General obligations of manufacturers 
2. Manufacturers shall establish, document, implement and maintain a 
system for risk management as described in Section 3 of Annex I. 
8……. 
The quality management system shall address at least the following 
aspects: 
(e) risk management as set out in Section 3 of Annex I; 
 Article 10 
General obligations of manufacturers 
2. Manufacturers shall establish, document, implement and maintain a 
system for risk management as described in Section 3 of Annex I. 
9………. 
The quality management system shall address at least the following 
aspects: 
(e) risk management as set out in in Section 3 of Annex I; 
 
 General obligations of manufacturers 
76. 
(2) Manufacturers must establish, document, implement and maintain 
a system for risk management as described in paragraph 3 of Schedule 
3. 
(14) The quality management system required by paragraph (13) 
must— 
(c) provide details of at least the following— 
(v) risk management as set out in paragraph 3 of Schedule 3; 
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N/A  Article 17 
Single-use devices and their reprocessing 
1. Reprocessing and further use of single-use devices may only take 
place where permitted by national law and only in accordance with 
this Article. 
2. Any natural or legal person who reprocesses a single-use device to 
make it suitable for further use within the Union shall be considered to 
be the manufacturer of the reprocessed device and shall assume the 
obligations incumbent on manufacturers laid down in this Regulation, 
which include obligations relating to the traceability of the reprocessed 
device in accordance with Chapter III of this Regulation.  
The reprocessor of the device shall be considered to be a producer for 
the purpose of Article 3(1) of Directive 85/374/EEC. 
3. By way of derogation from paragraph 2, as regards single-use 
devices that are reprocessed and used within a health institution, 
Member States may decide not to apply all of the rules relating to 
manufacturers' obligations laid down in this Regulation provided that 
they ensure that: 
(a) the safety and performance of the reprocessed device is equivalent 
to that of the original device and the requirements in points (a), (b), 
(d), (e), (f), (g) and (h) of Article 5(5) are complied with; 
(b) the reprocessing is performed in accordance with CS detailing the 
requirements concerning: 
— risk management, including the analysis of the construction and 
material, related properties of the device (reverse engineering) and 
procedures to detect changes in the design of the original device as 
well as of its planned application after reprocessing, 
— the validation of procedures for the entire process, including 
cleaning steps, 
— the product release and performance testing, 
— the quality management system, 
— the reporting of incidents involving devices that have been 
reprocessed, and 
— the traceability of reprocessed devices. 
Member States shall encourage, and may require, health institutions to 
provide information to patients on the use of reprocessed devices 
within the health institution and, where appropriate, any other relevant 
information on the reprocessed devices that patients are treated with. 
 Single-use devices and their reprocessing 
 
82.—(1) Reprocessing and further use of single-use devices may only 
take place in accordance with this Part. 
(2) Subject to paragraph (4), any person who reprocesses a single-use 
device to make it suitable for further use must be considered a 
manufacturer of the reprocessed device and must assume the 
obligations of a manufacturer in this Part. 
 
 
(3) A person who reprocesses a device must be considered to be the 
producer for the purposes of Part I of the 1987 Act. 
(4) Where single-use devices are reprocessed and used within a health 
institution, the Secretary of State may direct that not all the rules 
relating to manufacturers obligations laid down in this Part apply 
provided that the following conditions are met— 
 
(a) the safety and performance of the reprocessed device is equivalent 
to that of the original device and the requirements of regulation 71(5) 
are complied with; 
(b) the reprocessing is performed in accordance with the CS detailing 
requirements concerning— 
(i) risk management, including the analysis of the construction and 
material, related properties of the device (reverse engineering) and 
procedures to detect changes in the design of the original device as 
well as of its planned application after reprocessing; 
(ii) the validation of procedures for the entire process, including 
cleaning steps; 
(iii) the product release and performance testing; 
(iv) the quality management system; 
(v) the reporting of incidents involving devices that have been 
reprocessed; and 
(vi) the traceability of reprocessed devices. 
(5) The Secretary of State must encourage and may require health 
institutions to provide information to patients on the use of 
reprocessed devices within the health institution and, where 
appropriate, any other information on the reprocessed devices that 
patients are treated with. 
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  CHAPTER VI 
CLINICAL EVALUATION AND CLINICAL INVESTIGATIONS 
Article 61 
Clinical evaluation 
10. Without prejudice to paragraph 4, where the demonstration of 
conformity with general safety and performance requirements based 
on clinical data is not deemed appropriate, adequate justification for 
any such exception  
shall be given based on the results of the manufacturer's risk 
management and on consideration of the specifics of the interaction 
between the device and the human body, the clinical performance 
intended and the claims of the manufacturer. In such a case, the 
manufacturer shall duly substantiate in the technical documentation 
referred to in Annex II why it considers a demonstration of conformity 
with general safety and performance requirements that is based on the 
results of non-clinical testing methods alone, including performance 
evaluation, bench testing and pre-clinical evaluation, to be adequate. 
  
Clinical evaluation and clinical investigations 
Clinical evaluation 
 
(12) Without prejudice to paragraph (5), where the demonstration of 
conformity with general safety and performance requirements based 
on clinical data is not deemed appropriate, adequate justification for 
any such exception— 
(a) must be given based on the results of the manufacturer’s risk 
management and on consideration of the specifics of the interaction 
between the device and the human body, the clinical performance 
intended and the claims of the manufacturer; 
 
CHAPTER VII 
POST-MARKET SURVEILLANCE, VIGILANCE AND MARKET 
SURVEILLANCE 
Section 1 
Post – market surveillance 
Article 78 
Post-market surveillance system of the manufacturer 
3. Data gathered by the manufacturer's post-market surveillance 
system shall in particular be used: 
(a) to update the benefit-risk determination and to improve the risk 
management as referred to in Chapter I of Annex I; 
 CHAPTER VII 
POST-MARKET SURVEILLANCE, VIGILANCE AND MARKET 
SURVEILLANCE 
SECTION 1 
Post-market surveillance 
Article 83 
Post-market surveillance system of the manufacturer 
3. Data gathered by the manufacturer's post-market surveillance 
system shall in particular be used: 
(a) to update the benefit-risk determination and to improve the risk 
management as referred to in Chapter I of Annex I; 
  
POST-MARKET SURVEILLANCE, VIGILANCE AND MARKET 
SURVEILLANCE 
 
Post-market surveillance 
 
Post-market surveillance system of the manufacturer 
(3) The manufacturer must ensure that— 
(a) data gathered by the manufacturer’s post-market surveillance 
system is used in particular— 
(i) to update the benefit-risk determination and to improve the risk 
management as referred to in Part 1 of Schedule 3; 
Section 3 
Market surveillance 
Article 88 
Market surveillance activities 
1. The competent authorities shall perform appropriate checks on the 
conformity characteristics and performance of devices including, 
where appropriate, a review of documentation and physical or 
laboratory checks on the basis of adequate samples. The competent 
authorities shall, in particular, take account of established principles 
regarding risk assessment and risk management, vigilance data and 
complaints. 
 SECTION 3 
Market surveillance 
Article 93 
Market surveillance activities 
1. The competent authorities shall perform appropriate checks on the 
conformity characteristics and performance of devices including, 
where appropriate, a review of documentation and physical or 
laboratory checks on the basis of adequate samples. The competent 
authorities shall, in particular, take account of established principles 
regarding risk assessment and risk management, vigilance data and 
complaints. 
 Market surveillance 
Market surveillance activities 
130. 
—(1) The Secretary of State must— 
(b) take account of established principles regarding risk assessment 
and risk management, vigilance data and complaints. 
 
ANNEX I 
GENERAL SAFETY AND PERFORMANCE REQUIREMENTS 
In Vitro Diagnostic Devices. 
 ANNEX I 
GENERAL SAFETY AND PERFORMANCE REQUIREMENTS 
Medical Devices 
 SCHEDULE 3 Regulation 1A 
General safety and performance requirements for general medical 
Devices 
CHAPTER I 
GENERAL REQUIREMENTS 
 CHAPTER I 
GENERAL REQUIREMENTS 
 PART 1 
General requirements 
1. Devices shall  
achieve the performance intended by their manufacturer  
and shall be designed and manufactured in such a way that, during 
normal conditions of use, they are suitable for their intended purpose.  
 1. Devices 
shall achieve the performance intended by their manufacturer and  
shall be designed and manufactured in such a way that, during normal 
conditions of use, they are suitable for their intended purpose.  
 1. Devices must— 
(a) achieve the performance intended by their manufacturer; 
(b) be designed and manufactured in such a way that, during normal 
conditions of use, they are suitable for their intended purpose; 
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They shall be safe and effective  
and shall not compromise the clinical condition or the safety of 
patients, or the safety and health of users or, where applicable, other 
persons, provided that any risks which may be associated with their 
use constitute acceptable risks when weighed against the benefits to 
the patient and are compatible with a high level of protection of health 
and safety, taking into account the generally acknowledged state of the 
art. 
2. The requirement in this Annex to reduce risks as far as possible 
means the reduction of risks as far as possible without adversely 
affecting the benefit- risk ratio. 
3. Manufacturers shall establish, implement, document and maintain a 
risk management system. 
Risk management shall be understood as a continuous iterative process 
throughout the entire lifecycle of a device, requiring regular systematic 
updating. In carrying out risk management manufacturers shall: 
(a) establish and document a risk management plan for each device; 
(b) identify and analyse the known and foreseeable hazards associated 
with each device; 
(c) estimate and evaluate the risks associated with, and occurring 
during, the intended use and during reasonably foreseeable misuse; 
(d) eliminate or control the risks referred to in point (c) in accordance 
with the requirements of Section 4; 
(e) evaluate the impact of information from the production phase and, 
in particular, from the post-market surveillance system, on hazards and 
the frequency of occurrence thereof, on estimates of their associated 
risks, as well as on the overall risk, the benefit-risk ratio and risk 
acceptability; and 
(f) based on the evaluation of the impact of the information referred to 
in point (e), if necessary amend control measures in line with the 
requirements of Section 4. 
They shall be safe and effective and shall not compromise the clinical 
condition or the safety of patients, or the safety and health of users or, 
where applicable, other persons, provided that any risks which may be 
associated with their use constitute acceptable risks when weighed 
against the benefits to the patient and are compatible with a high level 
of protection of health and safety, taking into account the generally 
acknowledged state of the art. 
2. The requirement in this Annex to reduce risks as far as possible 
means the reduction of risks as far as possible without adversely 
affecting the benefit-risk ratio. 
3. Manufacturers shall establish, implement, document and maintain a 
risk management system. 
Risk management shall be understood as a continuous iterative process 
throughout the entire lifecycle of a device, requiring regular systematic 
updating. In carrying out risk management manufacturers shall: 
 
(a) establish and document a risk management plan for each device; 
(b) identify and analyse the known and foreseeable hazards associated 
with each device; 
(c) estimate and evaluate the risks associated with, and occurring 
during, the intended use and during reasonably foreseeable misuse; 
(d) eliminate or control the risks referred to in point (c) in accordance 
with the requirements of Section 4; 
(e) evaluate the impact of information from the production phase and, 
in particular, from the post-market surveillance system, on hazards and 
the frequency of occurrence thereof, on estimates of their associated 
risks, as well as on the overall risk, benefit-risk ratio and risk 
acceptability; and 
(f) based on the evaluation of the impact of the information referred to 
in point (e),  
if necessary amend control measures in line with the requirements of 
Section 4. 
(c) be safe and effective and not compromise the clinical condition or 
the safety of patients, or the safety and health of users or, where 
applicable, other persons, provided that any risks which may be 
associated with their use constitute acceptable risks when weighed 
against the benefits to the patient and are compatible with a high level 
of protection of health and safety, taking into account the generally 
acknowledged state of the art. 
2. The requirement in this Schedule to reduce risks as far as possible 
means the reduction of risks as far as possible without adversely 
affecting the benefit-risk ratio. 
3.—(1) Manufacturers must establish, implement, document and 
maintain a risk management system. 
(2) Risk management is to be understood as a continuous iterative 
process throughout the entire lifecycle of a device, which requires 
regular systematic updating and, in carrying out risk management, 
manufacturers must— 
(a) establish and document a risk management plan for each device; 
(b) identify and analyse the known and foreseeable hazards associated 
with each device; 
(c) estimate and evaluate the risks associated with, and occurring 
during, the intended use and during reasonably foreseeable misuse; 
(d) eliminate or control the risks referred to in sub-paragraph (c) in 
accordance with the requirements of paragraph 4; 
(e) evaluate the impact of information from the production phase and, 
in particular, from the post-market surveillance system, on hazards and 
the frequency of occurrence thereof, on estimates of their associated 
risks, as well as on the overall risk, benefit-risk ratio and risk 
acceptability; 
(f) based on the evaluation of the impact of the information referred to 
in paragraph 4 
(e), if necessary amend control measures in line with the requirements 
of paragraph 4. 
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4. Risk control measures adopted by manufacturers for the design and 
manufacture of the devices shall conform to safety principles, taking 
account of the generally acknowledged state of the art.  
To reduce risks, the manufacturers shall manage risks so that the 
residual risk associated with each hazard as well as the overall residual 
risk is judged acceptable.  
In selecting the most appropriate solutions, manufacturers shall, in the 
following order of priority: 
(a) eliminate or reduce risks as far as possible through safe design and 
manufacture; 
(b) where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated; and 
(c) provide information for safety (warnings/precautions/contra-
indications) and, where appropriate, training to users. 
Manufacturers shall inform users of any residual risks. 
5. In eliminating or reducing risks related to use error, the manufacturer 
shall: 
(a) reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended to be 
used (design for patient safety), and 
(b) give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
6. The characteristics and performance of a device shall not be adversely 
affected to such a degree that the health or safety of the patient or the 
user and, where applicable, of other persons are compromised during 
the lifetime of the device, as indicated by the manufacturer, when the 
device is subjected to the stresses which can occur during normal 
conditions of use and has been properly maintained in accordance with 
the manufacturer's instructions. 
 
 4. Risk control measures adopted by manufacturers for the design and 
manufacture of the devices shall conform to safety principles, taking 
account of the generally acknowledged state of the art.  
To reduce risks, Manufacturers shall manage risks so that the residual 
risk associated with each hazard as well as the overall residual risk is 
judged acceptable.  
In selecting the most appropriate solutions, manufacturers shall, in the 
following order of priority: 
(a) eliminate or reduce risks as far as possible through safe design and 
manufacture; 
(b) where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated; and 
(c) provide information for safety (warnings/precautions/contra-
indications) and, where appropriate, training to users. 
Manufacturers shall inform users of any residual risks. 
5. In eliminating or reducing risks related to use error, the 
manufacturer shall: 
(a) reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended to 
be used (design for patient safety), and 
(b) give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
6. The characteristics and performance of a device shall not be 
adversely affected to such a degree that the health or safety of the 
patient or the user and, where applicable, of other persons are 
compromised during the lifetime of the device, as indicated by the 
manufacturer, when the device is subjected to the stresses which can 
occur during normal conditions of use and has been properly 
maintained in accordance with the manufacturer's instructions. 
 4.—(1) Risk control measures adopted by manufacturers for the design 
and manufacture of the devices must conform to safety principles, 
taking account of the generallyacknowledged state of the art. 
(2) To reduce risks, manufacturers must manage risks so that the 
residual risk associated with each hazard as well as the overall residual 
risk is judged acceptable. 
(3) In selecting the most appropriate solutions, manufacturers must, in 
the following order of priority— 
(a) eliminate or reduce risks as far as possible through safe design and 
manufacture; 
(b) where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated; and 
(c) provide information for safety (warnings, precautions, contra-
indications) and, where appropriate, training to users; 
(d) inform users of any residual risks. 
5. In eliminating or reducing risks related to use error, the 
manufacturer must— 
(a) reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended to 
be used (design for patient safety); 
(b) give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
 6. The characteristics and performance of a device must not be 
adversely affected to such a degree that the health or safety of the 
patient or the user and, where applicable, of other persons are 
compromised during the lifetime of the device, as indicated by the 
manufacturer, when the device is subjected to the stresses which can 
occur during normal conditions of use and has been properly 
maintained in accordance with the manufacturer’s instructions. 
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7. Devices shall be designed, manufactured and packaged in such a way 
that their characteristics and performance during their intended use are 
not adversely affected during transport and storage, for example, 
through fluctuations of temperature and humidity, taking account of the 
instructions and information provided by the manufacturer. 
8. All known and foreseeable risks, and any undesirable effects shall 
be minimised and be acceptable when weighed against the evaluated 
potential benefits to the patients and/or the user arising from the 
intended performance of the device during normal conditions of use 
 7. Devices shall be designed, manufactured and packaged in such a 
way that their characteristics and performance during their intended 
use are not adversely affected during transport and storage, for 
example, through fluctuations of temperature and humidity, taking 
account of the instructions and information provided by the 
manufacturer. 
8. All known and foreseeable risks, and any undesirable side-effects, 
shall be minimised and be acceptable when weighed against the 
evaluated benefits to the patient and/or user arising from the achieved 
performance of the device during normal conditions of use. 
9. For the devices referred to in Annex XVI, the general safety 
requirements set out in Sections 1 and 8 shall be understood to mean 
that the device, when used under the conditions and for the purposes 
intended, does not present a risk at all or presents a risk that is no more 
than the maximum acceptable risk related to the product's use which is 
consistent with a high level of protection for the safety and health of 
persons. 
 7. Devices must be designed, manufactured and packaged in such a 
way that their characteristics and performance during their intended 
use are not adversely affected during transport and storage, for 
example, through fluctuations of temperature and humidity, taking 
account of the instructions and information provided by the 
manufacturer. 
8. All known and foreseeable risks, and any undesirable side-effects, 
must be minimized and be acceptable when weighed against the 
evaluated benefits to the patient or user arising from the achieved 
performance of the device during normal conditions of use. 
9. For the devices referred to in Schedule 16, the general safety 
requirements set out in paragraphs 1 and 8 must be understood to 
mean that the device, when used under the conditions and for the 
purposes intended, does not present a risk at all or presents a risk that 
is no more than the maximum acceptable risk related to the product’s 
use which is consistent with a high level of protection for the safety 
and health of persons. 
 
 
ANNEX I 
GENERAL SAFETY AND PERFORMANCE REQUIREMENTS 
In Vitro Diagnostic Devices. 
 ANNEX I 
GENERAL SAFETY AND PERFORMANCE REQUIREMENTS 
Medical Devices 
 SCHEDULE 3 Regulation 1A 
General safety and performance requirements for general medical 
Devices 
CHAPTER II 
REQUIREMENTS REGARDING PERFORMANCE, DESIGN AND 
MANUFACTURE 
 CHAPTER II 
REQUIREMENTS REGARDING DESIGN AND MANUFACTURE 
 PART 2 
Requirements regarding design and manufacture 
16. Electronic programmable systems — devices that incorporate 
electronic programmable systems and software that are devices in 
themselves 
16.2. For devices that incorporate software or for software that are 
devices in themselves, the software shall be developed and 
manufactured in accordance with the state of the art taking into 
account the principles of development life cycle, risk management, 
including information security, verification and validation. 
 17. Electronic programmable systems — devices that incorporate 
electronic programmable systems and software that are devices in 
themselves 
 
17.2. For devices that incorporate software or for software that are 
devices in themselves, the software shall be developed and 
manufactured in accordance with the state of the art taking into 
account the principles of development life cycle, risk management, 
including information security, verification and validation. 
 Electronic programmable systems — devices that incorporate 
electronic programmable systems and software that are devices in 
themselves 
17. 
(2) For devices that incorporate software or for software that are 
devices in themselves, the software must be developed and 
manufactured in accordance with the state of the art taking into 
account the principles of development life cycle, risk management, 
including information security, verification and validation. 
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There are requirements for single use devices in the IVDR but none 
comparable to the requirements of either MRD and UK requirements 
quoted here. 
 23.4. Information in the instructions for use 
The instructions for use shall contain all of the following particulars: 
 
(p) if the device bears an indication that it is for single use,  
information on known characteristics and technical factors known to 
the manufacturer that could pose a risk if the device were to be re-
used.  
This information shall be based on a specific section of the 
manufacturer's risk management documentation, where such 
characteristics and technical factors shall be addressed in detail. 
 If in accordance with point (d) of Section 23.1. no instructions for use 
are required, this information shall be made available to the user upon 
request; 
 PART 3 
Requirements regarding instructions for use Label and instructions for 
use Information in instructions for use 
23.  
(6) The instructions for use must contain all the following 
particulars— 
(p) if the device bears an indication that it is for single use— 
(i) information on known characteristics and technical factors known 
to the manufacturer that could pose a risk if the device were to be re-
used; 
(ii) the information must be based on a specific section of the 
manufacturer’s risk management documentation, where such 
characteristics and technical factors must be addressed in detail; 
(iii) if, in accordance with sub-paragraph (3)(d), no instructions for use 
are required, this information must be made available to the user upon 
request; 
 
 
ANNEX II 
TECHNICAL DOCUMENTATION 
 ANNEX II 
TECHNICAL DOCUMENTATION 
 SCHEDULE 4 Regulation 1A 
Device description and specification including variants and accessories 
Technical Documentation 
5. BENFIT-RISK ANALYSIS AND RISK MANAGEMENT 
The documentation shall contain information on: 
(a) the benefit-risk analysis referred to in Sections 1 and 8 of Annex I, 
and 
(b) the solutions adopted and the results of the risk management 
referred to in Section 3 of Annex I. 
 5. BENEFIT-RISK ANALYSIS AND RISK MANAGEMENT 
The documentation shall contain information on: 
(a) the benefit-risk analysis referred to in Sections 1 and 8 of Annex I, 
and 
(b) the solutions adopted and the results of the risk management 
referred to in Section 3 of Annex I. 
 Benefit-risk analysis and risk management 
6. The technical documentation must contain information on— 
(a) the benefit-risk analysis referred to in paragraphs 1 and 8 of 
Schedule 3; 
(b) the solutions adopted and the results of the risk management 
referred to in paragraph 3 of Schedule 3. 
 
ANNEX III 
TECHNICAL DOCUMENTATION ON POST-MARKET SURVEIL- 
LANCE 
(b) The post-market surveillance plan shall cover at least: 
— suitable indicators and threshold values that shall be used in the 
continuous reassessment of the benefit-risk analysis and of the risk 
management as referred to in Section 3 of Annex I; 
 ANNEX III 
TECHNICAL DOCUMENTATION ON POST-MARKET 
SURVEILLANCE 
(b) The post-market surveillance plan shall cover at least: 
— suitable indicators and threshold values that shall be used in the 
continuous reassessment of the benefit-risk analysis and of the risk 
management as referred to in Section 3 of Annex I; 
 SCHEDULE 5 Regulation 1A 
Technical documentation on post-market surveillance 
1. 
(3) The post-market surveillance plan must— 
(b) cover at least— 
(iii) suitable indicators and threshold values that must be used in the 
continuous reassessment of the benefit-risk analysis and of the risk 
management as referred to in paragraph 3 of Schedule 3; 
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These requirements given in EU IVD and MDR do not seem to be in the UK Legislation. 
 
ANNEX VII 
REQUIREMENTS TO BE MET BY NOTIFIED BODIES 
3. RESOURCE REQUIREMENTS 
3.2. Qualification criteria in relation to personnel 
3.2.5….. 
— appropriate knowledge and experience of risk management and 
related device standards and guidance documents; 
3.2.6….. 
— appropriate knowledge and experience of risk management and 
related device standards and guidance documents; 
4. PROCESS REQUIREMENTS 
4.5. Conformity assessment activities 
4.5.1. General…… 
— address the interface between the manufacturer's risk management 
process and its appraisal and analysis of the pre-clinical and clinical 
evaluation and to evaluate their relevance for the demonstration of 
conformity with the relevant requirements in Annex I, 
 
4.5.3. Product verification 
Assessment of the technical documentation 
— the allocation of appropriately qualified and authorised personnel for 
the examination of individual aspects such as use of the device, 
biocompatibility, clinical evaluation, risk management, and 
sterilisation, and…. 
 
 
 
4.5.4. Performance evaluation assessment ….. 
(c) the interface with the risk management process,…. 
…. The notified body shall ensure that the performance evaluation 
adequately addresses the relevant safety and performance requirements 
provided for in Annex I, that it is appropriately aligned with the risk 
management requirements and that it is conducted in accordance with 
Annex XIII and that it is appropriately reflected in the information 
provided relating to the device. 
 
 ANNEX VII 
REQUIREMENTS TO BE MET BY NOTIFIED BODIES 
3. RESOURCE REQUIREMENTS 
3.2. Qualification criteria in relation to personnel 
3.2.5….. 
— appropriate knowledge and experience of risk management and 
related device standards and guidance documents; 
3.2.6….. 
— appropriate knowledge and experience of risk management and 
related device standards and guidance documents; 
4. PROCESS REQUIREMENTS 
4.5. Conformity assessment activities 
4.5.1. General…… 
— address the interface between the manufacturer's risk management 
process and its appraisal and analysis of the pre-clinical and clinical 
evaluation and to evaluate their relevance for the demonstration of 
conformity with the relevant requirements in Annex I, 
4.5.3. Product verification 
Assessment of the technical documentation 
— the allocation of appropriately qualified and authorised personnel for 
the examination of individual aspects such as use of the device, 
biocompatibility, clinical evaluation, risk management, and 
sterilisation, and…. 
4.5.4. Pre-clinical evaluation assessment ….. 
(c) the interface with the risk management process, and ……… 
 
4.5.5. Clinical evaluation assessment …… 
— the interface with the risk management process, 
..........The notified body shall ensure that the clinical evaluation 
adequately addresses the relevant safety and performance requirements 
provided for in Annex I, that it is appropriately aligned with the risk 
management requirements, that it is conducted in accordance with 
Annex XIV and that it is appropriately reflected in the information 
provided relating to the device. 
  
 
 
4.8. Decisions and certifications 
— decide, based on the results of its assessment of the performance 
evaluation and risk management whether the post-market surveillance 
plan, including the PMPF plan, is adequate, 
4.11. Re-certification…. 
(c) experience from risk-management 
 4.8. Decisions and Certifications…. 
— decide, based on the results of its assessment of the clinical 
evaluation and risk management, whether the post-market surveillance 
plan, including the PMCF plan, is adequate, 
4.11. Re-certification….. 
(c) experience from risk management, 
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ANNEX IX 
CONFORMITY ASSESSMENT BASED ON A QUALITY 
MANAGEMENT SYSTEM AND ON ASSESSMENT OF 
TECHNICAL DOCUMENTATION 
CHAPTER I 
QUALITY MANAGEMENT SYSTEM 
2. Quality management system assessment 
2.2…..Moreover, the documentation to be submitted for the 
assessment of the quality management system shall include an 
adequate description of, in particular: 
(c) the procedures and techniques for monitoring, verifying, validating 
and controlling the design of the devices, and the corresponding 
documentation as well as the data and records arising from those 
procedures and techniques. Those procedures and techniques shall 
specifically cover: 
— risk management as referred to in Section 3 of Annex I, 
3. Surveillance assessment 
3.2. The manufacturer shall give authorisation to the notified body to 
carry out all the necessary audits, including on-site audits, and supply 
it with all relevant information, in particular: 
— the data stipulated in the part of the quality management system 
relating to design, such as the results of analyses, calculations, tests 
and the solutions adopted regarding the risk-management as referred 
to in Section 4 of Annex I, 
 ANNEX IX 
CONFORMITY ASSESSMENT BASED ON A QUALITY 
MANAGEMENT SYSTEM AND ON ASSESSMENT OF 
TECHNICAL DOCUMENTATION 
CHAPTER I 
QUALITY MANAGEMENT SYSTEM 
2. Quality management system assessment 
2.3…..Moreover, the documentation to be submitted for the 
assessment of the quality management system shall include an 
adequate description of, in particular: 
(c) the procedures and techniques for monitoring, verifying, validating 
and controlling the design of the devices and the corresponding 
documentation as well as the data and records arising from those 
procedures and techniques. Those procedures and techniques shall 
specifically cover: 
— risk management as referred to in Section 3 of Annex I, 
3. Surveillance assessment 
3.2. The manufacturer shall give authorisation to the notified body to 
carry out all the necessary audits, including on-site audits, and supply 
it with all relevant information, in particular: 
— the data stipulated in the part of the quality management system 
relating to design, such as the results of analyses, calculations, tests 
and the solutions adopted regarding the risk-management as referred to 
in Section 4 of Annex I, and 
 SCHEDULE 10 Regulation 1A 
Conformity assessment based on quality management system on 
assessment of technical documentation 
Chapter 1 
Quality management system 
Quality management system assessment 
(4) The documentation to be submitted for the assessment of the 
quality management system must include an adequate description of, 
in particular— 
 
d) those procedures and techniques must specifically cover— 
 
 
(ii) risk management as referred to in paragraph 3 of Schedule 3; 
Surveillance 
(7) The manufacturer must— 
(b) supply the notified body with all relevant information, in 
particular— 
(iii) the data stipulated in the part of the quality management system 
relating to design, such as the results of analyses, calculations, tests 
and the solutions adopted regarding the risk-management as referred to 
in paragraph 4 of Schedule 3; 
    SCHEDULE 13 Regulation 1A 
Procedure for custom-made devices 
For information this must include all the requirements of Schedule 3 
details of any areas not fully met. 
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ANNEX IX 
CONFORMITY ASSESSMENT BASED ON A QUALITY 
MANAGEMENT SYSTEM AND ON ASSESSMENT OF 
TECHNICAL DOCUMENTATION 
 ANNEX IX 
CONFORMITY ASSESSMENT BASED ON A QUALITY 
MANAGEMENT SYSTEM AND ON ASSESSMENT OF 
TECHNICAL DOCUMENTATION 
 SCHEDULE 10 Regulation 1A 
Conformity assessment based on quality management system on 
assessment of technical documentation 
 
CHAPTER II 
ASSESSMENT OF THE TECHNICAL DOCUMENTATION 
4. Assessment of the technical documentation of class B, C and D 
devices and batch verification applicable to class D devices 
4.6. The notified body shall verify that the clinical evidence and the 
performance evaluation are adequate and shall verify the conclusions 
drawn by the manufacturer on the conformity with the relevant general 
safety and performance requirements. That verification shall include 
consideration of the adequacy of the benefit-risk determination, the 
risk management, the instructions for use, the user training and the 
manufacturer's post-market surveillance plan, and include a review of 
the need for, and the adequacy of, the PMPF plan proposed, where 
applicable. 
 CHAPTER II 
ASSESSMENT OF THE TECHNICAL DOCUMENTATION 
4. Assessment of the technical documentation applicable to class III 
devices and to the class IIb devices referred to in the second 
subparagraph of Article 52(4) 
4.6. The notified body shall verify that the clinical evidence and the 
clinical evaluation are adequate and shall verify the conclusions drawn 
by the manufacturer on the conformity with the relevant general safety 
and performance requirements. That verification shall include 
consideration of the adequacy of the benefit-risk determination, the 
risk management, the instructions for use, the user training and the 
manufacturer's post- market surveillance plan, and include a review of 
the need for, and the adequacy of, the PMCF plan proposed, where 
applicable. 
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IVDR ANNEX XIII PERFORMANCE EVALUATION, PERFORMANCE STUDIES AND POST-MARKET PERFORMANCE FOLLOW-UP is equivalent to ANNEX XIV CLINICAL EVALUATION AND POST-MARKET CLINICAL 
FOLLOW-UP in the fact that they require similar risk management and device vigilance but from two different types of devices. 
ANNEX XIII 
PERFORMANCE EVALUATION, PERFORMANCE STUDIES 
AND POST-MARKET PERFORMANCE FOLLOW-UP 
 ANNEX XIV 
CLINICAL EVALUATION AND POST-MARKET CLINICAL 
FOLLOW-UP 
 SCHEDULE 14 Regulation 1A 
Clinical evaluation and post market clinical follow-up 
 
All below is given as it is referenced in Part B5, 5.2, (d) below. 
PART A 
PERFORMANCE EVALUATION AND PERFORMANCE 
STUDIES1.3.  
1. PERFORMANCE EVALUATION 
1.3. Clinical evidence and performance evaluation report 
1.3.1. The manufacturer shall assess all relevant scientific validity, 
analytical and clinical performance data to verify the conformity of its 
device with the general safety and performance requirements as referred 
to in Annex I. The amount and quality of that data shall allow the 
manufacturer to make a qualified assessment whether the device will 
achieve the intended clinical benefit or benefits and safety, when used 
as intended by the manufacturer. The data and conclusions drawn from 
this assessment shall constitute the clinical evidence for the device. The 
clinical evidence shall scientifically demonstrate that the intended 
clinical benefit or benefits and safety will be achieved according to the 
state of the art in medicine. 
1.3.2. Performance evaluation report 
The clinical evidence shall be documented in a performance evaluation 
report. This report shall include the scientific validity report, the 
analytical performance report, the clinical performance report and an 
assessment of those reports allowing demonstration of the clinical 
evidence. 
The performance evaluation report shall in particular include: 
— the justification for the approach taken to gather the clinical 
evidence; 
— the literature search methodology and the literature search protocol 
and literature search report of a literature review; 
— the technology on which the device is based, the intended purpose of 
the device and any claims made about the device's performance or 
safety; 
— the nature and extent of the scientific validity and the analytical and 
clinical performance data that has been evaluated; 
— the clinical evidence as the acceptable performances against the state 
of the art in medicine; 
— any new conclusions derived from PMPF reports in accordance with 
Part B of this Annex. 
1.3.3. The clinical evidence and its assessment in the performance 
evaluation report shall be updated throughout the life cycle of the 
device concerned with data obtained from the implementation of the 
manufacturer's PMPF plan in accordance with Part B of this Annex, as 
part of the performance evaluation and the post-market surveillance 
system referred to in Article 10(9). The performance evaluation report 
shall be part of the technical documentation. Both favourable and 
unfavourable data considered in the performance evaluation shall be 
included in the technical documentation. 
 The following part shown for reference as it is referenced in Part B 6, 
6.2 (d) below ** 
 
PART A 
CLINICAL EVALUATION 
4. The results of the clinical evaluation and the clinical evidence on 
which it is based shall be documented in a clinical evaluation report 
which  
shall support the assessment of the conformity of the device. 
The clinical evidence together with non-clinical data generated from 
non- clinical testing methods and other relevant documentation shall 
allow the manufacturer to demonstrate conformity with the general 
safety and performance requirements and shall be part of the technical 
documentation for the device in question. 
Both favourable and unfavourable data considered in the clinical 
evaluation shall be included in the technical documentation. 
 The following part shown for reference as it is referenced in Part B 5 
(3) (d) below ** 
Part A 
Clinical evaluation 
3. 
(4) The results of the clinical evaluation and the clinical evidence on 
which it is based must be documented in a clinical evaluation report 
which— 
(a) must support the assessment of the conformity of the device; 
(b) must include any non-clinical data generated from non-clinical 
testing and other relevant documentation which must allow the 
manufacturer to demonstrate conformity with the general safety and 
performance requirements and which must be part of the technical 
documentation for the device in question; 
(c) must include as part of the technical documentation favourable and 
unfavourable data considered in the clinical evaluation. 
PART B  PART B  PART B 
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POST-MARKET PERFORMANCE FOLLOW-UP POST-MARKET CLINICAL FOLLOW-UP Post –market clinical follow-up (PMCF) 
5. PMPF shall be performed pursuant to a documented method laid 
down in a PMPF plan. 
5.2. The PMPF plan shall include at least:  
(d) a reference to the relevant parts of the performance evaluation 
report referred to in Section 1.3 of this Annex and to the risk 
management referred to in Section 3 of Annex I; 
7. The conclusions of the PMPF evaluation report shall be taken into 
account for the performance evaluation referred to in Article 56 and 
Part A of this Annex and in the risk management referred to in Section 
3 of Annex I. If, through the PMPF, the need for preventive and/or 
corrective measures has been identified, the manufacturer shall 
implement them. 
 6. PMCF shall be performed pursuant to a documented method laid 
down in a PMCF plan. 
6.2. The PMCF plan shall include at least: 
(d) a reference to the relevant parts of the clinical evaluation report 
referred to in Section 4 and to the risk management referred to in 
Section 3 of Annex I; 
 
8. The conclusions of the PMCF evaluation report shall be taken into 
account  
for the clinical evaluation referred to in Article 61 and Part A of this 
Annex  
and in the risk management referred to in Section 3 of Annex I.  
If, through the PMCF, the need for preventive and/or corrective 
measures has been identified, the manufacturer shall implement them. 
 5.— (1) PMCF must be performed pursuant to a documented method 
laid down in a PMCF plan. 
(3) The PMCF plan must include at least— 
(d) a reference to the relevant parts of the clinical evaluation report 
referred to in paragraph 3(4) ** and to the risk management referred to 
in paragraph 3 of Schedule 3;  
7. 
(1) The conclusions of the PMCF evaluation report must be taken into 
account — 
(i) for the clinical evaluation referred to in regulation 102 and Part A of 
this Schedule; 
(ii) in the risk management referred to in paragraph 3 of Schedule 3; 
(2) If, through the PMCF, the need for preventive or corrective 
measures has been identified, the manufacturer must implement them. 
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  ANNEX XV 
CLINICAL INVESTIGATIONS 
 SCHEDULE 15 Regulation 1A 
Clinical investigations 
  CHAPTER II 
DOCUMENTATION REGARDING THE APPLICATION FOR 
CLINICAL INVESTIGATION 
2. Investigator's Brochure (IB) 
The investigator's brochure (IB) shall contain the clinical and non-
clinical information on the investigational device that is relevant for 
the investigation and available at the time of application.  
Any updates to the IB or other relevant information that is newly 
available shall be brought to the attention of the investigators in a 
timely manner.  
The IB shall be clearly identified and contain in particular the 
following information: 
2.5. Summary of the benefit-risk analysis and the risk management, 
including information regarding known or foreseeable risks, any 
undesirable side- effects, contraindications and warnings. 
2.6. In the case of devices that incorporate a medicinal substance, 
including a human blood or plasma derivative or devices 
manufactured utilising non- viable tissues or cells of human or animal 
origin, or their derivatives, detailed information on the medicinal 
substance or on the tissues, cells or their derivatives, and on the 
compliance with the relevant general safety and performance 
requirements and the specific risk management in relation to the 
substance or tissues, cells or their derivatives, as well as evidence for 
the added value of incorporation of such constituents in relation to the 
clinical benefit and/or safety of the device. 
 Chapter II 
Documentation regarding the application for clinical investigation 
Investigator’s brochure (IB) 
2.  
(1) An investigator’s brochure (IB) must contain the clinical and non-
clinical information on the investigational device that is relevant for 
the investigation and available at the time of application. 
(2) Any updates to the IB or other relevant information that is newly 
available must be brought to the attention of the investigators in a 
timely manner. 
(3) The IB must be clearly identified and contain in particular the 
following information— 
(e) a summary of the benefit-risk analysis and the risk management, 
including information regarding known or foreseeable risks, any 
undesirable effects, contraindications and warnings; 
(f) in the case of devices that incorporate a medicinal substance, 
including a human blood or plasma derivative or devices 
manufactured utilising non-viable tissues or cells of human or animal 
origin, or their derivatives, detailed information on the medicinal 
substance or on the tissues, cells or their derivatives, and on the 
compliance with the relevant general safety and performance 
requirements and the specific risk management in relation to the 
substance or tissues, cells or their derivatives, as well as evidence for 
the added value of incorporation of such constituents in relation to the 
clinical benefit or safety of the device; 
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  ANNEX XIV 
CLINICAL EVALUATION AND POST-MARKET CLINICAL 
FOLLOW-UP 
 SCHEDULE 14 Regulation 1A 
Clinical evaluation and post market clinical follow-up 
 
  The following part shown for reference as it is referenced in Part B 6, 
6.2 (d) below ** 
 
PART A 
CLINICAL EVALUATION 
4. The results of the clinical evaluation and the clinical evidence on 
which it is based shall be documented in a clinical evaluation report 
which  
shall support the assessment of the conformity of the device. 
The clinical evidence together with non-clinical data generated from 
non- clinical testing methods and other relevant documentation shall 
allow the manufacturer to demonstrate conformity with the general 
safety and performance requirements and shall be part of the technical 
documentation for the device in question. 
Both favourable and unfavourable data considered in the clinical 
evaluation shall be included in the technical documentation. 
 The following part shown for reference as it is referenced in Part B 5 
(3) (d) below ** 
Part A 
Clinical evaluation 
3. 
(4) The results of the clinical evaluation and the clinical evidence on 
which it is based must be documented in a clinical evaluation report 
which— 
(a) must support the assessment of the conformity of the device; 
(b) must include any non-clinical data generated from non-clinical 
testing and other relevant documentation which must allow the 
manufacturer to demonstrate conformity with the general safety and 
performance requirements and which must be part of the technical 
documentation for the device in question; 
(c) must include as part of the technical documentation favourable and 
unfavourable data considered in the clinical evaluation. 
  PART B 
POST-MARKET CLINICAL FOLLOW-UP 
 PART B 
Post –market clinical follow-up (PMCF) 
  6. PMCF shall be performed pursuant to a documented method laid 
down in a PMCF plan. 
6.2. The PMCF plan shall include at least: 
(d) a reference to the relevant parts of the clinical evaluation report 
referred to in Section 4 and to the risk management referred to in 
Section 3 of Annex I; 
 
8. The conclusions of the PMCF evaluation report shall be taken into 
account  
for the clinical evaluation referred to in Article 61 and Part A of this 
Annex  
and in the risk management referred to in Section 3 of Annex I.  
If, through the PMCF, the need for preventive and/or corrective 
measures has been identified, the manufacturer shall implement them. 
 5.— (1) PMCF must be performed pursuant to a documented method 
laid down in a PMCF plan. 
(3) The PMCF plan must include at least— 
(d) a reference to the relevant parts of the clinical evaluation report 
referred to in paragraph 3(4) ** and to the risk management referred to 
in paragraph 3 of Schedule 3;  
7. 
(1) The conclusions of the PMCF evaluation report must be taken into 
account — 
(i) for the clinical evaluation referred to in regulation 102 and Part A of 
this Schedule; 
(ii) in the risk management referred to in paragraph 3 of Schedule 3; 
(2) If, through the PMCF, the need for preventive or corrective 
measures has been identified, the manufacturer must implement them. 
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  ANNEX XV 
CLINICAL INVESTIGATIONS 
 SCHEDULE 15 Regulation 1A 
Clinical investigations 
  CHAPTER II 
DOCUMENTATION REGARDING THE APPLICATION FOR 
CLINICAL INVESTIGATION 
2. Investigator's Brochure (IB) 
The investigator's brochure (IB) shall contain the clinical and non-
clinical information on the investigational device that is relevant for 
the investigation and available at the time of application.  
Any updates to the IB or other relevant information that is newly 
available shall be brought to the attention of the investigators in a 
timely manner.  
The IB shall be clearly identified and contain in particular the 
following information: 
2.5. Summary of the benefit-risk analysis and the risk management, 
including information regarding known or foreseeable risks, any 
undesirable side- effects, contraindications and warnings. 
2.6. In the case of devices that incorporate a medicinal substance, 
including a human blood or plasma derivative or devices 
manufactured utilising non- viable tissues or cells of human or animal 
origin, or their derivatives, detailed information on the medicinal 
substance or on the tissues, cells or their derivatives, and on the 
compliance with the relevant general safety and performance 
requirements and the specific risk management in relation to the 
substance or tissues, cells or their derivatives, as well as evidence for 
the added value of incorporation of such constituents in relation to the 
clinical benefit and/or safety of the device. 
 Chapter II 
Documentation regarding the application for clinical investigation 
Investigator’s brochure (IB) 
2.  
(1) An investigator’s brochure (IB) must contain the clinical and non-
clinical information on the investigational device that is relevant for 
the investigation and available at the time of application. 
(2) Any updates to the IB or other relevant information that is newly 
available must bebrought to the attention of the investigators in a 
timely manner. 
(3) The IB must be clearly identified and contain in particular the 
following information— 
(e) a summary of the benefit-risk analysis and the risk management, 
including information regarding known or foreseeable risks, any 
undesirable effects, contraindications and warnings; 
(f) in the case of devices that incorporate a medicinal substance, 
including a human blood or plasma derivative or devices 
manufactured utilising non-viable tissues or cells of human or animal 
origin, or their derivatives, detailed information on the medicinal 
substance or on the tissues, cells or their derivatives, and on the 
compliance with the relevant general safety and performance 
requirements and the specific risk management in relation to the 
substance or tissues, cells or their derivatives, as well as evidence for 
the added value of incorporation of such constituents in relation to the 
clinical benefit or safety of the device; 
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Review of IVDR only to relevant UK requirements.  
CHAPTER I 
INTRODUCTORY PROVISIONS 
CHAPTER II 
MAKING AVAILABLE ON THE MARKET AND PUTTING INTO 
SERVICE OF DEVICES, OBLIGATIONS OF ECONOMIC 
OPERATORS, CE MARKING, FREE MOVEMENT 
   “PART IX 
The rights, powers, liabilities, obligations, restrictions, remedies and 
procedures recognised under the in vitro diagnostic Medical Devices 
Regulation (see regulation 4P) 
Scope and definitions 
Article 8 
Use of harmonised standards 
1. Devices that are in conformity with the relevant harmonised 
standards, or the relevant parts of those standards, the references of 
which have been published in the Official Journal of the European 
Union, shall be presumed to be in conformity with the requirements of 
this Regulation covered by those standards or parts thereof. 
The first subparagraph shall also apply to system or process 
requirements to be fulfilled in accordance with this Regulation by 
economic operators or sponsors, including those relating to quality 
management systems, risk management, post-market surveillance 
systems, performance studies, clinical evidence or post-market 
performance follow-up (‘PMPF’). 
Article 10 
General obligations of manufacturers 
2. Manufacturers shall establish, document, implement and maintain a 
system for risk management as described in Section 3 of Annex I. 
8……. 
The quality management system shall address at least the following 
aspects: 
(e) risk management as set out in Section 3 of Annex I; 
    
Use of standards 
143.—(1) Devices that are in conformity with the designated 
standards, or the relevant parts of those standards, are presumed to be 
in conformity with the requirements of this Part which cover those 
designated standards or relevant parts of those standards. 
(2) Paragraph (1) also applies to system or process requirements to be 
fulfilled in accordance with this Part by economic operators or 
sponsors, including those relating to quality management systems, risk 
management, post market surveillance systems, performance studies, 
clinical evaluation or post-market performance follow-up (‘PMPF’). 
 
 
General obligations of manufacturers 
145. 
(2) Manufacturers must establish, document, implement and maintain 
a system for risk management as described in paragraph 3 of Schedule 
17. 
(13) The quality management system required by paragraph (12) 
must—…… 
(v) risk management as set out in paragraph 3 of Schedule 17; 
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CHAPTER VII 
POST-MARKET SURVEILLANCE, VIGILANCE AND MARKET 
SURVEILLANCE 
Section 1 
Post – market surveillance 
Article 78 
Post-market surveillance system of the manufacturer 
3. Data gathered by the manufacturer's post-market surveillance 
system shall in particular be used: 
(a) to update the benefit-risk determination and to improve the risk 
management as referred to in Chapter I of Annex I; 
   Post-market surveillance, vigilance and market surveillance 
 
 
Post market surveillance system of the manufacturer 
 
186. 
(3) The manufacturer must ensure that— 
(a) data gathered by the manufacturer’s post-market surveillance 
system is used in particular— 
(i) to update the benefit-risk determination and to improve the risk 
management as referred to in Part 1 of Schedule 17 
Section 3 
Market surveillance 
Article 88 
Market surveillance activities 
1. The competent authorities shall perform appropriate checks on the 
conformity characteristics and performance of devices including, 
where appropriate, a review of documentation and physical or 
laboratory checks on the basis of adequate samples. The competent 
authorities shall, in particular, take account of established principles 
regarding risk assessment and risk management, vigilance data and 
complaints. 
   Market surveillance 
Market surveillance activities 
195. 
(1) The Secretary of State must— 
(a) perform appropriate checks on the conformity characteristics and 
performance of devices including, where appropriate, a review of 
documentation and physical or  
laboratory checks on the basis of adequate samples; 
(b) in doing so, take account of established principles regarding risk 
assessment and 
risk management, vigilance data and complaints. 
  
Page 365 of 513 
 
 
ANNEX I 
GENERAL SAFETY AND PERFORMANCE REQUIREMENTS 
In Vitro Diagnostic Devices. 
 N/A  SCHEDULE 17 Regulation 1A 
General safety and performance requirements- in vitro diagnostic 
medical devices 
CHAPTER I 
GENERAL REQUIREMENTS 
 N/A  PART 1 
General requirements for in vitro diagnostic medical devices 
1. Devices shall  
achieve the performance intended by their manufacturer  
and shall be designed and manufactured in such a way that, during 
normal conditions of use, they are suitable for their intended purpose.  
They shall be safe and effective  
and shall not compromise the clinical condition or the safety of 
patients, or the safety and health of users or, where applicable, other 
persons, provided that any risks which may be associated with their 
use constitute acceptable risks when weighed against the benefits to 
the patient and are compatible with a high level of protection of health 
and safety, taking into account the generally acknowledged state of the 
art. 
2. The requirement in this Annex to reduce risks as far as possible 
means the reduction of risks as far as possible without adversely 
affecting the benefit- risk ratio. 
3. Manufacturers shall establish, implement, document and maintain a 
risk management system. 
Risk management shall be understood as a continuous iterative process 
throughout the entire lifecycle of a device, requiring regular systematic 
updating. In carrying out risk management manufacturers shall: 
(a) establish and document a risk management plan for each device; 
(b) identify and analyse the known and foreseeable hazards associated 
with each device; 
(c) estimate and evaluate the risks associated with, and occurring 
during, the intended use and during reasonably foreseeable misuse; 
(d) eliminate or control the risks referred to in point (c) in accordance 
with the requirements of Section 4; 
(e) evaluate the impact of information from the production phase and, 
in particular, from the post-market surveillance system, on hazards and 
the frequency of occurrence thereof, on estimates of their associated 
risks, as well as on the overall risk, the benefit-risk ratio and risk 
acceptability; and 
(f) based on the evaluation of the impact of the information referred to 
in point (e), if necessary amend control measures in line with the 
requirements of Section 4. 
 N/A  1. Devices must— 
(a) achieve the performance intended by their manufacturer; 
(b) be designed and manufactured in such a way that, during normal 
conditions of use, they are suitable for their intended purpose; 
(c) be safe and effective; 
(d) not compromise the clinical condition or the safety of patients, or 
the safety and health of users or, where applicable, other persons, 
provided that any risks which may be associated with their use 
constitute acceptable risks when weighed against the benefits to the 
patient and are compatible with a high level of protection of health and 
safety, taking into account the generally acknowledged state of the art. 
2. The requirement in this Schedule to reduce risks as far as possible 
means the reduction of risks as far as possible without adversely 
affecting the benefit-risk ratio. 
3.—(1) Manufacturers must establish, implement, document and 
maintain a risk management system. 
(2) Risk management must be understood as a continuous iterative 
process throughout the entire lifecycle of a device, requiring regular 
systematic updating and in carrying out risk management 
manufacturers must— 
(a) establish and document a risk management plan for each device; 
(b) identify and analyse the known and foreseeable hazards associated 
with each device; 
(c) estimate and evaluate the risks associated with, and occurring 
during, the intended use and during reasonably foreseeable misuse; 
(d) eliminate or control the risks referred to in sub-paragraph (c) in 
accordance with the requirements of paragraph 4; 
(e) evaluate the impact of information from the production phase and, 
in particular, from the post-market surveillance system, on hazards and 
the frequency of occurrence thereof, on estimates of their associated 
risks, as well as on the overall risk, the benefit-risk ratio and risk 
acceptability; 
(f) based on the evaluation of the impact of the information referred to 
in point (e), if necessary amend control measures in line with the 
requirements of paragraph 4. 
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4. Risk control measures adopted by manufacturers for the design and 
manufacture of the devices shall conform to safety principles, taking 
account of the generally acknowledged state of the art.  
To reduce risks, the manufacturers shall manage risks so that the 
residual risk associated with each hazard as well as the overall residual 
risk is judged acceptable.  
In selecting the most appropriate solutions, manufacturers shall, in the 
following order of priority: 
(a) eliminate or reduce risks as far as possible through safe design and 
manufacture; 
(b) where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated; and 
(c) provide information for safety (warnings/precautions/contra-
indications) and, where appropriate, training to users. 
Manufacturers shall inform users of any residual risks. 
5. In eliminating or reducing risks related to use error, the manufacturer 
shall: 
(a) reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended to be 
used (design for patient safety), and 
(b) give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
6. The characteristics and performance of a device shall not be adversely 
affected to such a degree that the health or safety of the patient or the 
user and, where applicable, of other persons are compromised during 
the lifetime of the device, as indicated by the manufacturer, when the 
device is subjected to the stresses which can occur during normal 
conditions of use and has been properly maintained in accordance with 
the manufacturer's instructions. 
7. Devices shall be designed, manufactured and packaged in such a way 
that their characteristics and performance during their intended use are 
not adversely affected during transport and storage, for example, 
through fluctuations of temperature and humidity, taking account of the 
instructions and information provided by the manufacturer. 
8. All known and foreseeable risks, and any undesirable effects shall be 
minimised and be acceptable when weighed against the evaluated 
potential benefits to the patients and/or the user arising from the 
intended performance of the device during normal conditions of use. 
 N/A  4.—(1) Risk control measures adopted by manufacturers for the design 
and manufacture of the devices must conform to safety principles, 
taking account of the generally acknowledged state of the art. 
(2) To reduce risks, the manufacturers must manage risks so that the 
residual risk associated with each hazard as well as the overall residual 
risk is judged acceptable.  
(3) In selecting the most appropriate solutions, manufacturers must, in 
the following order of priority— 
(a) eliminate or reduce risks as far as possible through safe design and 
manufacture;  
(b) where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated; 
(c) provide information for safety (warnings, precautions, contra-
indications) and, where appropriate, training to users; 
(d) inform users of any residual risks. 
5. In eliminating or reducing risks related to use error, the manufacturer 
must— 
(a) reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended to be 
used (design for patient safety); 
(b) give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
6. The characteristics and performance of a device must not be adversely 
affected to such a degree that the health or safety of the patient or the 
user and, where applicable, of other persons are compromised during 
the lifetime of the device, as indicated by the manufacturer, when the 
device is subjected to the stresses which can occur during normal 
conditions of use and has been properly maintained in accordance with 
the manufacturer’s instructions. 
7. Devices must be designed, manufactured and packaged in such a way 
that their characteristics and performance during their intended use are 
not adversely affected during transport and storage, for example, 
through fluctuations of temperature and humidity, taking account of the 
instructions and information provided by the manufacturer. 
8. All known and foreseeable risks, and any undesirable effects must be 
minimised and be acceptable when weighed against the evaluated 
potential benefits to the patients or the user arising from the intended 
performance of the device during normal conditions of use. 
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CHAPTER II 
REQUIREMENTS REGARDING PERFORMANCE, DESIGN AND 
MANUFACTURE 
 N/A  PART 2 
Requirements regarding design and manufacture of in vitro diagnostic 
medical devices 
16. Electronic programmable systems — devices that incorporate 
electronic programmable systems and software that are devices in 
themselves 
16.2. For devices that incorporate software or for software that are 
devices in themselves, the software shall be developed and 
manufactured in accordance with the state of the art taking into account 
the principles of development life cycle, risk management, including 
information security, verification and validation. 
 N/A  Electronic programmable systems- devices that incorporate 
programmable systems and software that are devices in themselves 
16.  
(2) For devices that incorporate software or for software that is a device 
in itself , the software must be developed and manufactured in 
accordance with the state of the art taking into account the principles of 
development life cycle, risk management, including information 
security, verification and validation. 
 
ANNEX II 
TECHNICAL DOCUMENTATION 
 N/A  SCHEDULE 18 Regulation 1A 
Technical documentation- in vitro diagnostic medical devices 
5. BENFIT-RISK ANALYSIS AND RISK MANAGEMENT 
The documentation shall contain information on: 
(a) the benefit-risk analysis referred to in Sections 1 and 8 of Annex I, 
and 
(b) the solutions adopted and the results of the risk management referred 
to in Section 3 of Annex I. 
 N/A  Benefit-risk analysis and risk management 
6. The documentation must contain information on— 
(a) the benefit-risk analysis referred to in paragraphs 1 and 8 of Schedule 
17, 
(b) the solutions adopted and the results of the risk management referred 
to in paragraph 3 of Schedule 17. 
ANNEX III 
TECHNICAL DOCUMENTATION ON POST-MARKET SURVEIL- 
LANCE 
 N/A  SCHEDULE 19 Regulation 1A 
Technical documentation on post-market surveillance for in vitro 
diagnostic medical devices 
(b) The post-market surveillance plan shall cover at least: 
— suitable indicators and threshold values that shall be used in the 
continuous reassessment of the benefit-risk analysis and of the risk 
management as referred to in Section 3 of Annex I; 
 N/A  4. The post-market surveillance plan must cover at least— 
(c) suitable indicators and threshold values that must be used in the 
continuous reassessment of the benefit-risk analysis and of the risk 
management as referred to in paragraph 3 of Schedule 3; 
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ANNEX IX 
CONFORMITY ASSESSMENT BASED ON A QUALITY 
MANAGEMENT SYSTEM AND ON ASSESSMENT OF 
TECHNICAL DOCUMENTATION 
CHAPTER I 
QUALITY MANAGEMENT SYSTEM 
2. Quality management system assessment 
… Moreover, the documentation to be submitted for the assessment of 
the quality management system shall include an adequate description 
of, in particular: 
(c) the procedures and techniques for monitoring, verifying, validating 
and controlling the design of the devices, and the corresponding 
documentation as well as the data and records arising from those 
procedures and techniques. Those procedures and techniques shall 
specifically cover: 
— risk management as referred to in Section 3 of Annex I, 
 N/A  SCHEDULE 24 Regulation 1A 
Conformity assessment based on quality management system and on 
assessment of technical documentation- in vitro diagnostic medical 
devices 
PART 1 
Quality management system 
Quality management system assessment 
(4) The documentation to be submitted for the assessment of the quality 
management system must include an adequate description of, in 
particular— 
(c) the procedures and techniques for monitoring, verifying, validating 
and controlling the design of the devices, and the corresponding 
documentation as well as the data and records arising from those 
procedures and techniques and those procedures and techniques must 
specifically cover— 
(iii) risk management as referred to in paragraph 3 of Schedule 17; 
3. Surveillance assessment 
3.2. The manufacturer shall give authorisation to the notified body to 
carry out all the necessary audits, including on-site audits, and supply it 
with all relevant information, in particular:… 
— the data stipulated in the part of the quality management system 
relating to design, such as the results of analyses, calculations, tests and 
the solutions adopted regarding the risk-management as referred to in 
Section 4 of Annex I, 
 N/A   Surveillance applicable to Class C and Class D devices 
(7) The manufacturer of Class C and D devices must give authorisation 
to the notified body to carry out all the necessary audits, including on-
site audits, and supply it with all relevant information, in particular— 
(c) the data stipulated in the part of the quality management system 
relating to design, such as the results of analyses, calculations, tests and 
the solutions adopted regarding the risk-management as referred to in 
paragraph 4 of Schedule 17; 
CHAPTER II 
ASSESSMENT OF THE TECHNICAL DOCUMENTATION 
4. Assessment of the technical documentation of class B, C and D 
devices and batch verification applicable to class D devices 
4.6. The notified body shall verify that the clinical evidence and the 
performance evaluation are adequate and shall verify the conclusions 
drawn by the manufacturer on the conformity with the relevant general 
safety and performance requirements. That verification shall include 
consideration of the adequacy of the benefit-risk determination, the risk 
management, the instructions for use, the user training and the 
manufacturer's post-market surveillance plan, and include a review of 
the need for, and the adequacy of, the PMPF plan proposed, where 
applicable. 
 N/A  PART 2 
Assessment of technical documentation 
Assessment of the technical documentation of class B, C and D devices 
and batch verification applicable to class D devices 
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ANNEX XIII 
PERFORMANCE EVALUATION, PERFORMANCE STUDIES AND 
POST-MARKET PERFORMANCE FOLLOW-UP 
 N/A  SCHEDULE 27 Regulation 1A 
Performance evaluation, performance studies and post-market 
performance follow-up 
All below is given as it is referenced in Part B5, 5.2, (d) below. 
PART A 
PERFORMANCE EVALUATION AND PERFORMANCE 
STUDIES1.3.  
1. PERFORMANCE EVALUATION 
1.3. Clinical evidence and performance evaluation report 
1.3.1. The manufacturer shall assess all relevant scientific validity, 
analytical and clinical performance data to verify the conformity of its 
device with the general safety and performance requirements as referred 
to in Annex I. The amount and quality of that data shall allow the 
manufacturer to make a qualified assessment whether the device will 
achieve the intended clinical benefit or benefits and safety, when used 
as intended by the manufacturer. The data and conclusions drawn from 
this assessment shall constitute the clinical evidence for the device. The 
clinical evidence shall scientifically demonstrate that the intended 
clinical benefit or benefits and safety will be achieved according to the 
state of the art in medicine. 
1.3.2. Performance evaluation report 
The clinical evidence shall be documented in a performance evaluation 
report. This report shall include the scientific validity report, the 
analytical performance report, the clinical performance report and an 
assessment of those reports allowing demonstration of the clinical 
evidence. 
The performance evaluation report shall in particular include: 
— the justification for the approach taken to gather the clinical 
evidence; 
— the literature search methodology and the literature search protocol 
and literature search report of a literature review; 
— the technology on which the device is based, the intended purpose of 
the device and any claims made about the device's performance or 
safety; 
— the nature and extent of the scientific validity and the analytical and 
clinical performance data that has been evaluated; 
— the clinical evidence as the acceptable performances against the state 
of the art in medicine; 
— any new conclusions derived from PMPF reports in accordance with 
Part B of this Annex. 
1.3.3. The clinical evidence and its assessment in the performance 
evaluation report shall be updated throughout the life cycle of the device 
concerned with data obtained from the implementation of the 
manufacturer's PMPF plan in accordance with Part B of this Annex, as 
part of the performance evaluation and the post-market surveillance 
system referred to in Article 10(9). The performance evaluation report 
shall be part of the technical documentation. Both favourable and 
unfavourable data considered in the performance evaluation shall be 
included in the technical documentation. 
 N/A  All below is given as it is referenced in Part B 5 (3) (d) below. 
PART A 
Performance evaluation and performance studies 
Performance evaluation 
1. 
Clinical evidence and performance evaluation report 
(17) The manufacturer must assess all relevant scientific validity, 
analytical and clinical performance data to verify the conformity of its 
device with the general safety and performance requirements as referred 
to in Schedule 17. 
(18) The amount and quality of that data must allow the manufacturer 
to make a qualified assessment whether the device will achieve the 
intended clinical benefit or benefits and safety, when used as intended 
by the manufacturer. 
(19) The data and conclusions drawn from this assessment constitute the 
clinical evidence for the device. 
(20) The clinical evidence must scientifically demonstrate that the 
intended clinical benefit or benefits and safety will be achieved 
according to the state of the art in medicine. 
PART B 
POST-MARKET PERFORMANCE FOLLOW-UP 
 N/A  PART B 
Post–market performance follow-up (PMPF) 
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5. PMPF shall be performed pursuant to a documented method laid 
down in a PMPF plan. 
5.2. The PMPF plan shall include at least:  
(d) a reference to the relevant parts of the performance evaluation report 
referred to in Section 1.3 of this Annex and to the risk management 
referred to in Section 3 of Annex I; 
7. The conclusions of the PMPF evaluation report shall be taken into 
account for the performance evaluation referred to in Article 56 and Part 
A of this Annex and in the risk management referred to in Section 3 of 
Annex I. If, through the PMPF, the need for preventive and/or corrective 
measures has been identified, the manufacturer shall implement them. 
5.—(1) PMPF shall be performed pursuant to a documented method laid 
down in a PMPF plan. 
(3) The PMPF plan shall include at least— 
(d) reference to the relevant parts of the performance evaluation report 
referred to in sub-paragraphs (17) to (20) of paragraph 1 of this Schedule 
and to the risk management referred to in paragraph 3 of Schedule 17; 
7. The conclusions of the PMPF evaluation report must be taken into 
account for the performance evaluation referred to in regulation 167 and 
Part A of this Schedule and in the risk management referred to in 
paragraph 3 of Schedule 17 and if, through the PMPF, the need for 
preventive or corrective measures has been identified, the manufacturer 
must implement them. 
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ANNEX XIV 
INTERVENTIONAL CLINICAL PERFORMANCE STUDIES AND 
CERTAIN OTHER PERFORMANCE STUDIES 
 
 N/A  SCHEDULE 28 Regulation 1A 
Interventional clinical performance studies and certain other 
performance studies 
 
CHAPTER I 
DOCUMENTATION REGARDING THE APPLICATION FOR 
INTERVENTIONAL CLINICAL PERFORMANCE STUDIES AND 
OTHER PERFORMANCE STUDIES INVOLVING RISKS FOR THE 
SUBJECTS OF THE STUDIES 
 N/A  PART 1 
Documentation regarding the application for interventional clinical 
performance studies and other performance studies involving risks for 
the subjects of the studies 
2. Investigator's brochure 
The investigator's brochure (IB) shall contain the information on the 
device for performance study that is relevant for the study and available 
at the time of application. Any updates to the IB or other relevant 
information that is newly available shall be brought to the attention of 
the investigators in a timely manner. The IB shall be clearly identified 
and contain in particular the following information: 
2.5. Summary of the benefit-risk analysis and the risk management, 
including information regarding known or foreseeable risks and 
warnings. 
2.6. In the case of devices that include tissues, cells and substances of 
human, animal or microbial origins detailed information on the tissues, 
cells and substances, and on the compliance with the relevant general 
safety and performance requirements and the specific risk management 
in relation to those tissues, cells and substances. 
 N/A  Investigator’s brochure 
2. 
(2) The IB (investigator’s brochure) must be clearly identified and 
contain in particular the following information— 
 
 
 
(f) summary of the benefit-risk analysis and the risk management, 
including information regarding known or foreseeable risks and 
warnings; 
(g) in the case of devices that include tissues, cells and substances of 
human, animal or microbial origins detailed information on the tissues, 
cells and substances, and on the compliance with the relevant general 
safety and performance requirements and the specific risk management 
in relation to those tissues, cells and substances; 
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Appendix C4 7 Comparison: in vitro diagnostic Devices classification rules – UK v EU 
 
ANNEX VIII  
CLASSIFICATION RULES 
 SCHEDULE 23 Regulation 1A 
Classification Rules for in vitro diagnostic medical devices 
1. IMPLEMENTING RULES 
1.1. Application of the classification rules shall be governed by the 
intended purpose of the devices. 
1.2. If the device in question is intended to be used in combination 
with another device, the classification rules shall apply separately to 
each of the devices. 
1.3. Accessories for an in vitro diagnostic medical device shall be 
classified in their own right separately from the device with which 
they are used. 
1.4. Software, which drives a device or influences the use of a device, 
shall fall within the same class as the device. 
If the software is independent of any other device, it shall be classified 
in its own right. 
1.5. Calibrators intended to be used with a device shall be classified in 
the same class as the device. 
 Implementation rules 
1.—(1) Application of the classification rules must be governed by the 
intended purpose of the devices. 
(2) If the device in question is intended to be used in combination with 
another device, the classification rules must apply separately to each of 
the devices. 
(3) Accessories for an in vitro diagnostic medical device must be 
classified in their own right separately from the device with which 
they are used. 
(4) Software which— 
(a) drives a device or influences the use of a device, must fall within 
the same class as the device; 
(b) is independent of any other device, must be classified in its own 
right. 
(5) Calibrators intended to be used with a device must be classified in 
the same class as the device. 
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1.6. Control materials with quantitative or qualitative assigned values 
intended for one specific analyte or multiple analytes shall be 
classified in the same class as the device. 
1.7. The manufacturer shall take into consideration all classification 
and implementation rules in order to establish the proper classification 
for the device. 
1.8. Where a manufacturer states multiple intended purposes for a 
device, and as a result the device falls into more than one class, it shall 
be classified in the higher class. 
1.9. If several classification rules apply to the same device, the rule 
resulting in the higher classification shall apply. 
1.10. Each of the classification rules shall apply 
(6) Control materials with quantitative or qualitative assigned values 
intended for one specific analyte or multiple analytes must be 
classified in the same class as the device. 
(7) The manufacturer must take into consideration all classification 
and implementation rules in order to establish the proper classification 
for the device. 
(8) Where a manufacturer states multiple intended purposes for a 
device, and as a result the device falls into more than one class, it must 
be classified in the higher class. 
(9) If several classification rules apply to the same device, the rule 
resulting in the higher classification must apply. 
(10) Each of the classification rules must apply to first line assays, 
confirmatory assays and supplemental assays. 
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ANNEX VIII  
CLASSIFICATION RULES 
 SCHEDULE 23 Regulation 1A 
Classification Rules for in vitro diagnostic medical devices 
2. CLASSIFICATION RULES  Classification rules 
2.1. Rule 1 
Devices intended to be used for the following purposes are classified 
as class D: 
— detection of the presence of, or exposure to, a transmissible agent in 
blood, blood components, cells, tissues or organs, or in any of their 
derivatives, in order to assess their suitability for transfusion, 
transplantation or cell administration; 
— detection of the presence of, or exposure to, a transmissible agent 
that causes a life-threatening disease with a high or suspected high risk 
of propagation; 
— determining the infectious load of a life-threatening disease where 
monitoring is critical in the process of patient management. 
 Rule 1 
2.—(1) Devices intended to be used for the following purposes are 
classified as Class D— 
(a) detection of the presence of, or exposure to, a transmissible agent 
in blood, blood components, cells, tissues or organs, or in any of their 
derivatives, in order to assess their suitability for transfusion, 
transplantation or cell administration; 
(b) detection of the presence of, or exposure to, a transmissible agent 
that causes a life-threatening disease with a high or suspected high risk 
of propagation; 
(c) determining the infectious load of a life-threatening disease where 
monitoring is critical in the process of patient management. 
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2.2. Rule 2 
Devices intended to be used for blood grouping, or tissue typing to 
ensure the immunological compatibility of blood, blood components, 
cells, tissue or organs that are intended for transfusion or 
transplantation or cell administration, are classified as class C, except 
when intended to determine any of the following markers: 
— ABO system [A (ABO1), B (ABO2), AB (ABO3)]; 
— Rhesus system [RH1 (D), RHW1, RH2 (C), RH3 (E), RH4 (c), 
RH5 (e)]; 
— Kell system [Kel1 (K)]; 
— Kidd system [JK1 (Jka), JK2 (Jkb)]; 
— Duffy system [FY1 (Fya), FY2 (Fyb)]; 
in which case they are classified as class D. 
 Rule 2 
(2) Devices intended to be used for blood grouping, or tissue typing to 
ensure the immunological compatibility of blood, blood components, 
cells, tissue or organs that are intended for transfusion or 
transplantation or cell administration, are classified as class C, 
except when intended to determine any of the following markers— 
(a) ABO system [A (ABO1), B (ABO2), AB (ABO3)]; 
(b) Rhesus system [RH1 (D), RHW1, RH2 (C), RH3 (E), RH4 (c), 
RH5 (e)]; 
(c) Kell system [Kel1 (K)]; 
(d) Kidd system [JK1 (Jka), JK2 (Jkb)]; 
(e) Duffy system [FY1 (Fya), FY2 (Fyb)]; 
in which case they are classified as Class D. 
 
  
Page 376 of 513 
 
 
 
2.3. Rule 3 
Devices are classified as class C if they are intended: 
(a) for detecting the presence of, or exposure to, a sexually transmitted 
agent; 
(b) for detecting the presence in cerebrospinal fluid or blood of an 
infectious agent without a high or suspected high risk of propagation; 
(c) for detecting the presence of an infectious agent, if there is a 
significant risk that an erroneous result would cause death or severe 
disability to the individual, foetus or embryo being tested, or to the 
individual's offspring; 
(d) for pre-natal screening of women in order to determine their 
immune status towards transmissible agents; 
(e) for determining infective disease status or immune status, where 
there is a risk that an erroneous result would lead to a patient 
management decision resulting in a life-threatening situation for the 
patient or for the patient's offspring; 
(f) to be used as companion diagnostics; 
(g) to be used for disease staging, where there is a risk that an 
erroneous result would lead to a patient management decision 
resulting in a life- threatening situation for the patient or for the 
patient's offspring; 
(h) to be used in screening, diagnosis, or staging of cancer; 
 Rule 3 
(3) Devices are classified as Class C if they are intended— 
(a) for detecting the presence of, or exposure to, a sexually transmitted 
agent; 
(b) for detecting the presence in cerebrospinal fluid or blood of an 
infectious agent without a high or suspected high risk of propagation; 
(c) for detecting the presence of an infectious agent, if there is a 
significant risk that an erroneous result would cause death or severe 
disability to the individual, foetus or embryo being tested, or to the 
individual’s offspring; 
(d) for pre-natal screening of women in order to determine their 
immune status towards transmissible agents; 
(e) for determining infective disease status or immune status, where 
there is a risk that an erroneous result would lead to a patient 
management decision resulting in a lifethreatening situation for the 
patient or for the patient’s offspring; 
(f) to be used as companion diagnostics; 
(g) to be used for disease staging, where there is a risk that an 
erroneous result would lead to a patient management decision resulting 
in a life-threatening situation for the patient or for the patient’s 
offspring; 
(h) to be used in screening, diagnosis, or staging of cancer; 
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(i) for human genetic testing;  
 
(j) for monitoring of levels of medicinal products, substances or 
biological components, when there is a risk that an erroneous result 
will lead to a patient management decision resulting in a life-
threatening situation for the patient or for the patient's offspring; 
(k) for management of patients suffering from a life-threatening 
disease or condition; 
(l) for screening for congenital disorders in the embryo or foetus; 
(m) for screening for congenital disorders in new-born babies where 
failure to detect and treat such disorder could lead to life-threatening 
situations or severe disabilities. 
(i) for human genetic testing; 
 
(j) for monitoring of levels of medicinal products, substances or 
biological components, when there is a risk that an erroneous result 
will lead to a patient management decision resulting in a life-
threatening situation for the patient or for the patient’s offspring; 
(k) for management of patients suffering from a life-threatening 
disease or condition; 
(l) for screening for congenital disorders in the embryo or foetus; 
(m) for screening for congenital disorders in new-born babies where 
failure to detect and treat such disorders could lead to life-threatening 
situations or severe disabilities. 
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2.4. Rule 4 
(a) Devices intended for self-testing are classified as class C, except 
for  
devices for the detection of pregnancy,  
for fertility testing and 
for determining cholesterol level, 
and devices for the detection of glucose, erythrocytes, leucocytes and 
bacteria in urine, which are classified as class B. 
(b) Devices intended for near-patient testing are classified in their own 
right. 
 Rule 4 
(4) Devices intended for self-testing are classified as Class C, except 
for devices testing the following which are classified in Class D— 
(a) the detection of pregnancy; 
(b) fertility testing; 
(c) for determining cholesterol level; 
(d) for the detection of glucose, erythrocytes, leucocytes and bacteria 
in urine. 
(5) Devices intended for near-patient testing are classified in their own 
right. 
 
2.5. Rule 5 
The following devices are classified as class A: 
(a) products for general laboratory use, accessories which possess no 
critical characteristics, buffer solutions, washing solutions, and general 
culture media and histological stains, intended by the manufacturer to 
make them suitable for in vitro diagnostic procedures relating to a 
specific examination; 
(b) instruments intended by the manufacturer specifically to be used 
for in vitro diagnostic procedures; 
(c) specimen receptacles. 
 Rule 5 
(6) The following devices are classified as Class A— 
(a) products for general laboratory use, accessories which possess no 
critical characteristics, buffer solutions, washing solutions, and general 
culture media and histological stains, intended by the manufacturer to 
make them suitable for in vitro diagnostic procedures relating to a 
specific examination; 
(b) instruments intended by the manufacturer specifically to be used 
for in vitro diagnostic procedures; 
(c) specimen receptacles. 
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2.6. Rule 6 
Devices not covered by the above-mentioned classification rules are 
classified as class B. 
 Rule 6 
Devices not covered by the above-mentioned classification rules are 
classified as Class B. 
 
2.7. Rule 7 
Devices which are controls without a quantitative or qualitative 
assigned value are classified as class B 
 Rule 7 
Devices which are controls without a quantitative or qualitative 
assigned value are classified as Class B. 
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Appendix C4 8 Comparison: Medical Devices classification rules UK v EU 
 
 
ANNEX VIII 
CLASSIFICATION RULES 
CHAPTER I 
DEFINITIONS SPECIFIC TO CLASSIFICATION RULES 
 SCHEDULE 9 Regulation 1A 
Classification rules 
Chapter 1 
Definitions specific to classification rules 
1. DURATION OF USE 
1.1. ‘Transient’ means normally intended for continuous use for less 
than 60 minutes. 
1.2. ‘Short term’ means normally intended for continuous use for 
between 60 minutes and 30 days. 
1.3. ‘Long term’ means normally intended for continuous use for more 
than 30 days. 
 1. In this Schedule— 
(a) in relation to the duration of use— 
“long term” means normally intended for continuous use for more than 
30 days; 
“short term” means normally intended for continuous use for between 
60 minutes and 30 days; 
“transient” means normally intended for continuous use for less than 
60 minutes; 
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2. INVASIVE AND ACTIVE DEVICES 
2.1. ‘Body orifice’ means any natural opening in the body, as well as 
the external surface of the eyeball, or any permanent artificial opening, 
such as a stoma. 
2.2. ‘Surgically invasive device’ means: 
(a) an invasive device which penetrates inside the body through the 
surface of the body, including through mucous membranes of body 
orifices with the aid or in the context of a surgical operation; and 
(b) a device which produces penetration other than through a body 
orifice. 
2.3. ‘Reusable surgical instrument’ means an instrument intended for 
surgical use in cutting, drilling, sawing, scratching, scraping, 
clamping, retracting, clipping or similar procedures, without a 
connection to an active device and which is intended by the 
manufacturer to be reused after appropriate procedures such as 
cleaning, disinfection and sterilisation have been carried out. 
2.4. ‘Active therapeutic device’ means any active device used, 
whether alone or in combination with other devices, to support, 
modify, replace or restore biological functions or structures with a 
view to treatment or alleviation of an illness, injury or disability. 
2.5. ‘Active device intended for diagnosis and monitoring’ means any 
active device used, whether alone or in combination with other 
devices, to supply information for detecting, diagnosing, monitoring or 
 (b) in relation to invasive and active devices— 
“active device intended for diagnosis and monitoring” means any 
active device used, whether alone or in combination with other 
devices, to supply information for detecting, diagnosing, monitoring or 
treating physiological conditions, states of health, illnesses or 
congenital deformities; 
“active therapeutic device” means any active device used, whether 
alone or in combination with other devices, to support, modify, replace 
or restore biological functions or structures with a view to treatment or 
alleviation of an illness, injury or disability; 
“body orifice” means any natural opening in the body, as well as the 
external surface of the eyeball, or any permanent artificial opening, 
such as a stoma; 
“central circulatory  system” means the following blood vessels— 
arteriae pulmonales, aorta ascendens, arcus aortae, aorta descendens to 
the bifurcation aortae, arteriae coronariae, arteria carotis communis, 
arteria carotis externa, arteria carotis interna, arteriae cerebrales, 
truncus brachiocephalicus, venae cordis, venae pulmonales, vena cava 
superior and vena cava inferior; 
“central nervous system” means the brain, meninges and spinal cord; 
“injured skin or mucous membrane” means an area of skin or a 
mucous membrane presenting a pathological change or change 
following disease or a wound; 
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treating physiological conditions, states of health, illnesses or 
congenital deformities. 
2.6. ‘Central circulatory system’ means the following blood vessels: 
arteriae pulmonales, aorta ascendens, arcus aortae, aorta descendens to 
the bifurcatio aortae, arteriae coronariae, arteria carotis communis, 
arteria carotis externa, arteria carotis interna, arteriae cerebrales, 
truncus brachiocephalicus, venae cordis, venae pulmonales, vena cava 
superior and vena cava inferior. 
2.7. ‘Central nervous system’ means the brain, meninges and spinal 
cord. 
2.8. ‘Injured skin or mucous membrane’ means an area of skin or a 
mucous membrane presenting a pathological change or change 
following disease or a wound. 
“reusable surgical instrument” means an instrument intended for 
surgical use in cutting, drilling, sawing, scratching, scraping, 
clamping, retracting, clipping or similar procedures, without a 
connection to an active device and which is intended by the 
manufacturer to be reused after appropriate procedures such as 
cleaning, disinfection and sterilisation have been carried out; 
“surgically invasive device” means— 
(a) an invasive device which penetrates inside the body through the 
surface of the body, including through mucous membranes of body 
orifices with the aid or in the context of a surgical operation; and 
(b) a device which penetrates other than through a body orifice; 
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ANNEX VIII 
CLASSIFICATION RULES 
 SCHEDULE 9 Regulation 1A 
Classification rules 
CHAPTER II 
IMPLEMENTING RULES 
 Chapter 2 
Implementing rules 
3.1. Application of the classification rules shall be governed by the 
intended purpose of the devices. 
3.2. If the device in question is intended to be used in combination 
with another device, the classification rules shall apply separately to 
each of the devices. Accessories for a medical device shall be 
classified in their own right separately from the device with which 
they are used. 
3.3. Software, which drives a device or influences the use of a device, 
shall fall within the same class as the device. 
If the software is independent of any other device, it shall be classified 
in its own right. 
3.4. If the device is not intended to be used solely or principally in a 
specific part of the body, it shall be considered and classified on the 
basis of the most critical specified use. 
3.5. If several rules, or if, within the same rule, several sub-rules, 
apply to the same device based on the device's intended purpose, the 
strictest rule and sub-rule resulting in the higher classification shall 
apply. 
 2.—(1) Application of the classification rules must be governed by the 
intended purpose of the devices. 
(2) If the device in question is intended to be used in combination with 
another device— 
(a) the classification rules must apply separately to each of the devices; 
(b) accessories for a medical device and for a product listed in 
Schedule 16 must be classified in their own right separately from the 
device with which they are used. 
(3) Software, which drives a device or influences the use of a device, 
must fall within the same class as the device but, if the software is 
independent of any other device, it must be classified in its own right. 
(4) If the device is not intended to be used solely or principally in a 
specific part of the body, it must be considered and classified on the 
basis of the most critical specified use. 
(5) If several rules or, if, within the same rule, several sub-rules, apply 
to the same device based on the device’s intended purpose, the strictest 
rule and sub-rule resulting in the higher classification must apply. 
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3.6. In calculating the duration referred to in Section 1, continuous use 
shall mean: 
(a) the entire duration of use of the same device without regard to 
temporary interruption of use during a procedure or temporary 
removal for purposes such as cleaning or disinfection of the device. 
Whether the interruption of use or the removal is temporary shall be 
established in relation to the duration of the use prior to and after the 
period when the use is interrupted or the device removed; and 
(b) the accumulated use of a device that is intended by the 
manufacturer to be replaced immediately with another of the same 
type. 
3.7. A device is considered to allow direct diagnosis when it provides 
the diagnosis of the disease or condition in question by itself 
 (6) In calculating the duration of use referred to in paragraph 1(a), 
continuous use means— 
(a) the entire duration of use of the same device without regard to 
temporary interruption of use during a procedure or temporary 
removal for purposes such as cleaning or disinfection of the device 
(and, whether the interruption of use or the removal is temporary must 
be established in relation to the duration of the use prior to and after 
the period when the use is interrupted or the device removed); 
(b) the accumulated use of a device that is intended by the 
manufacturer to be replaced immediately with another of the same 
type. 
(7) A device is considered to allow direct diagnosis when it provides 
the diagnosis of the disease or condition in question by itself or when 
it provides decisive information for the diagnosis. 
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ANNEX VIII 
CLASSIFICATION RULES 
 SCHEDULE 9 Regulation 1A 
Classification rules 
Chapter 3 
Classification rules 
 Chapter 3 
Classification rules 
4. NON-INVASIVE DEVICES  Non-invasive devices 
4.1. Rule 1 
All non-invasive devices are classified as class I, unless one of the 
rules set out hereinafter applies. 
 Rule 1 
3.—(1) All non-invasive devices are classified as Class I, unless one of 
the other rules set out in this Schedule applies. 
4.2. Rule 2 
All non-invasive devices intended for channelling or storing blood, 
body liquids, cells or tissues, liquids or gases for the purpose of 
eventual infusion, administration or introduction into the body are 
classified as class IIa: 
— if they may be connected to a class IIa, class IIb or class III active 
device; or — if they are intended for use for channelling or storing 
blood or other body liquids or for storing organs, parts of organs or 
body cells and tissues, except for blood bags; blood bags are classified 
as class IIb. 
In all other cases, such devices are classified as class I. 
 Rule 2 
(2) All non-invasive devices intended for channelling or storing blood, 
body liquids, cells or tissues, liquids or gases for the purpose of 
eventual infusion, administration or introduction into the body are 
classified as Class IIa— 
(a) if they may be connected to a Class IIa, Class IIb or Class III active 
device; or 
(b) if they are intended for use for channelling or storing blood or 
other body liquids or for storing organs, parts of organs or body cells 
and tissues, except for blood bags which are classified as Class IIb; 
such devices are classified as Class I, in all other cases. 
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4.3. Rule 3 
All non-invasive devices intended for modifying the biological or 
chemical composition of human tissues or cells, blood, other body 
liquids or other liquids intended for implantation or administration into 
the body are classified as class IIb, unless the treatment for which the 
device is used consists of filtration, centrifugation or exchanges of gas, 
heat, in which case they are classified as class IIa. 
All non-invasive devices consisting of a substance or a mixture of 
substances intended to be used in vitro in direct contact with human 
cells, tissues or organs taken from the human body or used in vitro 
with human embryos before their implantation or administration into 
the body are classified as class III 
 Rule 3 
(3) All non-invasive devices intended for modifying the biological or 
chemical composition of human tissues or cells, blood, other body 
liquids or other liquids intended for implantation or administration into 
the body are classified as Class IIb, unless the treatment for which the 
device is used consists of filtration, centrifugation or exchanges of gas, 
heat, in which case they are classified as Class IIa. 
(4) All non-invasive devices consisting of a substance or a mixture of 
substances intended to be used in vitro in direct contact with human 
cells, tissues or organs taken from the human body or used in vitro 
with human embryos before their implantation or administration into 
the body are classified as Class III. 
4.4. Rule 4 
All non-invasive devices which come into contact with injured skin or 
mucous membrane are classified as: 
— class I if they are intended to be used as a mechanical barrier, for 
compression or for absorption of exudates; 
— class IIb if they are intended to be used principally for injuries to 
skin which have breached the dermis or mucous membrane and can 
only heal by secondary intent; 
— class IIa if they are principally intended to manage the micro-
environment of injured skin or mucous membrane; and 
— class IIa in all other cases. 
 Rule 4 
(5) All non-invasive devices which come into contact with injured skin 
or mucous membrane are classified as— 
(a) Class I if they are intended to be used as a mechanical barrier, for 
compression or for absorption of exudates; 
(b) Class IIb if they are intended to be used principally for injuries to 
skin which have breached the dermis or mucous membrane and can 
only heal by secondary intent; 
(c) Class IIa if they are principally intended to manage the micro-
environment of injured skin or mucous membrane; 
(d) Class IIa in all other cases. 
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This rule applies also to the invasive devices that come into contact 
with injured mucous membrane. 
This rule also applies to the invasive devices that come into contact 
with injured mucous membrane. 
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5. INVASIVE DEVICES  Invasive devices 
5.1. Rule 5 
All invasive devices with respect to body orifices, other than 
surgically invasive devices, which are not intended for connection to 
an active device or which are intended for connection to a class I 
active device are classified as: 
— class I if they are intended for transient use; 
— class IIa if they are intended for short-term use, except if they are 
used in the oral cavity as far as the pharynx, in an ear canal up to the 
ear drum or in the nasal cavity, in which case they are classified as 
class I; and 
— class IIb if they are intended for long-term use, except if they are 
used in the oral cavity as far as the pharynx, in an ear canal up to the 
ear drum or in the nasal cavity and are not liable to be absorbed by the 
mucous membrane, in which case they are classified as class IIa. 
All invasive devices with respect to body orifices, other than 
surgically invasive devices, intended for connection to a class IIa, 
class IIb or class III active device, are classified as class IIa. 
 Rule 5 
4.—(1) All invasive devices with respect to body orifices, other than 
surgically invasive devices, which are not intended for connection to 
an active device or which are intended for connection to a Class I 
active device are classified as— 
(a) Class I if they are intended for transient use; 
(b) Class IIa if they are intended for short-term use, except if they are 
used in the oral cavity as far as the pharynx, in an ear canal up to the 
ear drum or in the nasal cavity, in which case they are classified as 
class I; 
(c) Class IIb if they are intended for long-term use, except if they are 
used in the oral cavity as far as the pharynx, in an ear canal up to the 
ear drum or in the nasal cavity and are not liable to be absorbed by the 
mucous membrane, in which case they are classified as class IIa. 
All invasive devices with respect to body orifices, other than surgically 
invasive devices, intended for connection to a Class IIa, Class IIb or 
Class III active device, are classified as Class IIa. 
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5.2. Rule 6 
All surgically invasive devices intended for transient use are classified 
as class IIa unless they: 
— are intended specifically to control, diagnose, monitor or correct a 
defect of the heart or of the central circulatory system through direct 
contact with those parts of the body, in which case they are classified 
as class III; 
— are reusable surgical instruments, in which case they are classified 
as class I; 
— are intended specifically for use in direct contact with the heart or 
central circulatory system or the central nervous system, in which case 
they are classified as class III; 
— are intended to supply energy in the form of ionising radiation in 
which case they are classified as class IIb; 
— have a biological effect or are wholly or mainly absorbed in which 
case they are classified as class IIb; or 
— are intended to administer medicinal products by means of a 
delivery system, if such administration of a medicinal product is done 
in a manner that is potentially hazardous taking account of the mode of 
application, in which case they are classified as class IIb. 
 Rule 6 
(2) All surgically invasive devices intended for transient use are 
classified as class IIa unless they— 
(a) are intended specifically to control, diagnose, monitor or correct a 
defect of the heart or of the central circulatory system through direct 
contact with those parts of the body, in which case they are classified 
as Class III; 
(b) are reusable surgical instruments, in which case they are classified 
as class I; 
(c) are intended specifically for use in direct contact with the heart or 
central circulatory system or the central nervous system, in which case 
they are classified as Class III; 
(d) are intended to supply energy in the form of ionising radiation in 
which case they are classified as Class IIb; 
(e) have a biological effect or are wholly or mainly absorbed in which 
case they are classified as Class IIb; or 
(f) are intended to administer medicinal products by means of a 
delivery system, if such administration of a medicinal product is done 
in a manner that is potentially hazardous taking account of the mode of 
application, in which case they are classified as Class IIb. 
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5.3. Rule 7 
All surgically invasive devices intended for short-term use are 
classified as class IIa unless they: 
— are intended specifically to control, diagnose, monitor or correct a 
defect of the heart or of the central circulatory system through direct 
contact with those parts of the body, in which case they are classified 
as class III; 
— are intended specifically for use in direct contact with the heart or 
central circulatory system or the central nervous system, in which case 
they are classified as class III; 
— are intended to supply energy in the form of ionizing radiation in 
which case they are classified as class IIb; 
— have a biological effect or are wholly or mainly absorbed in which 
case they are classified as class III; 
— are intended to undergo chemical change in the body in which case 
they are classified as class IIb, except if the devices are placed in the 
teeth; or 
— are intended to administer medicines, in which case they are 
classified as class IIb. 
 Rule 7 
(3) All surgically invasive devices intended for short-term use are 
classified as Class IIa unless they— 
(a) are intended specifically to control, diagnose, monitor or correct a 
defect of the heart or of the central circulatory system through direct 
contact with those parts of the body, in which case they are classified 
as class III; 
(b) are intended specifically for use in direct contact with the heart or 
central circulatory system or the central nervous system, in which case 
they are classified as Class III; 
(c) are intended to supply energy in the form of ionizing radiation in 
which case they are classified as Class IIb; 
(d) have a biological effect or are wholly or mainly absorbed in which 
case they are classified as Class III; 
(e) are intended to undergo chemical change in the body in which case 
they are classified as Class IIb, except if the devices are placed in the 
teeth; or 
(f) are intended to administer medicines, in which case they are 
classified as Class IIb. 
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5.4. Rule 8 
All implantable devices and long-term surgically invasive devices are 
classified as class IIb unless they: 
— are intended to be placed in the teeth, in which case they are 
classified as class IIa; 
— are intended to be used in direct contact with the heart, the central 
circulatory system or the central nervous system, in which case they 
are classified as class III; 
— have a biological effect or are wholly or mainly absorbed, in which 
case they are classified as class III; 
— are intended to undergo chemical change in the body in which case 
they are classified as class III, except if the devices are placed in the 
teeth; 
— are intended to administer medicinal products, in which case they 
are classified as class III; 
— are active implantable devices or their accessories, in which cases 
they are classified as class III; 
— are breast implants or surgical meshes, in which cases they are 
classified as class III; 
— are total or partial joint replacements, in which case they are 
classified as class III, with the exception of ancillary components such 
as screws, wedges, plates and instruments; or 
 Rule 8 
(4) All implantable devices and long-term surgically invasive devices 
are classified as Class IIb unless they— 
(a) are intended to be placed in the teeth, in which case they are 
classified as Class IIa; 
(b) are intended to be used in direct contact with the heart, the central 
circulatory system or the central nervous system, in which case they 
are classified as Class III; 
(c) are intended to undergo chemical change in the body in which case 
they are classified as Class III, except if the devices are placed in the 
teeth; 
(d) are intended to administer medicinal products, in which case they 
are classified as Class III; 
(e) are active implantable devices or their accessories, in which case 
they are classified as Class III; 
(f) are breast implants or surgical meshes, in which cases they are 
classified as Class III; 
(g) are total or partial joint replacements, in which case they are 
classified as Class III, with the exception of ancillary components such 
as screws, wedges, plates and instruments; or 
(h) are spinal disc replacement implants or are implantable devices 
that come into contact with the spinal column, in which case they are 
Page 392 of 513 
 
 
— are spinal disc replacement implants or are implantable devices that 
come into contact with the spinal column, in which case they are 
classified as class III with the exception of components such as 
screws, wedges, plates and instruments. 
classified as Class III with the exception of components such as 
screws, wedges, plates and instruments. 
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6. ACTIVE DEVICE  Active devices 
6.1. Rule 9 
All active therapeutic devices intended to administer or exchange 
energy are classified as class IIa unless their characteristics are such 
that they may administer energy to or exchange energy with the 
human body in a potentially hazardous way, taking account of the 
nature, the density and site of application of the energy, in which case 
they are classified as class IIb. 
All active devices intended to control or monitor the performance of 
active therapeutic class IIb devices, or intended directly to influence 
the performance of such devices are classified as class IIb. 
All active devices intended to emit ionizing radiation for therapeutic 
purposes, including devices which control or monitor such devices, or 
which directly influence their performance, are classified as class IIb. 
All active devices that are intended for controlling, monitoring or 
directly influencing the performance of active implantable devices are 
classified as class III. 
 Rule 9 
5.—(1) All active therapeutic devices intended to administer or 
exchange energy are classified as Class IIa unless their characteristics 
are such that they may administer energy to or exchange energy with 
the human body in a potentially hazardous way, taking account of the 
nature, the density and site of application of the energy, in which case 
they are classified as Class IIb. 
(2) All active devices intended to control or monitor the performance 
of active therapeutic Class IIb devices, or intended directly to 
influence the performance of such devices are classified as Class IIb. 
(3) All active devices intended to emit ionizing radiation for 
therapeutic purposes, including devices which control or monitor such 
devices, or which directly influence their performance, are classified 
as Class IIb. 
(4) All active devices that are intended for controlling, monitoring or 
directly influencing the performance of active implantable devices are 
classified as Class III. 
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6.2. Rule 10 
Active devices intended for diagnosis and monitoring are classified as 
class IIa: 
— if they are intended to supply energy which will be absorbed by the 
human body, except for devices intended to illuminate the patient's 
body, in the visible spectrum, in which case they are classified as class 
I;  
— if they are intended to image in vivo distribution of 
radiopharmaceuticals; or 
— if they are intended to allow direct diagnosis or monitoring of vital 
physiological processes, unless they are specifically intended for 
monitoring of vital physiological parameters and the nature of 
variations of those parameters is such that it could result in immediate 
danger to the patient, for instance variations in cardiac performance, 
respiration, activity of the central nervous system, or they are intended 
for diagnosis in clinical situations where the patient is in immediate 
danger, in which cases they are classified as class IIb. 
Active devices intended to emit ionizing radiation and intended for 
diagnostic or therapeutic radiology, including interventional radiology 
devices and devices which control or monitor such devices, or which 
directly influence their performance, are classified as class IIb. 
 Rule 10 
(5) Active devices intended for diagnosis and monitoring are classified 
as Class IIa— 
(a) if they are intended to supply energy which will be absorbed by the 
human body, except for devices intended to illuminate the patient’s 
body, in the visible spectrum, in which case they are classified as class 
I; 
(b) if they are intended to image in vivo distribution of 
radiopharmaceuticals; 
(c) if they are intended to image in vivo distribution of 
radiopharmaceuticals; or 
(d) if they are intended to allow direct diagnosis or monitoring of vital 
physiological processes, unless they are specifically intended for 
monitoring of vital physiological parameters and the nature of 
variations of those parameters is such that it could result in immediate 
danger to the patient, for instance variations in cardiac performance, 
respiration, activity of the central nervous system, or they are intended 
for diagnosis in clinical situations where the patient is in immediate 
danger, in which cases they are classified as Class IIb. 
(6) Active devices intended to emit ionizing radiation and intended for 
diagnostic or therapeutic radiology, including interventional radiology 
devices and devices which control or monitor such devices, or which 
directly influence their performance, are classified as Class IIb. 
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6.3. Rule 11 
Software intended to provide information which is used to take 
decisions with diagnosis or therapeutic purposes is classified as class 
IIa, except if such decisions have an impact that may cause: 
— death or an irreversible deterioration of a person's state of health, in 
which case it is in class III; or 
— a serious deterioration of a person's state of health or a surgical 
intervention, in which case it is classified as class IIb. 
Software intended to monitor physiological processes is classified as 
class IIa, except if it is intended for monitoring of vital physiological 
parameters, where the nature of variations of those parameters is such 
that it could result in immediate danger to the patient, in which case it 
is classified as class IIb. 
All other software is classified as class I. 
 Rule 11 
(7) Software intended to provide information which is used to take 
decisions with diagnosis or therapeutic purposes is classified as Class 
IIa, except if such decisions have an impact that may cause— 
(a) death or an irreversible deterioration of a person’s state of health, 
in which case it is in class III; or 
(b) a serious deterioration of a person’s state of health or a surgical 
intervention, in which case it is classified as Class IIb. 
(8) Software intended to monitor physiological processes is classified 
as Class IIa, except if it is intended for monitoring of vital 
physiological parameters, where the nature of variations of those 
parameters is such that it could result in immediate danger to the 
patient, in which case it is classified as Class IIb. 
(9) All other software is classified as Class I. 
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6.4. Rule 12 
All active devices intended to administer and/or remove medicinal 
products, body liquids or other substances to or from the body are 
classified as class IIa, unless this is done in a manner that is potentially 
hazardous, taking account of the nature of the substances involved, of 
the part of the body concerned and of the mode of application in which 
case they are classified as class IIb. 
 Rule 12 
(10) All active devices intended to administer or remove medicinal 
products, body liquids or other substances to or from the body are 
classified as Class IIa, unless this is done in a manner that is 
potentially hazardous, taking account of the nature of the substances 
involved, of the part of the body concerned and of the mode of 
application in which case they are classified as Class IIb. 
 
 
 
 
6.5. Rule 13 
All other active devices are classified as class I. 
 Rule 13 
(11) All other active devices are classified as Class I. 
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7. SPECIAL RULES  Special rules 
7.1. Rule 14 
All devices incorporating, as an integral part, a substance which, if 
used separately, can be considered to be a medicinal product, as 
defined in point 2 of Article 1 of Directive 2001/83/EC, including a 
medicinal product derived from human blood or human plasma, as 
defined in point 10 of Article 1 of that Directive, and that has an action 
ancillary to that of the devices, are classified as class III. 
 Rule 14 
6.—(1) All devices incorporating, as an integral part, a substance 
which, if used separately, can be considered to be a medicinal product, 
as defined in regulation 2(1) of the Human Medicines Regulations 
2012, including a medicinal product derived from human blood or 
human plasma, and that has an action ancillary to that of the devices, 
are classified as Class III. 
7.2. Rule 15 
All devices used for contraception or prevention of the transmission of 
sexually transmitted diseases are classified as class IIb, unless they are 
implantable or long term invasive devices, in which case they are 
classified as class III. 
 Rule 15 
(2) All devices used for contraception or prevention of the 
transmission of sexually transmitted diseases are classified as Class 
IIb, unless they are implantable or long term invasive devices, in 
which case they are classified as class III. 
7.3. Rule 16 
All devices intended specifically to be used for disinfecting, cleaning, 
rinsing or, where appropriate, hydrating contact lenses are classified as 
class IIb. 
All devices intended specifically to be used for disinfecting or 
sterilising medical devices are classified as class IIa, unless they are 
disinfecting solutions or washer-disinfectors intended specifically to 
be used for disinfecting invasive devices, as the end point of 
processing, in which case they are classified as class IIb. 
 Rule 16 
(3) All devices intended specifically to be used for disinfecting, 
cleaning, rinsing or, where appropriate, hydrating contact lenses are 
classified as Class IIb. 
(4) All devices intended specifically to be used for disinfecting or 
sterilising medical devices are classified as Class IIa, unless they are 
disinfecting solutions or washerdisinfectors intended specifically to be 
used for disinfecting invasive devices, as the end point of processing, 
in which case they are classified as Class IIb. 
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This rule does not apply to devices that are intended to clean devices 
other than contact lenses by means of physical action only. 
(5) Rule 16 does not apply to devices that are intended to clean devices 
other than contact lenses by means of physical action only. 
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7.4. Rule 17 
Devices specifically intended for recording of diagnostic images 
generated by X-ray radiation are classified as class IIa. 
 Rule 17 
(6) Devices specifically intended for recording of diagnostic images 
generated by X-ray radiation are classified as Class IIa. 
7.5. Rule 18 
All devices manufactured utilising tissues or cells of human or animal 
origin, or their derivatives, which are non-viable or rendered non-
viable, are classified as class III, unless such devices are manufactured 
utilising tissues or cells of animal origin, or their derivatives, which 
are non-viable or rendered non-viable and are devices intended to 
come into contact with intact skin only. 
 Rule 18 
(7) All devices manufactured utilising tissues or cells of human or 
animal origin, or their derivatives, which are non-viable or rendered 
non-viable, are classified as class III, unless such devices are 
manufactured utilising tissues or cells of animal origin, or their 
derivatives, which are non-viable or rendered non-viable and are 
devices intended to come into contact with intact skin only. 
7.6. Rule 19 
All devices incorporating or consisting of nanomaterial are classified 
as: 
— class III if they present a high or medium potential for internal 
exposure; 
— class IIb if they present a low potential for internal exposure; and 
— class IIa if they present a negligible potential for internal exposure. 
 Rule 19 
(8) All devices incorporating or consisting of nanomaterial are 
classified as— 
(a) Class III if they present a high or medium potential for internal 
exposure; 
(b) Class IIb if they present a low potential for internal exposure; 
(c) Class IIa if they present a negligible potential for internal exposure. 
 
7.7. Rule 20 
All invasive devices with respect to body orifices, other than 
surgically invasive devices, which are intended to administer 
medicinal products by inhalation are classified as class IIa, unless their 
mode of action has an essential impact on the efficacy and safety of 
 Rule 20 
(9) All invasive devices with respect to body orifices, other than 
surgically invasive devices, which are intended to administer 
medicinal products by inhalation are classified as lass IIa, unless their 
mode of action has an essential impact on the efficacy and safety of 
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the administered medicinal product or they are intended to treat life-
threatening conditions, in which case they are classified as class IIb. 
 
the administered medicinal product or they are intended to treat life-
threatening conditions, in which case they are classified as Class IIb. 
7.8. Rule 21 
Devices that are composed of substances or of combinations of 
substances that are intended to be introduced into the human body via 
a body orifice or applied to the skin and that are absorbed by or locally 
dispersed in the human body are classified as: 
— class III if they, or their products of metabolism, are systemically 
absorbed by the human body in order to achieve the intended purpose; 
— class III if they achieve their intended purpose in the stomach or 
lower gastrointestinal tract and they, or their products of metabolism, 
are systemically absorbed by the human body; 
— class IIa if they are applied to the skin or if they are applied in the 
nasal or oral cavity as far as the pharynx, and achieve their intended 
purpose on those cavities; and 
— class IIb in all other cases. 
 Rule 21 
(10) Devices that are composed of substances or of combinations of 
substances that are intended to be introduced into the human body via 
a body orifice or applied to the skin and that are absorbed by or locally 
dispersed in the human body are classified as— 
(a) Class III if they, or their products of metabolism, are systemically 
absorbed by the human body in order to achieve the intended purpose; 
(b) Class III if they achieve their intended purpose in the stomach or 
lower gastrointestinal tract and they, or their products of metabolism, 
are systemically absorbed by the human body; 
(c) Class IIa if they are applied to the skin or if they are applied in the 
nasal or oral cavity as far as the pharynx, and achieve their intended 
purpose on those cavities; 
(d) Class IIb in all other cases. 
7.9. Rule 22 
Active therapeutic devices with an integrated or incorporated 
diagnostic function which significantly determines the patient 
management by the device, such as closed loop systems or automated 
external defibrillators, are classified as class III. 
 Rule 22 
(11) Active therapeutic devices with an integrated or incorporated 
diagnostic function which significantly determines the patient 
management by the device, such as closed loop systems or automated 
external defibrillators, are classified as Class III. 
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Appendix C5 1 OCE General Safety and Performance Requirements Matrix  
The following is a list of standards which may be applicable to the OCE system 
 
Standard 
1.  EN ISO 13485:2016 
Medical devices - Quality management systems - Requirements for regulatory purposes (ISO 
13485:2016) 
EN ISO 13485:2016/AC:2018 
2.  EN 13612:2002 
Performance evaluation of in vitro diagnostic medical devices 
EN 13612:2002/AC:2002 
3.  EN 13641:2002 
Elimination or reduction of risk of infection related to in vitro diagnostic reagents 
4.  EN 13975:2003 
Sampling procedures used for acceptance testing of in vitro diagnostic medical devices - 
Statistical aspects 
5.  EN 14136:2004 
Use of external quality assessment schemes in the assessment of the performance of in vitro 
diagnostic examination procedures 
6.  EN 14254:2004 
In vitro diagnostic medical devices - Single-use receptacles for the collection of specimens, 
other than blood, from humans 
7.  EN ISO 14971:2012 
Medical devices - Application of risk management to medical devices (ISO 14971:2007, 
Corrected version 2007-10-01) 
8.  EN ISO 15223-1:2016 
Medical devices - Symbols to be used with medical device labels, labelling and information to 
be supplied - Part 1: General requirements (ISO 15223-1:2016, Corrected version 2017-03) 
9.  EN ISO 18113-1:2011 
In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 
1: Terms, definitions and general requirements (ISO 18113-1:2009) 
10.  EN ISO 18113-2:2011 
In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 
2: In vitro diagnostic reagents for professional use (ISO 18113-2:2009) 
11.  EN ISO 18113-3:2011 
In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 
3: In vitro diagnostic instruments for professional use (ISO 18113-3:2009) 
12.  EN 61010-2-101:2002 
Safety requirements for electrical equipment for measurement, control, and laboratory use - Part 
2-101: Particular requirements for in vitro diagnostic (IVD) medical equipment 
13.  EN 61326-2-6:2006 
Electrical equipment for measurement, control and laboratory use - EMC requirements - Part 2-
6: Particular requirements - In vitro diagnostic (IVD) medical equipment 
14.  EN 62304:2006 
Medical device software - Software life-cycle processes (IEC 62304:2006) 
EN 62304:2006/AC:2008 
15.  EN 62366:2008 
Medical devices - Application of usability engineering to medical devices 
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Refer to both the  EN 60601 and 61010 family of standard as a supplement for the actual 
design of the hardware and software  
e.g. 
BS EN 60601-1:2006 Medical electrical equipment - Part 1: General requirements for 
basic safety and essential performance (IEC 60601-1:2005) 
BS EN 61010-1:2010+A1:2019 Safety requirements for electrical equipment for 
measurement, control, and laboratory use. 
Also 
EN 1041:2008 Information supplied by the manufacturer of medical devices 
EN ISO 15223-1:2016 Medical devices - Symbols to be used with medical device labels, 
labelling and information to be supplied - Part 1: General requirements (ISO 15223-
1:2016, Corrected version 2017-03) 
 
 
 
 
 
 
 
 
 
 
Page 403 of 513 
 
 
ANNEX I  
GENERAL SAFETY AND PERFORMANCE REQUIREMENTS  
CHAPTER I 
GENERAL REQUIREMENTS  
Essential Requirement  A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
1. Devices shall achieve the performance intended by their 
manufacturer and shall be designed and manufactured in such a way 
that, during normal conditions of use, they are suitable for their 
intended purpose. They shall be safe and effective and shall not 
compromise the clinical condition or the safety of patients, or the 
safety and health of users or, where applicable, other persons, 
provided that any risks which may be associated with their use 
constitute acceptable risks when weighed against the benefits to the 
patient and are compatible with a high level of protection of health 
and safety, taking into account the generally acknowledged state of 
the art. 
A IVDR 
 
 
EN ISO 13485:2016 
EN ISO 15189:2012 
 
EN ISO 
14971:2012/2019 
 
 
EN 61010-2-101:2002 
 
EN ISO 15223-1:2016 
 
EN 61326-2-6:2006 
 
EN 62304:2006 
 
 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-1:2016 
WIRD01 Regulatory Legislative 
Technical File contents.  
BSI QA Certificate MD  
UKAS Certificiate  
 
WIRD05 Risk Analysis 
WIRD07 Classification Rules 
IVDR 
 
WIMPI08 Electrical Safety 
Testing of Medical Equipment. 
 
Symbols used detailed in User 
guide and technical file 
 
Review of EMC checks 
 
 
WIRD12 Software Development  
 
Cleaning information retained in 
the User Guide and technical file. 
OCE Technical File held in Q-
Pulse 
Copy held in Q-Pulse 
Copy held in Q-Pulse 
 
 
OCE Risk Assessment and 
Classification review held in Q-
Pulse 
 
See e-Quip record for this 
device. 
 
OCE User Guide and Technical 
File in Q-Pulse. 
 
EMC review in OCE Technical 
File  
 
Software design held in OCE 
Technical File. 
 
OCE USER Guide in Technical 
File held in Q-Pulse. 
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Essential Requirement  A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
2. The requirement in this Annex to reduce risks as far as possible 
means the reduction of risks as far as possible without adversely 
affecting the benefit-risk ratio. 
A EN ISO 
14971:2012/2019 
 
Risk Assement for OCE system 
 
OCE Risk Assessment file held 
in Q-Pulse 
 
3. Manufacturers shall establish, implement, document and maintain a 
risk management system. 
 Risk management shall be understood as a continuous iterative 
process throughout the entire lifecycle of a device, requiring regular 
systematic updating. In carrying out risk management manufacturers 
shall: 
(a) establish and document a risk management plan for each device; 
(b) identify and analyse the known and foreseeable hazards associated 
with each device; 
(c) estimate and evaluate the risks associated with, and occurring 
during, the intended use and during reasonably foreseeable misuse; 
(d) eliminate or control the risks referred to in point (c) in accordance 
with the requirements of Section 4; 
(e) evaluate the impact of information from the production phase and, 
in particular, from the post-market surveillance system, on hazards 
and the frequency of occurrence thereof, on estimates of their 
associated risks, as well as on the overall risk, the benefit-risk ratio 
and risk acceptability; and 
(f) based on the evaluation of the impact of the information referred to 
in point (e), if necessary amend control measures in line with the 
requirements of Section 4. 
A EN ISO 
14971:2012/2019 
 
 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-1:2016 
 
 
WIRD05 Risk Analysis 
WIRD07 Classification Rules 
IVDR 
 
QP20 Reporting and Review of 
Incidents  
QP26 Customer Feedback 
OCE Risk Assessment and 
Classification review held in Q-
Pulse 
 
User guide and technical file for 
details of information passed to 
users relating to residual risks 
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Essential Requirement  A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
4. Risk control measures adopted by manufacturers for the design and 
manufacture of the devices shall conform to safety principles, taking 
account of the generally acknowledged state of the art. To reduce 
risks, the manufacturers shall manage risks so that the residual risk 
associated with each hazard as well as the overall residual risk is 
judged acceptable. In selecting the most appropriate solutions, 
manufacturers shall, in the following order of priority: 
(a) eliminate or reduce risks as far as possible through safe design and 
manufacture; 
(b) where appropriate, take adequate protection measures, including 
alarms if necessary, in relation to risks that cannot be eliminated; 
and 
(c) provide information for safety (warnings/precautions/contra-
indications) and, where appropriate, training to users. 
Manufacturers shall inform users of any residual risks. 
A UK Legislation 
 
 
EN ISO 
14971:2012/2019 
 
 
EN 61010-2-101:2002 
 
 
EN ISO 15223-1:2016 
 
Appropriate parts of EN 
ISO 18113 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-1:2016 
WIRD01 regulatory legislative 
technical file contents 
 
WIRD05 Risk Analysis 
WIRD07 Classification Rules 
IVDR 
 
WIMPI08 Electrical Safety 
Testing of Medical Equipment. 
 
 
Symbols used detailed in User 
guide and technical file 
 
OCE user guide and technical file 
Technical File for OCE held in 
Q-Pulse 
 
OCE Risk Assessment and 
Classification review held in Q-
Pulse 
 
Review of electrical safety in q-
pulse and test results held in e-
quip 
 
OCE user guide held in q-pulse 
 
Both held in q-pulse 
 
 
5.   In eliminating or reducing risks related to use error, the 
manufacturer shall: 
(a) reduce as far as possible the risks related to the ergonomic features 
of the device and the environment in which the device is intended to 
be used (design for patient safety), and 
(b) give consideration to the technical knowledge, experience, 
education, training and use environment, where applicable, and the 
medical and physical conditions of intended users (design for lay, 
professional, disabled or other users). 
A 
 
NA 
 
 
A 
 
 
EN 62366:2008 
 
 
EN ISO 
14971:2012/2019 
 
 
 
Ergonomics not fully reviewed as 
this is a prototype device 
 
WIRD05 Risk Analysis 
 
 
 
 
 
 
OCE user manual held in Q-
Pulse states trained users only to 
operate the OCE system. 
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Essential Requirement  A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
6. The characteristics and performance of a device shall not be adversely 
affected to such a degree that the health or safety of the patient or 
the user and, where applicable, of other persons are compromised 
during the lifetime of the device, as indicated by the manufacturer, 
when the device is subjected to the stresses which can occur during 
normal conditions of use and has been properly maintained in 
accordance with the manufacturer's instructions. 
A EN ISO 
14971:2012/2019 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-1:2016 
WIRD05 Risk Analysis 
Correct use details found in the 
user manual. 
OCE user manual held in Q-
Pulse . As this is a prototype 
device and under development 
this area needs to be reviewed 
after each modification or 
change both hardware and 
software. 
7. Devices shall be designed, manufactured and packaged in such a way 
that their characteristics and performance during their intended use 
are not adversely affected during transport and storage, for example, 
through fluctuations of temperature and humidity, taking account of 
the instructions and information provided by the manufacturer. 
A IVDR  
BS EN 60601-1 and BS 
EN 61010 – and 
associated standards 
 
OCE Technical File  OCE technical file retained in –
Q-Pulse. 
8. All known and foreseeable risks, and any undesirable effects shall be 
minimised and be acceptable when weighed against the evaluated 
potential benefits to the patients and/or the user arising from the 
intended performance of the device during normal conditions of use. 
 EN ISO 
14971:2012/2019 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-1:2016 
WIRD05 Risk Analysis. Residual 
risks detailed in the user manual.  
OCE user manual held in Q-
Pulse .  
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CHAPTER II 
REQUIREMENTS REGARDING PERFORMANCE, DESIGN AND MANUFACTURE  
Essential Requirement 9 Performance characteristics A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
9.1. Devices shall be designed and manufactured in such a way that 
they are suitable for the purposes referred to in point (2) of Article 
2, as specified by the manufacturer, and suitable with regard to the 
performance they are intended to achieve, taking account of the 
generally acknowledged state of the art. They shall achieve the 
performances, as stated by the manufacturer and in particular, 
where applicable: 
(a) the analytical performance, such as, analytical sensitivity, 
analytical specificity, trueness (bias), precision (repeatability and 
reproducibility), accuracy (resulting from trueness and precision), 
limits of detection and quantitation, measuring range, linearity, 
cut-off, including determination of appropriate criteria for 
specimen collection and handling and control of known relevant 
endogenous and exogenous interference, cross-reactions; and 
(b) the clinical performance, such as diagnostic sensitivity, diagnostic 
specificity, positive predictive value, negative predictive value, 
likelihood ratio, expected values in normal and affected 
populations. 
A 
 
 
 
 
 
 
 
A 
IVDR 
Specification and 
testing of the device 
 
Appropriate parts of BS 
EN 61010 and BS EN 
60101 
 
EN 13612:2002 
 
 
 
 
 
UOD and NHST ethics 
requriements  
 
Technical File especially design 
specification and tests results.  
Design and manufacturing 
documentation detailing how the 
device meets the specification. 
Testing of performance will use 
the relevant parts of 13612. If this 
is relevant then use 60601 or 
61010 family. 
 
 
Ethics approval certificate as 
proof that checking of the 
samples done in accordance with 
UK ethics approval legislation. 
 
Design specification details 
expected performance and 
sensitivity. 
Technical File retained in Q-
Pulse. This file contains 
specification and test results 
showing how the device meets 
requirements.  
The testing specification should 
also detail how the performance 
of the device is evaluated and 
then checked by scanning real 
biopsy samples and comparing 
these scans against 
histopathology reports on same 
samples. 
 
Ethics approval number quoted 
in the OCE technical files. 
9.2. The performance characteristics of the device shall be maintained 
during the lifetime of the device as indicated by the manufacturer. 
A BS EN 60601 and BS 
EN 61010 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-1:2016 
Design life given in technical 
file. Calibration detailed in 
design file and user information 
to ensure OCE system maintains 
performance. 
Technical file and user 
information held in q-Pulse. 
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Essential Requirement 9 Performance characteristics A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
9.3. Where the performance of devices depends on the use of 
calibrators and/or control materials, the metrological traceability 
of values assigned to calibrators and/or control materials shall be 
assured through suitable reference measurement procedures and/or 
suitable reference materials of a higher metrological order. Where 
available, metrological traceability of values assigned to 
calibrators and control materials shall be assured to certified 
reference materials or reference measurement procedures. 
A EN 13612:2002 
EN 13975:2003 
 
BS EN 60601 
BS EN 61010 
 
The OCE device does not use a 
calibrator or control materials in 
the normal sense of IVDDs but 
test parts. Hence the standards 
given for IVDD may not be 
correct and hence need to refer to 
either 60601 or 61010 standards. 
The final choice and check to be 
detailed in the calibration details 
of the  technical file –  
Technical file held in Q-Pulse 
9.4. The characteristics and performances of the device shall be 
specifically checked in the event that they may be affected when 
the device is used for the intended use under normal conditions: 
(a) for devices for self-testing, performances obtained by laypersons; 
(b) for devices for near-patient testing, performances obtained in 
relevant environments (for example, patient home, emergency 
units, ambulances). 
 
 
 
NA 
 
NA 
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Essential Requirement 10 Chemical, physical and biological 
properties 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
10.1. Devices shall be designed and manufactured in such a way as to 
ensure that the characteristics and performance requirements 
referred to in Chapter I are fulfilled. 
 Particular attention shall be paid to the possibility of impairment 
of analytical performance due to physical and/or chemical 
incompatibility between the materials used and the specimens, 
analyte or marker to be detected (such as biological tissues, cells, 
body fluids and micro-organisms), taking account of the intended 
purpose of the device. 
A 
 
 
 
NA 
BS EN 60601 
BS EN 61010 
 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-1:2016 
The OCE does not carry out 
chemical analysis and does not 
suffer from incompatibility 
problems. The user guide details 
how the biopsy sample is to be 
handled and presented to the 
OCE system. 
User guide held in q-pulse. 
10.2. Devices shall be designed, manufactured and packaged in such a 
way as to minimise the risk posed by contaminants and residues to 
patients, taking account of the intended purpose of the device, and 
to the persons involved in the transport, storage and use of the 
devices. Particular attention shall be paid to tissues exposed to 
those contaminants and residues and to the duration and frequency 
of exposure. 
NA  The sample is removed from the 
patient surgically and then 
passed for scanning away from 
the patient. In use there is no 
contact between the patient and 
the OCE device.  
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Essential Requirement 10 Chemical, physical and biological 
properties 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
10.3. Devices shall be designed and manufactured in such a way as to 
reduce to a level as low as reasonably practicable the risks posed 
by substances or particles, including wear debris, degradation 
products and processing residues, that may be released from the 
device. Special attention shall be given to substances which are 
carcinogenic, mutagenic or toxic to reproduction (‘CMR’), in 
accordance with Part 3 of Annex VI to Regulation (EC) No 
1272/2008 of the European Parliament and of the Council (1), and 
to substances having endocrine disrupting properties for which 
there is scientific evidence of probable serious effects to human 
health and which are identified in accordance with the procedure 
set out in Article 59 of Regulation (EC) No 1907/2006 of the 
European Parliament and of the Council (2). 
A BS EN 60601 
BS EN 61010 
EN ISO 
14971:2012/2019 
 
Device has some moving parts 
plus a sample vibration system. 
None of the parts move in such a 
manner as to produce debris. Also 
the device is not intended to be 
used with in the patient areas – 
the operating room. Technical 
details of these parts given in the 
manufacturing section of the 
technical file. A review of the risk 
of debris from these parts is given 
in the risk review control by 
WIRD05 Risk Analysis 
 
Technical details and risk 
review held in technical file 
which is retained in Q-Pulse. 
10.4. Devices shall be designed and manufactured in such a way as to 
reduce as far as possible the risks posed by the unintentional 
ingress of substances into the device, taking into account the 
device and the nature of the environment in which it is intended to 
be used. 
A BS EN 60601 
BS EN 61010 
EN ISO 
14971:2012/2019 
 
The device has designed with 
appropriate covers and reviewed 
by NHS Tayside infection 
control and found to meet 
requirments.WIRD05 Risk 
Analysis 
Infection control review 
contained in OCE technical file 
– risk review. 
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Essential Requirement 11 Infection and microbial contamination A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
11.1. Devices and their manufacturing processes shall be designed in 
such a way as to eliminate or reduce as far as possible the risk of 
infection to the user or, where applicable, other persons. The 
design shall: 
(a) allow easy and safe handling; 
(b) reduce as far as possible any microbial leakage from the device 
and/or microbial exposure during use; 
 and, where necessary 
(c) prevent microbial contamination of the device during use and, in 
the case of specimen receptacles, the risk of contamination of the 
specimen. 
A BS EN 60601 
BS EN 61010 
EN ISO 
14971:2012/2019 
 
Device design risk assessed and 
reviewed to ensure infection risk 
to user is reduce to a minimum. 
User guide and ethics 
agreements detail how to 
maintain safety for the user. 
WIRD05 Risk Analysis 
Details held in OCE technical 
files located in the Q-Pulse 
system. 
11.2. Devices labelled either as sterile or as having a specific microbial 
state shall be designed, manufactured and packaged to ensure that 
their sterile condition or microbial state is maintained under the 
transport and storage conditions specified by the manufacturer 
until that packaging is opened at the point of use, unless the 
packaging which maintains their sterile condition or microbial 
state is damaged. 
NA  The device is not delivered or 
used sterile. Nor used in a 
specific microbial state. 
 
11.3. Devices labelled as sterile shall be processed, manufactured, 
packaged and, sterilised by means of appropriate, validated 
methods. 
NA  The device is not delivered or 
used sterile. 
 
11.4. Devices intended to be sterilised shall be manufactured and 
packaged in appropriate and controlled conditions and facilities. 
NA  The device is not delivered or 
used sterile. 
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Essential Requirement 11 Infection and microbial contamination A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
11.5. Packaging systems for non-sterile devices shall maintain the 
integrity and cleanliness of the product and, where the devices are 
to be sterilised prior to use, minimise the risk of microbial 
contamination; the packaging system shall be suitable taking 
account of the method of sterilisation indicated by the 
manufacturer. 
NA  No packaging.  
11.6. The labelling of the device shall distinguish between identical or 
similar devices placed on the market in both a sterile and a non-
sterile condition additional to the symbol used to indicate that 
devices are sterile. 
  Device not delivered or to be 
used stereile 
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Essential Requirement 12 Devices incorporating materials of 
biological origin 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
Where devices include tissues, cells and substances of animal, human or 
microbial origin, the selection of sources, the processing, preservation, 
testing and handling of tissues, cells and substances of such origin and 
control procedures shall be carried out so as to provide safety for user or 
other person. 
 
In particular, safety with regard to microbial and other transmissible 
agents shall be addressed by implementation of validated methods of 
elimination or inactivation in the course of the manufacturing process. 
This might not apply to certain devices if the activity of the microbial 
and other transmissible agent are integral to the intended purpose of the 
device or when such elimination or inactivation process would 
compromise the performance of the device. 
 
NA  The device does not use such 
substances. 
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Essential Requirement 13. Construction of devices and interaction 
with their environment 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
13.1. If the device is intended for use in combination with other 
devices or equipment, the whole combination, including the 
connection system, shall be safe and shall not impair the specified 
performances of the devices. Any restrictions on use applying to 
such combinations shall be indicated on the label and/or in the 
instructions for use. 
NA    
13.2. Devices shall be designed and manufactured in such a way as to 
remove or reduce as far as possible: 
(a) the risk of injury, in connection with their physical features, 
including the volume/pressure ratio, dimensional and where 
appropriate ergonomic features; 
(b) risks connected with reasonably foreseeable external influences or 
environmental conditions, such as magnetic fields, external 
electrical and electromagnetic effects, electrostatic discharge, 
radiation associated with diagnostic or therapeutic procedures, 
pressure, humidity, temperature, variations in pressure and 
acceleration or radio signal interferences; 
(c) the risks associated with the use of the device when it comes into 
contact with materials, liquids, and substances, including gases, to 
which it is exposed during normal conditions of use; 
(d) the risks associated with the possible negative interaction between 
software and the IT environment within which it operates and 
interacts; 
(e) the risks of accidental ingress of substances into the device; 
(f) the risk of incorrect identification of specimens and the risk of 
erroneous results due to, for example, confusing colour and/or 
numeric and/or character codings on specimen receptacles, 
removable parts and/or accessories used with devices in order to 
perform the test or assay as intended; 
(g) the risks of any foreseeable interference with other devices. 
A BS EN 60601 
BS EN 61010 
EN ISO 
14971:2012/2019 
 
WIRD05 Risk Analysis. Device 
designed and risks reviewed. 
Details of how any risks noted 
are reduced to zero or an 
acceptable level are detailed in 
the OCE risk review.  
Risk review can be found in 
the OCE technical file held 
on Q-Pulse. 
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Essential Requirement 13. Construction of devices and interaction 
with their environment 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
13.3. Devices shall be designed and manufactured in such a way as to 
minimise the risks of fire or explosion during normal use and in 
single fault condition. Particular attention shall be paid to devices 
the intended use of which includes exposure to or use in 
association with flammable or explosive substances or substances 
which could cause combustion. 
A BS EN 60601 
BS EN 61010 
EN ISO 
14971:2012/2019 
EN 13641:2002 
EN 1041:2008 
EN ISO 15223-
1:2016 
User guide states device not to 
be used in oxygen rich or in area 
where flammable gasses are 
present e.g. anesthetic gases. 
Also risk review looks at such 
situations and details how these 
risks are reduced to an 
acceptable level. 
User guide and risk review 
held in OCE technical file 
located in Q-Pulse system, 
13.4. Devices shall be designed and manufactured in such a way that 
adjustment, calibration, and maintenance can be done safely and 
effectively. 
A EN ISO 
14971:2012/2019 
 
Calibration details are given in 
the user manual and discussed in 
the design files 
User details and desing file 
held in the OCE technical file 
held in Q-Pulse system. 
13.5. Devices that are intended to be operated together with other 
devices or products shall be designed and manufactured in such a 
way that the interoperability and compatibility are reliable and 
safe. 
NA  Stand alone device.  
13.6. Devices shall be designed and manufactured in such a way as to 
facilitate their safe disposal and the safe disposal of related waste 
substances by users, or other person. To that end, manufacturers 
shall identify and test procedures and measures as a result of 
which their devices can be safely disposed after use. Such 
procedures shall be described in the instructions for use. 
A EN 13641:2002 
EN 1041:2008 
EN ISO 15223-
1:2016 
Disposal information given in 
the user manual 
User manual held in the OCE 
technical file – Q-Pulses 
system. 
13.7 The measuring, monitoring or display scale (including colour 
change and other visual indicators) shall be designed and 
manufactured in line with ergonomic principles, taking account of 
the intended purpose, users and the environmental conditions in 
which the devices are intended to be used. 
A EN 13641:2002 
EN 1041:2008 
EN ISO 15223-
1:2016 
The display is of the OCE scan 
results and the way it is 
displayed has been reviewed by 
various medical and pathology 
staff.  
See review results in the OCE 
technical file. File maintained 
in Q-Pulse. 
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Essential Requirement 14. Devices with a measuring function A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
14.1. Devices having a primary analytical measuring function shall be 
designed and manufactured in such a way as to provide 
appropriate analytical performance in accordance with point (a) of 
Section 9.1 of Annex I, taking into account the intended purpose 
of the device. 
NA  Device does not have an 
analytical function. 
 
14.2. The measurements made by devices with a measuring function 
shall be expressed in legal units conforming to the provisions of 
Council Directive 80/181/EEC (3). 
A Directive as detailed.  The measurements for distance 
and depth are in SI units. The 
Elastic measurements are a ratio 
and hence do not have units. 
See OCE technical file held in 
Q-pulse. 
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Essential Requirement 15. Protection against radiation 
 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
15.1. Devices shall be designed, manufactured and packaged in such a 
way that exposure of users or other persons to radiation (intended, 
unintended, stray or scattered) is reduced as far as possible and in 
a manner that is compatible with the intended purpose, whilst not 
restricting the application of appropriate specified levels for 
diagnostic purposes. 
 BS EN 60601 
BS EN 61010 
EN ISO 
14971:2012/2019 
 
 
The device has been risk 
assessed and design to ensure 
any unintended emissions have 
been reviewed and reduced to 
minimum. See risk review for 
details of these reduction 
measures.  
Risk review detailed in the 
OCE technical file held in Q-
Pulse system 
15.2. When devices are intended to emit hazardous, or potentially 
hazardous, ionizing and/or non-ionizing radiation, they shall as 
far as possible be: 
(a) designed and manufactured in such a way as to ensure that the 
characteristics and the quantity of radiation emitted can be 
controlled and/or adjusted; and 
(b) fitted with visual displays and/or audible warnings of such 
emissions. 
NA  Device does is not designed to 
emit hazardous radiation – 
ionising or non-ionising. 
 
15.3. The operating instructions for devices emitting hazardous or 
potentially hazardous radiation shall contain detailed information 
as to the nature of the emitted radiation, the means of protecting 
the user, and on ways of avoiding misuse and of reducing the 
risks inherent to installation as far as possible and appropriate. 
Information regarding the acceptance and performance testing, 
the acceptance criteria, and the maintenance procedure shall also 
be specified. 
NA  Device does is not designed to 
emit hazardous radiation – 
ionising or non-ionising. 
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Essential Requirement 16. Electronic programmable systems — 
devices that incorporate electronic programmable systems and 
software that are devices in themselves. 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
16.1. Devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
shall be designed to ensure repeatability, reliability and 
performance in line with their intended use. In the event of a 
single fault condition, appropriate means shall be adopted to 
eliminate or reduce as far as possible consequent risks or 
impairment of performance. 
NA    
16.2. For devices that incorporate software or for software that are 
devices in themselves, the software shall be developed and 
manufactured in accordance with the state of the art taking into 
account the principles of development life cycle, risk 
management, including information security, verification and 
validation. 
NA    
16.3. Software referred to in this Section that is intended to be used in 
combination with mobile computing platforms shall be designed 
and manufactured taking into account the specific features of the 
mobile platform (e.g. size and contrast ratio of the screen) and the 
external factors related to their use (varying environment as 
regards level of light or noise). 
NA    
16.3. Software referred to in this Section that is intended to be used in 
combination with mobile computing platforms shall be designed 
and manufactured taking into account the specific features of the 
mobile platform (e.g. size and contrast ratio of the screen) and the 
external factors related to their use (varying environment as 
regards level of light or noise). 
NA    
16.4. Manufacturers shall set out minimum requirements concerning 
hardware, IT networks characteristics and IT security measures, 
including protection against unauthorised access, necessary to run 
the software as intended. 
A EN 62304:2006 
 
WIRD01 Regulatory Legislative 
Technical File contents. 
WIRD12 Software 
Development 
See user manual and software 
information for details of 
system and other software 
requirements.  
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Essential Requirement. 17. Devices connected to or equipped 
with an energy source 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
17.1. For devices connected to or equipped with an energy source, in 
the event of a single fault condition, appropriate means shall be 
adopted to eliminate or reduce as far as possible consequent risks. 
NA    
17.2. Devices where the safety of the patient depends on an internal 
power supply shall be equipped with a means of determining the 
state of the power supply and an appropriate warning or 
indication for when the capacity of the power supply becomes 
critical. If necessary, such warning or indication shall be given 
prior to the power supply becoming critical. 
NA    
17.3. Devices shall be designed and manufactured in such a way as to 
reduce as far as possible the risks of creating electromagnetic 
interference which could impair the operation of the device in 
question or other devices or equipment in the intended 
environment. 
A BS EN 60601 
BS EN 61010 
EN 61326-2-6:2006 
WIRD01 Regulatory 
Legislative Technical File 
contents.  
See review of emc and emf 
interference and immunity risk 
and methods detailed in the risk 
analysis and design files. 
Held in OCE technical on Q-
Pulse. 
17.4. Devices shall be designed and manufactured in such a way as to 
provide a level of intrinsic immunity to electromagnetic 
interference such that is adequate to enable them to operate as 
intended. 
A BS EN 60601 
BS EN 61010 
EN 61326-2-6:2006 
WIRD01 Regulatory 
Legislative Technical File 
contents.  
See review of emc and emf 
interference and immunity risk 
and methods detailed in the risk 
analysis and design files. 
Held in OCE technical on Q-
Pulse. 
17.5. Devices shall be designed and manufactured in such a way as to 
avoid as far as possible the risk of accidental electric shocks to the 
user, or other person both during normal use of the device and in 
the event of a single fault condition in the device, provided the 
device is installed and maintained as indicated by the 
manufacturer. 
A BS EN 60601 
BS EN 61010 
 
Review of electrical hazards 
and testing of final device as 
per WIMPI08 Electrical Safety 
Testing of Medical Equipment 
Held in OCE technical on Q-
Pulse. 
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Essential Requirement. 18. Protection against mechanical and 
thermal risks 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
18.1. Devices shall be designed and manufactured in such a way as to 
protect users and other persons against mechanical risks. 
A BS EN 60601 
BS EN 61010 
WIRD01 Regulatory 
Legislative Technical File 
contents 
WIRD05 Risk Analysis.  
Risk assessment of the 
mechanical design for risk and 
design information details 
reduction of mechanical risks.  
Risk assessment and design 
details held in OCE technical 
file on Q-Pulse 
18.2. Devices shall be sufficiently stable under the foreseen operating 
conditions. They shall be suitable to withstand stresses inherent to 
the foreseen working environment, and to retain this resistance 
during the expected lifetime of the devices, subject to any 
inspection and maintenance requirements as indicated by the 
manufacturer. 
A BS EN 60601 
BS EN 61010 
WIRD01 Regulatory 
Legislative Technical File 
contents 
WIRD05 Risk Analysis.  
 
Review of stability 
undertaken. See details in 
OCE  Technical File  
18.3. Where there are risks due to the presence of moving parts, risks 
due to break-up or detachment, or leakage of substances, then 
appropriate protection means shall be incorporated.  
 Any guards or other means included with the device to provide 
protection, in particular against moving parts, shall be secure and 
shall not interfere with access for the normal operation of the 
device, or restrict routine maintenance of the device as intended 
by the manufacturer. 
NA    
18.4. Devices shall be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from vibration 
generated by the devices, taking account of technical progress and 
of the means available for limiting vibrations, particularly at 
source, unless the vibrations are part of the specified 
performance. 
A BS EN 60601 
BS EN 61010 
WIRD01 Regulatory 
Legislative Technical File 
contents 
WIRD05 Risk Analysis.  
No vibration risks found. 
Risk assessment review held 
in OCE Technical File 
retained in Q-Pulse. 
18.5. Devices shall be designed and manufactured in such a way as to 
reduce to the lowest possible level the risks arising from the noise 
emitted, taking account of technical progress and of the means 
A BS EN 60601 
BS EN 61010 
Noise due to the sample 
vibration system reviewed. 
Reduced by changing the 
Details of noise reduction held 
in OCE technical file design 
section  
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available to reduce noise, particularly at source, unless the noise 
emitted is part of the specified performance. 
vibration device and using 
sound deadening materials 
inside the enclosure.  
18.6. Terminals and connectors to the electricity, gas or hydraulic and 
pneumatic energy supplies which the user or other person has to 
handle, shall be designed and constructed in such a way as to 
minimise all possible risks. 
A BS EN 60601 
BS EN 61010 
Industry standard connectors 
used and those parts which a user 
may have to access are detailed 
in the user manual. 
See parts list and user manual 
held in OCE technical file on 
Q-Pulse. 
18.7. Errors likely to be made when fitting or refitting certain parts 
which could be a source of risk shall be made impossible by the 
design and construction of such parts or, failing this, by 
information given on the parts themselves and/or their housings. 
 The same information shall be given on moving parts and/or their 
housings where the direction of movement needs to be known in 
order to avoid a risk. 
A BS EN 60601 
BS EN 61010 
Any parts which user may have 
to remove or refit are detailed in 
the user manual. No dangerous 
moving parts are accessible 
Also see risk analysis as per 
WIRD05 Risk Analysis.  
 
Details retained in OCE 
technical file held in Q-Pulse 
18.8. Accessible parts of devices (excluding the parts or areas intended 
to supply heat or reach given temperatures) and their 
surroundings shall not attain potentially dangerous temperatures 
under normal conditions of use. 
A BS EN 60601 
BS EN 61010 
No parts are intended to generate 
heat are fitted to the device. 
Enclosures are fitted and the 
design is such that any parts 
which might heat up – electrical 
power supplies are not accessible 
or touchable. 
Also see risk analysis as per 
WIRD05 Risk Analysis.  
See risk review and design 
details held in OCE technical 
file on Q-Pulse. 
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Essential Requirement. 19. Protection against the risks posed by 
devices intended for self-testing or 
near-patient testing 
A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
19.1. Devices intended for self-testing or near-patient testing shall be 
designed and manufactured in such a way that they perform 
appropriately for their intended purpose taking into account the 
skills and the means available to the intended user and the 
influence resulting from variation that can be reasonably 
anticipated in the intended user's technique and environment. The 
information and instructions provided by the manufacturer shall be 
easy for the intended user to understand and apply in order to 
correctly interpret the result provided by the device and to avoid 
misleading information. In the case of near-patient testing, the 
information and the instructions provided by the manufacturer shall 
make clear the level of training, qualifications and/or experience 
required by the user. 
A EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113  
User manual states only trained 
staff to use this device and as it 
is a prototype under 
development the procedures 
detailed in the ethics approval 
must also be followed. 
User manual and ethics 
apporcal reference held in the 
OCE technical file maintained 
in Q-Pulse. 
19.2. Devices intended for self-testing or near-patient testing shall be 
designed and manufactured in such a way as to: 
(a) ensure that the device can be used safely and accurately by the 
intended user at all stages of the procedure if necessary after 
appropriate training and/or information; and 
(b) reduce as far as possible the risk of error by the intended user in the 
handling of the device and, if applicable, the specimen, and also in 
the interpretation of the results. 
A EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 
User guide details how the 
device is to be used. Trained 
staff to operate the unit only. 
Plus the use of the device at this 
time is to determine the actual 
accuracy of the device. 
See User manual in OCE 
technical file held in Q-Pulse. 
19.3. Devices intended for self-testing and near-patient testing shall, 
where feasible, include a procedure by which the intended user: 
(a) can verify that, at the time of use, the device will perform as 
intended by the manufacturer; and 
(b) be warned if the device has failed to provide a valid result. 
A BS EN 60601 
BS EN 61010 
EN ISO 
14971:2012/2019 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 
Details of how to check the 
device given in the user manual 
plus risk assessment of how 
results given detailed in risk 
review.  
See OCE technical file for 
details and risk review. 
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CHAPTER III 
REQUIREMENTS REGARDING INFORMATION SUPPLIED WITH THE DEVICE  
The following information must retained in the technical file.  
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
20.1. General requirements regarding the information supplied by the 
manufacturer 
 Each device shall be accompanied by the information needed to 
identify the device and its manufacturer, and by any safety and 
performance information relevant to the user or any other person, 
as appropriate. Such information may appear on the device itself, 
on the packaging or in the instructions for use, and shall, if the 
manufacturer has a website, be made available and kept up to date 
on the website, taking into account the following: 
(a) The medium, format, content, legibility, and location of the label 
and instructions for use shall be appropriate to the particular 
device, its intended purpose and the technical knowledge, 
experience, education or training of the intended user(s). In 
particular, instructions for use shall be written in terms readily 
understood by the intended user and, where appropriate, 
supplemented with drawings and diagrams. 
(b) The information required on the label shall be provided on the 
device itself. If this is not practicable or appropriate, some or all of 
the information may appear on the packaging for each unit. If 
individual full labelling of each unit is not practicable, the 
information shall be set out on the packaging of multiple devices. 
A 
 
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
 
NA 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 
User manual gives relevant 
details of how to use the device 
and what the various labels 
mean and were they are found, 
The Manufacturing instructions 
detail were labels will be placed.  
 
 
All Labels will be industry 
standard and in English. 
 
 
 
 
There is no packaging 
associated with the device. 
Only one such OCE device. 
See OCE technical file for user 
manual, labelling information 
and the manufacturing 
instructions.  
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Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(c) Labels shall be provided in a human-readable format and may be 
supplemented by machine-readable information, such as radio-
frequency identification or bar codes. 
(d) Instructions for use shall be provided together with devices. 
However, in duly justified and exceptional cases instructions for 
use shall not be required or may be abbreviated if the device can be 
used safely and as intended by the manufacturer without any such 
instructions for use. 
(e) Where multiple devices, with the exception of devices intended for 
self-testing or near-patient testing, are supplied to a single user 
and/or location, a single copy of the instructions for use may be 
provided if so agreed by the purchaser who in any case may 
request further copies to be provided free of charge. 
(f) When the device is intended for professional use only, instructions 
for use may be provided to the user in non-paper format (e.g. 
electronic), except when the device is intended for near-patient 
testing. 
(g) Residual risks which are required to be communicated to the user 
and/or other person shall be included as limitations, contra-
indications, precautions or warnings in the information supplied by 
the manufacturer. 
(h) Where appropriate, the information supplied by the manufacturer 
shall take the form of internationally recognised symbols, taking 
into account the intended users. Any symbol or identification 
colour used shall conform to the harmonised standards or CS. In 
areas for which no harmonised standards or CS exist, the symbols 
and colours shall be described in the documentation supplied with 
the device. 
A 
 
 
NA 
 
 
 
 
 
NA 
 
 
 
 
 
A 
 
 
 
A 
 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 
 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
Labels are only human readable. 
 
Only the given user manual is 
issued. 
 
 
Only one OCE device has been 
manufactured just now if this 
changes this requirement will be 
reviewed.  
 
Electronic copy of the user 
manual is held on Q-Pulse. 
 
These details held in the user 
manual. 
 
 
User manual explains meaning 
of labels and symbols used. 
These labels and symbols are 
industry standard symbols and 
are also detailed in the labels 
and symbols part of the 
technical file. 
See OCE technical file for user 
manual, labelling information 
and the manufacturing 
instructions.  
 
 
 
 
 
 
 
 
 
User manual contained in OCE 
technical file found in Q-Pulse 
 
 
User manual and labels and 
symbols used detail contained 
in OCE technical file found in 
Q-Pulse. 
. 
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Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(i) In the case of devices containing a substance or a mixture which 
may be considered as being dangerous, taking account of the nature 
and quantity of its constituents and the form under which they are 
present, relevant hazard pictograms and labelling requirements of 
Regulation (EC) No 1272/2008 shall apply. Where there is 
insufficient space to put all the information on the device itself or 
on its label, the relevant hazard pictograms shall be put on the label 
and the other information required by Regulation (EC) No 
1272/2008 shall be given in the instructions for use. 
(j) The provisions of Regulation (EC) No 1907/2006 on the safety 
data sheet shall apply, unless all relevant information, as 
appropriate, is already made available in the instructions for use. 
NA 
 
 
 
 
 
 
 
 
 
NA 
 OCE system does not use such 
substances or mixtures 
 
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
20.2. Information on the label 
The label shall bear all of the following particulars: 
(a) the name or trade name of the device; 
(b) the details strictly necessary for a user to identify the device and, 
where it is not obvious for the user, the intended purpose of the 
device; 
(c) the name, registered trade name or registered trade mark of the 
manufacturer and the address of its registered place of business; 
(d) if the manufacturer has its registered place of business outside the 
Union, the name of its authorised representative and the address of 
the registered place of business of the authorised representative; 
A 
 
 
A 
 
A 
 
 
A 
 
 
NA 
 
 
A 
 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
The manufacturing 
documentation details the 
information labels to be placed 
on the OCE system to enable the 
device to be identified as 
detailed in this section. 
Details of labels and the 
information they contain are 
given in the labels section of 
the of the  OCE technical file 
found in Q-Pulse. 
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(e) an indication that the device is an in vitro diagnostic medical 
device, or if the device is a ‘device for performance study’, an 
indication of that fact; 
(f) the lot number or the serial number of the device preceded by the 
words LOT NUMBER or SERIAL NUMBER or an equivalent 
symbol, as appropriate; 
(g) the UDI carrier as referred to in Article 24 and Part C of Annex VI; 
(h) an unambiguous indication of the time limit for using the device 
safely, without degradation of performance, expressed at least in 
terms of year and month and, where relevant, the day, in that order; 
(i) where there is no indication of the date until when it may be used 
safely, the date of manufacture. This date of manufacture may be 
included as part of the lot number or serial number, provided the 
date is clearly identifiable; 
 
 
A 
 
 
NA 
 
NA 
 
 
A 
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(j) where relevant, an indication of the net quantity of contents, 
expressed in terms of weight or volume, numerical count, or any 
combination of thereof, or other terms which accurately reflect the 
contents of the package; 
(k) an indication of any special storage and/or handling condition that 
applies; 
(l) where appropriate, an indication of the sterile state of the device 
and the sterilisation method, or a statement indicating any special 
microbial state or state of cleanliness; 
(m) warnings or precautions to be taken that need to be brought to the 
immediate attention of the user of the device or to any other 
person. This information may be kept to a minimum in which case 
more detailed information shall appear in the instructions for use, 
taking into account the intended users; 
NA 
 
 
A 
 
NA 
 
A 
 
 
 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
Device not delivered nor 
shipped hence this information 
not required..  
 
Storage details held in the user 
manual.  
 
Not a sterile device nor used 
sterile.  
 
Warning labels detailed in the 
user manual. Position of labels 
detailed in the labels section of 
OCE technical file and the 
manufacturing instructions.  
 
See OCE technical file for user 
manual, labelling information 
and the manufacturing 
instructions.  
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(n) if the instructions for use are not provided in paper form in 
accordance with point (f) of Section 20.1, a reference to their 
accessibility (or availability), and where applicable the website 
address where they can be consulted; 
(o) where applicable, any particular operating instructions; 
(p) if the device is intended for single use, an indication of that fact. A 
manufacturer's indication of single use shall be consistent across 
the Union; 
(q) if the device is intended for self-testing or near-patient testing, an 
indication of that fact; 
(r) where rapid assays are not intended for self-testing or near-patient 
testing, the explicit exclusion hereof; 
A 
 
 
A 
NA 
 
A 
 
NA 
A copy of user manual given but 
an indication of electronic copy 
given on label on OCE system, 
 
Operating information given in 
the user manual 
Not a single use device. 
 
 
 
User manual states for near 
patient testing  
 
Not such a device. 
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(s) where device kits include individual reagents and articles that are 
made available as separate devices, each of those devices shall 
comply with the labelling requirements contained in this Section 
and with the requirements of this Regulation; 
(t) the devices and separate components shall be identified, where 
applicable in terms of batches, to allow all appropriate action to 
detect any potential risk posed by the devices and detachable 
components. As far as practicable and appropriate, the information 
shall be set out on the device itself and/or, where appropriate, on 
the sales packaging; 
(u) the label for devices for self-testing shall bear the following 
particulars: 
(i) the type of specimen(s) required to perform the test (e.g. blood, 
urine or saliva); 
A 
 
 
 
 
A 
 
 
 
 
 
NA 
 
 
A 
 
NA 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
The Glass slides for holding the 
biopsy sample 
 
 
Batch information of the glass 
slides to be retained to allow 
tractability to tested biopsy 
sample. 
 
OCE system is not for self-
testing. 
Detailed in the user manual  
See OCE technical file for user 
manual, labelling information 
and the manufacturing 
instructions.  
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(ii) the need for additional materials for the test to function properly; 
(iii) contact details for further advice and assistance. 
 The name of devices for self-testing shall not reflect an intended 
purpose other than that specified by the manufacturer. 
 
A 
 
 
Unit does not use additional test 
materials. 
Contact details for help given in 
the user manual. 
 
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
20.3. Information on the packaging which maintains the sterile 
condition of a device (‘sterile packaging’): 
The following particulars shall appear on the sterile packaging: 
(a) an indication permitting the sterile packaging to be recognised as 
such, 
(b) a declaration that the device is in a sterile condition, 
(c) the method of sterilisation, 
(d) the name and address of the manufacturer, 
(e) a description of the device, 
(f) the month and year of manufacture, 
NA EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
Device not delivered sterile nor 
used in sterile state. 
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(g) an unambiguous indication of the time limit for using the device 
safely, expressed at least in terms of year and month and, where 
relevant, the day, in that order, 
(h) an instruction to check the instructions for use for what to do if the 
sterile packaging is damaged or unintentionally opened before use. 
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
20.4. Information in the instructions for use 
20.4.1. The instructions for use shall contain all of the following 
particulars: 
(a) the name or trade name of the device; 
(b) the details strictly necessary for the user to uniquely identify the 
device; 
(c) the device's intended purpose: 
(i) what is detected and/or measured; 
(ii) its function (e.g. screening, monitoring, diagnosis or aid to 
diagnosis, prognosis, prediction, companion diagnostic); 
(iii) the specific information that is intended to be provided in the 
context of: 
— a physiological or pathological state; 
— congenital physical or mental impairments; 
— the predisposition to a medical condition or a disease; 
A EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
User manual  See OCE technical file for user 
manual, labelling information 
and the manufacturing 
instructions.  
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— the determination of the safety and compatibility with potential 
recipients; 
— the prediction of treatment response or reactions; 
— the definition or monitoring of therapeutic measures; 
(iv) whether it is automated or not; 
(v) whether it is qualitative, semi-quantitative or quantitative; 
(vi) the type of specimen(s) required; 
(vii) where applicable, the testing population; and 
(viii) for companion diagnostics, the International Non-proprietary 
Name (INN) of the associated medicinal product for which it is a 
companion test. 
(d) an indication that the device is an in vitro diagnostic medical 
device, or, if the device is a ‘device for performance study’, an 
indication of that fact; 
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(e) the intended user, as appropriate (e.g. self-testing, near patient and 
laboratory professional use, healthcare professionals); 
(f) the test principle; 
(g) a description of the calibrators and controls and any limitation 
upon their use (e.g. suitable for a dedicated instrument only); 
(h) a description of the reagents and any limitation upon their use (e.g. 
suitable for a dedicated instrument only) and the composition of 
the reagent product by nature and amount or concentration of the 
active ingredient(s) of the reagent(s) or kit as well as a statement, 
where appropriate, that the device contains other ingredients which 
might influence the measurement; 
(i) a list of materials provided and a list of special materials required 
but not provided; 
(j) for devices intended for use in combination with or installed with 
or connected to other devices and/or general purpose equipment: 
A 
 
A 
 
NA 
 
 
NA 
 
 
 
 
 
A 
 
NA 
 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
Detailed in the user manual. 
 
Detailed in the user manual. 
 
No such calibrators and control 
used with the OCE system. 
 
No reagents used. 
 
 
 
 
 
Detial of how to make the 
silicon/agar base and glass slide. 
Not used in combination with 
other devices. 
See OCE technical file for 
user manual, labelling 
information and the 
manufacturing instructions.  
Page 431 of 513 
 
 
— information to identify such devices or equipment, in order to 
obtain a validated and safe combination, including key 
performance characteristics, and/or 
— information on any known restrictions to combinations of devices 
and equipment. 
(k) an indication of any special storage (e.g. temperature, light, 
humidity, etc.) and/or handling conditions which apply; 
(l) in-use stability which may include the storage conditions, and shelf 
life following the first opening of the primary container, together 
with the storage conditions and stability of working solutions, 
where this is relevant; 
 
 
 
 
 
 
 
A 
 
 
NA 
 
 
 
 
 
 
 
Storage instructions given in the 
user manual. 
No stability issues with the OCE 
device. 
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Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(m) if the device is supplied as sterile, an indication of its sterile state, 
the sterilisation method and instructions in the event of the sterile 
packaging being damaged before use; 
(n) information that allows the user to be informed of any warnings, 
precautions, measures to be taken and limitations of use regarding 
the device. That information shall cover, where appropriate: 
(i) warnings, precautions and/or measures to be taken in the event of 
malfunction of the device or its degradation as suggested by 
changes in its appearance that may affect performance, 
(ii) warnings, precautions and/or measures to be taken as regards the 
exposure to reasonably foreseeable external influences or 
environmental conditions, such as magnetic fields, external 
electrical and electromagnetic effects, electrostatic discharge, 
radiation associated with diagnostic or therapeutic procedures, 
pressure, humidity, or temperature, 
(iii) warnings, precautions and/or measures to be taken as regards the 
risks of interference posed by the reasonably foreseeable presence 
of the device during specific diagnostic investigations, evaluations, 
therapeutic treatment or other procedures such as electromagnetic 
interference emitted by the device affecting other equipment, 
(iv) precautions related to materials incorporated into the device that 
contain or consist of CMR substances, or endocrine disrupting 
substances or that could result in sensitisation or an allergic 
reaction by the patient or user, 
(v) if the device is intended for single use, an indication of that fact. A 
manufacturer's indication of single use shall be consistent across 
the Union, 
(vi) if the device is reusable, information on the appropriate processes 
to allow reuse, including cleaning, disinfection, decontamination, 
packaging and, where appropriate, the validated method of re-
sterilisation. Information shall be provided to identify when the 
NA 
 
 
 
A 
 
 
A 
 
 
A 
 
 
 
 
 
A 
 
 
 
 
NA 
 
 
 
NA 
 
 
A 
 
 
 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
OCE not supplied sterile. 
 
 
 
All this information contained in 
the user manual. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No such materials contained in 
the OCE system, 
 
 
No a single use device. 
 
 
 
See OCE technical file for 
user manual, labelling 
information and the 
manufacturing instructions.  
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device should no longer be reused, such as signs of material 
degradation or the maximum number of allowable reuses; 
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Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(o) any warnings and/or precautions related to potentially infectious 
material that is included in the device; 
(p) where relevant, requirements for special facilities, such as a clean 
room environment, or special training, such as on radiation safety, 
or particular qualifications of the intended user; 
(q) conditions for collection, handling, and preparation of the 
specimen; 
(r) details of any preparatory treatment or handling of the device 
before it is ready for use, such as sterilisation, final assembly, 
calibration, etc., for the device to be used as intended by the 
manufacturer; 
(s) the information needed to verify whether the device is properly 
installed and is ready to perform safely and as intended by the 
manufacturer, together with, where relevant: 
— details of the nature, and frequency, of preventive and regular 
maintenance, including cleaning and disinfection; 
— identification of any consumable components and how to replace 
them; 
— information on any necessary calibration to ensure that the device 
operates properly and safely during its intended lifetime; 
— methods for mitigating the risks encountered by persons involved 
in installing, calibrating or servicing devices. 
(t) where applicable, recommendations for quality control procedures; 
NA 
 
 
A 
 
 
A 
 
 
A 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
A 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
No such material contained in 
the OCE. 
 
The user to be trained in 
interpretation of the scans. 
 
Sample collection is a surgical 
procedure – only undertaken by 
trained surgeons. 
Device preparation detailed in 
user manual – basically is it 
clean and does it setup correctly. 
 
Setup and peruse checks 
detailed in the user manual. 
 
 
 
 
 
 
 
 
 
 
 
OCE system calibration detailed 
in the user manual. 
See OCE technical file for user 
manual, labelling information 
and the manufacturing 
instructions.  
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
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(u) the metrological traceability of values assigned to calibrators and 
control materials, including identification of applied reference 
materials and/or reference measurement procedures of higher order 
and information regarding maximum (self-allowed) batch to batch 
variation provided with relevant figures and units of measure; 
(v) assay procedure including calculations and interpretation of results 
and where relevant if any confirmatory testing shall be considered; 
where applicable, the instructions for use shall be accompanied by 
information regarding batch to batch variation provided with 
relevant figures and units of measure; 
(w) analytical performance characteristics, such as analytical 
sensitivity, analytical specificity, trueness (bias), precision 
(repeatability and reproducibility), accuracy (resulting from 
trueness and precision), limits of detection and measurement range, 
(information needed for the control of known relevant 
interferences, cross-reactions and limitations of the method), 
measuring range, linearity and information about the use of 
available reference measurement procedures and materials by the 
user; 
(x) clinical performance characteristics as defined in Section 9.1 of 
this Annex; 
(y) the mathematical approach upon which the calculation of the 
analytical result is made; 
(z) where relevant, clinical performance characteristics, such as 
threshold value, diagnostic sensitivity and diagnostic specificity, 
positive and negative predictive value; 
NA 
 
 
 
 
 
NA 
 
 
 
 
 
A 
 
 
 
 
 
 
 
 
A 
 
A 
 
 
A 
 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
 
Material calibrators and the like 
not used with the OCE. 
 
 
There is no assay involved with 
the OCE. 
 
 
 
 
 
 
How to review the scan 
information is by training and 
presentation of results is detailed 
in the user manual 
 
 
 
 
 
Performance defined in the user 
manual and OCE specification. 
Defined in the OCE 
specification and outlined in the 
user manual. 
Defined in the user manual. 
 
 
See OCE technical file for user 
manual, labelling information 
and the manufacturing 
instructions.  
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(aa) where relevant, reference intervals in normal and affected 
populations; 
NA 
 
 
EN 1041:2008  
EN ISO 15223-1:2016 
Not used in this manner. 
 
 
See OCE technical file for user 
manual, labelling information 
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(ab) information on interfering substances or limitations (e.g. visual 
evidence of hyperlipidaemia or haemolysis, age of specimen) that 
may affect the performance of the device; 
(ac) warnings or precautions to be taken in order to facilitate the 
safe disposal of the device, its accessories, and the consumables 
used with it, if any. This information shall cover, where 
appropriate: 
(i) infection or microbial hazards, such as consumables contaminated 
with potentially infectious substances of human origin; 
(ii) environmental hazards such as batteries or materials that emit 
potentially hazardous levels of radiation); 
(iii) physical hazards such as explosion. 
 
(ad) the name, registered trade name or registered trade mark of the 
manufacturer and the address of its registered place of business at 
which he can be contacted and its location be established, together 
with a telephone number and/or fax number and/or website address 
to obtain technical assistance; 
(ae) date of issue of the instructions for use or, if they have been 
revised, date of issue and identifier of the latest revision of the 
instructions for use, with a clear indication of the introduced 
modifications; 
(af) a notice to the user that any serious incident that has occurred in 
relation to the device shall be reported to the manufacturer and the 
competent authority of the Member State in which the user and/or 
the patient is established; 
NA 
 
 
A 
 
 
 
 
A 
 
NA 
 
A 
 
A 
 
 
 
 
A 
 
 
 
A 
 
EN ISO 18113 and 
other standards for 
symbols 
 
No interfering substances 
 
 
Disposal information contained 
in user manual. 
 
 
 
Disposal of contaminated slides 
detailed in user manual 
No such material with the OCE 
 
Such risk detailed in the user 
instructions.  
User manual contain these 
details. 
 
 
 
Issue and revision information 
contained in the user manual. 
 
 
Feedback instruction detailed in 
the user manual. 
 
and the manufacturing 
instructions.  
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(ag) where device kits include individual reagents and articles that 
may be made available as separate devices, each of these devices 
shall comply with the instructions for use requirements contained 
in this Section and with the requirements of this Regulation; 
NA 
 
 
 
 
EN 1041:2008  
EN ISO 15223-1:2016 
EN ISO 18113 and 
other standards for 
symbols 
OCE does not user reagents and 
similar materials. 
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(ah) for devices that incorporate electronic programmable systems, 
including software, or software that are devices in themselves, 
minimum requirements concerning hardware, IT networks 
characteristics and IT security measures, including protection 
against unauthorised access, necessary to run the software as 
intended. 
NA  OCE does not contain such 
systems.  
 
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
20.4.2   In addition, the instructions for use for devices intended for 
self-testing shall comply with all of the following principles: 
(a) details of the test procedure shall be given, including any reagent 
preparation, specimen collection and/or preparation and 
information on how to run the test and interpret the results; 
(b) specific particulars may be omitted provided that the other 
information supplied by the manufacturer is sufficient to enable the 
user to use the device and to understand the result(s) produced by 
the device; 
(c) the device's intended purpose shall provide sufficient information 
to enable the user to understand the medical context and to allow 
the intended user to make a correct interpretation of the results; 
(d) the results shall be expressed and presented in a way that is readily 
understood by the intended user; 
(e) information shall be provided with advice to the user on action to 
be taken (in case of positive, negative or indeterminate result), on 
the test limitations and on the possibility of false positive or false 
negative result. Information shall also be provided as to any factors 
that can affect the test result such as age, gender, menstruation, 
infection, exercise, fasting, diet or medication; 
(f) the information provided shall include a statement clearly directing 
that the user should not take any decision of medical relevance 
without first consulting the appropriate healthcare professional, 
information on disease effects and prevalence, and, where 
available, information specific to the Member State(s) where the 
NA  OCE system is not for self-
testing 
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device is placed on the market on where a user can obtain further 
advice such as national helplines, websites; 
Essential Requirement. 20. Label and instructions for use A 
NA 
Standard Supporting Documentation Location of supporting 
documentation 
(g) for devices intended for self-testing used for the monitoring of a 
previously diagnosed existing disease or condition, the information 
shall specify that the patient should only adapt the treatment if he 
has received the appropriate training to do so. 
NA  The OCE system is not for self-
testing. 
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Appendix C5 2 Risk Classification For the OCE System  
Risk Classification for OCE system using the M&H work instruction. 
 
Implementation rules 
1.—(1) Application of the classification rules must be governed by the intended 
purpose of the devices. - The device is intended to scan prostrate biopsy samples 
to determine if they contain possible cancerous cells or growths 
(2) If the device in question is intended to be used in combination with another 
device, the classification rules must apply separately to each of the devices. - The 
OCE is a standalone device. 
(3) Accessories for an in vitro diagnostic medical device must be classified in 
their own right separately from the device with which they are used. - The OCE 
has no accessories. 
(4) Software which— 
(a) drives a device or influences the use of a device, must fall within the same 
class as the device; 
(b) is independent of any other device, must be classified in its own right. 
The software used is an integral component of the OCE system. 
(5) Calibrators intended to be used with a device must be classified in the same 
class as the device. - The calibration devices are physical devices and hence not 
required to meet this point. 
(6) Control materials with quantitative or qualitative assigned values intended for 
one specific analyte or multiple analytes must be classified in the same class as 
the device.  - No such material used with the OCE system 
(7) The manufacturer must take into consideration all classification and 
implementation rules in order to establish the proper classification for the device. 
- Only one classification rule applies. 
(8) Where a manufacturer states multiple intended purposes for a device, and as a 
result the device falls into more than one class, it must be classified in the higher 
class. - The OCE system is intended to perform a single task as detailed in one 
1-(1) above. 
(9) If several classification rules apply to the same device, the rule resulting in the 
higher classification must apply.-  Single rule applies. 
(10) Each of the classification rules must apply to first line assays, confirmatory 
assays and supplemental assays. - The OCE does not use assays to perform its 
analysis.  
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Classification rules 
Rule 1  NOT APPLICABLE 
2.—(1) Devices intended to be used for the following purposes are classified as 
Class D— 
(a) detection of the presence of, or exposure to, a transmissible agent in blood, 
blood components, cells, tissues or organs, or in any of their derivatives, in 
order to assess their suitability for transfusion, transplantation or cell 
administration; 
(b) detection of the presence of, or exposure to, a transmissible agent that 
causes a life-threatening disease with a high or suspected high risk of 
propagation; 
(a) (c)determining the infectious load of a life-threatening disease where 
monitoring is critical in the process of patient management. 
Rule 2  NOT APPLICABLE 
(2) Devices intended to be used for blood grouping, or tissue typing to ensure the 
immunological compatibility of blood, blood components, cells, tissue or organs 
that are intended for transfusion or transplantation or cell administration, are 
classified as class C, except when intended to determine any of the following 
markers— 
(a) ABO system [A (ABO1), B (ABO2), AB (ABO3)]; 
(b) Rhesus system [RH1 (D), RHW1, RH2 (C), RH3 (E), RH4 (c), RH5 (e)]; 
(c) Kell system [Kel1 (K)]; 
(d) Kidd system [JK1 (Jka), JK2 (Jkb)]; 
(e) Duffy system [FY1 (Fya), FY2 (Fyb)]; 
in which case they are classified as Class D. 
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Rule 3  APPLICABLE see point (h). 
(3) Devices are classified as Class C if they are intended— 
(a) for detecting the presence of, or exposure to, a sexually transmitted agent; 
(b) for detecting the presence in cerebrospinal fluid or blood of an infectious 
agent without a high or suspected high risk of propagation; 
(c) for detecting the presence of an infectious agent, if there is a significant 
risk that an erroneous result would cause death or severe disability to the 
individual, foetus or embryo being tested, or to the individual’s offspring; 
(d) for pre-natal screening of women in order to determine their immune 
status towards transmissible agents; 
(e) for determining infective disease status or immune status, where there is a 
risk that an erroneous result would lead to a patient management decision 
resulting in a life-threatening situation for the patient or for the patient’s 
offspring; 
(f) to be used as companion diagnostics; 
(g) to be used for disease staging, where there is a risk that an erroneous result 
would lead to a patient management decision resulting in a life-threatening 
situation for the patient or for the patient’s offspring; 
(h) to be used in screening, diagnosis, or staging of cancer; 
(i) for human genetic testing; 
(j) for monitoring of levels of medicinal products, substances or biological 
components, when there is a risk that an erroneous result will lead to a 
patient management decision resulting in a life-threatening situation for 
the patient or for the patient’s offspring; 
(k) for management of patients suffering from a life-threatening disease or 
condition; 
(l) for screening for congenital disorders in the embryo or foetus; 
(m) for screening for congenital disorders in new-born babies where failure to 
detect and treat such disorders could lead to life-threatening situations or 
severe disabilities. 
Rule 4  NOT APPLICABLE 
(4) Devices intended for self-testing are classified as Class C, except for devices 
testing the following which are classified in Class D— 
(a) the detection of pregnancy; 
(b) fertility testing; 
(c) for determining cholesterol level; 
(d) for the detection of glucose, erythrocytes, leucocytes and bacteria in urine. 
(5) Devices intended for near-patient testing are classified in their own right. 
Device is class C due to Rule 3 point (h) 
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Rule 5  NOT APPLICABLE 
(6) The following devices are classified as Class A— 
(a) products for general laboratory use, accessories which possess no critical 
characteristics, buffer solutions, washing solutions, and general culture 
media and histological stains, intended by the manufacturer to make them 
suitable for in vitro diagnostic procedures relating to a specific 
examination; 
(b) instruments intended by the manufacturer specifically to be used for in 
vitro diagnostic procedures; 
(c) specimen receptacles. 
Rule 6  NOT APPLICABLE 
Devices not covered by the above-mentioned classification rules are classified as 
Class B. 
Rule 7  NOT APPLICABLE 
Devices which are controls without a quantitative or qualitative assigned value are 
classified as Class B. 
 
Classification Review Summary 
 
Classification Rule Review 
 
RULE Details of why are rule applies or not Rule Review 
Result – A or 
N/A 
1 Does not apply as device not used for the purposes 
of determining infection load or infection 
transmissibility.  
N/A 
2 The devices is not used for compatibility checking N/A  
3 The device is used for screening and in the 
diagnosis of cancer. 
A – Class C 
4 Device is not intended for self-testing but near 
patient testing as per Rule 4 point (5) hence rule 3 
still applies. 
N/A 
5 The device is a device in itself.  N/A 
6 Device is cover by Rule 3 N/A 
7 Device is cover by Rule 3 N/A 
 
Final Review Classification – THIS IVDD DEVICE IS A CLASS C DEVICE. 
Only one classification rule applies to this device due to its intended purpose.  
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Summary  
The device is intended to scan prostrate biopsy samples to determine if they 
contain possible cancerous cells or growths. The device is intended for near 
patient testing. Rule 3 point (h) applies hence the Class C determination. 
The OCE is a standalone device. 
The OCE has no accessories. 
The software used is an integral component of the OCE system. 
The calibration devices are physical devices and hence not required to meet this 
point. 
No control materials are used with the OCE system 
Only one classification rule applies. 
The OCE system is intended to perform a single task - analysis of biopsy 
samples. 
The OCE does not use assays to perform its analysis.  
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Appendix C5 3 IVDD Exemption Regulations UK legislation Only 
 
IVDD Exemption parts UK legislation 
UK legislation 2019 No. 791 
EXITING THE EUROPEAN UNION CONSUMER PROTECTION 
The Medical Devices (Amendment etc.) (EU Exit) Regulations 
2019 - Made 1st April 2019 
The section  
PART 3 
New part IX of the Medical Devices Regulations  
11. After regulation 135 (as inserted by regulation 10) insert— 
“PART IX 
The rights, powers, liabilities, obligations, restrictions, remedies and procedures recognised under 
the in vitro diagnostic Medical Devices Regulation (see regulation 4P) 
… text deleted …….  
Making available on the market and putting into service of devices, obligations of economic 
operators, CE marking 
Placing on the market and putting into service 
140.—(1) A device to which this Part applies may be placed on the market or put into service only 
if it complies with this Part when duly supplied and properly installed, maintained and used in 
accordance with its intended purpose. 
(2) A device to which this Part applies must meet the general safety and performance requirements 
set out in Schedule 17 which apply to it, taking into account its intended purpose. 
(3) Demonstration of conformity with the general safety and performance requirements must 
include a performance evaluation in accordance with regulation 167. 
(4) Devices that are manufactured and used within health institutions, with the exception of 
devices for performance studies, must be considered as having been put into service. 
(5) With the exception of the relevant general safety and performance requirements set out in 
Schedule 17, the requirements of this Part do not apply to a device which is manufactured and 
used only within a health institution, provided that all of the following conditions are met— 
(a) the device is not transferred to another legal entity; 
(b) manufacture and use of the devices occur under appropriate quality management systems; 
(c) the laboratory of the health institution is compliant with standard EN ISO 15189 and, where 
applicable, provisions regarding accreditation; 
(d) the health institution justifies in its documentation that the specific needs of the target patient 
group cannot be met, or cannot be met at the appropriate level of performance by an equivalent 
device available on the market;  
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(e) on request from the Secretary of State, the health institution provides the Secretary of State 
with information (which must include justification for its manufacturing, modification and use of 
such devices) on the use of the device to the Secretary of State; 
(f) the health institution draws up a declaration which it must make publicly available, 
including— 
(i) the name and address of the manufacturing health institution; 
(ii) the details necessary to identify the devices; 
(iii) a declaration that the device meets the general safety and performance requirements set out in 
Schedule 17 and, where applicable, information on which requirements are not fully met and a 
reasoned justification for not meeting those requirements; 
(g) for Class D devices (and for other classes of device in accordance with the rules set out in 
Schedule 23) the health institution draws up a document which makes it possible to have an 
understanding of the manufacturing facility, the manufacturing process, the design and 
performance data of the devices and the intended purpose, and which is sufficiently detailed to 
enable the Secretary of State to ascertain that the general safety and performance requirements set 
out in Schedule 17 are met; 
(h) the Secretary of State may apply the provisions of sub-paragraph (g) also to Class A, B or C 
devices in accordance with the rules set out in Schedule 23; 
(i) the health institution must take all necessary measures to ensure that all devices are 
manufactured in accordance with the document referred to in sub-paragraph (g); 
(j) the health institution reviews experience gained from clinical use of the devices an takes all 
necessary corrective actions. 
(6) The Secretary of State may require a health institution which has complied with paragraph (5) 
to submit to the Secretary of State any further relevant information about such devices which it has 
manufactured and used. 
(7) The Secretary of State may restrict the manufacture and use of a specified type of device 
manufactured in accordance with paragraph (5) and, for the purposes of considering such a 
restriction, must be permitted access to inspect the activities of the health institutions. 
(8) Paragraph (5) does not apply to the devices that are manufactured on an 
industrial scale. 
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Appendix C5 4 Declaration of Conformance OCE System  
The Department of Medical Physics, NHS Tayside, declares that the Optical 
Coherence Elastography system meets the exemption requirements detailed in  
Paragraph 140, ‘Placing on the market and putting into service’ part (5)  
UK legislation 2019 No. 791, Exiting the European Union Consumer Protection, 
The Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 - Made 1st 
April 2019. 
The OCE system has been design and developed under an accredited BS EN ISO 
1345:2016 quality assurance system BSI certificate MD 77843. 
Justification for the manufacture of the OCE system.  
The OCE system has been manufactured to determine the feasibility using Optical 
Coherence Tomography coupled with vibrational Elastography to review biopsy 
samples for the presence of cancerous nodules. No such device exists on the 
market at present. If such a device were available the time take to review such 
samples would be reduce from 3 days to one hour. This reduction in the time to 
review a biopsy sample may allow a surgeon to perform the biopsy operation, 
review the scan results and operate on the cancerous region without the patient 
leaving the operation room and having to return another day. 
The device is identified in the NHS Tayside medical assessment management 
system by the following equipment asset number  
OCE scanning part  MP 
Power amplifier  MP 
Signal generator MP 
 
Photographs of the OCE system are contained in the device description part of the 
OCE Technical File. Once such photograph is presented below to assist in 
identifying the OCE system. 
The technical file containing full details of the OCE system including its design, 
manufacture, risk and hazard analysis and user information is retained in the 
Medical Physics Q-Pulse system – ‘OCE Technical File’. This file also contains a 
full review of the General Safety and Performance Requirements as set out in 
Schedule 17 of the above UK legislation.. 
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The General Safety and Performance Requirements have been reviewed against 
the following standards – 
Standard Name 
EN ISO 13485:2016 (ISO 
13485:2016)  
EN ISO 13485:2016/AC:2018 
Medical devices - Quality management systems - Requirements 
for regulatory purposes  
EN 13612:2002 
EN 13612:2002/AC:2002 
Performance evaluation of in vitro diagnostic medical devices 
EN 13641:2002 Elimination or reduction of risk of infection related to in vitro 
diagnostic reagents 
EN ISO 14971:2012 
(ISO 14971:2007, Corrected 
version 2007-10-01) 
EN ISO 14971:2019 
Medical devices - Application of risk management to medical 
devices  
EN ISO 15223-1:2016  
(ISO 15223-1:2016, Corrected 
version 2017-03) 
Medical devices - Symbols to be used with medical device labels, 
labelling and information to be supplied - Part 1: General 
requirements  
EN ISO 18113-1:2011 
(ISO 18113-1:2009) 
In vitro diagnostic medical devices - Information supplied by the 
manufacturer (labelling) - Part 1: Terms, definitions and general 
requirements  
EN ISO 18113-2:2011 
(ISO 18113-2:2009) 
In vitro diagnostic medical devices - Information supplied by the 
manufacturer (labelling) - Part 2: In vitro diagnostic reagents for 
professional use  
EN ISO 18113-3:2011 In vitro diagnostic medical devices - Information supplied by the 
manufacturer (labelling) - Part 3: In vitro diagnostic instruments 
for professional use (ISO 18113-3:2009) 
EN 61010-2-101:2002 Safety requirements for electrical equipment for measurement, 
control, and laboratory use - Part 2-101: Particular requirements 
for in vitro diagnostic (IVD) medical equipment 
EN 61326-2-6:2006 Electrical equipment for measurement, control and laboratory 
use - EMC requirements - Part 2-6: Particular requirements - In 
vitro diagnostic (IVD) medical equipment 
EN 62304:2006  
(IEC 62304:2006) EN 
62304:2006/AC:2008 
Medical device software - Software life-cycle processes (IEC 
62304:2006) EN 62304:2006/AC:2008 
EN 62366:2008 Medical devices - Application of usability engineering to medical 
devices 
EN 1041:2008 +A1:201 Information supplied by the manufacturer of medical devices  
BS EN 60601-1:2006  Medical electrical equipment - Part 1: General requirements for 
basic safety and essential performance (IEC 60601-1:2005) 
BS EN 61010-1:2010+A1:2019  Safety requirements for electrical equipment for measurement, 
control, and laboratory use. 
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Note that the design of the OCE system refers to both the  EN 60601 and 61010 
family of standard as a supplement for the actual design of the hardware and 
software  
 
The following standards have not been used as the device does not test or produce 
results from the study of chemical reactions. 
EN 13975:2003 Sampling procedures used for acceptance testing of in vitro 
diagnostic medical devices - Statistical aspects 
EN 14136:2004 Use of external quality assessment schemes in the assessment 
of the performance of in vitro diagnostic examination 
procedures 
EN 14254:2004 In vitro diagnostic medical devices - Single-use receptacles for 
the collection of specimens, other than blood, from humans 
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Appendix C5 5 Initial risk analysis for the OCE system   
This appendix details the initial draft hazard and risk assessment for the OCE 
system.  
Hazard and Risk Assessment, Review and Reduction Report OCE System 
Device outline 
The OCE system is being developed to determine the feasibility to use combined 
optical coherence and elastography to determine if biopsy sample contain 
cancerous nodes. The initial biopsy samples being tested are from the prostrate.  
The device consists of  
1. An optical coherence system using a solid state laser as the light source 
2. A sample vibration system driven by an external amplifier driven from a signal 
generator. The sample vibration system is mounted on an x, y, z positioning 
system.  
3. A control PC, digital and analogue input output cards used to control the OCE 
system and to digitise the signal from the optical coherence microscope. 
4. A pneumatic anti-vibration table  
All parts of the system, apart from the power amplifier and the signal generator, 
are contained within a wheeled enclosure. The amplifier and the signal generator 
are on a separate small table. 
Application of the device. 
The device will be used to scan prostrate samples of approximately 20mm x 2 mm 
or less. The samples taken during routine prostrate examination within Ninewells 
Hospital Urology theatre. The samples are passed from theatre to the location of 
the OCE system for scanning and then returned to theatre. The samples are the 
passed to Histopathology for review and reporting.  
The results from OCE scanning are compared to those from Histopathology to 
determine the accuracy of the OCE results. 
Policy for the determining the acceptable level of risk/hazard. 
The device should not present any residual risk over and above that expected from 
an item of laboratory equipment used to optically scan biopsy samples e.g.  no 
radiation hazards, no hazards from the mechanical properties of the OCE device, 
no residual hazards due to scanning a biopsy sample, no electrical hazards.. 
The Verification Plan 
The output from the final risk and hazard risk analysis will be reviewed by the 
academic supervisor, supervising clinical/medical staff and medical staff. The risk 
and hazard analysis may need to be revised in light of comments from these 
review due to new risk or hazards being highlighted or comments made on the 
risk and hazards detailed in the analysis.  
Only when all parties carrying out the verification of the risk and hazard risk 
analysis, can this analysis be deemed complete. The statement informing that the 
use of the device out weights any residual risk or hazards will be signed by both 
the academic lead and senior medical physics clinical engineered or scientist. 
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Allocation of responsibility 
Lead academic developer schedule review meeting 
Other academic developers to attend meetings as required.  
M&H quality representative to assist/guide in the review process 
M&H technical staff to act as independent experts 
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Risk/hazard analysis review scope and scheduling 
The reviews will look at all possible risk or hazards associated with the device, its 
development and manufacture, its use, the users and location of use. The reviews 
may include risk or hazards foreseen if the device is made commercially, if the 
results are to be used medically or those arising from possible extensions of use. 
The reviews should also look at the risk to the samples due to the actually 
scanning process and the journey the sample takes from patient to final reporting. 
Documentation to be produced 
Each review and risk/hazard analysis discussion will be documented and retained. 
The output of the final risk/hazard review and any comments from the reviews on 
this by academic lead, clinical lead and medical physics will be retained.  
The gathering and review of in use, post manufacture or production data for the 
OCE system. The data to be retained with the associated risk/hazard analysis. 
Copies of all feedback received by users or interested parties will be retained on 
Q-Pulse attached to the relevant Action Form.  
Controls to ensure any data or feedback relating to the OCE system is correctly 
recorded and reported to the M&H quality system. This will be achieved by 
ensuring the E-Quip entry for the OCE system and associated power amplifier and 
signal generator has the manufacturer noted as Medical Physics – UOD. This will 
highlight to staff that this is an in-house manufactured device and problems with 
the device should be flagged to the quality system. 
Each year a review of the feedback and in use data relating to the OCE system 
will be made available to notified bodies or regulatory authority (MHRA/HFS). 
The need and contents of this review will be added to WI RD 14 – Notified / 
Regulatory Review Reports. 
Risk/Hazard reviews will be retained with the Technical File for the OCE system 
– maintained on Q-Pulse. 
Action forms relating to feedback and in use data are retained on Q-Pulse 
Reviews for external bodies are retained in the Technical File for the OCE system. 
E-Quip is the asset management system used by Medical Physics. All details of 
equipment repair and service are retained on this system.  
Q-Pulse and e-Quip are accessed via appropriate login and maintained on NHS 
Tayside services. 
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Hazard/Risk identification Form.  
 
Session/Date Hazard Type Hazard Description 
1 dd/mm/yyyy   
 Acoustic noise The sample vibration system is noisy. Is 
the noise above recommended HSE 
levels.  
 Weight The power amplifier is about 5 Kg. Not 
secure to table. 
 Weight  The main body of the OCE is over 40Kg. 
Stability. 
 Weight Mounting of both PC and Touchscreen.  
 Motion Are braked castors fitted on  the OCE 
main body and the table for the power 
amplifier and signal generator. 
 electrical / electricity Check electrical layout and current 
capabilities of the wiring. 
 Moving parts Safety of motorised XYZ position 
controller for sample vibration system. 
 Sample holder Is it biocompatible with the biopsy 
sample? Do the user instructions inform 
use once only 
 Sample holder Does the sample holder material cause 
artefacts on the scanned image? 
 User instructions Full reviewed? Contain all the relevant 
safety information and user instructions. 
 Cleaning instructions Reviewed by infection control? Do the 
instructions state clean after use.  
 Cleaning instructions These detail full the action to take if the 
sample or sample fluids falls into the 
OCE scanning area. 
 electrical / electricity Only trained personnel to carry out 
repairs on the unit and they must ensure 
safety from electric shock risks  
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 Biological hazards Do the user instructions state no samples 
to be left inside the OCE after use?   
 magnetic fields e.g. MRI Device is not MRI compatible. 
 Anaesthetic gases  Device is not to be used in an explosion 
risk area – oxygen enriched or with 
anaesthetic gases present.  
 
Review of Example Hazards List  
The example listing of hazards and risks was reviewed those deemed not 
applicable have been crossed out 
Acoustic energy  
Infrasound, 
 
 produce high sound pressure, ultrasonic source, noise nuisance, susceptible to 
external noise or acoustic vibration. 
Electric energy / Electric fields 
Leakage current - earth leakage, enclosure leakage, leakage to accessories or other 
devices. 
Magnetic fields – operating in a magnetic field or generates a magnetic field. 
Static discharge – has materials which have a propensity to produce static 
discharge 
Voltage / Current– hazardous AC and DC, AC and DC output sources  
Mechanical / Kinetic energy/Potential (stored) energy -  
Falling objects, high pressure fluid injection, moving parts, vibrating parts, 
bending, compression, cutting, shearing, gravitational pull, suspended mass, 
tension, torsion, springs 
Radiation energy  
Ionizing radiation - accelerated particles (alpha particles, electrons, protons, 
neutrons). Gamma, x-ray 
Non-ionizing radiation – infrared, microwave, ultraviolet, laser, other high power 
visible or electromagnetic field. 
Thermal energy 
Cryogenic effects 
Hyperthermic effects 
Biological agents 
Bacteria, fungi, parasites, prions, toxins, viruses,  
Chemical agents 
Carcinogenic, mutagenic, reproductive, caustic, corrosive (acidic, alkaline, 
oxidants) 
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Flammable, combustible, explosive, fumes, vapours 
Osmotic 
Particles (including micro- and nanoparticles) 
Pyrogenic 
Solvents 
Toxic – asbestos, heavy metals, inorganic or organic toxicants, silica 
Immunological agents 
Allergenic - antiseptic substances, latex, talc 
Immunosuppressive 
Irritants - cleaning residues 
Sensitizing 
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Data 
Access, non-availability, loss of confidentiality, inability to transfer, failure of 
data integrity. 
Delivery 
Quantity of flow, over or under delivery, incorrect or erratic rate, wrong mixture 
of chemical or gas or liquid. 
Diagnostic information 
Examination result lost or corrupt, image artefacts, image orientation, image 
resolution, integrity of patient identity/information 
Functionality 
Alarm, critical performance, measurement, calibration, incorrect stated lifetime or 
limits of test acceptability.  
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Appendix 2 
Table of Risk Probability Estimation 
Probability Score 
Incredible 
1:50 million - impossible chances 
0 
Improbable 
1:500 thousand - extremely remote 
1 
Remote 
1:5000 - not likely but definitely possible 
2 
Occasional 
1:50 - will occur quite often 
3 
Probable 
1:5 - expected regularly 
4 
Frequent 
1:1 - one or more during each use 
5 
 
Risk Severity Estimation 
Severity of Consequences Score 
Negligible 
e.g. a scare, a loud bang 
0 
Marginal 
e.g. hitting thumb with hammer 
1 
Significant 
e.g. a cut requiring stitches 
2 
Critical 
e.g. a broken limb 
3 
Catastrophic 
e.g. death 
5 
Major Disaster 
e.g. multiple fatalities 
6 
Note. The scores are such that any possibility of a risk producing even a rare 
catastrophic incident will automatically generate a minimum score of 4 and must 
be reviewed to define reduction measures. Remote but possible catastrophic risks 
will always generate a score of 9 or above and must be must be formally 
reviewed. 
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Risk Management Summary 
Each risk noted to be evaluated, given an initial probability and severity. These two multiplied by each other give the initial risk. Control 
measures are then determined and the residual probability and severity are evaluated and these multiplied together to give the residual risk. If this 
residual risk is deemed acceptable then no other work needs to be carried out on the risk. If not further measures to be determined or the hazard 
or risk re-evaluated, 
Hazard Reason IP IS IR Control Measures RP RS RR 
Acoustic noise The sample vibration system is noisy. Is 
the noise above recommended HSE 
levels? Hear damage to users or those 
constantly in the area when OCE being 
used. 
5 2 10 1. The sample vibration system can 
be noisy so either fit quieter 
vibrator or ensure noise reduction 
foam is fitted. 
2. Also need to check if the noise 
levels are within HSE guidelines.  
 
5 1 5 
Weight The power amplifier is about 5 Kg. Not 
secured to table. May fall off and cause 
injury. 
2 3 6 1 Add note to user guide to inform 
to check power amp is positioned 
well on table.  
2. If possible have power amp 
somehow fixed to the table.  
1 3 3 
Weight The main body of the OCE is over 
40Kg. Stability. If it were to topple over 
it could cause serious injury to anybody 
underneath it. 
2 3 6 Perform tilt test. The unit is stable 
up to 20°. (Test required is not over 
tilt if placed at 10° from vertical. 
Test carried out at each side of 
unit.) 
1 3 4 
Weight Mounting of both PC and Touchscreen. 
Secured and not able to fall off. Again a 
possible injury to anybody this 
assembly fell on. 
3 2 6 Checked the PC and Touch screen 
are both assembled secured to the 
trolley.  
1 
 
2 
 
2 
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Hazard Reason IP IS IR Control Measures RP RS RR 
Motion  Are braked castors fitted to the OCE 
main body? Stop unit moving 
unattended or in use. 
3 2 6 Check if braked castors fitted. If 
not have them fitted . 
2 2 4 
Motion Braked castors fitted to the table for the 
power amplifier and signal generator. 
Stop unit moving unattended or in use. 
3 2 6 Check if braked castors fitted. If 
not have them fitted. 
 
2 2 4 
Moving parts 
 
Safety of motorised XYZ position 
controller for sample vibration system – 
finger trapping 
2 2 4 Ensure that user instructions inform 
to take care when moving the XYZ 
position controller and the front 
cover is off. The movement is very 
slow hence persons should be able 
to move fingers out of the way 
before an injury occurs. 
 
1 2 3 
electrical / electricity Check electrical layout. Wires coming 
loose and causing metal parts to carry 
currents. Electric shock risk 
2 5 10 Electric shock if wiring becomes 
disconnect. R&D technicians have 
checked the wiring and 
connections. Rerouted and tidied up 
as required. 
 
1 5 5 
electrical / electricity Current capabilities of the wiring. 
Incorrect current capabilities could lead 
to a fire. 
2 5 10 Check wiring is rated correctly. 
R&D technicians have carried this 
out. 
1 5 5 
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Hazard Reason IP IS IR Control Measures RP RS RR 
Sample holder Is it biocompatible with the biopsy 
sample? To ensure the sample is not 
degraded during scan and prior to 
sending to pathology for definitive 
checking. 
5 5 25 Sample holder is made of 
laboratory grade glass. Hence yes.  
0 0 0 
Sample holder Do the user instructions inform sample 
holder is single use only. Cross 
contamination between samples. 
2 5 10 Check user instructions do state this 
– new sample holder for each new 
biopsy sample.. 
0 0 0 
Sample holder Does the sample holder material cause 
artefacts on the scanned image? Might 
cause a positive to be a negative or vice 
versa. 
2 5 10 What testing done with the glass 
holders to check for this??? 
   
User instructions Contain all the relevant safety 
information and user instructions to 
ensure the use of the OCE does not 
cause harm to user or patient – via the 
end diagnosis.  
3 5 15 Review of user information to 
1. double check all the safety 
precautions included 
2. scanning process and review 
fully detailed 
3. actions to be taken if problems 
4. contact details 
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Hazard Reason IP IS IR Control Measures RP RS RR 
User instructions  Contain cleaning instructions. If not 
clean correctly could cause OCE 
damage due to chemicals in incorrect 
cleaning materials. Cross contamination 
due to inadequate cleaning procedures. 
2 3 6 Are these in the user information?    
Cleaning instructions Reviewed by infection control to make 
sure OCE is reviewed for infection risks 
by experts. 
2 3 6 Check if reviewed and ok     
Cleaning instructions State clean after each use. Reduction of 
infection risks  
2 3 6 Check if included    
Cleaning instructions Detail the action to take if the sample or 
sample fluids falls into the OCE 
scanning area. IT is done correctly and 
no damage to the scanning systems. 
2 3 6 Review the cleaning information to 
ensure this is covered. 
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Hazard Reason IP IS IR Control Measures RP RS RR 
User instructions Only trained personnel to carry out 
repairs on the unit. Wrong service or 
repair can stop the unit from working or 
cause the scan data to give wrong 
results putting patient in danger. 
3 5 15 Check user information for this 
warning. Plus is there a label on the 
OCE to this effect? See BS EN BS 
EN ISO 15223-1:2016  
1 5 5 
User instructions electric shock risks exists inside the 
unit. 
2 5 10 OCE Warning symbols and to be 
detailed in the user manual 
1 5 5 
User instructions User instructions state no samples to be 
left inside the OCE after use? - 
Biological hazards to users 
3 5 15 Check the OCE user manual to 
ensure that this is so. See the 
various standards for lab 
equipment. 
1 5 5 
User instructions Device is not MRI compatible - 
magnetic fields  
2 5 10 Make sure that the user instructions 
state the device not to be used in 
MRI area or field. 
1 5 5 
User instructions Device is not to be used in an explosion 
risk area e.g. oxygen enriched, 
anaesthetic gases present.  
2 5 10 User instructions to state this.  1 5  
Laser  Laser interlock required? Fitted. Reduce 
danger to eyes from laser energy. 
3 3 9 Check and have non ionising safety 
officer check if all other warnings 
and precautions taken into account. 
1 3 3 
Labels What ones are required? Third party 
check. 
3 5 15 Review all labels and symbols are 
as expected. Check for any not 
attached to the OCE system.  
1 5 5 
User instructions Details what the labels mean and where 
fitted? To make sure users understand 
what they mean. 
3 5 15 lables – all explained in the user 
manual??.  
1 5 5 
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Hazard Reason IP IS IR Control Measures RP RS RR 
Interpretation of the 
scan result. 
How have these been verified? To make 
sure the users understand what they are 
looking at when viewing a scan  
3 5 15 Review of the verification and 
validation of the scanning checks 
and tests. Are these sufficient. 
What was actually done?  
1 5 5 
Scan result. How to ensure results are correctly tag 
with the correct patient ID.  
3 6 18 Review of the methods and storage 
of the results. 
1 5 5 
Scan result. Data protection of results and patient 
details. Keeping information 
confidential 
3 3 9 Is access to patient test results 
restricted or are the results saved 
such that they are secure from 
unauthorised access? 
1 3 3 
Device 
calibration/checking 
verification/validation 
Optical coherence part – Does it work 
as intended specified and correctly? 
2 5 10 Check the verification and 
validation testing to determine if 
the optical image is true and 
accurate.  
1 5 5 
Device 
calibration/checking 
verification/validation 
Elastography part – working correctly 
and does it resolve the small differences 
in stiffness? 
2 5 10 Need to ensure that the 
Elastography part is showing up 
differences in the stiffness inside 
the material….check on how this 
was achieved and what the min 
differences that can been seen and 
are these clinically relevant.  
1 5 5 
Enclosures and lids 
and things. 
Enclosure fitted and secured during use 
especially when system used outside the 
laboratory setting. 
2 5 10 User guide check to ensure states 
this is on, secured, clean 
0 5 0 
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Appendix C5 6 Proposed control of academic work within M&H. 
This is a draft of QP.03G. It is only intended for the purposes of this 
thesis. 
 
0.1 General  
 
Work carried out within Medical Physics and Hydatidiform Mole Follow-Up 
(Scotland), ‘HMFUS’, includes the following: 
1. design, development and/or manufacture of medical devices, and in vitro 
diagnostic devices 
2. creating new clinical testing methods and 
3. providing bespoke services for a range of end users 
These products may solely for ‘in-house’ use, passed to other users outside NHS 
Tayside or passed to 3rd parties for further development or manufacture. 
 
This ‘Product Realisation’ procedure controls the work required to ensure these 
products: 
1. fulfil customer needs 
2. meet statutory or regulatory requirements 
3. are fit for their intended use 
4. have been fully risk assessed and all foreseeable risks in the use of these 
products have been reviewed and reduced to an acceptable level 
5. have documentation including manufacturing and delivery requirements 
6. undergo clinical testing as required  which ensure results are accurate and 
fully validated 
7. have documentation to describe services required or provided to meet 
customer needs 
8. Most importantly, this procedure is developed to ensure that such products 
meet the requirements of UK and EU legislation relating to the design, 
development and manufacture of medical and in vitro diagnostic devices which 
are to be placed into service out with the legal entity know as NHS Tayside. 
 
The word ‘work’ is used throughout this document to denote any task to develop 
or manufacture a new device, reagent, patient test, service or other item required 
by a customer, patient or NHS colleague.  
 
Within the healthcare environment, various regulatory or statutory requirements, 
standards and professional guidelines must be adhered to. The product or service 
to be developed will determine which of these must be followed. For example a 
medical device might be controlled by UK statue ‘The Medical Devices 
(Amendment etc.) (EU Exit) Regulations 2019’ or the equivalent EU regulation 
for Medical Device or In Vitro Diagnostic Device.  
 
All work undertaken by academics or other 3rd parties, which might lead to a 
medical device, diagnostic test or service relating to the medical environment will 
have their initial project brief reviewed by the section head of R&D. The R&D 
section head or nominee will determine the level of control and hence 
documentation required during the project work. The documentation detailed in 
Page 464 of 513 
 
 
QP.02A ‘Academic and 3rd Party Project Work’ will be completed at the start of 
such work and signed off by the Medical Physics project supervisor. 
 
This procedure is based on BS EN ISO 13485:2016 standard and will use the 
applicable clauses of this standard for reference. Where areas of the 13485 
standard are covered by the Medical Physics and Hydatidiform Mole Follow-Up 
(Scotland) Quality Manual, these areas will be referenced as required. Where 
these are not sufficient on their own, additional requirements will be detailed. 
 
This procedure is not intended to control the design, development or manufacture 
of: 
1. non-medical devices, services, tests, etc.  
2. medical or in vitro diagnostic devices produced under the exemptions detailed 
in both the UK  
 
Control of this work is detailed in QP.02 ‘Project and Product Realisation Work’. 
 
This procedure is developed to ensure devices, products, services or modifications 
to medical devices or in vitro diagnostic devices meet the legislative or regulatory 
requirements of the following  
 
1. UK Statue 2019 No. 791 Exiting The European Union Consumer 
Protection – The Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 
- Para 71 - Placing on the market and putting into service  
2. Regulation (EU) 2017/745 of the European Parliament and of the Council 
of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation 
(EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council 
Directives 90/385/EEC and 93/42/EEC - Article 5 Placing on the market and 
putting into service 
3. Regulation (EU) 2017/745 of the European Parliament and of the Council 
of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 
98/79/EC and Commission Decision 2010/227/EU - Article 5 Placing on the 
market and putting into service 
 
0.2 Legal Entity 
 
Medical Physics and Hydatidiform Mole Follow-Up (Scotland) are sections 
within NHS Tayside, part of NHS Scotland. These areas will be denoted as MP 
and HMFUS or referenced jointly as M&H. 
 
0.3 Responsibility and authority 
 
The QA team will ensure this procedure and other relevant documentation are 
adhered to as required. 
M&H staff will ensure any changes to this procedure are flagged to the QA team 
or appropriate senior staff. 
Senior staff will ensure that this procedure is implemented as required in their 
areas of responsibility. 
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1. Product Realisation Overview 
The following 6 broad steps: Definition, Planning, Work, Testing, Review and 
Transfer will be carried out and some or all of these steps may need to be repeated 
once or several times during the project. 
1. Definition – What is to be developed, realised, made, etc. 
2. Planning – How we are going to produce the device, process, etc. 
including the producing the necessary outputs/paperwork to enable the idea to be 
used or made. 
3. Work: 
a) Research, Design and Development of a new product or modification to an 
existing product. 
b) Producing an end product, i.e. item, service or test. 
4. Testing – How to prove the device, process, service, etc. will:  
a) Meet the needs of the users, patients and regulatory bodies. 
b) Fulfil any specifications or constraints defined. 
5. Review – To ensure the project is proceeding as expected, problems are 
address and any requested changes reviewed and responded to. 
6. Transfer – If the work results in, for example, a product to be 
manufactured, a test to be put into clinical practice or a service for a customer, the 
documentation required for the end product to be delivered is known as the 
Transfer Documentation. 
 
2. Scope of Product realisation 
 
The areas of the BS EN ISO 13485:2016 standard which are not applicable to the 
work of MP and HMFUS are detailed in QM Section 1.5 Quality System 
Exclusions/Exemptions.  
For reference these not applicable clauses are: 
13485 Clause  Description 
7.5.3 Installation Activities - No medical devices require installation 
7.5.5 Particular Requirements for Sterile Devices - No sterilisation undertaken. 
7.5.7 Particular Requirements for Validation of Processes for Sterilisation and 
Sterile Barrier Systems -No sterilisation undertaken. 
7.5.9.2 Particular Requirements for Implantable Medical Devices - No 
implantable devices are produced. 
 
M&H will not act as importer or authorised representative.  
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3. References: 
 
BS EN ISO 9001 
BS EN ISO 13485 
BS EN ISO 17025 
BS EN ISO 15189 
UK legislation relating to medical devices and in vitro diagnostic devices - 
- 2019 No. 791 Exiting the European Union, Consumer Protection, The Medical 
Devices (Amendment etc.) (EU Exit) Regulations 2019  
EU regulations– 
Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 
April 2017 on medical devices, amending ….etc. 
 
Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 
April 2017 on in vitro diagnostic medical devices, amending….etc. 
 
M&H Quality Manual and associated supporting documentation. 
QP.01 CONTROL OF DOCUMENTATION AND DATA 
QP.05 ORDERING, RECEIVING AND TRACEABILITY OF GOODS AND 
SERVICES 
QP.06 CUSTOMER SPECIAL REQUIREMENTS 
QP.08 CALIBRATION CONTROL 
QP.10 CONTROL OF STANDARDS AND REGULATORY 
DOCUMENTATION 
QP.11 SUPPLIER PERFORMANCE 
QP.23 DISPOSAL OF SCRAP MATERIALS 
QP.24 CONTROL OF RECORDS 
QP.26 CUSTOMER SATISFACTION  
QP.27 COMPETENCE, AWARENESS AND TRAINING 
QP.29 INTERNAL AUDIT 
QP.30 HANDLING / STORAGE  
QP.31 DESPATCH/RECORD DOCUMENTATION 
QP.35 POSITIVE RECALL PROCEDURE 
 
The following work instruction have been developed to to assist in the 
documentation of the work. Their use will be highlighted in the body of this 
document.  
 
WI-RD-01 EC Technical File Contents and Control 
WI-RD-02 Labelling and Instructions for Use 
WI-RD.03 Product Feedback 
WI-RD-04 Competent Authority Notification 
WI-RD-05 Risk Analysis 
WI-RD-06  Medical Device Classification Rules  
WI-RD-07 In Vitro Diagnostic Devices Classification Rules 
WI-RD-10 IVDDR Essential Requirements Matrix 
WI-RD-11 MDR Essential Requirements Matrix 
WI-RD-12 Software Development 
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4. Quality Management System 
 
4.1 General requirements 
 
4.1.1 Overview of the system 
 
This is detailed in the QM point 4.1.1 - Overview of the system with the following 
additions: 
A full review of both the M&H QM and of this procedure will be undertaken in 
the event of the BS EN ISO 13485:2016 standard being revised. Changes to the 
standard will be incorporated as required to either the QM or this procedure. 
Changes to applicable regulatory requirements or additional regulatory 
requirements will be reviewed and relevant documentation amended, produced or 
withdrawn as required  
M&H will not act as importer or authorised representative.  
 
4.1.2 Processes, their interaction and associated risk to the organisation 
 
Any new processes required to enable product realisation will be requested via an 
Action Form (AF) See QP.20. The AF will detail: 
1. the need for the new process; 
2. how the new process interacts with other relevant parts of the QMS; 
3. any risks associated with the introduction of this process and also any 
residual risks once the process has been implemented; 
4. the risks associated if the proposed process is not introduced.  
 
4.1.3 System Requirements  
 
In addition to the details given in the QM 4.1.1 Overview of the System the need 
to demonstrate how this procedure and associated work conforms to the 
13485:2016 standard is achieved via internal and external audits, review of AF’s 
and any feedback relating to work undertaken or products resulting from this 
procedure.  
 
4.1.4 Procedure and related process management  
 
In addition to QM 4, which details the management of the QMS and the 
interaction of procedures and related processes. Any changes to the QMS 
impacting on this procedure or affecting the result of product realisation,  whether 
this is a medical device, an in vitro device, a developed test in use, or a service 
provided to a third party, these changes will be managed in accordance with the 
requirements of BS EN ISO 13485 and relevant regulatory or statutory 
requirements.  
 
4.1.5 Subcontracting  
 
Responsibility for the conformity of any work outsourced to 3rd parties relating to 
this procedure will be retained by M&H.  
As required by BS EN ISO 13485 M&H will retain responsibility for conformity 
to the standard, relevant regulatory, statutory requirements and customer 
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obligations for work undertaken by 3rd parties. Such 3rd party work will be 
monitored to ensure it meets agreed specification. The work will only commence 
once the capability of the 3rd party to undertake the work has been reviewed as 
satisfactory and the risks involved with using the 3rd party fully evaluated. A 
formal agreement of the required work shall be drawn up and signed. See also 7.4 
of this procedure. 
 
4.1.6 Software Validation 
 
See QM 4.4 - Software Validation. 
 
Note software validation or revalidation is controlled and documented as detailed 
in QP.01 and WI GEN 01. 
 
4.2 Documentation requirements 
 
4.2.1 General 
 
As detailed in QM 4.2.1 
 
4.2.2 Quality manual 
 
As detailed in QM 4.2.2 
 
4.2.3 Medical device file/Technical File 
 
For product realisation work undertaken, a record will be maintained of the work 
carried out, even if this work does not come to a conclusion. The following 
information relating to the medical device, diagnostic test or service will be 
retained or referenced in the record: 
1. A general description, 
2. intended use/purpose,  
3. specifications for product, 
4. required labelling,  
5. instructions for use, including user servicing, maintenance, calibration and 
disposal instructions as required, 
6. service delivery agreement – these are agreements with 3rd parties for 
work carried out by Medical Physics e.g. maintenance of 3rd party hoists, repair 
and service of GP practice medical equipment, design and development activities, 
etc., 
7. full details of how the device is to be manufactured and tested prior to 
passing to customers/users, 
8. device packaging, shipping, storage and handling during distribution and 
in use. 
9. test details and how this testing meets the requirements of BS EN ISO 
15189 
10. output of reviews undertaken during the product realisation to ensure the 
various phases are progressing as planned, the work outputs are as required and 
any problems are resolved, 
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11. reviews of feedback from the users of devices, or services delivered to 
ensure they continue to meet requirements. If any problems are not resolved, the 
appropriate action, including reporting to relevant authorities is undertaken. 
  
The following work instructions will be used to document legislative requirements 
and the production of the technical file content. 
WI Reference WI Title 
WI-RD-01 EC Technical File Contents and Control 
WI-RD-02 Labelling and Instructions for Use Requirements 
WI-RD.03 Product Feedback 
WI-RD-04 Competent Authority Notification 
WI-RD-05 Risk Analysis 
WI-RD-06  Medical Device Classification Rules  
WI-RD-07 In Vitro Diagnostic Devices Classification Rules 
WI-RD-08 IVDDR Manufacturing and Packaging Documentation   
WI-RD-09 MDR Manufacturing and Packing Documentation  
WI-RD-10 IVDDR Essential Requirements Matrix 
WI-RD-11 MDR Essential Requirements Matrix 
 
As detailed in Section 2 Scope of Product realisation the organisation does not 
carry out installation. 
 
4.2.4 Control of documents 
This is detailed in QM 4.2.3 and QP.01 
 
4.2.5 Control of records 
 
This is detailed in QM 4.2.4, QP.01 and QP.24.  
QP.24 states that records relating to medical devices are maintained for the 
lifetime of the equipment plus 5 years.  
 
5. Management responsibility 
 
5.1 Management commitment 
Detailed in QM 5.1 
 
5.2 Customer focus 
Detailed in QM 5.2.  
 
5.3 Quality policy 
The quality policy is detailed in QM 5.3 
 
5.4 Planning 
 
5.4.1 Quality objectives 
See QM 5.4.1 plus related quality policies for areas within this quality 
system. 
 
5.4.2 Quality management system planning 
See QM 5.4.2 
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5.5 Responsibility, authority and communication 
 
5.5.1 Responsibility and authority 
See QM 5.1 and 5.5.1. 
 
5.5.2 Management representative 
See QM 5.5.2  
 
5.5.3 Internal communication 
See QM 5.5.3 
 
5.6 Management review 
5.6.1 General 
 
See QM 5.6.1 
 
5.6.2 Review input 
 
All detailed in QM 5.6.2. To ensure full compliance with the requirements of BS 
EN 13485:2016, the following must be reviewed during the yearly cycle of 
Quality Review Meetings: 
1. feedback from customers or users of medical devices , diagnostic tests and 
services to 3rd parties manufactured by M&H; 
2. complaint handling related to work resulting from this procedure; 
3. a review of any reports issued to regulatory authorities and actions arising; 
4. the results of monitoring and measurement of processes – Are the 
processes associated with this procedure operating correctly and efficiently? 
5. the results of monitoring and measurement of product – Do products or 
services meet their specification throughout the manufacturing process and at the 
point of use? 
6. have any applicable new or revised regulatory or statutory requirements 
been issued– Why are they relevant and what is the plan for their introduction? 
 
5.6.3 Review output 
 
The review output will be formally recorded as detailed in QM 5.6.3. In the case 
of actions relating to this procedure, the record will include:  
1. details of why changes are needed to the QMS to maintain the suitability, 
adequacy and effectiveness of the system and processes; 
2. any improvements affecting customer or product stated requirements; 
3. details of the action required to implement relevant new or revised 
regulatory or statutory requirements. 
All actions resulting from quality review meetings will be documented on AF’s 
(See QP.20).  Time scales and staff responsible for implementing these actions 
will be detailed in the relevant AF.   
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6. Resource management 
 
6.1 Provision of resources 
See QM 6.1 
 
6.2 Human resources 
See QM 6.2 (6.2.1 and 6.2.2) 
 
6.3 Infrastructure 
Specifically for this procedure, the following requirements will be implemented. 
The infrastructure will be reviewed to ensure product requirements can be met and 
maintained. The infrastructure and environment are such that we ensure any 
manufactured product or items relating to the manufacturing process can be stored 
and handled appropriately without mix up between types, batches or any non-
conforming product found. 
Where maintenance of equipment required or services needed may affect the 
output of product realisation or end product quality, the risk associated with these 
activities will be documented. The results of risk mitigation will be reviewed and 
documented. Note equipment and services include – production equipment, test 
equipment, calibration standards, environment control system, power and IT 
systems.  
 
6.4 Work environment and contamination control 
See QM 6.4 with the additions detailed below. 
 
6.4.1 Work environment 
If special conditions are required for product realisation or production, these shall 
be documented. See also the requirements for BS EN ISO 15189 for the 
production of patient testing devices. These special conditions may be handling 
and storage of chemicals, parts, etc., the actual work environment or even the 
process equipment.  
Health and Safety, PPE and special cleanliness or contamination prevention 
requirements will be documented. Staff, including temporary staff, working under 
these conditions will be trained in the use of PPE, how to work in any special 
environment and how to maintain appropriate cleanliness or contamination 
control.  
 
6.4.2 Contamination control 
 
In accordance with NHS Tayside Policy, the control of materials contaminated 
biologically or by hazardous waste, will be documented. The documentation will 
detail methods of segregation, disposal and control. 
The arrangements to prevent contamination of product will be documented. This 
documentation will detail prevention of cross contamination, actions to be taken 
with product or items that do become contaminated, including storage until 
disposal. The documentation will detail action to be taken in the event of human 
or environment contamination. Where required appropriate decontamination 
equipment will be available. This can be in the form of chemical spill kits or 
washes. For the manufacture of patient testing devices the requirements of BS EN 
ISO 15189 must be adhered to in full.  
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7. Product realisation 
 
This procedure covers the requirements to meet EU and UK legislation for 
Medical and In vitro Diagnostic devices being placed on the market or into 
service. QM 7 details the requirements of product realization for products, 
services or tests which do not require to be CE marked or are exempt from CE 
marking. 
The following controls ensure the M&H QMS meets requirements of the BS EN 
ISO 13485:2016 standard, associated regulatory or statutory requirements and 
current industry practice and guidelines. In the case of IVDD device or laboratory 
patient testing the product realisation work must also meet the relevant 
requirements of BS EN ISO 15189. 
Product realisation requirements: 
1. full understanding of what is required; 
2. document and review these requirements so they are fully understood and 
no unstated requirements remain undocumented – e.g. regulatory, statutory, 
product performance or special user needs; 
3. the work to be undertaken is reviewed to ensure we can do this work. For 
example do we have the appropriate staff, facilities, procedures and processes in 
place to undertake the work?  
4. the work is monitored to ensure it is proceeding as expected and the result 
of the work meets the requirements;  
5. at the end of the product realisation we have full documentation to prove 
we have produced the required product, it meets requirements and we can 
replicate the product or service as and when required;  
6. appropriate user instructions are produced.  
The above is true for products in the design and development stages and also for 
customer requests for completed product. These products may be a new medical 
device, a new diagnostic test or a service provided to a third party. 
All documentation or records will be retained or referenced in the design and 
development file/Technical File. Each design and development has a unique 
job/work reference or batch number. For example clinical engineering this is the 
e-Quip job number and for HMFUS this is HMFUS Tech File 01, 02, etc. 
  
7.2 Planning of product realisation 
 
Each new product realisation request is risk assessed to ensure any risks 
associated with the new work are informed to appropriate management. 
Organisational risks must be passed to the head of the appropriated service.  
A review will be carried out prior to new product realisation work to ensure that 
current procedures, processes (work instructions, protocols or standard operating 
protocols) are adequate for the work to be undertaken. If required, an action plan 
to produce required documentation will be drawn up. The action will also detail 
how the documentation will be risk assessed to ensure consistency with the 
current QMS. 
Planning of product realisation will be documented per this quality management 
system. ???The level of documentation will be appropriate to the work required or 
the type of product being realised. The following points will be assessed and 
documented as required.  
1. customer requirements, 
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2. the need for the work and any particular objectives for the output of the 
product realisation. 
3. regulatory and statutory requirements, 
4. special technical or intended user requirements (is the user trained, 
disabled, a career, etc.), 
5. if a diagnostic test, specific requirements under the current BS EN ISO 
15189 standard.  
6. how to monitor the progress of the work,  
7. foreseen requirements for any measurement, inspection and test – work 
stages or final product  
8. special handling, storage and distribution. 
9. special traceability requirements of the final product or items used in the 
manufacture or the product.  
10. details of required product verification and validation and when to carry 
these out. 
11. details of how the final product will be checked to ensure it meets 
documented requirements.  
Risk assessment of product realisation work should reference ISO 14971 and WI-
RD 05 ‘Risk Analysis’ 
  
7.3 Customer-related processes 
 
7.3.1 Determination of requirements related to product 
 
Prior to agreeing to a customer request M&H will ensure they fully understand 
and document the customer requirements. These include 
1. the customer requirements, including the volume required, special 
instructions regarding delivery of product or service, if a site visit is request post-
delivery actives including technical/specialist training, test report layouts and 
billing arrangements, 
2. requirements not specified by the customer but required to ensure product 
meets customer or user requirements, include determining the clinical context for 
patient testing or sample analysis, 
3. regulatory or statutory requirements related to the product to ensure it can 
be delivered, 
4. user training to ensure correct and safe operation of the product, 
5. additional requirements imposed by M&H or NHS Tayside management. 
7.3.2 Review of requirements related to product 
Prior to delivery of product or fulfilment of a work request, whether this product 
is an item, test or service, a review will be conducted to ensure that:  
1. the documented product or work requirements or specification are 
reviewed to ensure they are understood and agreed by all interested parties, 
2. the specified regulatory, statutory, professional and industry standard 
requirements have been met, 
3. identified user or customer training is planned or available, 
4. M&H have the staff and infrastructure to meet the stated requirements or 
customer request, 
5. the original requirements or request are reviewed to ensure they have not 
changed. If they have, a review of the changes must be undertaken to ensure these 
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changes can be accommodated. This review must be undertaken for repeat orders 
or work requests. 
The results of the review and any actions arising will be documented and 
maintained as per this QMS.  
Where no customer requirements are stated, M&H will determine relevant 
requirements and agree these with the customer prior to fulfilling requests. 
When product requirements are changed, the organization shall ensure that 
relevant documents are amended and that relevant personnel are made aware of 
the changed requirements. 
7.3.3 Communication 
M&H will ensure customers are kept informed of; 
1. the progress of customer complaints or feedback given. See QP.20 and 
QP.26 
2. the progress of customer enquiries, contracts or amendments to requests or 
requirements. See QP.20, 
3. new products, services or tests which might be of interest to the customer, 
4. advisory Notices. See QP.35. QP.35 also details communication with 
relevant regulatory and statutory authorities.  
 
  
7.4 Design and development 
 
7.4.1 General 
This procedure, related Work Instructions and relevant BS EN ISO 15189 
protocols and Standard Operating Procedures document the requirements of 
design and development and any documentation to be produced at each stage of 
the work, this documentation will include all the information required to produce 
a device, carry out a diagnostic test or carry out work for a 3rd party.  
7.4.2 Design and development planning 
Each design and development activity is planned and those responsible for 
activity are identified. The plans are reviewed and updated as the work evolves. 
The plans will detail the review, validation and verification requirements 
necessary for the various design and development activities. Planning 
documentation will be retained with the work documentation. The plans will also 
include identification of organisational and technical interfaces between the 
different groups within M&H. The plans will be reviewed and updated as the 
design and development work evolves  
Planning documentation will include: 
1. The required design and development stages needed to produce the 
product. 
2. Identification of the responsibility and authority for the design and 
development stages/activities. 
3. Resource required.  
4. Special staff training/competence.  
5. Verification, validation and transfer activities between one stage and the 
next. 
6. How transfer activities are monitored to ensure the outputs from one stage 
are correctly transferred to the next. 
Transfer activity - how information, parts or other items are passed between 
design and development stages. This enables the output of one stage/activity to be 
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correctly passed to a second stage/activity for design and development input. For 
example, the final transfer activity for a product encompasses all the information 
to enable the product to be manufactured. 
 
7.4.3 Design and development inputs 
Design and development inputs define the product. If a product is complex and 
requires many design and development stages or activities, these inputs may be 
required to enable a design and development stage or activity to start. Design and 
development inputs will be documented and reviewed to ensure they are adequate 
and well defined.  How the inputs can be verified and validated will also be 
documented. Design and development inputs must not conflict.  
For an overall product these inputs will include: 
1. Applicable specified regulatory, statutory, professional and industry 
standard guidelines or requirements. 
2. List of standards, national or international, to be adhered to or met. 
3. Details of other similar devices, products or patient tests which may enable 
better understanding of the actual work to be carried out. 
4. The nature of the end user or the environment the product will be used in. 
5. Details of foreseen risks or results of risk assessments carried out,specially 
the result of risk assessments carried out in the planning stage. 
6. Any special storage or protection requirements for items used in the design 
and development activities, 
7. Details of the expected outcome of the design and development work: 
a) for a product then functionality, performance, usability, physical 
properties, special training requirements, target market, if professional or general 
public, complexity of user guide and safety requirements. 
b) for a patient test then the pass fail criteria, type of equipment required to 
undertake the testing, level of competence of intended user – professional or 
general public, required user guide and disposal information. 
c) for a 3rd party service – staffing required, equipment population, locality 
of the work, reporting and invoicing methods and type of contractual agreement 
required. 
8. For design and development work with interrelated activities or stages, the 
inputs to each stage will depend on the output of previous stages. These outputs 
could be a software application, a mechanical or electric module, a completed 
scientific study, or the results of a clinical trial. These outputs must be defined, 
have levels of acceptability and be documented. Stage/activities should only 
commence after these inputs (or outputs from the previous stage) have been 
reviewed and deemed acceptable. 
9. Traceability requirements of the product, materials, parts or items used, 
monitoring of production and calibration equipment, etc. 
10. Other design and development inputs may also be documented. 
 
See also IEC 62366–1. 
  
7.4.4 Design and development outputs 
Documentation of the design and development activity will be maintained. This 
documentation will include detailed records of any research, design and 
development and testing carried out. The outputs of design and development shall 
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be in a form suitable for verification against the inputs. Any disparity between the 
outputs and inputs will be reviewed and resolved. 
These outputs will only be released for use once reviewed and accepted. 
Design output shall:  
1. meet the requirements detailed in 7.3.3 Design and development inputs – 
for the overall project and for each activity or stage; 
2. enable the product to be manufactured or supplied, patient or sample test 
to be put into use or the 3rd party service carried out. This can include purchasing 
information, production and assembly information and schedules of work; 
3. contain or reference product acceptance criteria; 
4. contain or reference the protection of materials or parts used during the 
manufacture of product, the product itself while in storage or while shipping 
product or components parts; 
5. identify those characteristics of the final product that are crucial to the safe 
and proper operation of the product.  
Other outputs may be required or defined. 
  
7.4.5 Design and development review 
Reviews are held to check that the design and development activities are meeting 
the input requirements. Actions are proposed to resolve any problems identified 
during these reviews. The reviews are held as detailed in the design and 
development plan, 7.3.2, or as required by those managing the work. 
Reviews will be carried out by staff knowledgeable and/or expert in the work 
being reviewed. Records of such reviews will be held or referenced in the design 
and development file/Technical File 
 
7.4.6 Design and development verification 
• Verification: Did we design or produce the device correctly? Does it work 
the way it is supposed to? Does it meet technical or scientific specification? Did 
the offered service meet the contractual specification? 
The definition of verification is the act of determining whether a product or 
service can meet a specific requirement. One of the most critical and fundamental 
components of product creation includes ensuring the product will perform as 
intended. 
This stage ensures that the design output meets the design input requirements. 
Have we produced an item that meets it technical, scientific, regulatory, 
quantifiable requirements defined in the design and development input? 
Verification activities or reviews will be carried out as planned and be 
documented. These verification activities can include: 
a) holding and recording design reviews; 
b) undertaking qualification tests or functional design testing and 
demonstrations; 
c) comparing the new design with similar proven designs, if available; 
d) if the product is intended to work in combination with other products, 
verification will also be carried out in these intended combinations, 
e) carrying out clinical investigations and trials. 
 
7.4.7 Design and development validation 
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• Design Validation: Did you design the correct device? Did we make what 
the customer wanted? Is this what was intended at the start of the design and 
development activity or have we ended up answering a different question? 
According to the American Society for Quality, the definition of validation in a 
quality environment is the act of confirming that a product or service meets the 
need for which it was created. 
Design validation tests are used to ensure that the product/service meets the 
customers’ application or intended use. Validation testing can include 
environmental and emissions testing, customer/patient acceptance checks and 
further clinical investigations and trials. Validation activities will be documented. 
The documentation will include the validation plans, methods of testing and the 
pass fail criteria for tests carried out.  
Depending on the type and nature of the product statistically valid sample sizes 
will be required when conducting validation testing. How the samples are chosen 
and the sample size determined will also be documented. 
Where required clinical evaluations or performance evaluations of the device will 
be carried out in accordance with relevant regulatory and statutory requirements 
or as required by professional body guidelines. Note: devices used for such 
clinical or performance evaluations are not to be passed for customer use.  
If the product is intended to be used in combination with other products then 
validation will also be carried out with these intended combinations.  
Validation shall be completed prior to release for use of the product to the 
customer. 
7.4.8 Design and development transfer 
The results of design and development work will need to be documented, 
reviewed and verified to enable, for example, a product to be produced, a 
diagnostic test to be put into practice or a service to be delivered. The contents of 
design and development transfer documentation will be varied.  
The following are examples of design and development transfer documentation. 
1. For a device, the documentation will contain sufficient detail for the 
device to be manufactured, tested, packaged and shipped/passed to the end 
user/customer. The documentation includes as required: 
a) Assembly and layout drawings, schematics and final software required, 
parts lists along with supplier details and special material or component 
requirements. 
b) Details of manufacturing steps, 
c) Identification of manufacturing status or stage,  
d) Module or component testing, assembly checks and final calibration 
methods and pass fail criteria. Documentation of results and production of 
relevant certificates. 
e) User instructions and labels and labelling instructions 
f) Packaging and transport details. 
g) Device identification , UDI, or traceability, 
h) Any other details required to ensure the device is manufactured and 
shipped to a customer such that it functions as expected. 
2. For a test kit or constituent part: 
a)  the instructions to enable the kit/part to be manufactured; 
b) The limits of acceptability, the validation and verification details of each 
component part of the kit, limits of acceptability and final test methods; 
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c) Details of chemicals, constituent parts or other materials, their suppliers 
and any special supplier material or component requirements; 
d) Identification of manufacturing status or stage,  
e) User instructions and labels and labelling instructions 
f) Packaging and transport details. 
g) Device identification , UDI, or traceability, 
h) Results of a review that the product can be manufactured as envisaged – in 
house, subcontract, etc,  
i) Any other details required to ensure the test kit or part is manufactured and 
shipped to a customer such that it performs as expected. 
  
3. A new diagnostic test will require protocols to detail  
a) how the test is to be performed, outcomes expected and how to 
documented test results.,  
b) Interpretation of results – both clinically and in lay terms if deemed 
necessary. 
c) Equipment to be used, and, if required how calibrated and operated. 
d) Testing environment, 
e) Any other details required to ensure the test kit or part is manufactured and 
shipped to a customer such that it performs as expected. 
4. A new service 
a) The required work and any special methods to be employed, 
b) The required level of service, 
c) Where the work is to be performed, 
d) Financial arrangements 
e) Reporting arrangements 
f) Service review arrangements. 
g) If this is a service accepted on behalf of NHS Scotland the agreement 
between NHS Tayside and NHS Scotland will detail the service arrangements. 
 
  
7.4.9 Control of design and development changes 
Changes to the agreed design and development including plans, input or output 
requirements, validation or verification requirements, shall be identified, 
documented and approved using the Q-Pulse to raise an AF according to QP.20.  
Changes will be reviewed to determine how they may have or will affect the 
design and development. Changes will also be reviewed to determine their impact 
on completed design and development tasks, items already in the post design and 
development phase including products, tests or services already in use.  
The review should include the impact to performance, characteristic, usability and 
safety. What affect has the change made to services already performed or to 
products delivered or tests performed?  
Most importantly any changes to regulatory or statutory requirements or the 
intended use of a device or patient test will be highlighted and the requested 
change reviewed with the customer, relevant senior staff and a member of the QA 
team. 
Prior to accepting and implementing a design change it will be reviewed, verified, 
validated, approved, appropriate documentation produced or amended to enable 
the change to be implemented and communicated as to relevant staff, user groups, 
required relevant authorities or professional bodies. 
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7.4.10 Design and development files 
The information and documentation produced during the design and development 
work is retained either in one file or referenced in a master file. This information 
and documentation will include details showing how conformity to the design and 
development inputs was achieved and any changes reviewed whether 
implemented or not. This file will also reference the location of any technical file 
or technical documentation produced to fulfil regulatory or statutory requirements. 
 
  
7.5 Purchasing 
QP.05 - Ordering, Receiving and Traceability of Goods and Services, describes 
the process of ordering goods and services within NHS Tayside. 
7.5.1 Purchasing process 
See QM 7.4.1 with the following addition: 
1. Consideration must be given to the risk a particular supplier may have on 
product realisation.  
2. Delivered product non-conformance or delivery missed or out with 
stipulated delivery requirements will be one method used in the ongoing 
evaluation suppliers  
3. Supplier non-conformance will be evaluated on the risk associated with 
the non-conformance.  
See also QP.20 and QP.11 
7.5.2 Purchasing information 
See QM 7.4.2 with the following additions: 
1. Design and development documentation and transfer documentation will 
detail any special product acceptance requirements e.g. acceptance procedures, 
equipment – for handling or testing of purchased product, special storage needs, 
etc. 
2. Details of any specialist qualifications or training required by the 
supplier’s staff, 
3. Agreed certification to supply specialist materials. 
4. Prior notice to the supplier of materials which require certificates of 
conformance or material history/provenance.  
5. Prior to placing orders with a new supplier, special requirements will be 
documented and agreed. 
6. Changes to agreed product specification will be notified ASAP by the 
supplier to relevant M&H staff or by M&H staff to the supplier. 
7. Purchasing information will be reviewed prior to authorising orders. 
7.5.3 Verification of purchased product 
See QM 7.4.3 with the addition of:  
A formal review will be held to determine the effect of any delivered products 
which are found to be outside the required purchasing specification may have had 
to either product delivered to customers, undergoing manufacture or to the 
outcome of design and development activities or stages. 
 
  
7.6 Production and service provision 
This section relates to any activity to produce an end product, have this product 
delivered to the customer and ensure the customer can use the product. Further the 
Page 480 of 513 
 
 
section also relates to any related services provided to the customer, including 
invoicing, finance, repair or service of equipment, supply and management of 
work for NHS Scotland or others – GP practices, health centres, etc.  
This section details the controls to ensure we provide products e.g. medical 
devices, patient test, 3rd party services under controlled conditions and that the 
ancillary activities to ensure this happens are similarly controlled and 
documented. 
7.6.1 Control of production and service provision 
See QM 7.5.1 with the following additions: 
1. Will the envisaged infrastructure and environment: 
a) be suitable for manufacture of the product? 
b) not harm the end product? 
c) allow it to support customer or internal services to be fulfilled? 
2. Where required, document the checking and measurement of process 
parameters and product characteristics; 
3. Ensure that labelling and packaging instructions are clearly defined; 
4. Determine the activities for product release and delivery (e.g. specialist 
transport or handling)  
5. If required, determine and document post-delivery activities including 
training, calibration and implementation of service schedules. 
6. For all physical products or tests, the level of product traceability required 
and how this is controlled will be documented. 
7.6.2 Cleanliness of product 
Any special cleaning or contamination control requirements will be documented. 
Documentation will be produced if:  
1. Cleaning or decontamination of the device, its constituent modules, 
assemblies or materials will occur during the manufacturing processes, 
2. The product requires special cleaning prior to use but is not to be 
sterilised, 
3. The product is supplied non-sterile but must be cleaned prior to 
sterilization or use, 
4. The product is supplied clean prior to sterilisation or use, 
5. The product is supplied unclean, but it must be cleaned or sterilised prior 
to use. 
 
7.6.3 Installation activities 
No product installation is undertaken under this QMS. Installation in this case 
relates to providing instructions for the installation of product, providing building 
or infrastructure requirements.  
  
7.6.4 Servicing activities 
See QM 7.5.1 a, b and c with the following additions: 
Servicing Activities 
If servicing activities are required by the customer, the organization must 
document the servicing procedures, reference materials, and reference 
measurements for performing servicing activities and ensuring product 
requirements relating to this activity are met. 
Where a product requires servicing or calibration to ensure it is fit for use, these 
activities will be documented in either the user instructions or a separate specialist 
technical manual. This information will detail the appropriate servicing, 
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calibration or final test/pre use procedures, any required materials, reference 
measurements, special tools or instruments and the acceptable pass/ fail criteria.  
Analyses of M&H, users or suppliers feedback of such servicing or calibration 
activities will be undertaken. The output from this analysis should be used to: 
1. Instigate product improvement; 
2. Inform if a review of service/calibration activities to be undertaken; 
3. Instigate a review of service or calibration intervals; 
4. Determine if a customer complaint should be raised. 
7.6.5 Particular requirements for sterile medical devices 
For devices requiring sterilisation or special cleaning prior to use or delivery, only 
3rd party approved and documented processes will be used. This will be 
documentation as 7.5.2 ‘Cleanliness of product’ above. 
7.6.6 Validation of processes for production and service provision 
Validation of process for production and service provision 
Process validation is required when you are not able to verify the output of a 
process afterwards, so that problems only become apparent during product or 
service use. When this is the case, you validate your process to make sure it 
achieves the planned results and this is, of course, very specific to the processes in 
the company. ??? 
Processes, including servicing, which cannot be verified by inspection or testing 
and where deficiencies in such processes might become apparent after a period of 
time, shall be documented. The documentation shall include the qualification of 
the personnel, equipment to be used, specific methods, criteria for end of process 
or work acceptance, procedures of work and record keeping required. 
These types of processes will be validated/tested to demonstrate reliable process 
outcomes. Any statistical techniques used will be documented and rational for 
their use, including choice of sample sizes, given. 
The process and relevant documentation will have scheduled review to ensure it 
remains fit for purpose. 
Following changes to the process, equipment or material specification, the process 
and associated documentation must be reviewed and if required revalidated. 
Control and maintenance of computer software used in the testing and/or 
inspection of work carried out will be documented. Pre-use validation and 
revalidation, if software is updated or modified, shall be proportionate to the risk 
associated with the use of the software, including the effect on the ability of the 
product to conform to specifications. See also QM 4.4, QP.01 and WI??? 
7.6.7 Particular requirements for validation of processes for sterilization 
and sterile barrier systems 
No Sterilisation processes are undertaken under this QMS. For devices requiring 
sterilisation or special cleaning prior to use or delivery, only 3rd party 
appropriately approved and documented processes will be used.  
7.6.8 Identification 
See also QM 7.3.5 and QP.05 
HMFUS assign Starting Material Numbers to identify the product and associated 
materials and items during production, as appropriate. Product traceability is 
maintained by recording these in quality documents where applicable. The 
production paperwork will be followed at all times and signed off as each activity 
is accomplished. This allows the status of the product, including the monitoring 
and measurements status, to be known at all times during production. 
Page 482 of 513 
 
 
Clinical Engineering assign a unique e-Quip work number to all new work. This 
number identifies the product. All items or paper work used in the production of a 
device is referenced by this number. The various tasks to be undertaken and their 
sequence are documented in the manufacturing documentation. Staff will follow 
the work sequence as detailed in the manufacturing document, they enter the work 
they have carried out into the-Quip system. They will also record any monitoring 
and measurement undertaken as required, either directly into the e-Quip system or 
into designated forms.  
Each medical product will be identified as detailed in the design and development 
transfer documentation. HMFUS products are given product batch numbers as 
detailed in HMFUS production documentation and for Clinical Engineering, each 
product is given a Serial number and requires a UDI as detailed in Clinical 
Engineering production documentation. 
Products returned for inspection, review, rework or otherwise will be labelled 
with a non-conformance hold label, see QP.20, The non-conformance hold label 
will be retained with the product until the required action to deal with the product 
has been established and carried out. 
See also 7.3.8 Design and development transfer above. 
 
7.6.9 Traceability 
 
7.5.9.1 General 
. 
QM 7.3.5 and in particular procedure QP.05 details the tractability requirements 
for all areas covered by the QMS. Additionally the design and development inputs 
include a requirement for traceability and recording of traceability to be in 
accordance with the relevant regulatory, statutory, professional or industry 
requirements. See 7.3.3 Design and development inputs above. 
7.5.9.2 Particular requirements for implantable medical devices 
No implantable devices are manufactured by M&H and hence are not within the 
scope of this QMS 
  
7.6.10 Customer property 
Customer supplied property for the use or incorporation into the manufacture of 
product will be treated as per QM 7.5.4.  
7.6.11 Preservation of product 
See QM 7.5.5 with the additional requirement: 
Any special requirements regarding the protection of items used in the design and 
development of product, the manufacture of product or while shipping product or 
components parts will be documented in the transfer documentation,  
 
7.7 Control of monitoring and measuring equipment 
The following additional requirements to QM 7.6, QP.08 and associated 
instructions will be followed: 
1. Special monitoring and measurement required to ensure end product 
requirements are achieved will be documented; 
2. If no national or international standards exist, documented reasoning for 
the method of calibration and verification of the monitoring or measurement will 
be produced; 
3. The need for any adjustments or readjustments will be recorded; 
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4. Such equipment or materials to be protected from harm, deterioration, 
contamination or inadvertent adjustment will be identified; 
5. when monitoring or measurement devices or standards are found to be in 
error, the validity of previous results using these devices or standards will be 
reviewed and assessed to determine the effect of the error has been on the work 
undertaken, in progress or any released products. (Product already issued may 
need to be recalled see QP.35) 
6. computer software or applications used will be validated or revalidate 
prior to use. The actual validation or revalidation undertaken will be proportionate 
to the risk the software poses to this QMS and to M&H. See also QM 4.4, and 
WI…… 
  
8. Measurement, analysis and improvement 
 
8.1 General 
The requirements given in QM 8.1 will be extended to demonstrate conformity of 
product and the provisions detailed in 7.5 Production and service provision of this 
procedure. 
 
All the elements of QM 8.2 apply and the following additional requirements: 
 
8.2.1 Feedback 
Feedback is controlled and documented as detailed in QP.26 and QP.20. Feedback 
is an agenda item for the QMS review. For the specific requirements of this 
procedure, feedback will include reports relating to product, manufacturing and 
service. 
8.2.2 Complaint handling 
Complaint handling is detailed in QP.26 and QP.20. Feedback is reviewed to 
determine: 
1. if a complaint should be raised on behalf of a customer; 
2. if regulatory or statutory reporting is required; 
3. the action to be taken with problems related to product; 
4. the reasons for not investigating an incident - this must be documented on 
the relevant AF; 
5. if subcontractors or other 3rd parties are involved – they must be included 
in complaint investigation or review. 
8.2.3 Reporting to regulatory authorities 
QP.35 details positive recall and reporting to regulatory or statutory authorities.  
8.2.4 Internal audit 
QM 8.2.2 details the requirements in relation to audits while QP.29 is the control 
procedure for internal audits. All audits, internal or external, are recorded in Q-
Pulse. 
8.2.5 Monitoring and measurement of processes 
See QM 8.2.3 
8.2.6 Monitoring and measurement of product 
See QM 8.2.4. Monitoring and measurement for each product is detailed in the 
transfer documents, 7.3.8 Design and development transfer. Only after appropriate 
review and sign off will product be available for issue or a service put into use.  
8.3 Control of nonconforming product 
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The requirements of QM 8.3 and QP.20 apply to this section with the following 
additions: 
8.3.1 General 
When non-conforming products or services are found or an action taken to 
prevent a possible non-conformance, an AF will be raised (See QP.20). The non-
conformance or possible non-conformance will be detailed in the …. Section and 
the AF passed to the appropriate member of staff to detail action to resolve the 
problem.  
  
8.3.2 Actions in response to non-conforming product detected before 
delivery 
The following actions in response to non-conforming product detected before 
delivery or a non-conforming services found prior to being put into use may be 
undertaken: 
1. Carrying out required action to remove the non-conformity 
2. Removing the product or stopping the service from being put into use 
3. Authorising a concession for : 
a) use, 
b) product release, or 
c) acceptance for use if an item or part used in the manufacturing process.  
4. Authorising a concession for the service to be used. 
Concessions will be requested via an AF. Those reviewing concessions will need 
to demonstrate regulatory or statutory requirements are being adhered to and 
justify the granting of the concession. 
 
8.3.3 Actions in response to non-conforming product detected after delivery 
When product or services are found to be non-conforming after they have been 
put into use or service a full review of the consequences will be undertaken. The 
results of the review will be retained in an AF. The nature of any recall action will 
depend on the results of the review. QP35 details recall and notification of 
medical device regulator authority.  
 
8.3.4 Rework 
Rework to bring a product up to specified requirement will be documented. This 
may be simple instructions appended to the AF related to the non-conformance or, 
for more complex rework activities, a rework instruction will be drawn up and 
issued in accordance to QP.01. 
For services requiring to be modified to ensure they meet requirements the 
documentation will documented in the AF related to the non-conformance. 
 
8.4 Analysis of data 
QM 8.4 details the general analysis of data used to ensure the QMS, procedures 
and related documentation are effective and that product or services produced or 
provided are meeting requirements.  
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8.5 Improvement 
The following requirements are in addition to those given in QM 8.5:  
 
8.5.1 General 
In addition to QM 8.5.1 the following information will be used to highlight areas 
of improvement to the quality management system, related documentation and to 
ensure the safety of medical devices produced.  
1. data from post market surveillance, 
2. corrective actions,  
3. preventive actions, 
4. the use of concessions relating to non-conforming product or services, 
 
8.5.2 Corrective action 
QM 8.5.2 and QP.20. QP.20 details the control of corrective actions. The 
following are in addition the requirements of QP.20 for work controlled by this 
procedure control. Such work includes: 
1. medical product or related service realisation;  
2. medical device or related service design and development,  
3. manufacture of medical or related product,  
4. delivery of service related to medical product 
5. procedures, process and documentation  related to this work. 
Corrective action is used to describe any action to remove an error or problem 
found within the QMS or during the manufacturing/production of a product or a 
problem found or reported with a completed product or service.  
Such problems will be documented using the Q-Pulse AF  
The ‘Details’ section will be a description of the problem or error.  
The ‘Action Required’ section will be completed by the relevant senior staff and 
will detail  
9. the root cause/reason the problem/non-conformance occurred andthe 
action plan, including required documentation to clear the problem or non-
conformance and prevent it from reoccurring.  
The ‘review action taken’ section will be completed by the QSM or nominee in 
conjunction with relevant senior staff who will determine if: 
1. the problem/non-conformance been reviewed correctly and is the root 
cause/reason adequate; 
2. the action plan detailed has cleared the problem/non-conformance; 
3. the action plan ensures the problem/non-conformance does not reoccur; it 
is correct and effective;  
4.  the above action plan has not had any adverse effect on the QMS, the 
product or service requirements or safety or any resultant device. 
The above process will also be implemented for complaints raised against work 
controlled by this procedure.  
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8.5.3 Preventive action 
QM 8.5.3 and QP.20.  
QP.20 details how the prevention of potential non-conformities, possible 
deviation from specified requirements, errors relating to work or other possible 
risks. Preventative action can be proactive, for example staff training, outputs 
from quality review meeting, PPM schedules for critical equipment, review of 
supplier errors, review of procedures and related documentation relating to the 
work, customer feedback review and internal and external audits.  
Preventable actions may be the results of audit findings, staff suggestions or trend 
analysis.  
The following relates to areas where specific preventative actions need to be 
undertaken: 
1. medical product or related service realisation;  
2. medical device or related service design and development,  
3. manufacture of medical or related product,  
4. delivery of service related to medical product, or 
5. procedures, processes and documentation affecting work related to this 
procedure. 
Action Forms as detailed in QP.20 shall be used to document the preventative 
action as follows. 
The ‘Details’ section will be a description of the possible problem or preventative 
action.  
The ‘Action Required’ section will be completed by the relevant senior staff and 
will detail  
1. the risk to the QMS if the possible problem is not resolved or the 
preventative action is not implemented. 
2. the action plan, including required documentation to remove the possible 
problem or instigate the preventable action.  
The ‘review action taken’ section will be completed by the QSM or nominee in 
conjunction with relevant senior staff who will determine if: 
1. the possible problem or preventative action been reviewed correctly and if 
the risk to the QMS been defined appropriately; 
2. the action plan was sufficient; 
3. the action plan ensures the possibility of the problem occurring has been 
removed and the preventative action is correct and effective; 
4. the above action plan has not had any adverse effect on the QMS, the 
product or service requirements or safety or any resultant device. 
The above process will also be implemented when, after initial review, customer 
feedback is deemed as a possible complaint. 
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